{
    "0": {
        "output": "Based on the patient note provided, let's go through the inclusion criteria for the clinical trial one by one to assess the patient's eligibility:\n\n- Must live in the United States: The patient note does not specify the patient\u2019s location. Further information is needed to confirm this criterion.\n- Must understand and write English: The patient note does not provide information about the patient's language abilities. Further information is needed to confirm this criterion.\n- Must have access to a computer with e-mail and expect to have this access for at least 3 years: The patient note does not mention the patient's access to a computer or email. Further information is needed to confirm this criterion.\n- Must be 18 years old: The patient is 58 years old, which satisfies this criterion.\n- Must have seen a doctor for back pain at least once in the past year: The patient presents with chest pain, not back pain. There is no mention of back pain or a history of back pain in the patient note. Therefore, this criterion is not met.\n\nBased on the information provided in the patient note, the patient does not meet one of the key inclusion criteria for the clinical trial, which is having seen a doctor for back pain at least once in the past year. However, since other necessary information regarding residency, language ability, and computer access is missing, a final determination cannot be made solely based on the information provided.\n\nTherefore, the trial-level eligibility for this patient based on the information given would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "1": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the Beta-Blocker Heart Attack Trial (BHAT).\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known history of hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Men and women, ages 30 to 69.\n- Documented myocardial infarction.\n\nAssessment:\nThe patient's age fits within the inclusion criteria (ages 30 to 69). However, there is no documentation of a myocardial infarction presented in the patient note. The symptoms described could potentially be related to a cardiac event, but there is no clear evidence of a documented myocardial infarction based on the information provided. For this patient to be eligible for the BHAT, there needs to be a documented myocardial infarction, which is not indicated in the patient note.\n\nGiven the information provided, the patient does not currently meet the specific inclusion criterion of having a documented myocardial infarction. Therefore, the patient would not be referred for this clinical trial based on the data available.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "2": {
        "output": "Upon reviewing the patient's information and the clinical trial details, here are the key points for consideration:\n\nPatient Information:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Non-smoker, no diabetes, no hypercholesterolemia, no family history of heart disease\n- Not currently on any medication\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Information:\n- Title: Hypertension Prevention Trial (HPT) Feasibility Study\n- Focus: Nutritional interventions for the primary prevention of hypertension\n- Inclusion Criteria:\n  - Men and women, ages 25 to 49\n  - Diastolic blood pressure between 78 and 89 mm Hg\n  - Free of major disease\n  - Not on a special diet or antihypertensive medication at entry\n  - Some mild to moderately obese subjects\n\nAssessment of Eligibility:\n- The patient is 58 years old, which is outside the specified age range of 25 to 49 years.\n- The patient has hypertension and obesity, which could be relevant to the trial's focus on nutritional interventions for hypertension prevention. However, the trial specifically aims at the primary prevention of hypertension, and the patient is already known to have hypertension.\n- The patient\u2019s current diastolic blood pressure is not provided in the note, so we cannot assess whether it falls within the specified range of 78 to 89 mm Hg.\n- The patient is not on a special diet or antihypertensive medication, which aligns with one of the trial's inclusion criteria.\n\nBased on the information provided, the patient does not meet the age criterion for the clinical trial. Even though other aspects of her condition might be of interest to the study, the age criterion is a hard stop, and therefore, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "3": {
        "output": "To determine the eligibility of the patient for the clinical trial titled \"Diabetes and Heart Disease Risk in Blacks,\" we need to compare the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial:\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Not currently on any medications\n\nInclusion criteria:\n- Ethnicity: Black (African Americans born in the United States with American-born parents or Africans living in the United States with African-born parents)\n- Age: Between 18 and 70 years\n- Medical History: Self-identified as healthy, without established coronary artery disease as evidenced by history of myocardial infarction, coronary artery bypass surgery, or PTCA, or if they have such a history, they are not currently having angina\n\nExclusion criteria:\n- Black Ethnicity other than American or African\n- Medications known to alter the parameters under investigation\n- Diabetes\n- Pregnant or breastfeeding women, or women with an infant less than four months of age\n- Women on injectable hormonal contraception\n\nAssessment:\n- The patient is a 58-year-old African-American woman, which fits the ethnic and age criteria.\n- The patient identifies as having hypertension and obesity but does not report any history of diabetes, which is specifically listed in the exclusion criteria.\n- There is no indication that the patient is taking any medications that would alter study parameters or that she is pregnant, breastfeeding, or on injectable hormonal contraception.\n- The patient's medical history does not include an established coronary artery disease with current angina, which could have excluded her based on the inclusion criteria.\n\nConsidering the information provided, the patient appears to meet the inclusion criteria and does not fall under any of the exclusion criteria. Therefore, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "4": {
        "output": "Based on the information provided, the patient in the note is a 58-year-old African-American woman who presents with episodic chest pain, hypertension, and obesity. However, the clinical trial is specifically looking to prevent recurrent strokes in African Americans who have had a non-cardioembolic ischemic stroke at least 7 days, but no more than 90 days before entering the trial.\n\nThe patient note does not mention a history of stroke, let alone a non-cardioembolic ischemic stroke within the specified time frame. Therefore, based on the inclusion criteria provided, this patient would not be eligible for the clinical trial focused on stroke prevention.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "5": {
        "output": "Assessing the patient's eligibility for the \"Muscatine Heart Study\" clinical trial:\n\nThe patient is a 58-year-old African-American woman presenting with symptoms that might suggest a cardiac event, such as episodic pressing/burning anterior chest pain that radiates to the back and is associated with nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n\nThe clinical trial in question is the \"Muscatine Heart Study,\" which aims to study risk factors for coronary heart disease and hypertension among children and adults. The trial has no specific eligibility criteria listed.\n\nGiven that there are no eligibility criteria provided for this clinical trial, theoretically, any patient could be considered for inclusion. However, it is essential to note that the patient's current clinical presentation should be adequately addressed and stabilized before considering her participation in any study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "6": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial titled \"The Jackson Heart Study of Cardiovascular Disease Among African Americans.\"\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Non-specific EKG changes\n\nClinical Trial Inclusion Criteria:\n- African American\n- Residents of Jackson, Mississippi\n\nAssessment:\nThe patient meets the African American ethnicity criterion for the clinical trial. However, there is no information about the patient's residency to confirm whether she is a resident of Jackson, Mississippi, which is a specific inclusion criterion for this clinical trial.\n\nWithout confirmation of the patient's residency, we cannot fully determine her eligibility. If the patient is indeed a resident of Jackson, Mississippi, she would be eligible. This information needs to be verified before a final decision can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "7": {
        "output": "Given that the clinical trial titled \"Racial Variation in ACE--Genetic and Physiologic Bases\" does not provide specific inclusion criteria, and considering that the patient is an African-American woman who presents with hypertension, which is related to blood pressure variation, she could potentially be of interest for the study given its focus on blood pressure variation in African Americans.\n\nHowever, it's important to note that without detailed inclusion criteria, it's not possible to definitively ascertain her eligibility based solely on the information provided. Therefore, additional information would be required from the clinical trial's organizers to make a fully informed decision.\n\nBased on the information available, I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "8": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial titled \"Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure,\" we need to match the patient's characteristics and medical history with the inclusion and exclusion criteria of the trial.\n\nFrom the patient note, we have the following information about the patient:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Currently takes no medications\n- Normal physical examination\n- The EKG shows nonspecific changes\n\nThe inclusion criteria for the trial are:\n- Age \u2265 18 years\n- Ischemic or nonischemic cardiomyopathy with symptoms of NYHA Class III or IV chronic heart failure\n- LVEF \u2264 35%\n- LVEDD > 2.7 cm/m^2\n- On optimal conventional heart failure therapy\n- Failed initiation or up-titration of a beta-blocker due to hemodynamic intolerance\n\nBased on the patient note, there is no evidence that the patient has chronic heart failure, let alone NYHA Class III or IV chronic heart failure. The patient also does not have a documented left ventricular ejection fraction (LVEF) or left ventricular end diastolic dimension (LVEDD). Additionally, there is no indication that the patient has been on heart failure therapy or has had issues tolerating beta-blockers.\n\nSince the patient does not meet the key inclusion criteria related to the diagnosis of chronic heart failure and the specific requirements regarding heart function and treatment history, we would not consider this patient eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "9": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain,\" let's assess the patient's eligibility:\n\nPatient Characteristics:\n- Age: 58 years old\n- Presenting symptoms: episodic pressing/burning anterior chest pain, radiating to the back, with nausea, diaphoresis, and mild dyspnea\n- Known medical history: hypertension, obesity\n- Medication: No current medications\n- Physical examination: Normal\n- EKG: Nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Chronic back pain for at least 6 months\n- Treatment by medication or physical therapy\n\nComparison:\n- The patient does not mention chronic back pain; instead, she has episodic chest pain that started very recently.\n- There is no indication that the patient has been treated for back pain, either by medication or physical therapy.\n\nSince the patient does not have chronic back pain and is not undergoing treatment for such a condition, she does not meet the inclusion criteria for the clinical trial, which is specifically targeting individuals with chronic back pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "10": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman who presents to the ER with episodic pressing/burning anterior chest pain and is known to have hypertension and obesity. The clinical trial in question is investigating the influence of amlodipine on the mortality of patients with end-stage renal failure who are undergoing chronic hemodialysis treatment.\n\nTo determine the eligibility of the patient for the clinical trial, we must compare the patient's characteristics and medical condition with the inclusion criteria of the trial:\n\nInclusion criteria for the clinical trial:\n- End-stage renal disease\n- Hemodialysis\n- Hypertension\n- Written informed consent\n\nPatient characteristics and medical condition:\n- 58-year-old African-American woman\n- Hypertension\n- Episodic chest pain\n- No indication of end-stage renal disease or hemodialysis treatment\n\nWhile the patient does have hypertension, which is one of the inclusion criteria, there is no mention in the patient note of end-stage renal disease or that the patient is undergoing hemodialysis treatment. Since the clinical trial specifically requires participants to have end-stage renal failure and be on chronic hemodialysis treatment, this patient does not meet the key inclusion criteria for the trial.\n\nTherefore, based on the information given, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "11": {
        "output": "Based on the patient note provided, the 58-year-old woman presents with hypertension, evidenced by her known medical condition, but there is no mention of her having type 2 diabetes or impaired glucose tolerance. The clinical trial in question is specifically looking for hypertensive patients with a clinical diagnosis of type 2 diabetes or impaired glucose tolerance.\n\nSince the patient does have a clinical diagnosis of hypertension, she meets part of the inclusion criteria. However, without information on her glucose tolerance or a diagnosis of type 2 diabetes, we cannot fully determine her eligibility for this trial. Additional information would be required to make a complete assessment.\n\nGiven the information available, I would consider referring this patient to the clinical trial upon further investigation to determine if she has type 2 diabetes or impaired glucose tolerance.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "12": {
        "output": "Let's assess the patient's eligibility for the clinical trial based on the provided inclusion criteria:\n\nPatient Characteristics:\n- Age: 58 years old\n- Known hypertension\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- No current medications\n- No history of diabetes, hypercholesterolemia, or family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Outpatients aged 65 years or older, and less than 85 years\n- Current antihypertensive treatment with monotherapy\n- SBP \u2265 140mmHg or DBP \u2265 90mmHg on two measurements on two clinic visits\n- At least one of the following risk factors:\n  - Diabetes mellitus Type 2\n  - History of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or TIA\n  - Diagnosis of asymptomatic cerebrovascular disease\n  - History of myocardial infarction\n  - Diagnosis of angina pectoris or heart failure (NYHA I or II)\n  - Diagnosis of left ventricular hypertrophy\n  - Diagnosis of aortic aneurysm\n  - History of aortic dissection\n  - Diagnosis of arteriosclerotic peripheral arterial obstruction\n  - Serum creatinine: 1.2-2.5mg/dL (male); 1.0-2.5mg/dL (female)\n  - Proteinuria: \u2265 +1\n\nComparison of Patient Characteristics to Inclusion Criteria:\n- The patient is 58 years old, which is younger than the required 65 years or older for the trial.\n- The patient is not currently on antihypertensive treatment, as they are not taking any medications.\n- Blood pressure measurements are not provided, so we cannot assess this criterion.\n- There is no mention of any of the listed risk factors, such as diabetes type 2, history of cardiovascular or cerebrovascular events, diagnosis of left ventricular hypertrophy, or laboratory results for serum creatinine and proteinuria.\n\nConclusion:\nBased on the information provided, the patient does not meet the age criterion, is not currently receiving antihypertensive treatment with monotherapy, and there is no evidence of the specified risk factors or lab results. Therefore, this patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "13": {
        "output": "The patient note describes a 58-year-old African-American woman who presents with new-onset chest pain, hypertension, and obesity. The patient's chest pain is not typical for angina, as it does not increase on inspiration and is accompanied by nausea, diaphoresis, and mild dyspnea. The patient's EKG shows nonspecific changes, and she is not currently on any medication for her hypertension.\n\nThe clinical trial is focused on individuals with mild essential hypertension to study the effects of an ACE inhibitor and an ARB on blood pressure and hormonal responses. The inclusion criteria for the clinical trial are as follows:\n\n- Essential Hypertension\n- SBP 140-159 mmHg\n- DBP 90-99 mmHg\n\nThe patient note indicates that she has hypertension, which is one of the inclusion criteria. However, the patient's specific blood pressure values (SBP and DBP) at the time of the evaluation are not provided. Essential hypertension is typically diagnosed based on repeated blood pressure measurements, and we do not have enough information from the patient note to determine if she has been diagnosed with essential hypertension or if her blood pressure falls within the specified range. \n\nBased on the information given, we cannot confirm her eligibility without further investigation into her diagnosis and blood pressure readings. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "14": {
        "output": "Based on the patient note and the clinical trial criteria provided, let's evaluate the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical Trial Criteria:\n- Outpatients \u226518 years of age\n- Diagnosed with clinically stable angina pectoris\n\nThe patient is over 18 years of age and presents with symptoms that could be suggestive of angina pectoris, such as episodic chest pain that began recently. However, the diagnosis of \"clinically stable angina pectoris\" has not been established yet based on the information in the patient note. Further investigations would be required to confirm the diagnosis and ascertain whether the angina is stable.\n\nWithout confirmation of stable angina, it's not possible to definitively say that the patient meets all the inclusion criteria. Therefore, further investigation is needed before the patient could be referred to the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "15": {
        "output": "The patient note describes a 58-year-old African-American woman presenting with symptoms that may be indicative of a cardiovascular event, such as chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea. She has a known history of hypertension and obesity, which are two risk factors mentioned in the inclusion criteria for the KYOTO HEART Study. The patient does not have diabetes, a smoking habit, hypercholesterolemia, or a family history of heart disease. There's no mention of chronic heart failure or a history of ischemic heart disease (IHD) or cerebrovascular disease. The EKG shows nonspecific changes, which could be interpreted as an electrocardiogram (ECG) abnormality.\n\nBased on the information provided:\n\n- The patient has a clinical diagnosis of hypertension.\n- The patient has obesity, which is one of the risk factors listed in the inclusion criteria (BMI>25 is assumed based on the mention of obesity).\n- There are nonspecific changes on the EKG, which might be considered an ECG abnormality; however, this would require further clarification since \"nonspecific changes\" can mean various things and may not necessarily equate to the LVH mentioned in the inclusion criteria.\n\nGiven the patient has at least two risk factors from the inclusion criteria (hypertension and obesity), I would consider referring this patient to the KYOTO HEART Study upon further investigation, particularly to clarify the EKG findings and ensure they meet the trial's definition of ECG abnormality.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "16": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not meet the eligibility criteria as specified for the trial. The trial is specifically targeting patients with a history of diabetes for at least 5 years, and the patient in the note does not mention having diabetes, only hypertension and obesity. Since having diabetes is a requirement for the trial, and there is no indication that the patient has diabetes, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "17": {
        "output": "Based on the inclusion criteria provided for the clinical trial titled \"Understanding Pediatric Chest Pain and Other Symptoms,\" the key points are:\n\n- Age between 8-18 years old\n- Pediatric patients with referrals for innocent heart murmurs\n- Pediatric patients experiencing chest pain\n- Must be English speaking\n\nThe patient in the provided note is a 58-year-old African-American woman who presents with chest pain. This patient does not meet the age criteria, as she is well beyond the 8-18 years of age requirement for the study.\n\nTherefore, the patient is not eligible for the clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "18": {
        "output": "Upon reviewing the patient's presentation and the inclusion criteria of the clinical trial, it appears that the patient's symptoms suggest she may be experiencing an episode related to a cardiovascular condition, potentially ischemic heart disease (IHD), given the description of episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea. However, there is no definitive diagnosis of heart failure (HF) or ischemic heart disease provided in the patient note, which are specific conditions required for eligibility in the clinical trial.\n\nFurthermore, the clinical trial is focused on improving the quality of prescribing for patients with chronic cardiovascular disease, specifically CHF or IHD, who are not currently being treated with ACE inhibitors/angiotensin receptor blockers for HF or statins for IHD. Since the patient is not on any medications, she might fit this part of the criteria if she were to have a diagnosis of HF or IHD.\n\nGiven that the patient\u2019s current symptoms and medical history have not yet established a diagnosis of chronic cardiovascular disease such as CHF or IHD, further investigation would be necessary to determine if the patient fits the diagnosis criteria for the trial. Therefore, at this stage, the patient's eligibility for the trial is uncertain, and more information is needed.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "19": {
        "output": "Based on the information provided in the patient note, we have a 58-year-old African-American woman who presents with hypertension, one of the conditions being targeted in the clinical trial. She is also above 18 years of age, which meets another inclusion criterion for the trial.\n\nThe patient's presenting symptoms do not seem to be directly related to her hypertension, as they are more indicative of an acute coronary syndrome rather than uncontrolled hypertension. However, since the trial is comparing different combinations of medications for the treatment of high blood pressure and she is known to have hypertension, her condition aligns with the study's focus.\n\nThe trial does not mention the need for the hypertension to be uncontrolled or resistant to treatment, nor does it specify any additional criteria such as the severity of hypertension or any previous treatment.\n\nGiven the information provided, the patient meets the basic inclusion criteria for age (>18 years) and has a diagnosis of high blood pressure. Therefore, she could potentially be eligible for the trial that aims to compare hypertension treatments.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "20": {
        "output": "The patient in the note is presenting with symptoms suggestive of a cardiac event (episodic pressing/burning anterior chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea). The patient has a history of hypertension and obesity and is currently not on any medications. There is no mention of breast cancer in the patient's history.\n\nThe clinical trial in question is designed for metastatic breast cancer (MBC) patients who are resistant to hormonal therapy, have ER (-) status, have not been treated with anthracyclines for MBC or taxanes before, and who are within a certain age range with specific blood counts and liver function tests.\n\nSince the patient note does not mention metastatic breast cancer or any cancer diagnosis, the patient does not meet the disease-specific inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "21": {
        "output": "Given the patient's presentation of episodic pressing/burning anterior chest pain that began while walking and radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea, there is a possibility of stable angina pectoris. The patient has risk factors such as hypertension and obesity, which could contribute to angina. However, there are a few considerations before determining the trial-level eligibility:\n\n1. The patient note does not confirm a diagnosis of chronic stable angina pectoris. While the symptoms are suggestive, a confirmed diagnosis would be necessary.\n2. There is no mention of documented coronary artery disease in the patient note.\n3. The patient has not been described as having been previously treated with atenolol or any other beta-blocker agent.\n4. There's no information provided on an exercise tolerance test, which is one of the inclusion criteria.\n\nConsidering these points, while the patient may potentially have angina, there is not enough evidence in the patient note to confirm that she meets all the inclusion criteria for the trial. Further investigation would be needed to confirm the diagnosis of stable angina pectoris, the presence of coronary artery disease, previous beta-blocker treatment, and exercise tolerance test results.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "22": {
        "output": "The patient is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain that started while walking. The pain radiates to the back and is accompanied by nausea, diaphoresis, and mild dyspnea. She has hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. The EKG shows nonspecific changes.\n\nLet's assess her eligibility against the inclusion criteria for the clinical trial titled \"Rosiglitazone Versus Placebo in Chronic Stable Angina\":\n\n1. Chronic stable angina - The patient presents with chest pain, but there is no mention of whether it has been diagnosed as chronic stable angina. Further investigation is required to confirm this diagnosis.\n2. Previous positive exercise tolerance test - There is no information provided about any previous exercise tolerance tests.\n3. Disease not suitable for coronary intervention - There is no information provided about the suitability of the disease for coronary intervention.\n4. Do not have overt diabetes - The patient denies diabetes, meeting this criterion.\n5. Body mass index (BMI) greater than 25 - The patient is described as obese, which likely meets the BMI criterion, but the exact BMI is not provided.\n\nBased on the available information, the patient may potentially meet some of the inclusion criteria for the clinical trial. However, there is a need for further investigation to confirm the diagnosis of chronic stable angina, the history of exercise tolerance tests, and whether the patient's disease is not suitable for coronary intervention. Therefore, the appropriate level of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "23": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis,\" let's evaluate the patient's eligibility:\n\nPatient Characteristics:\n- Age: 58-year-old\n- Gender: Female\n- Health Conditions: Episodic pressing/burning anterior chest pain, hypertension, obesity\n- Other Information: No current medications, non-smoker, no diabetes, no hypercholesterolemia, no family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Women aged 50 and older\n- Lumbar spine BMD (L1 to L4) T score between 0 and -2.0\n- At least 3 years postmenopausal\n\nThe patient meets the age and gender requirements for the clinical trial as she is a 58-year-old woman. However, there is no information provided about her menopausal status or bone mineral density (BMD) T score. Without this information, we cannot conclude that she fully meets the inclusion criteria. Therefore, further investigation is necessary to determine her menopausal status and BMD T score.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "24": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- Age: 58 years old\n- Presents with: episodic pressing/burning anterior chest pain, hypertension, obesity\n- No current medications\n- No mention of low back pain (LBP)\n\nClinical Trial Inclusion Criteria:\n- Age: 21 to 55 years old\n- Diagnosis: Idiopathic mechanical low back pain (LBP)\n- LBP classified as subacute (4-12 weeks) or chronic (more than 12 weeks), with the current episode at least four weeks prior\n- Required: Written Informed Consent\n- A minimum baseline score on the Roland Morris Disability Questionnaire (RMQ) of 6 points\n\nThe patient does not meet the age criterion, as she is 58 years old and the trial specifies an age range of 21 to 55 years. Additionally, the patient does not present with low back pain, which is a requirement for the clinical trial. Therefore, this patient would not be eligible for referral to the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "25": {
        "output": "Based on the information provided, the 58-year-old African-American woman presents with symptoms that could suggest acute coronary syndrome (ACS), such as episodic pressing/burning anterior chest pain with associated symptoms like nausea, diaphoresis, and mild dyspnea. Her EKG shows nonspecific changes, which does not rule out the possibility of ACS.\n\nThe clinical trial in question is targeting patients with ACS, specifically looking to evaluate the efficacy and safety of intravenous versus sublingual isosorbide dinitrate for the relief of acute anginal pain episodes in ACS patients.\n\nTo determine if this patient is eligible for the clinical trial, we need to match her characteristics and situation with the inclusion criteria:\n\n- Age > 18 years or older. (The patient is 58, so this criterion is met.)\n- Admission to the ICCU with ACS (non-ST elevation acute coronary syndrome or 24 hours after ST elevation myocardial infarction). (The patient's description suggests a potential ACS, but there is no clear statement that she has been admitted with ACS. Further investigation, such as troponin levels and a more comprehensive EKG interpretation, would be required.)\n- Presence of ischemic symptoms (\u22655 minutes) during hospitalization. (The patient has had symptoms suggesting ischemia, but we would need confirmation of hospitalization and symptom duration during that time.)\n- Pain assessment of 3 out of 10 on Visual Analog Scale (VAS) 1 or dynamic ECG findings (ST segment deviation \u22650.05 mV or T wave inversion \u2265 0.3 mV). (The patient has chest pain and nonspecific EKG changes, but specific measurements of ST deviation or T wave inversion are not provided, nor is a pain assessment on the VAS.)\n- Willing and able to provide written informed consent according to the regulations of the Ministry of Health and the Helsinki committee instructions. (There is no information on the patient's willingness or ability to consent.)\n\nGiven the current information, the patient potentially fits the age and symptom criteria for the clinical trial, but additional information would be necessary to confirm her eligibility, especially regarding the diagnosis of ACS, the severity and duration of her symptoms during hospitalization, and her consent to participate.\n\nTherefore, the assessment of trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "26": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with symptoms of episodic chest pain, hypertension, and obesity. There is no mention of her having pulmonary hypertension, let alone chronic thromboembolic pulmonary hypertension (CTEPH), which is the condition specified in the inclusion criteria of the clinical trial.\n\nThe clinical trial is specifically looking for patients with a diagnosis of CTEPH to participate in a study regarding gene mutations in secondary pulmonary hypertension. Since the patient does not have a documented diagnosis of CTEPH, she does not meet the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "27": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- Non-specific EKG changes\n\nClinical trial:\n- Title: Evaluating the Link Between Neighborhood Environments and Obesity Among African American Women\n- Inclusion criteria:\n  - Participating in the BWHS study\n  - Residing in New York, Los Angeles, or Chicago\n\nThe patient in the note is an African-American woman with obesity, which aligns with the population of interest for the clinical trial. However, the inclusion criteria specifically state that participants must be part of the Black Women's Health Study (BWHS) and must reside in New York, Los Angeles, or Chicago. The patient note does not mention if the patient is a part of the BWHS study, nor does it specify her residence.\n\nGiven the information available, we cannot confirm the patient's participation in the BWHS study or her residency in one of the specified cities. Therefore, we would not be able to refer her for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "28": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain that began two days earlier. The pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea but is not increased on inspiration. The patient has a history of hypertension and obesity, and the EKG shows nonspecific changes.\n\nThe clinical trial is seeking patients with an acute episode of chest pain of less than 7 days' duration as the primary reason for admission to a chest pain clinic, who are suspected of acute coronary infarction but with a negative diagnosis confirmed by normal coronary enzymes and normal ECG, and with pain arising from the thorax and/or neck. Additionally, patients must be able to read and understand Danish.\n\nGiven that the patient note does not mention the status of coronary enzymes, which is a key factor in determining the eligibility for the clinical trial, we cannot be certain if the patient fits the criteria of having a negative diagnosis confirmed by normal coronary enzymes. Moreover, the ability to read and understand Danish is a requirement, and there is no information about the patient's language abilities.\n\nWithout confirmation of normal coronary enzymes and the patient's ability to read and understand Danish, we cannot determine with high certainty if the patient is eligible for the trial. Therefore, based on the information available, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "29": {
        "output": "Based on the patient note provided, the patient is a 58-year-old African-American woman presenting with chest pain, hypertension, and obesity. There is no mention of Prader-Willi syndrome (PWS) or Early-onset Morbid Obesity (EMO) before the age of 4 years in the patient's note. Additionally, the patient exceeds the age limit of 30 years for the EMO group as specified in the inclusion criteria of the clinical trial.\n\nGiven the patient's age, the absence of a documented medical history of Early-onset Morbid Obesity, and no mention of Prader-Willi syndrome, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "30": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the eligibility of the patient for the trial:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic pressing/burning anterior chest pain\n- Symptoms started while walking, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- More than 10 years old\n- Electrocardiographic diagnosis of SVT\n- SVT not converted by the vagal manoeuvres\n\nComparison:\n- The patient is more than 10 years old, which meets the age criterion.\n- However, the clinical trial specifically requires an electrocardiographic diagnosis of Supraventricular Tachycardia (SVT), and the patient's EKG only shows nonspecific changes, not a diagnosis of SVT.\n- There is no indication from the patient note that SVT was diagnosed or that vagal manoeuvres were attempted or failed to convert an SVT episode.\n\nGiven that the patient does not have a documented diagnosis of SVT, which is a critical inclusion criterion for participation in the trial, she would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "31": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic anterior chest pain, which is not related to primary spontaneous pneumothorax. The clinical trial in question is focused on the prevention of recurrence in patients who have experienced a first episode of primary spontaneous pneumothorax.\n\nBased on the inclusion criteria detailed for the clinical trial, the patient does not meet several key eligibility requirements:\n\n1. Age between 15 and 40 years old \u2013 The patient is 58 years old, which is outside the specified age range for the trial.\n2. First episode of spontaneous pneumothorax \u2013 There is no indication in the patient's note that she has experienced a pneumothorax.\n3. Symptomatic (dyspnea or chest pain) or the rim of air is > 2cm on CXR requiring simple aspiration \u2013 The patient's symptoms are related to chest pain, but there is no indication of pneumothorax or the need for simple aspiration based on chest x-ray findings.\n4. Complete or nearly complete and persistent lung expansion immediately following manual aspiration \u2013 Again, there is no indication of a procedure for pneumothorax that the patient has undergone.\n\nGiven the information provided, this patient does not meet the inclusion criteria for the clinical trial focused on primary spontaneous pneumothorax and minocycline pleurodesis. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "32": {
        "output": "Based on the information provided in the patient note, the patient is a 58-year-old African-American woman who presents with chest pain, hypertension, and obesity. There is no mention in the patient note of her having pulmonary arterial hypertension (PAH) or any indication that she has participated in the NCT00046319 study, which is a prerequisite for enrollment in the AMB-220-E study.\n\nThe inclusion criteria for the clinical trial are as follows:\n\n1. Must have completed Visit 14/Week 24 of the NCT00046319 study.\n2. Women of childbearing potential must have a negative urine pregnancy test at the Screening/Enrollment Visit and agree to use reliable double barrier methods of contraception until study completion and for >=4 weeks following their final study visit.\n3. Must have completed the Down-titration Period of NCT00046319 prior to enrollment in AMB-220-E and will meet the following additional criteria:\n   - Subjects with a diagnosis of HIV must have stable disease status at the time of Screening/Enrollment.\n4. Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening Visit.\n\nSince there is no evidence that the patient meets the specific inclusion criteria for the clinical trial, particularly the requirement of having completed a prior study related to PAH (NCT00046319), she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "33": {
        "output": "Given the patient's description and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nThe patient is a 58-year-old African-American woman presenting with hypertension, as indicated by her known medical condition. The clinical trial's inclusion criteria specify the following:\n\n1. Outpatients aged 65 years or older, and less than 85 years (at the time of informed consent), regardless of sex.\n2. Systolic blood pressure (SBP) \u2265140 mmHg or diastolic blood pressure (DBP) \u226590 mmHg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications.\n3. Systolic blood pressure (SBP) \u2265160 mmHg or diastolic blood pressure (DBP) \u2265100 mmHg in a sitting position on two consecutive measurements at clinic without antihypertensive medication.\n4. Require at least one of the following medical history or risk factors.\n\nThe patient does not meet the age criterion, as she is 58 and the study requires participants to be 65 or older. Furthermore, the patient's blood pressure measurements are not provided, so we cannot confirm whether she meets the hypertension criteria. There is no mention of her having any of the listed medical history or risk factors required by the trial.\n\nBased on the information provided, the patient does not meet the age inclusion criteria and insufficient data is available regarding her blood pressure and risk factors to determine eligibility in those areas. Therefore, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "34": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility for the clinical trial titled \"Treatment Study Comparing Manual Treatment or Advice in Acute, Musculoskeletal Chest Pain.\"\n\nPatient Note Evaluation:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Pain started while walking, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- No increase in pain on inspiration\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Not currently on any medications\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Have chest pain as their primary complaint. (Patient has chest pain as the primary complaint)\n- Have an acute episode of pain of less than 7 days duration before admission. (Patient's pain began two days earlier)\n- Consent to the standardized evaluation program at the chest pain clinic. (Assuming consent can be obtained)\n- Have pain in the thorax and/or neck. (Patient has thorax pain)\n- Be able to read and understand Danish. (No information provided)\n- Be between 18 and 75 years of age. (Patient is 58 years old)\n- Be a resident of the Funen County. (No information provided)\n\nExclusion Criteria for the Clinical Trial:\n- ACS or other obvious reasons for chest pain have been excluded. (No information on whether ACS or other conditions have been excluded)\n- Patients will not be included if they have had PCI or CABG, or if they have a verified clinical condition resulting in chest pain, inflammatory joint disease, insulin-dependent diabetes, fibromyalgia, malignant disease, apoplexy, dementia, unable to cooperate, major osseous anomaly, osteoporosis, pregnancy, or do not want to participate. (None of these exclusion criteria are mentioned in the patient note)\n\nBased on the available information, the patient appears to meet some of the inclusion criteria: primary complaint of chest pain, acute episode of pain of less than 7 days, pain in the thorax, age between 18 and 75 years, and no exclusion criteria are explicitly mentioned. However, we do not have information about the patient's ability to read and understand Danish or whether they are a resident of Funen County. Additionally, we do not know if ACS or other conditions have been excluded as potential causes of her chest pain, which would be necessary to determine before inclusion in the study.\n\nGiven these gaps in information, further investigation would be required to determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "35": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the following reasons:\n\n1. The patient is a 58-year-old African-American woman.\n2. The clinical trial is specifically looking for male participants.\n3. The trial requires a diagnosis of stable angina with support from the patient's history, diagnostic exercise test, or angiographic evidence of CAD.\n\nSince the trial's inclusion criteria explicitly state that participants must be male and have angina, and the patient in the note is a woman who presents with chest pain but without a confirmed diagnosis of angina, she would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "36": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with chest pain, hypertension, and obesity. She has no diagnosis of gastric carcinoma and no mention of previous treatments for such a disease.\n\nThe clinical trial is specifically looking for participants with advanced gastric cancer that is ErbB2 amplified and who have undergone specific prior treatments for gastric carcinoma (including 5-fluoropyrimidine and/or cisplatin). The patient does not meet the key inclusion criteria of having gastric cancer or having received the specified prior treatments. Additionally, the patient does not fit any of the other detailed inclusion or exclusion criteria related to the specific medical condition and treatment history required for this study.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "37": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, we can determine the following:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain. She has known risk factors for cardiovascular disease, including hypertension and obesity. She denies smoking, diabetes, and hypercholesterolemia. The clinical trial is looking for participants with at least one modifiable cardiovascular risk factor.\n\nGiven that the patient has hypertension and obesity, which are listed as modifiable cardiovascular risk factors in the trial's inclusion criteria, she would be eligible for the trial. Her age is not a disqualifying factor, and her presentation with chest pain is relevant to the focus of the trial on cardiovascular risk-related behaviors and health attitudes.\n\nThe patient's physical examination is normal, and there are nonspecific changes on the EKG, which do not exclude her from participating in the trial. Since there is no mention of other exclusion criteria and the patient meets the trial's inclusion criteria, she would be considered a suitable candidate for referral.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "38": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet the specified criteria for the trial. The patient presents with symptoms potentially indicative of a cardiac event, but there is no mention of Hodgkin Lymphoma (HL) in their medical history. Additionally, the trial requires participants to have a biopsy-proven diagnosis of HL and to have participated in specific IRB-approved protocols for the first-line treatment of HL between 1975-2000.\n\nSince the patient note does not include any history of Hodgkin Lymphoma or treatment for it, the patient would not be eligible for this specific clinical trial focused on the quality of life among survivors of Hodgkin Lymphoma.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "39": {
        "output": "The patient in the note is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The patient does not meet the specific inclusion criteria for the clinical trial, which requires that the patient must have been investigated for chest pain or palpitation 6 months ago at the Cardiological Out-patient Clinic, Molde Hospital. Since there is no information indicating that the patient has been previously investigated at the specified clinic, she does not qualify for the trial based on the provided criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "40": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to meet the criteria for the trial:\n\n- The patient in the note is presenting with chest pain, hypertension, and obesity. There is no mention of systemic sclerosis or digital ulcers, which are the focus of the clinical trial.\n- The trial is specifically for patients with digital gangrene or ulcers in the context of severe secondary Raynaud's phenomenon associated with systemic sclerosis. \n- The trial also requires patients to be on stable therapy with vasoactive drugs and unchanged immunosuppressive therapy 3 months before the treatment with sildenafil. The patient note does not provide any information on such treatments.\n- There is no mention of the patient having any effect of prostacyclin treatment, contraindications for prostacyclins, or reasons for excluding this therapy, which are part of the inclusion criteria.\n\nGiven these observations, the patient described in the note does not match the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "41": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of a cardiac event, such as episodic anterior chest pain with radiation to the back, accompanied by nausea, diaphoresis, and mild dyspnea. The patient has a history of hypertension and obesity, but there is no mention of a malignant pleural effusion or any indication that she is undergoing or requires pleurodesis.\n\nThe clinical trial in question is focused on patients who are undergoing pleurodesis for malignant pleural effusion. Inclusion criteria specify that the patient must have a diagnosis of malignant pleural effusion confirmed by histological evidence or typical features seen during thoracoscopy, among other criteria related to health status and previous treatments.\n\nSince the patient does not have a documented diagnosis of malignant pleural effusion and there is no evidence that she is undergoing or requires pleurodesis, she does not meet the disease characteristic criteria for the clinical trial.\n\nTherefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "42": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and situation with the inclusion criteria of the trial. Let's review the patient note and the inclusion criteria:\n\nPatient note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- No current medications\n- Normal physical examination\n- Nonspecific changes on EKG\n\nClinical trial inclusion criteria:\n- Men and women admitted for an IHD event (acute coronary syndrome or revascularization procedure) who are at low or moderate risk\n- Regular Internet access (home, work, or other environment)\n- Over 18 years of age\n- Permission of the attending physician\n- Able to read, write and understand English without difficulty\n- No physical limitations to regular activity\n\nBased on the information provided in the patient note, there is no clear indication that the patient has been admitted for an ischemic heart disease (IHD) event such as acute coronary syndrome or a revascularization procedure. The patient presents with symptoms that could be suggestive of an IHD event, but there is no confirmation of such a diagnosis or admission for such an event in the note provided.\n\nAs the patient's eligibility for the clinical trial hinges on confirmation of an IHD event and the other criteria, more information would be required to make a definitive determination regarding her eligibility. For instance, if further investigation confirmed an IHD event and the patient met all other inclusion criteria, she might be eligible to participate in the trial.\n\nGiven the information at hand, which does not confirm an IHD event, the patient does not currently meet all the inclusion criteria as specified. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "43": {
        "output": "The patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of a cardiovascular event (chest pain, nausea, diaphoresis, and mild dyspnea), but there is no mention of diabetes in her medical history. She is known to have hypertension and obesity, which are risk factors for type 2 diabetes, yet she does not have a current diagnosis of diabetes nor is there any indication that she has been recently diagnosed with diabetes.\n\nThe clinical trial in question is specifically targeting individuals with a new onset of type 2 diabetes and a BMI greater than 25 kg/m^2. Since the patient does not have a diagnosis of type 2 diabetes, she would not meet the inclusion criteria for the trial.\n\nBased on the patient's information and the trial's inclusion criteria, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "44": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain with accompanying symptoms\n- Known to have hypertension and obesity\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Currently takes no medications\n- Normal physical examination\n- EKG shows nonspecific changes\n- There is no mention of breast cancer in the patient's history or current medical issues\n\nClinical Trial:\n- Title: A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx\n- Inclusion Criteria: Patients with metastatic breast cancer\n\nThe patient in the note does not have a diagnosis of metastatic breast cancer, which is a specific requirement for the clinical trial in question. Therefore, she would not be eligible for this trial as she does not meet the primary inclusion criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "45": {
        "output": "Based on the information provided, the patient does not meet the inclusion criteria for the clinical trial:\n\n- The patient does not have a clinical diagnosis of COPD.\n- There is no indication that the patient has a smoking history, let alone a > 15 pack year smoking history.\n\nGiven that the patient does not meet the primary inclusion criteria for the clinical trial, which specifically targets individuals with COPD and a significant smoking history, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "46": {
        "output": "Based on the given patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial.\n\nPatient note summary:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiating to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Takes no medications\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical trial summary:\n- Title: Neuromuscular Balance in Low Back Pain\n- Interventional study to investigate the effectiveness of neuromuscular balance in lumbar pain\n- Inclusion Criteria: Patients with low back pain between 20 and 55 years old, submitted to a physical therapy treatment\n\nThe patient's age (58 years old) is beyond the specified age range for the clinical trial (20 to 55 years old). Therefore, this patient would not meet the age inclusion criteria for this trial. Additionally, the patient does not present with low back pain, which is another key inclusion criterion for participation in the neuromuscular balance study.\n\nGiven these factors, the patient does not meet the inclusion criteria of the clinical trial due to age and the absence of low back pain as a presenting complaint.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "47": {
        "output": "Based on the provided patient note, the 58-year-old African-American woman does not meet the inclusion criteria of the clinical trial. The trial is focusing on African American women at high risk for HIV and requires participants to have current substance abuse, current high-risk sexual behavior, and African American racial identification.\n\nThe patient in question presents with symptoms that suggest a possible cardiac issue rather than being at high risk for HIV. There is no mention of substance abuse or high-risk sexual behavior in her history. Therefore, she would not be eligible for this trial based on the information presented.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "48": {
        "output": "To determine the patient's eligibility for the clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria provided for the trial.\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier\n- Pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No medications currently taken\n- Physical examination normal\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Age between 18 and 80 years\n- Females of childbearing potential must have a negative pregnancy test, not be breastfeeding, and be on a method of contraception\n- Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation\n- Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or ECG changes\n- Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System)\n- Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0\n- All anti-angina regimen discontinued, except short-acting nitroglycerin and one beta-blocker or calcium channel blocker\n- Patient must understand and be willing, able, and likely to comply with all study procedures and restrictions\n- Patient must be able to give voluntary written informed consent\n\nAssessment:\n- The patient is within the age range required for the trial.\n- The patient is a female, and if of childbearing potential, would need to meet the trial's requirements regarding pregnancy testing and contraception, which we don't have information on.\n- The patient presents with chest pain that could be indicative of angina, but there is no documented evidence of chronic stable angina for over 3 months, nor is there confirmation of significant coronary artery disease.\n- The patient's angina classification cannot be determined based on the information provided; more investigation would be needed to determine if it is moderate angina (Class II or III).\n- There is no information on the patient's exercise tolerance or results of an exercise tolerance test (ETT).\n- The patient is not on any anti-angina regimen, so this criterion is not applicable.\n- The patient's ability to understand and comply with the study procedures, as well as to provide informed consent, cannot be assessed from the information provided.\n\nGiven the available information, the patient does not clearly meet several key inclusion criteria, such as documented history of myocardial infarction or significant coronary artery disease, and there is no evidence of chronic stable angina. Therefore, further investigation would be necessary to determine if the patient's recent onset of chest pain qualifies as chronic stable angina and to obtain documentation of coronary artery disease.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "49": {
        "output": "The patient presented is a 58-year-old African-American woman with episodic anterior chest pain, hypertension, and obesity. There is no mention of heart failure or any objective evidence of systolic dysfunction (ejection fraction \u226440%) in the patient note. Additionally, the patient is not currently taking any medications, which means there is no information about her being beta-blocker na\u00efve or having been excluded from beta-blockers within the previous 30 days, as per the inclusion criteria of the clinical trial.\n\nThe clinical trial in question is focusing on patients with Class C heart failure who are beta-blocker na\u00efve and have objective evidence of systolic dysfunction. Since the patient's note does not provide information that the patient fits these criteria, she does not meet the specific inclusion criteria outlined for the trial.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "50": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the clinical trial focused on the prevalence and outcome of brachial artery endothelial function in morbidly obese patients undergoing bariatric surgery.\n\nThe patient is described as a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, known hypertension, and obesity. The clinical trial is looking for morbidly obese patients who fulfill the NIH criteria for surgical intervention. The NIH criteria for bariatric surgery typically include a body mass index (BMI) of 40 or higher (morbid obesity), or a BMI of 35 or higher with obesity-related conditions. The note does not provide specific information about the patient's BMI or whether she fulfills the NIH criteria for surgical intervention.\n\nSince the patient note does not provide enough information about the patient's BMI to determine if she is morbidly obese according to the NIH criteria, we cannot immediately conclude that she is eligible for the trial. Further investigation into her BMI and eligibility for bariatric surgery would be necessary before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "51": {
        "output": "The patient described is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, and she is known to have hypertension and obesity. There is no mention of her having diabetes or impaired glucose tolerance. Additionally, there is no indication that she has undergone bariatric surgery, which is part of the study's second part. The patient's eligibility for the clinical trial titled \"The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study\" is based on the inclusion criteria provided:\n\n1. Lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance\n2. Obese (BMI >30 kg/m2) subjects also with normal glucose tolerance.\n3. Obese with impaired glucose tolerance\n4. Obese with diet-controlled diabetes mellitus\n5. Morbid obesity, type 2 diabetes, and post-bariatric surgery (study part 2)\n\nSince the patient is described as obese, she could potentially fit into categories 2, 3, or 4, but it is not clear from the patient note whether she has normal glucose tolerance, impaired glucose tolerance, or diet-controlled diabetes mellitus as there is no information regarding her glucose tolerance status.\n\nGiven the information available, the patient could potentially be eligible based on her obesity, but further investigation is required to determine her glucose tolerance status. Therefore, it is appropriate to consider referring the patient to the clinical trial upon further investigation to establish her glucose tolerance status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "52": {
        "output": "Based on the provided patient note and the clinical trial information, the patient presents with episodic chest pain, but there is no documentation of her having heart failure, which is the condition being studied in the clinical trial. The clinical trial is specifically interested in randomized controlled trials of beta-blocker therapy in patients with documented heart failure.\n\nSince the patient does not have a documented history of heart failure, she would not meet the inclusion criteria for this clinical trial. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "53": {
        "output": "",
        "label": 0
    },
    "54": {
        "output": "",
        "label": 0
    },
    "55": {
        "output": "After reviewing the patient note and the clinical trial inclusion criteria, we can determine the patient's eligibility as follows:\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea\n- Hypertension and obesity\n- Takes no medications\n- Normal physical examination\n- Nonspecific changes in EKG\n\nClinical Trial Inclusion Criteria:\n- Between the age of 19 and 55 years old\n- Able to walk without assistance and/or assistive devices at least 4.7 meters\n- Have adequate hearing acuity to detect verbal instructions\n- Have adequate visual acuity to walk safely in usual ambient lighting without holding onto objects\n- Be able to speak and comprehend English\n- Have sufficient cognitive ability to follow instructions, and to provide informed consent, as defined by a Mini Mental Status Examination score of greater than 23 out of 30, performed by the research coordinator\n\nThe patient does not meet the age requirement of the clinical trial (the patient is 58 years old, while the trial requires participants to be between 19 and 55 years old). Therefore, this patient would not be eligible for this clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "56": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it does not appear that the patient would be eligible for this trial. The patient presents with episodic chest pain, hypertension, and obesity, but there is no indication of a diagnosis of malignant pleural effusion or any cancer. The inclusion criteria for the trial specifically require a clinically confident diagnosis of malignant pleural effusion requiring pleurodesis, which is not mentioned in the patient's presentation. Therefore, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "57": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient in question does not appear to meet the specific criteria required for participation in the trial. The inclusion criteria for the trial specify that participants must have Type 2 diabetes or Pre-Diabetes. The patient note does not mention that the patient has Type 2 diabetes or Pre-Diabetes; rather, it mentions hypertension and obesity without any reference to diabetes.\n\nGiven that the patient does not meet the key inclusion criteria for the clinical trial, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "58": {
        "output": "To assess the eligibility of the 58-year-old African-American woman for the clinical trial titled \"Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment,\" let's review the inclusion criteria against the patient's note:\n\n1. Patients over 18 years of age - The patient is 58 years old, which meets this criterion.\n2. Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg) - The patient has a known history of hypertension, but specific blood pressure values are not provided. We would need this information to determine eligibility definitively.\n3. Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation) - The patient note does not mention any previous treatment with ACE inhibitors, nor does it indicate any intolerance to such medications. This information would be needed to assess eligibility.\n\nBased on the information provided in the patient's note, there is not enough evidence to determine if the patient meets the second and third inclusion criteria for the clinical trial. Therefore, further investigation would be necessary to determine her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "59": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment, let's assess the patient's eligibility:\n\nThe inclusion criteria for the clinical trial are:\n1. Healthy\n2. 20-49 years old\n3. Pregnant with a singleton\n4. Low back pain began during pregnancy and has lasted more than one week\n5. Low back pain is reproducible with palpation\n\nThe patient note describes a 58-year-old African-American woman who presents with episodic pressing/burning anterior chest pain. There is no indication that the patient is pregnant, which is a key inclusion criterion for the trial. Furthermore, the patient's age is outside the specified range of 20-49 years old. Additionally, the patient's symptoms do not match the requirement of low back pain that began during pregnancy.\n\nGiven these mismatches with the inclusion criteria, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "60": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No mention of sickle cell disease (SCD) or hemoglobinopathy\n- No mention of sPLA2 levels\n- No mention of fever or chest radiograph findings\n\nClinical Trial Inclusion Criteria:\n- Hemoglobin diagnosis of SS, SC, or S-\u03b2 thalassemia\n- No clinically apparent ACS\n- No prior participation in the study\n- For the Trial Cohort: sPLA2 level greater than 100 ng/mL, fever greater than 38.0\u00ba C, chest radiograph negative for new pulmonary infiltrate, hemoglobin levels equal or less than 10 g/dL, informed consent\n\nThe patient in the note does not mention a diagnosis of sickle cell disease, which is a key inclusion criterion for the study. Additionally, there is no information provided about sPLA2 levels, fever, or chest radiograph findings that are required for the trial cohort. Since the patient's presentation and medical history do not align with the specific requirements of the clinical trial, she does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "61": {
        "output": "The patient note describes a 58-year-old African-American woman who presents to the ER with symptoms that could be consistent with acute coronary syndromes, such as episodic pressing/burning anterior chest pain radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea. These symptoms align with the inclusion criteria for the clinical trial, which is investigating the biomarker copeptin in patients with Acute Myocardial Infarction (AMI). She meets the age criteria and presents with symptoms consistent with acute coronary syndromes. However, it is not explicitly stated when the symptoms began, except that the pain started two days earlier, and the latest episode ended half an hour prior to her arrival.\n\nThe inclusion criteria require that the subject must present to the Emergency Department within 6 hours of the onset of the most recent symptoms. Since it is not clear whether her most recent episode of pain, which ended half an hour prior to her arrival, started less than 6 hours before presenting to the ER, this information would need to be verified.\n\nAdditionally, the patient must agree to abide by all aspects of the protocol, including all telephone follow-up, which is not addressed in the patient note and would require further confirmation from the patient.\n\nGiven the information, the patient appears to meet most inclusion criteria but requires confirmation regarding the timing of the most recent symptoms and her agreement to follow the protocol.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "62": {
        "output": "The patient in the note is a 58-year-old African-American woman presenting with symptoms consistent with possible cardiac issues. The clinical trial in question is looking at the effectiveness of the MEND Programme in treating childhood obesity. The inclusion criteria for the clinical trial specifically require participants to be children aged 7-13 years old who are overweight or obese and are enrolled in the MEND Programme.\n\nBased on the information provided in the patient note, the patient does not meet the age criteria, as she is 58 years old, and the trial targets children between 7-13 years of age. Additionally, there is no mention of the patient being enrolled in the MEND Programme or her being a child with obesity.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "63": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we can analyze the patient's eligibility for the trial as follows:\n\nThe patient:\n- Is a 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier.\n- Has pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- Has known hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Takes no medications.\n- Has a physical examination that is normal.\n- EKG shows nonspecific changes.\n\nThe clinical trial's inclusion criteria:\n- Patients with intermediate (>20%, <90%) risk of ischemic heart disease (IHD) based on age, gender, symptoms, and exercise stress test results.\n\nThe patient's presentation with episodic chest pain that began during exertion and is accompanied by other symptoms suggestive of cardiac ischemia (nausea, diaphoresis, mild dyspnea) could indicate an intermediate risk of ischemic heart disease. However, we do not have information about the results of an exercise stress test, which is a necessary component of the risk assessment according to the clinical trial's inclusion criteria.\n\nGiven that the patient presents with symptoms that could suggest IHD and the risk assessment is based on several factors, including symptoms, without additional information particularly the results of an exercise stress test, it is not possible to definitively determine the patient's risk level for IHD.\n\nTherefore, the patient might be a candidate for further investigation to establish her risk level of IHD, which would include an exercise stress test and potentially other assessments as per the trial's inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "64": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain.\n- The pain started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- She currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria Analysis:\n- Patients must have a medical history and physical and neurological examinations that support a clinical diagnosis of acute low back pain that is felt down to the lower leg below the knee, with the onset no longer than 30 days before Visit 1.\n- Patients must report qualifying pain intensity scores at Visit 1.\n- Patients must be appropriate candidates for treatment with oral opioid pain medication in the investigator's clinical judgment.\n- Patients must be able to verbalize pain characteristics and complete all protocol-required measurements/assessments without assistance.\n- Patients must be medically stable on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening.\n\nComparison:\n- The patient's symptoms are primarily related to chest pain, not low back pain. There is no mention of low back pain or pain that is felt down to the lower leg below the knee.\n- The onset of the patient's symptoms and whether they are associated with low back pain are not specified.\n- The patient's overall presentation does not seem to match the clinical diagnosis of acute low back pain required by the trial.\n\nGiven the information provided in the patient note, the patient's condition does not seem to meet the specific inclusion criteria related to the diagnosis of acute low back pain, which is the focus of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "65": {
        "output": "",
        "label": 0
    },
    "66": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we need to assess if the patient is eligible for the trial which is focused on patients with hypertension and obstructive sleep apnea (OSA) who are not well controlled on continuous positive airway pressure (CPAP) therapy.\n\nFrom the patient note:\n- The patient is 58 years old, which meets the age criterion of being \u2265 18 years.\n- The patient has hypertension, one of the conditions of interest for the trial.\n- There is no mention of the patient having obstructive sleep apnea or being treated with CPAP.\n- There is no information provided regarding the patient's blood pressure measurements to confirm if the hypertension is uncontrolled by the standards of the trial (systolic >130 mmHg or diastolic >80 mmHg).\n\nThe patient does not clearly meet two critical inclusion criteria:\n1. Diagnosis of OSA and treatment with CPAP.\n2. Uncontrolled hypertension despite CPAP therapy.\n\nWithout evidence of OSA or CPAP use, and without blood pressure readings, it's impossible to definitively conclude the patient's eligibility for the trial. Therefore, further investigation would be needed to determine if the patient has OSA, if they have been treated with CPAP, and if their hypertension is uncontrolled despite CPAP therapy.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "67": {
        "output": "Based on the provided patient note, the 58-year-old African-American woman presents with episodic chest pain, hypertension, and obesity. However, there is no mention of type-II-diabetes mellitus in her medical history or current health status.\n\nThe inclusion criteria for the clinical trial titled \"Resistant Hypertension in Patients With Type-II-Diabetes Mellitus\" are:\n\n- Age 18-80 years\n- Informed consent\n- Hypertension\n- Type-II-diabetes mellitus\n\nThe patient does meet the age criteria and has hypertension but does not meet the criteria for type-II-diabetes mellitus, which is a requirement for this specific clinical trial. Therefore, she would not be a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "68": {
        "output": "Considering the patient note and the inclusion criteria for the clinical trial on Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- No medication currently taken.\n- No known history of smoking, diabetes, hypercholesterolemia, or family history of heart disease.\n- EKG shows nonspecific changes.\n\nClinical trial inclusion criteria:\n- Over 18 years old.\n- CCT > 60 ml/min (not provided in the patient note).\n- No IHD (Ischemic heart disease) (patient's condition suggests a need for differential diagnosis but IHD is not confirmed).\n- No hyper/hypoparathyroidism (not provided in the patient note).\n- No active malignancy (not provided in the patient note).\n- Not taking calcium, phosphate (patient is not currently taking any medications).\n\nBased on the information available from the patient note, the patient meets some of the inclusion criteria (age over 18, not currently taking exclusory medications). However, there is missing information about the patient's creatinine clearance (CCT), history of hyper/hypoparathyroidism, active malignancy, and whether she has ischemic heart disease (IHD), which would require further investigation before a referral could be made. The symptoms described in the patient note might be suggestive of a cardiac issue, which could potentially be IHD. This would need to be clarified as part of the further investigation.\n\nGiven the need for additional information to conclusively determine eligibility, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "69": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Pain not increased on inspiration\n- Known to have hypertension and obesity\n- No medications currently taken\n- Normal physical examination\n- EKG shows nonspecific changes\n- No history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n\nClinical Trial Inclusion Criteria:\n- Aged \u226518 years at the time of randomization\n- Presumed diagnosis of STE-ACS with onset of symptoms of >20 minutes and <12 hours with specific EKG criteria\n- Provided written informed consent before initiation of any study-related procedures\n- Presented either via ambulance or to a center where PCI is not performed\n- Emergent angiography and primary PCI if indicated <2 hours after first medical contact\n\nComparison:\n- The patient is 58 years old, which meets the age criterion.\n- The patient's symptoms could suggest acute coronary syndrome (ACS), but the EKG does not show ST segment elevation, new left bundle branch block, or the specific infero-lateral myocardial infarction pattern described in the trial's inclusion criteria.\n- Since the EKG changes are nonspecific and do not meet the trial's defined criteria for STE-ACS, the patient's condition does not align with the presumed diagnosis required for the trial.\n- There is no mention of the patient presenting via ambulance or to a center where PCI is not performed, nor is there any indication that written informed consent has been provided or that angiography and PCI are planned within the specified timeframe.\n\nGiven the information from the patient note, the patient does not appear to meet the specific diagnostic criteria for STE-ACS as required by the clinical trial. As such, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "70": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial in question. The patient presents with symptoms suggestive of cardiac issues, and there is no mention of allergic conjunctivitis or a positive bilateral conjunctival allergen challenge reaction, which are required for inclusion in the study on the efficacy of AC-150 for the treatment of allergic conjunctivitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "71": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents to the ER with symptoms that suggest she may be experiencing angina: episodic pressing/burning anterior chest pain that began while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. She also has a history of hypertension and obesity.\n\nThe clinical trial in question is looking to compare vascular remodeling between different antianginal medications. It mentions specific inclusion criteria related to the type of angina and the treatment history:\n\n1. Stable angina patients whose coronary lesions are confirmed by angiography or who receive PCI.\n2. Unstable Angina/NSTEMI patients who completed PCI for main lesions.\n3. Patients with either systolic blood pressure > 130 mmHg or diastolic > 80 mmHg, or patients on anti-hypertensive drugs.\n\nThe patient in the note presents with hypertension and is likely to have a systolic blood pressure > 130 mmHg or diastolic > 80 mmHg, although specific blood pressure values are not provided. However, the inclusion criteria also require confirmation of coronary lesions by angiography or a history of PCI, which is not mentioned in the patient's history.\n\nGiven the lack of specific information on confirmed coronary lesions or PCI history, and the fact that the woman is presenting with her first episode of this kind of chest pain, it is not clear if she would meet the specific clinical requirements for the trial. There is a possibility she could be experiencing stable angina, but further investigation is needed to confirm this and whether her condition fits the trial's requirements. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "72": {
        "output": "Given the information provided in the patient note, we know the following:\n\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain.\n- She has a history of hypertension and obesity.\n- She is a non-smoker.\n- Her physical examination is normal, with nonspecific EKG changes.\n\nNow, comparing this to the inclusion criteria of the clinical trial:\n\n- Subjects with BMI over 25.0 kg/m^2\n- Non-smoker\n\nThe patient note confirms that the patient is obese and a non-smoker, which matches the inclusion criteria of the clinical trial. However, there is no specific Body Mass Index (BMI) value provided in the patient note. Since the patient is described as obese, it can be inferred that her BMI is over 30 kg/m^2, which would meet the criterion of a BMI over 25.0 kg/m^2.\n\nBased on the information given, it seems that the patient does meet the inclusion criteria of being overweight/obese and a non-smoker. There are no other exclusion criteria provided that would disqualify the patient from participating in the trial based on the information available in the patient note.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "73": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility step by step.\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain that started while walking, with radiation to the back, nausea, diaphoresis, and mild dyspnea.\n- The patient has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Currently takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Diagnosis of unstable angina and non-Q wave myocardial infarction\n- Age 18-75 years\n- Diameter stenosis of coronary artery <70% diameter stenosis by visual estimation\n- Blood pressure >110/70 mmHg\n- Heart rate 60-100 bpm\n- No cardiac arrhythmias\n\nEligibility Assessment:\n- Age: The patient is 58 years old, which falls into the required age range of 18-75 years.\n- Diagnosis: The patient presents with chest pain that could possibly be due to unstable angina; however, there is no confirmed diagnosis of unstable angina or non-Q wave myocardial infarction provided in the note.\n- Diameter stenosis: There is no information about the patient having a confirmed diameter stenosis of the coronary artery.\n- Blood pressure: The patient's blood pressure is not mentioned in the note.\n- Heart rate: The patient's heart rate is not mentioned in the note.\n- Cardiac arrhythmias: The patient's EKG shows nonspecific changes, but there is no mention of cardiac arrhythmias.\n\nGiven the provided information, we cannot confirm that the patient has a diagnosis of unstable angina or non-Q wave myocardial infarction, nor do we have data on coronary artery stenosis, blood pressure, or heart rate. Due to the lack of specific diagnostic information and other required clinical parameters, the patient does not clearly meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "74": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, hypertension, and obesity. She does not have a history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease and takes no medications.\n\nThe clinical trial is assessing the use of E-Z Clean ACE electrosurgical electrodes in certain surgical procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lift, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.\n\nUpon reviewing the inclusion criteria for the clinical trial, the patient does not meet the criteria for several reasons:\n1. There is no indication that the patient is undergoing any of the listed surgeries (abdominoplasty, bilateral breast reduction, etc.).\n2. The patient's current medical condition (chest pain, hypertension, obesity) is not related to the target of the clinical trial, which is focused on surgical procedures.\n3. The patient's age fits within the specified range (>18 years of age or < 60 years old), which is the only matching criterion.\n\nSince the patient does not meet the necessary clinical trial criteria aside from age, it would not be appropriate to refer her for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "75": {
        "output": "Upon reviewing the provided patient note and the inclusion criteria of the clinical trial, here is the assessment:\n\nPatient note summary:\n- 58-year-old African-American woman with episodic anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- No current medications.\n- Physical examination normal.\n- EKG shows nonspecific changes.\n\nClinical trial inclusion criteria:\n- Ischemic heart disease patient.\n- Given loading or maintenance dose of clopidogrel and in need of it for 1 or more months.\n- In need of additional drug for optimal blood pressure control (aim blood pressure <130/90) or angina control.\n\nThe patient presents with symptoms suggestive of ischemic heart disease (angina-like chest pain) and is known to have hypertension, which might require additional medication for optimal blood pressure control. However, there is no clear indication that she has been diagnosed with ischemic heart disease or that she is currently taking clopidogrel, which are both required for participation in the clinical trial.\n\nTherefore, before referring this patient to the clinical trial, further investigation is required to confirm a diagnosis of ischemic heart disease and to determine whether she is a candidate for clopidogrel therapy. If these conditions are met, she may also require additional medication for blood pressure control, which aligns with the trial's requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "76": {
        "output": "The patient in question is a 58-year-old African-American woman presenting with episodic anterior chest pain, known to have hypertension, and is not currently taking any medications. The clinical trial in question is investigating the tolerability of telmisartan treatment in patients who had to stop previous ACE-I treatment due to cough.\n\nLet's assess this patient's eligibility for the trial based on the inclusion criteria:\n\n- Hypertension: The patient has hypertension.\n- Age > 18: The patient is 58 years old.\n- ACE-I related cough: There is no mention in the patient note of her having a cough related to ACE-I treatment. In fact, the patient currently takes no medications, which implies she has not been on ACE-I treatment, or at least not recently.\n\nBased on the information provided, this patient does not meet all the inclusion criteria specifically because there is no evidence of an ACE-I related cough or previous treatment with an ACE-I.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "77": {
        "output": "The patient is a 58-year-old African-American woman presenting with chest pain, known hypertension, and obesity. She does not have a history of cancer, specifically no mention of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx supraglottix, or any cancer for that matter. The clinical trial in question is specifically looking for patients with histologically confirmed squamous cell carcinoma in specific regions of the head and neck, with locally advanced disease.\n\nThe patient's presentation does not meet the inclusion criteria for the clinical trial, which are clearly defined and centered around a specific cancer diagnosis and stage. As such, this patient would not be eligible for the clinical trial focused on the treatment of locally advanced head and neck cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "78": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note summary:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea but no increase in pain on inspiration.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- She is not on any medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n- There is no mention of the patient having acute renal failure (ARF) or requiring renal replacement therapy.\n\nClinical trial summary:\n- The study is comparing continuous versus intermittent hemodialysis in ICU patients.\n- The inclusion criteria are all ICU patients requiring renal replacement therapy.\n\nAssessment of eligibility:\nThe patient does not meet the inclusion criteria for the clinical trial, as there is no indication that she has acute renal failure or is in need of renal replacement therapy. As such, she is not a candidate for a trial that is focused on patients with ARF who are in the ICU requiring renal replacement therapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "79": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Treatment of Coronary Heart Disease With Amiloride,\" let's assess the patient's eligibility:\n\nPatient's characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Male or female; age 35-75 years having angina (Canada Cardiovascular Society Class II-IV)\n- Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure \u2265140 mm Hg, or diastolic blood pressure \u226590 mmHg\n- ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study criteria, with typical LV strain pattern, or isoelectric, inverted or biphasic T waves)\n- ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves)\n- Serum potassium < 5.0 mmol/L prior to randomization\n- Negative pregnancy test in child-bearing potential women\n- Willing to comply with scheduled visits\n- Informed consent form signed by the subject\n\nFrom the information provided:\n- The patient is within the age range specified (35-75 years).\n- The patient is known to have hypertension, which could meet the hypertension requirement if documented blood pressure readings are within the specified range or if she starts taking anti-hypertensive medication.\n- The patient has chest pain, which might be angina, but this is not confirmed as being of the Canada Cardiovascular Society Class II-IV. Further investigation would be needed to determine the classification of her angina.\n- The EKG shows nonspecific changes, which does not clearly meet the criteria for ST-T changes of LVH or ischemia. More detailed ECG analysis or additional tests may be required to clarify this.\n- Serum potassium levels are not reported, so this would need to be measured.\n- Assuming she is not pregnant and willing to give informed consent, the last two criteria could be met.\n\nDue to the lack of specific information regarding the classification of the patient's chest pain, the detailed blood pressure measurements, the exact nature of the EKG changes, and the serum potassium level, I would not be able to refer this patient for the clinical trial without further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "80": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No mention of chronic low back pain or use of pain medication for such pain\n- No information about waist circumference\n- No mention of episodes of low back pain or ability to participate in exercise\n- No information about cardiovascular responses during a screening graded maximal walk test\n\nClinical Trial Inclusion Criteria:\n- Chronic low back pain for >6 months\n- >3 pain episodes per week\n- Waist circumferences \u226588 cm for women\n- Willing and able to participate in regular exercise for 14 weeks\n- Using pain medications to control low back pain\n- Free of abnormal cardiovascular responses during a screening graded maximal walk test\n\nComparison:\n- The patient does not mention having chronic low back pain, which is a primary requirement for the clinical trial.\n- There is no information on the frequency of pain episodes or use of pain medication for back pain, as the patient's presenting symptoms are related to chest pain.\n- The patient's waist circumference is not provided.\n- We do not have information on the patient's willingness or ability to participate in an exercise program or the results of a cardiovascular screening test.\n\nConclusion:\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which specifically targets obese older adults with chronic low back pain. Since the patient's presenting problem is unrelated to the focus of the study, she would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "81": {
        "output": "Assessing the eligibility of the 58-year-old African-American woman for the clinical trial titled \"Expressive Writing for Heart Healing\" based on the inclusion criteria provided:\n\nInclusion Criteria for the Trial:\n1. Obesity\n2. Ischemic Heart Disease (IHD)\n3. Signed informed consent\n\nPatient Information:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- EKG shows nonspecific changes\n\nThe patient fulfills the criterion for obesity. However, there is currently no specific diagnosis of Ischemic Heart Disease (IHD) mentioned in the patient's note. The symptoms described could be suggestive of IHD, and further investigation such as cardiac enzyme tests, further EKGs, or imaging might be warranted to confirm a diagnosis of IHD.\n\nGiven the information provided, the patient meets the criterion of obesity but has not been confirmed to have Ischemic Heart Disease. Therefore, she would not be immediately eligible for the trial based on the criteria provided. Further investigation into the cause of her chest pain is needed to determine if it is due to IHD.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "82": {
        "output": "",
        "label": 0
    },
    "83": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study,\" we must compare the patient's characteristics and conditions to the inclusion criteria of the study.\n\nThe inclusion criteria specify:\n\n1. Age 18 to 80, male or female.\n2. Patients must fulfill the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin for the previous 3 months (with symptom onset at least 6 months before diagnosis), including all of the following:\n   - Midline chest pain or discomfort that is not of burning quality.\n   - Absence of evidence that gastroesophageal reflux is the cause of the symptom.\n   - Absence of histopathology-based esophageal motility disorders.\n3. Persistent symptoms despite a trial of antidepressant therapy, as defined by either:\n   - Chest pain despite at least a continuous 4-week trial of at least one antidepressant within the last 6 months; or\n   - Intolerance of at least one antidepressant within the last 6 months.\n4. Negative cardiac evaluation (negative cardiac stress test or negative coronary angiogram).\n5. Negative gastrointestinal evaluation for the cause of the pain, defined by the absence of Los Angeles grade C or D erosive esophagitis on endoscopy, persistent chest pain on PPI therapy, and no association of chest pain with reflux episodes on an ambulatory pH or pH-impedance study, defined as a symptom index <50% or symptom association probability <95% for chest pain.\n\nThe patient note presents a 58-year-old African-American woman with episodic pressing/burning anterior chest pain that began two days earlier. She has a history of hypertension and obesity but no history of heart disease or gastroesophageal reflux disease (GERD). She has not been on any medications, including antidepressants.\n\nFrom the information provided, the patient:\n\n- Meets the age criterion (1).\n- Does not meet the Rome III criteria for Functional Chest Pain of Presumed Esophageal Origin (2) as the patient's chest pain is of burning quality.\n- Does not have a documented trial of antidepressant therapy for chest pain, nor is there mention of intolerance to such therapy (3).\n- The patient's cardiac evaluation has nonspecific changes, but it's unclear if a full cardiac workup including stress tests or coronary angiograms has been performed (4).\n- There is no information on a gastrointestinal evaluation for the cause of the pain, including endoscopy or pH-impedance study (5).\n\nGiven the information available, the patient does not clearly meet several of the inclusion criteria, particularly those related to the specific type of chest pain and the required trials of antidepressant therapy. Additionally, we lack information on formal cardiac and gastrointestinal evaluations. Based on the information provided, the patient would not be eligible for the trial as the chest pain does not fit the characteristics defined by the inclusion criteria, and there is no documented trial of antidepressant therapy or completion of the required evaluations.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "84": {
        "output": "After reviewing the patient's details and the clinical trial's inclusion criteria, here's the assessment:\n\nPatient Details:\n- A 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back\n- Accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Currently takes no medications\n- Physical examination is normal\n- The EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Major\n- Men\n- Obese BMI>30\n- No aspirin treatment before inclusion\n- Coronary exploration: coronary angiography or tomography coronary angiography\n- Chest pain like stable angina\n\nAssessment:\nThe patient meets some of the inclusion criteria such as being obese. However, the major inclusion criteria specify \"Men,\" which implies that the study is looking specifically for male participants. Given that the patient is a woman, she does not meet this criterion. Additionally, there's no information provided about whether she has undergone coronary exploration (coronary angiography or tomography coronary angiography), which is another inclusion criterion.\n\nTherefore, despite the patient having some of the conditions of interest (obesity and chest pain like stable angina), she does not meet the gender requirement, which is a major inclusion criteria for the trial. Hence, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "85": {
        "output": "The patient is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, known hypertension and obesity, and no medications. The clinical trial is looking to study the contribution of osteopathy on the reduction of pain in adult patients with cystic fibrosis.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Diagnosis of cystic fibrosis (positive sweat test and/or presence of 2 disease-causing mutations in the CFTR gene)\n- Age > 18 years\n- Patient with chronic chest, neck, or back pain\n- Written Informed Consent\n- With health insurance\n\nBased on the information provided in the patient note, there is no mention of the patient having cystic fibrosis or a diagnosis that fits the inclusion criteria for the clinical trial. Therefore, this patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "86": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient, a 58-year-old African-American woman presenting with chest pain, does not meet the inclusion criteria which specifically require a positive bilateral conjunctival allergen challenge (CAC) reaction, indicating allergic conjunctivitis. Since the patient's symptoms and medical history do not suggest allergic conjunctivitis, and there is no mention of a positive CAC reaction, she would not be eligible for this clinical trial focused on the efficacy of AC-170 for treating allergic conjunctivitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "87": {
        "output": "",
        "label": 0
    },
    "88": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient does not appear to meet the necessary criteria for this specific clinical trial. The trial is targeting patients with asthma or COPD, and there is no mention of either condition in the patient's history. Instead, the patient presents with symptoms that could be indicative of a cardiac issue, such as chest pain, which is not relevant to the criteria for this trial.\n\nThe inclusion criteria for the trial are:\n1. A documented diagnosis of asthma or COPD in accordance with guidelines.\n2. A stable condition, defined as a disease without exacerbation for at least 1 month prior to study enrolment.\n3. A mean heart rate (HR) in Holter ECG recording of \u2265 60 bpm.\n\nThe patient note does not mention asthma or COPD, nor is there any information about a heart rate measurement or the stability of any chronic obstructive airway disease.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "89": {
        "output": "",
        "label": 1
    },
    "90": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion and exclusion criteria, the patient appears to have symptoms that could suggest acute coronary syndrome (ACS), such as episodic pressing/burning anterior chest pain that started during physical activity, with accompanying nausea, diaphoresis, and mild dyspnea. The patient's age (58 years old) and her racial background (African-American) are also consistent with the inclusive nature of the trial, which does not specify any racial or ethnic restrictions.\n\nThe inclusion criteria for the trial are as follows:\n- Acute myocardial infarction, acute coronary syndrome, unstable angina\n- Men and women\n- All races and ethnicities\n\nThe exclusion criteria for the trial are as follows:\n- Age < 21 years\n\nThe patient does not fall into the exclusion criteria, as she is 58 years old. Given that the patient's symptoms could be consistent with ACS and the trial is looking for individuals with ACS care-seeking behavior, it would be appropriate to consider referring this patient for further evaluation to confirm the diagnosis and determine her eligibility for the clinical trial. It is important to note that a definitive diagnosis of ACS is not confirmed in the patient note, but the symptoms are suggestive enough to warrant further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "91": {
        "output": "Given the patient's description and the clinical trial's inclusion criteria, we can assess the eligibility of the patient for the trial.\n\nPatient's characteristics:\n- Age: 58 years old\n- Gender: Female\n- Known health conditions: Hypertension, obesity\n- No medications currently being taken\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n\nClinical trial's inclusion criteria:\n- Age 18 to 50 years\n- Understanding and willingness to sign informed consent\n- Ability to participate in all study aspects and comply with study requirements\n- BMI of 40 - 45 or 30 to 39.9 with one or more co-morbid diseases (hypertension, dyslipidemia, obstructive sleep apnea, diabetes mellitus)\n- Fully ambulatory without chronic reliance on walking aids\n- Sufficient and stable medical health\n- Has a primary care physician\n- Has failed standard obesity therapy\n- Agrees to refrain from certain surgeries affecting body weight during the trial\n\nBased on the above information, the patient does not meet the age criterion for the clinical trial, which specifies that participants must be between 18 and 50 years old. The patient is 58 years old, which is outside the specified age range.\n\nIn this case, no further investigation is needed as the age criterion is a hard stop, and the patient does not qualify for the trial based on this critical inclusion criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "92": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman has a history of hypertension, which is one of the inclusion criteria for the clinical trial. However, there is no mention of her being treated with angiotensin converting enzyme (ACE) inhibitors, which is another requirement for eligibility in the trial.\n\nThe clinical trial is focused on patients who are already being treated with ACE inhibitors and aims to study the effects of switching to Angiotensin II Receptor Type I (AT1) blockers. Since the patient is not currently taking any medications, including ACE inhibitors, she does not meet this specific inclusion criterion.\n\nTherefore, the patient would not be eligible for this clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "93": {
        "output": "In reviewing the patient's information and comparing it to the inclusion criteria of the clinical trial, we can determine the patient's eligibility:\n\nPatient's Characteristics:\n- A 58-year-old African-American woman\n- Presents with chest pain, hypertension, and obesity\n- No history of cancer mentioned\n- No medications currently taken\n\nClinical Trial Inclusion Criteria:\n- Patient age 18 years or older who self-identifies as African-American (the patient meets this criterion)\n- In early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancer (the patient's note does not mention breast cancer)\n- Receiving health care primarily through an HMO (no information is given regarding this)\n- Exclusion for breast cancer survivors with other major disabling medical conditions (the patient's note does not mention any psychiatric or substance abuse conditions)\n\nBased on the available information, the patient does not meet the key inclusion criterion of being a breast cancer survivor. Therefore, she would not be eligible for this clinical trial focused on breast cancer survivors.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "94": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial on chronic stable angina, let's evaluate the patient's eligibility:\n\n- The patient is a 58-year-old African-American woman. This meets the age requirement of >20 years set by the study.\n- The patient presents with episodic pressing/burning anterior chest pain that started while walking, which could be consistent with effort-induced angina. However, there is no mention of the pain being relieved by rest or nitroglycerin, nor is there any mention of catheterization-documented coronary artery disease or previous myocardial infarction.\n- The patient does not have a history of myocardial infarction within the preceding 3 months, which fits the exclusion criteria.\n- The EKG shows nonspecific changes, not necessarily indicative of ST-segment depression, which is a requirement for inclusion (positive ETT with ST-segment depression \u2265 1 mm).\n- There are no details provided about the patient's menopausal status, contraception use, lactation status, or pregnancy test results, which are necessary to fully assess eligibility. However, these could potentially be determined with further investigation.\n- The patient's physical examination is normal, and there is no mention of any conditions that would interfere with performance of an exercise tolerance test.\n\nGiven the information available, the patient may potentially have effort-induced angina but does not clearly meet all the inclusion criteria for the clinical trial. Specifically, there is a lack of documented coronary artery disease or previous myocardial infarction and no clear evidence of a positive ETT. Therefore, further investigation would be needed to determine her eligibility, such as confirming the nature of her chest pain and conducting an exercise tolerance test to meet the inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "95": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block\", let's evaluate the patient's eligibility:\n\nPatient's characteristics:\n- Age: 58 years old, which falls within the 18 - 75 years age range required by the trial.\n- Symptoms: The patient presents with episodic pressing/burning anterior chest pain, which began two days earlier and could be considered as ischemic discomfort. The pain is at rest and has been present for more than 20 minutes within the previous 24 hours.\n- EKG findings: The EKG shows nonspecific changes; there is no mention of left bundle-branch block (LBBB).\n- Additional factors: The patient has hypertension and obesity, but there is no mention of acute coronary syndrome (ACS) or the need for urgent coronary angiography.\n\nThe inclusion criteria for the trial are as follows:\n- Age 18 - 75 years (the patient meets this criterion).\n- Ischemic discomfort at rest \u226520 minutes within previous 24 hours (the patient meets this criterion based on the description).\n- Any LBBB on the EKG (the patient's EKG does not mention LBBB).\n- Urgent coronary angiography, ideally within 90 minutes after admission (there is no information provided about the need for urgent coronary angiography).\n\nSince the patient's EKG does not show LBBB, one of the key inclusion criteria for the trial is not met. Therefore, despite meeting other criteria, this factor alone would exclude the patient from participating in the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "96": {
        "output": "Based on the provided patient note and the inclusion criteria for the GENOCOR clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, which could be indicative of ischemic heart disease.\n- The pain started while she was walking and radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- No current medications are being taken.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nClinical Trial Inclusion Criteria:\n- Patients affected by a history of ischemic heart disease (IHD) with a non-fatal evolution (angina or AMI as the first manifestation).\n- Age at the onset of the disease (<50 or >60 years).\n- Patients with acute coronary syndrome as the first manifestation of coronary disease, admitted to the coronary unit within 6 hours from the onset of symptoms.\n\nComparative Assessment:\n- The patient's age fits one of the criteria for the trial (>60 years).\n- The patient's symptoms could suggest an acute coronary syndrome, which is relevant to the trial's focus on ischemic heart disease.\n- However, there is no clear indication that the patient has a confirmed diagnosis of IHD or that this is the first manifestation of coronary disease.\n- There is no information on whether the patient was admitted to the coronary unit within 6 hours from the onset of symptoms.\n\nConclusion:\nGiven the potential relevance of the patient's symptoms to ischemic heart disease and the fact that her age aligns with the inclusion criteria, further investigation is needed to confirm a diagnosis of IHD or acute coronary syndrome. If confirmed, she could potentially fit the trial's criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "97": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific requirements for the clinical trial that focuses on sacroiliac joint pain. The patient presents with episodic pressing/burning anterior chest pain, which is unrelated to sacroiliac joint pain. Furthermore, there is no mention of unilateral pain near the sacroiliac joint or positive results on sacroiliac joint provocation tests. The symptoms and history given in the patient note suggest a cardiovascular rather than musculoskeletal issue.\n\nTherefore, this patient would not be a suitable candidate for the clinical trial on the effectiveness of the compression belt for patients with sacroiliac joint pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "98": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, this patient does not appear to be a candidate for the clinical trial in question. The patient presents with symptoms potentially indicative of cardiovascular issues (chest pain, nausea, diaphoresis, and mild dyspnea), while the clinical trial is focused on patients with Primary Open Angle Glaucoma (POAG) and involves assessing intraocular pressure (IOP) fluctuations in relation to a specific surgical intervention (Deep Sclerectomy With Collagen Implant).\n\nThe inclusion criteria for the clinical trial specifically mention:\n- Diagnosis of POAG\n- Documented glaucomatous visual field (VF) damage\n- Progressing glaucomatous damage justifying a surgical procedure (DSCI)\n- Age \u226518 years\n- Specific requirements regarding refractive error of the study eye\n\nThe patient note does not indicate that the patient has POAG or any visual field damage. There is no mention of glaucoma or any related treatments, surgeries, or symptoms. The patient's presentation is unrelated to the diseases and conditions being studied in the trial, and there is no information to suggest that she would meet the specific requirements for refractive error, as her visual status is not discussed.\n\nTherefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "99": {
        "output": "",
        "label": 0
    },
    "100": {
        "output": "Based on the information provided in the patient note, the 58-year-old African-American woman presents with episodic pressing/burning anterior chest pain, hypertension, and obesity. She does not have a history of smoking, diabetes, hypercholesterolemia, or a family history of heart disease. Her EKG shows nonspecific changes, and there is no mention of inappropriate sinus tachycardia or any heart rate measurements.\n\nThe inclusion criteria for the clinical trial on Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia require a diagnosis of inappropriate sinus tachycardia characterized by a heart rate (HR) greater than 100 bpm at rest on an ECG and/or a medium Holter ECG HR greater than 90 bpm, in addition to being over 18 years of age.\n\nGiven that the patient note does not provide any information on the patient's heart rate or a diagnosis of inappropriate sinus tachycardia, we cannot conclude that she meets the inclusion criteria based on the data provided. Therefore, further investigation would be needed to assess her heart rate and determine if she has inappropriate sinus tachycardia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "101": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, the patient does not appear to meet the specific conditions required for the clinical trial in question. The clinical trial is specifically for HER-2 negative metastatic breast cancer patients, and there is no indication in the patient note that the woman has been diagnosed with breast cancer, let alone HER-2 negative metastatic breast cancer. Instead, the patient presents with symptoms that may be indicative of a cardiac issue, not cancer.\n\nThe clinical trial inclusion criteria also require the patient to have had exposure to anthracyclines and taxanes in either a neoadjuvant/adjuvant or metastatic setting and to have documented disease progression after the first or second line of treatment. None of these details is provided in the patient's note, which further supports the idea that the patient does not have a history of breast cancer treatment.\n\nSince the patient does not have a documented diagnosis of metastatic breast cancer, nor any treatment history that aligns with the inclusion criteria of the trial, she is not eligible to participate in this clinical study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "102": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with episodic anterior chest pain, which is non-acute since it started two days earlier. The pain is not increased on inspiration, and she has a history of hypertension and obesity, which are risk factors for coronary artery disease (CAD). However, she denies other risk factors such as diabetes, hypercholesterolemia, or a family history of heart disease. The EKG shows nonspecific changes.\n\nThe clinical trial in question is focused on the use of CT calcium scoring in patients with suspected stable angina. The inclusion criteria specify that the patient should have non-acute chest pain, should have undergone CT calcium scoring, and all relevant risk factor information should be available.\n\nThe patient appears to have non-acute chest pain, which is one of the inclusion criteria. However, it is not indicated in the patient note whether she has undergone CT calcium scoring or if all relevant risk factor information is available. For a patient to be eligible for this trial, it is necessary to have already undergone a CT calcium scoring or to be a candidate for such a test based on the clinical assessment.\n\nGiven the information presented, it's not entirely clear whether the patient has undergone CT calcium scoring, which is a critical part of the trial's inclusion criteria. The patient does have non-acute chest pain, which is aligned with the trial's focus, but the absence of CTCS in her history makes her eligibility uncertain.\n\nTherefore, additional information would be needed to determine her eligibility. If she is a candidate for CT calcium scoring, she could potentially be referred to the trial. However, without confirmation that she meets all the inclusion criteria, it would not be appropriate to refer her at this time.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "103": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, it appears that the patient's condition does not match the focus of the study. The patient presents with symptoms that are suggestive of a cardiac issue rather than a renal condition. The clinical trial is specifically evaluating the protective effects of certain substances against renal injuries induced by extracorporeal shock wave lithotripsy in patients with a solitary renal stone.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Well functioning kidney (serum creatinine <1.2 mg/dl).\n2. Solitary renal stone.\n3. Size: 25 mm or less in the largest diameter.\n\nThe patient note does not mention any renal issues, kidney stones, or the need for extracorporeal shock wave lithotripsy. Instead, it describes a presentation that could be consistent with an acute coronary syndrome or other cardiac conditions, which is unrelated to the focus of the clinical trial.\n\nTherefore, the patient described in the note does not meet the inclusion criteria for the clinical trial, and I would not refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "104": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman who presents with episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The patient's current condition does not indicate that she has been diagnosed with severe hypertension based on the provided note; however, she is known to have hypertension, which is a relevant factor. \n\nThe inclusion criteria for the clinical trial are a diagnosis of severe hypertension, which must be determined through current findings, medical history, and physical examination.\n\nGiven that the patient note indicates a history of hypertension, it is possible that further investigation could reveal whether her hypertension is considered severe, which would make her eligible for the study. Therefore, the patient may be a candidate for the clinical trial upon further investigation to confirm the severity of her hypertension.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "105": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question does not meet the inclusion criteria for the clinical trial. The trial is specifically interested in women undergoing an Elective Lower Segment Caesarean Section (EL LSCS) with a viable, singleton pregnancy of at least 37 weeks gestation. The patient presenting to the ER does not fit this description, as there is no mention of her being pregnant or undergoing an EL LSCS. Additionally, the clinical trial is focused on the haemodynamic and cardiovascular effects of carbetocin and oxytocin during and after this specific type of caesarean section, which is not relevant to the patient's presenting symptoms of chest pain.\n\nTherefore, the patient is not eligible for this clinical trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "106": {
        "output": "",
        "label": 2
    },
    "107": {
        "output": "Based on the patient note provided, the patient is a 58-year-old African-American woman who presents with episodic pressing/burning anterior chest pain that began for the first time in her life, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. She has hypertension and obesity but denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. The patient takes no medications, and the physical examination is normal with nonspecific changes in the EKG.\n\nThe clinical trial in question is focused on the usefulness of chest wall tenderness as a bedside test to exclude acute coronary syndrome in different demographic groups. The inclusion criteria for the trial are:\n\n- All patients over the age of 18 years presenting with the leading symptom of first-time or recurrent acute chest pain in the emergency room.\n- The exclusion criteria include missing informed consent, cardiopulmonary unstable patients, no self-reported chest pain, recent thoracic surgery within 1 year, inflammatory joint disease, fibromyalgia, and cardiogenic shock.\n\nThe patient in question meets the age requirement and presents with acute chest pain, which is the leading symptom required for inclusion in the study. There are no indications in the patient note that she is cardiopulmonary unstable, has not provided informed consent, or has any of the other listed exclusion criteria.\n\nTherefore, based on the information provided in the patient note and the inclusion/exclusion criteria of the clinical trial, the patient seems to be an appropriate candidate for this study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "108": {
        "output": "",
        "label": 0
    },
    "109": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Efficacy of Euminz\u00ae for Tension-Type Headache,\" we will assess the patient's eligibility for the trial.\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain that radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea. The symptoms started while she was walking and are not increased on inspiration. She has a history of hypertension and obesity. The EKG shows nonspecific changes.\n\nThe inclusion criteria for the trial are:\n- Male and female patients from 18 years onwards\n- History of episodic tension-type headache (ETTH) for at least one year, with \u22652 days per month with such a headache\n- Onset of TTH below 65 years of age\n- At least 10 previous headache attacks meeting specific criteria (lasting 30 minutes to 7 days, certain pain characteristics, not accompanied by nausea/vomiting, not accompanied by both photophobia and phonophobia)\n- 3 months retrospective history\n- Willingness and ability to keep a patient's diary and comply with procedures\n- Written informed consent\n\nThe patient's symptoms are more indicative of chest pain rather than tension-type headache. The pain does not meet the criteria for TTH, such as pressing or tightening quality, bilateral location, and not being aggravated by routine physical activity. Additionally, the patient's headache is not described, and there is no indication that she meets the criteria related to the headache characteristics required by the trial.\n\nGiven the information in the patient note, there is no evidence that this patient has a history of ETTH, and her current symptoms do not align with the characteristics of TTH as described in the inclusion criteria.\n\nTherefore, this patient does not meet the inclusion criteria for the \"Efficacy of Euminz\u00ae for Tension-Type Headache\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "110": {
        "output": "To assess this patient's eligibility for the clinical trial titled \"The ACS Ethnicity Platelet Function Study,\" we need to compare the patient's characteristics and condition with the inclusion criteria provided by the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Female (postmenopausal or surgically sterile) and/or male aged 18 years or older.\n2. Presenting with Acute Coronary Syndrome (ACS) fulfilling the following:\n   - Symptoms or new ECG changes (ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG).\n   - Elevation of biomarkers (CK-MB \u22652 ULN or troponin \u2265 ULN).\n3. Self-identified as African-American.\n4. Treatment with 75-100mg ASA daily.\n\nThe patient note provides the following information:\n\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea.\n- Physical examination is normal, but the EKG shows nonspecific changes.\n- There is no information provided about the patient's menopausal status, biomarker levels, or if she is taking ASA (Aspirin).\n\nBased on the information provided:\n\n- The patient is African-American, which meets one of the inclusion criteria.\n- The patient is a woman, and while her menopausal status is not specified, her age suggests she could be postmenopausal, which would meet the gender and age criteria.\n- The patient has chest pain and nonspecific EKG changes, which could suggest ACS, but we do not have information about ST segment elevation/depression or biomarker levels to confirm ACS according to the trial's definition.\n- There is no information on ASA treatment.\n\nGiven the lack of specific information on menopausal status, biomarker levels, and ASA treatment, it is unclear whether the patient fully meets all the inclusion criteria. Therefore, further investigation would be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "111": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman is presenting with episodic pressing/burning anterior chest pain, which started while walking and is accompanied by nausea, diaphoresis, and mild dyspnea. There is no mention of her experiencing chronic low back pain, nor is there any indication that she has a neuropathic pain component in her condition. The clinical trial in question is specifically for patients with severe chronic low back pain with a neuropathic component, and since the patient's symptoms do not match the trial's inclusion criteria, she would not be eligible for this trial.\n\nTo summarize, the patient:\n- Does not have a diagnosis of chronic low back pain.\n- There is no mention of her pain requiring a strong analgesic or having a pain intensity score of 6 points or higher.\n- There is no provided painDETECT diagnostic screening questionnaire score.\n- There are no details suggesting her pain has a neuropathic component.\n\nGiven the mismatch between the patient's condition and the trial's inclusion criteria, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "112": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the specific requirements for the trial. The trial is specifically for patients with Pulmonary Arterial Hypertension (PAH) who have already completed a previous study (AC-055-401). The patient in the note presents with symptoms that may suggest a cardiovascular issue, but there is no mention of a PAH diagnosis or participation in the specified prior study. Additionally, the patient's current medical presentation is not directly related to PAH or the trial's focus.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "113": {
        "output": "Based on the information provided, let's evaluate the patient's eligibility for the clinical trial titled \"Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease\":\n\n1. The patient has hypertension, which could potentially lead to left ventricular hypertrophy (LVH), but there is no indication in the note that she has been diagnosed with LVH or that an echocardiogram has been performed to determine LVMI.\n\n2. The patient has no documented history of diabetes and is not currently taking any medications, which suggests that she may have normal glucose tolerance; however, this has not been confirmed with testing.\n\n3. The patient's presentation of chest pain could be indicative of coronary artery disease (CAD) or a previous myocardial infarction, but this has not been confirmed. The patient has not been documented to have angiographically documented coronary artery disease or a previous history of myocardial infarction.\n\n4. The patient's blood pressure is not provided in the note, so we cannot confirm whether it meets the trial's criteria (office BP < 130/80 mm Hg).\n\n5. There is no evidence in the provided note that the patient has been diagnosed with ischemic heart disease (IHD).\n\nBased on the information available in the patient note, we do not have sufficient evidence to confirm that the patient meets the inclusion criteria for the clinical trial. Specifically, we lack confirmation of normal glucose tolerance, documented IHD, and the presence of LVH. Additionally, there is no information on the patient's blood pressure readings.\n\nTherefore, the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "114": {
        "output": "",
        "label": 0
    },
    "115": {
        "output": "The patient is a 58-year-old African-American woman presenting with symptoms that could be indicative of an acute coronary syndrome (ACS), such as chest pain, nausea, diaphoresis, and mild dyspnea. However, the patient note does not confirm a diagnosis of STEMI or NSTEMI, which is a requirement for the clinical trial in question.\n\nThe clinical trial is focused on patients hospitalized for ACS within 24 hours of symptom onset with a confirmed diagnosis of STEMI or NSTEMI. In this case, the patient is in the ER, and there is no mention of hospitalization or a confirmed diagnosis of STEMI or NSTEMI, only nonspecific EKG changes.\n\nBased on the information provided, we cannot confirm whether this patient would meet the inclusion criteria of being hospitalized and diagnosed with STEMI or NSTEMI. Therefore, the patient may need further evaluation, such as additional cardiac imaging or biomarkers, to confirm the diagnosis.\n\nGiven this, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "116": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the \"Healthy Body Study\" clinical trial, it appears that the patient does not meet the specified criteria for participation in the study. The patient is a 58-year-old African-American woman with hypertension and obesity, presenting with episodic chest pain, but there is no mention of body image concerns, sub-threshold eating disorder symptomatology, or being overweight but not obese as per the defined BMI range. Moreover, the study specifically notes that it is only open to patients at the Mount Sinai Adolescent Health Center, and there is no indication that the patient is connected to this center.\n\nGiven that the patient's characteristics do not match the inclusion criteria and the study's location requirement, it is clear that the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "117": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the trial. The clinical trial is specifically for patients undergoing removal of a chest tube after lung surgery and requires patients to be able to indicate the pain score. The patient in the note presents with episodic chest pain unrelated to lung surgery or chest tube removal; therefore, she does not meet the inclusion criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "118": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial titled \"Diet and Prevention of Ischemic Heart Disease: a Translational Approach.\"\n\nPatient Characteristics:\n- 58-year-old African-American woman \n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Not currently taking medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Healthy men and women aged 30 to 65 years\n- One or more self-assessed ischemic heart disease risk factors at screening: physical inactivity, overweight or obese (BMI \u2265 25/m^2), waist circumference (\u2265 80 cm for women, \u2265 94 cm for men)\n- Motivation and willingness to be randomized to any of the groups and to follow the given protocol\n\nComparison:\n- Age: The patient is 58 years old, which matches the age criterion (30 to 65 years).\n- Risk factors: The patient has hypertension and obesity, which are risk factors for ischemic heart disease.\n- Motivation and willingness: While the patient's motivation and willingness are not explicitly mentioned in the note, we could infer that if she is seeking medical help for her condition, she might be motivated to participate in a study to improve her health.\n\nBased on the available information, the patient meets the criteria of being within the age range and having risk factors for ischemic heart disease (hypertension and obesity). However, as the trial specifies healthy individuals and the patient presents with symptoms that could be indicative of active cardiac issues, it is not clear if she would be considered \"healthy\" in the context of the study. Furthermore, there is no information on her physical activity levels or willingness to participate in such a trial. Therefore, additional information would be needed to fully ascertain her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "119": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- Currently takes no medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical trial inclusion criteria:\n- Live in Ribeir\u00e3o Preto, S\u00e3o Paulo - Brazil\n- Age between 18 and 40 years old\n- Female gender\n- Regular menses\n- Weight inferior than 120 Kg and BMI between 30 and 40 kg/m^2, for the group with obesity\n- BMI between 18.5 and 24.9 kg/m^2, for the group without obesity\n\nComparison:\n- The patient is a woman, which fits the gender requirement.\n- However, the patient's age (58) is outside the specified range of 18 to 40 years old.\n- The trial requires participants to live in Ribeir\u00e3o Preto, S\u00e3o Paulo - Brazil. There is no information on the patient's residence.\n- There is no information on the patient's menstrual status or exact weight and BMI to determine if she fits the obesity criteria in terms of BMI between 30 and 40 kg/m^2.\n\nGiven the lack of information on some of the criteria and the clear mismatch in the age requirement, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "120": {
        "output": "Based on the information provided:\n\nThe patient is a 58-year-old African-American woman presenting with episodic pressing/burning anterior chest pain, nausea, diaphoresis, and mild dyspnea. She has a history of hypertension and obesity. The EKG shows nonspecific changes. There's no mention of a previous diagnosis of chronic stable angina, which is one of the inclusion criteria for the clinical trial.\n\nThe clinical trial is focused on patients with chronic stable angina of at least 2 months duration. Additionally, after a screening visit, the patient must have a positive exercise ECG, dobutamine stress echocardiogram, myocardial perfusion scan (MPI), or coronary angiogram to be included in the study.\n\nGiven that the patient's chest pain began only two days earlier and there is no indication that she has been diagnosed with chronic stable angina, she does not currently meet the inclusion criteria of having angina for at least 2 months. Furthermore, she has not undergone any of the required diagnostic tests that would qualify her for the trial following a screening visit.\n\nSince the information provided does not indicate that this patient has chronic stable angina or has undergone any of the specific tests required for inclusion in the study, there is not enough evidence to suggest she would be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "121": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we need to assess the following:\n\n- The patient's age is 58 years old, which meets the age criterion of being 18 years or older.\n- The patient presents with chest pain and is in the emergency room, but there is no mention of requiring intubation and mechanical ventilation.\n- The patient is known to have obesity, but there is no specific BMI provided. The inclusion criteria require a BMI of \u226540 kg/m^2.\n- There is no information provided about the patient's intra-abdominal pressure (IAP), which needs to be \u226512 mmHg for inclusion.\n\nGiven that the patient does not currently meet the specific criteria of requiring intubation and mechanical ventilation and there is no information on BMI or IAP, it is not possible to conclude that this patient would be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "122": {
        "output": "The patient in the note is a 58-year-old African-American woman with obesity and hypertension. She presents with symptoms suggestive of a cardiac event, but her eligibility for the clinical trial in question is based on the inclusion criteria specific to weight and age.\n\nThe inclusion criteria for the trial are:\n1. Subjects aged between 21 -65 years\n2. Subjects with BMI > 23 Kg/m^2\n\nThe patient fits the age criteria as she is 58 years old. Although her exact BMI is not provided, it is mentioned that she is known to have obesity. The clinical definition of obesity typically involves having a BMI over 30 Kg/m^2, which exceeds the trial's requirement of a BMI over 23 Kg/m^2. \n\nGiven the information provided, the patient meets both inclusion criteria for age and BMI. Therefore, she is highly likely to be eligible for the clinical trial on Protein Supplementation and Weight Loss.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "123": {
        "output": "Based on the provided patient note and the clinical trial information:\n\nPatient Note:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known to have hypertension and obesity\n- No current medications\n- Normal physical examination\n- Non-specific changes on EKG\n\nClinical Trial:\n- Title: Dietary Nitrate in COPD\n- Focus: Improvement of exercise capacity in COPD patients through acute nitrate consumption\n- Inclusion criteria: \n  - Information consenting out-patients with a previous physician diagnosis of COPD\n  - Clinically stable\n  - Ambulatory\n\nThe patient in the note does not have a physician diagnosis of COPD. The symptoms described (chest pain, radiating to the back, accompanied by nausea, diaphoresis, and mild dyspnea) are not indicative of COPD, which is typically characterized by chronic respiratory symptoms such as chronic cough, sputum production, and shortness of breath. Thus, there is no evidence in the patient note to suggest that the patient has COPD, which is a requirement for the clinical trial.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial, as there is no mention of a COPD diagnosis, which is a key inclusion criterion. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "124": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Empowered Sisters Project Making Choices Reducing Risks,\" let's assess the patient's eligibility:\n\n- The patient is a 58-year-old African-American woman, which aligns with the criteria for African American/ African Caribbean/African heritage/Mixed.\n- The age criteria for the trial is 18 - 44 years, and the patient is 58 years old, which exceeds the maximum age limit.\n- There is no mention of abuse by an intimate male partner in the patient note, which is a requirement for the trial.\n- There is no information provided about the patient's residency or plans to remain in the US Virgin Islands for the next two years.\n\nGiven this information, the patient does not meet several key inclusion criteria: she is over the age limit, and there is no indication of abuse by an intimate partner or her residency in the US Virgin Islands. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "125": {
        "output": "Based on the information provided in the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 58-year-old African-American woman\n- Presents with chest pain, nausea, diaphoresis, and mild dyspnea\n- Has hypertension and obesity\n- No current medications\n- Normal physical examination\n- Non-specific EKG changes\n- No mention of end-stage renal disease (ESRD) or hemodialysis\n\nClinical trial inclusion criteria:\n- Able to give informed consent\n- Age \u2265 18 years\n- Body weight > 100 lb or BMI > 18.5\n- End-stage renal disease with hemodialysis in-center three times per week\n- Not missing any treatments in the preceding two weeks and in compliance with health care provider instructions\n- At least two episodes of intra-dialytic hypotension (IDH) in the last month\n- Hemoglobin greater than or equal to 9.0 g/dL and up to 15.0 g/dL\n\nThe patient does not meet several key inclusion criteria for the trial, most notably, she does not have a diagnosis of end-stage renal disease, is not on hemodialysis, and there is no mention of her experiencing intra-dialytic hypotension. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "126": {
        "output": "To assess the patient's eligibility for the clinical trial, we need to match the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain, radiates to the back, accompanied by nausea, diaphoresis, and mild dyspnea\n- Known to have hypertension and obesity\n- No history of smoking, diabetes, hypercholesterolemia, or family history of heart disease\n- Not currently on any medications\n- Physical examination is normal\n- EKG shows nonspecific changes\n\nClinical Trial Inclusion Criteria:\n- Female or male aged \u226518 years\n- A patient information letter has been sent by the Investigator to the patient\n- Patient discharged alive from the hospital to home following ACS (diagnosed with STEMI, NSTEMI, or UA)\n- ACS is either UA or myocardial infarction of Type 1\n- ACS after 1st July 2012 and before 1st June 2013\n- Patient on ticagrelor, prasugrel, or clopidogrel treatment at discharge following an ACS\n\nBased on the information provided, the patient has not yet been diagnosed with ACS, and there is no mention of her being treated with ticagrelor, prasugrel, or clopidogrel at discharge. Additionally, the patient's episode of chest pain started two days ago, and there is no indication that it falls within the specified date range of the clinical trial (after 1st July 2012 and before 1st June 2013). Therefore, the patient does not meet several key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "127": {
        "output": "",
        "label": 0
    },
    "128": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Efficacy and Safety of Lacidipine in Chronic Stable Angina,\" we need to compare the patient's characteristics and symptoms with the inclusion criteria of the trial.\n\nHere are the patient's relevant characteristics from the note:\n- The patient is a 58-year-old African-American woman.\n- Presents with episodic pressing/burning anterior chest pain that began two days earlier.\n- The pain is exertional, starting while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- Known to have hypertension and obesity.\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease.\n- Takes no medications.\n- Physical examination is normal.\n- The EKG shows nonspecific changes.\n\nNow let's look at the clinical trial inclusion criteria:\n- Age 18 to 80 years.\n- History of stable, exertional angina pectoris (CCS class II to III) for at least 3 months prior to enrolment.\n- Not currently receiving treatment with antianginal medication (other than short-acting nitrates).\n- Two treadmill exercise tests demonstrating \u2265 0.1 mV of horizontal or down sloping ST-segment depression.\n- Difference in symptom-limited exercise duration between two tests must not exceed 20%.\n- Total treadmill exercise duration > 3 minutes on a standard Bruce protocol.\n- Coronary artery disease, preferably documented by myocardial infarction or coronary angiography showing \u2265 50% reduction in luminal diameter of one or more coronary arteries.\n\nBased on the patient note, the patient does present with episodic pressing/burning anterior chest pain that is exertional, which could suggest angina, but there are several pieces of information missing to fully determine eligibility:\n- The patient's chest pain is a new occurrence, not documented for at least 3 months.\n- It is not specified if her angina is of the stable type required by the trial (CCS class II to III).\n- There is no documentation of the patient performing treadmill exercise tests or results showing ST-segment depression.\n- There is no mention of any previous diagnosis of coronary artery disease, myocardial infarction, or results of coronary angiography.\n\nAt this stage, the patient's eligibility for the trial is uncertain due to insufficient information. Further investigation and testing would be required to determine if the patient's condition aligns with stable exertional angina pectoris and to document the presence of coronary artery disease as per the trial's inclusion criteria.\n\nGiven the lack of information and the newness of the patient's symptoms, it seems premature to refer this patient to the clinical trial without further diagnostic work to establish the chronicity and nature of the angina, as well as to confirm the presence of coronary artery disease.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "129": {
        "output": "Based on the information provided, the patient is a 58-year-old African-American woman with hypertension and obesity, which are two of the comorbidities listed in the inclusion criteria of the clinical trial. The clinical trial is looking for morbidly obese patients with a BMI >30 who also have one of the comorbidities: type 2 diabetes, dyslipidemia, or hypertension, or patients with a BMI >35.\n\nAlthough the patient's exact BMI is not provided, she is identified as having obesity. Since she has hypertension, she meets the first part of the inclusion criteria if her obesity is indeed morbid (BMI >30). However, without explicit information confirming her BMI as over 30 or over 35, we cannot definitively conclude her eligibility.\n\nGiven the information available, she is a potential candidate for the study because she has a comorbidity associated with morbid obesity (hypertension). However, further investigation is required to confirm her BMI and ensure that it meets the trial's definition of morbid obesity.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "130": {
        "output": "",
        "label": 1
    },
    "131": {
        "output": "Based on the information provided in the patient note, the patient is a 58-year-old African-American woman with episodic chest pain, hypertension, and obesity. However, there is no mention of carpal tunnel syndrome or that she underwent surgery for it, particularly under intravenous regional anesthesia between January 2009 and January 2010, which is the specific inclusion criterion for the clinical trial provided.\n\nGiven that the patient does not meet the primary inclusion criteria for the clinical trial (having been operated on due to carpal tunnel syndrome under intravenous regional anesthesia within the specified timeframe), she would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "132": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility as follows:\n\n- The patient is 58 years old, which meets the criterion of being \u2265 18 years of age.\n- The patient is of African-American descent, which is one of the ethnicities included in the criteria.\n- The patient presents with chest pain, but there is no mention of atrial fibrillation (AF) or a history of AF episodes. The inclusion criteria specifically require a history of typical or early-onset symptomatic paroxysmal/persistent AF with \u22652 episodes/month.\n- The EKG shows nonspecific changes, and there is no indication that it shows atrial fibrillation or that AF was recorded within 1 month of randomization.\n\nSince there is no mention of atrial fibrillation in the patient's history or EKG, the patient does not meet the specific disease criteria required for the clinical trial. Therefore, the patient would not be eligible for this atrial fibrillation pharmacogenetic study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "133": {
        "output": "Based on the patient's presentation and the inclusion criteria for the clinical trial titled \"Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome,\" let's evaluate the patient's eligibility:\n\n1. The patient is a 58-year-old African-American woman. The inclusion criteria specify women age 18 years or older, so she meets the age criterion.\n\n2. The patient presents with episodic pressing/burning anterior chest pain that began two days earlier, which is consistent with the trial's requirement for symptoms of non-ST-elevation acute coronary syndrome (new onset chest discomfort that occurs at rest or with low levels of activity/emotion within the preceding 48 hours).\n\n3. However, the inclusion criteria also require one of the following: elevated troponin T, elevated creatinine kinase MB-isoenzyme, elevated NT-pro-BNP, ST-segment depression, or a TIMI risk score greater than 2. The patient note does not provide information on these specific tests or results, which are essential for confirming the diagnosis and severity of acute coronary syndrome.\n\nSince the patient's note lacks specifics regarding the required diagnostic criteria (elevated cardiac biomarkers or EKG changes), we cannot definitively determine her eligibility. However, given her symptoms and the high suspicion of an acute coronary syndrome, it would be prudent to consider referring her for the clinical trial upon further investigation, which would include the necessary cardiac biomarker tests and EKG analysis.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "134": {
        "output": "To assess the patient's eligibility for the ACE Stapler Sub Study, we will compare the patient's characteristics and conditions with the inclusion criteria listed for the clinical trial.\n\nPatient Characteristics:\n- 58-year-old African-American woman\n- Presents with episodic pressing/burning anterior chest pain\n- Known hypertension and obesity\n- Denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease\n- No current medications\n- BMI is not specified but is described as obese\n- Physical examination is normal\n- Has reliable transportation and sufficient time to attend all follow-up visits (assumed)\n- Failed standard obesity therapy is not mentioned\n- Willingness to sign informed consent, willingness to participate, and having a primary care physician are not mentioned but could potentially be met upon further discussion with the patient\n\nInclusion Criteria for the ACE Stapler Sub Study:\n- Must understand and be willing to sign an informed consent document\n- Must be willing and able to participate in all aspects of the study and comply with study requirements\n- BMI of 40 - 45 or 30 to 39.9 with one or more co-morbid diseases expected to improve with weight loss (hypertension, dyslipidemia, obstructive sleep apnea, diabetes mellitus)\n- Fully ambulatory, without chronic reliance on walking aids\n- Sufficient and stable medical health\n- Have a primary care physician to manage co-morbid conditions\n- Failed standard obesity therapy (diet, exercise, behavior modification, pharmacologic agents)\n- Agrees to refrain from reconstructive surgery that may affect body weight during the trial\n- Must be included in the main study\n\nBased on the information provided, the patient is obese and has hypertension, which are two criteria that potentially qualify her for the main ACE stapling study. However, the patient's BMI is not provided, which is necessary to determine eligibility. Furthermore, there is no mention of her having failed standard obesity therapies or of her willingness to participate in the study, which are both required criteria for inclusion.\n\nGiven the lack of specific information on her BMI and previous obesity treatments, as well as confirmation of her willingness to participate and other logistical requirements, I would say:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would include obtaining the patient's BMI, confirming her failure with standard obesity therapies, assessing her willingness to sign the informed consent and participate in the study, and ensuring she has a primary care physician for management of her co-morbid conditions.",
        "label": 2
    },
    "135": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the specific inclusion criteria for the study. The clinical trial is evaluating a monitoring method for the effectiveness of sympathetic blocks, specifically lumbar sympathetic blocks, and the inclusion criteria are:\n\n- Patients presenting for sympathetic block of the lower extremity (lumbar sympathetic block)\n- Ages 18-99\n\nThe patient in the note is presenting with episodic anterior chest pain, nausea, diaphoresis, and mild dyspnea, which are not indicative of a condition requiring a sympathetic block of the lower extremity. There is no mention of the patient needing or being evaluated for a lumbar sympathetic block. Therefore, the patient's symptoms and current medical evaluation do not align with the clinical trial's focus or requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "136": {
        "output": "The patient presented is a 58-year-old African-American woman with episodic pressing/burning anterior chest pain, hypertension, and obesity. She has no history of surgery indicated in the note and is not described as having undergone a unilateral total hip replacement (THR) or total knee replacement (TKR), which are the types of patients the clinical trial is targeting.\n\nThe clinical trial in question is focused on monitoring postoperative pain in patients who have undergone THR or TKR surgeries using electrical skin conductance. The inclusion criteria for this clinical trial are:\n\n- Patients undergoing unilateral THR and TKR who are between the ages of 18 and 85 regardless of the anesthesia and postoperative analgesia type.\n- Patients participating in other studies may participate in this study as well.\n- Patients with Motor Activity Assessment Scale (MAAS) Score of 3 and 4.\n\nThe patient in the note does not fit the profile of the clinical trial's target population as there is no indication that she has undergone or is scheduled for THR or TKR surgery, and there is no mention of her MAAS score.\n\nTherefore, based on the information provided in the patient note and the clinical trial's inclusion criteria, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "137": {
        "output": "Based on the information given in the patient note, the patient is a 58-year-old African-American woman presenting with episodic chest pain, hypertension, and obesity. There is no mention of her having multiple sclerosis (MS) or any related symptoms. The clinical trial in question is specifically for patients with relapsing-remitting multiple sclerosis (RRMS) who meet the McDonald criteria, have had an onset of MS within one year before enrolment, have \u2265 1 Gd+ lesions at a brain MRI scan performed within three months before enrolment, have not received previous disease-modifying and/or immunosuppressive treatments for MS, and have a baseline EDSS between 0.0 and 5.0.\n\nSince the patient in the note does not have a diagnosis of MS, nor any indication that she has RRMS or meets any of the other specific inclusion criteria related to MS, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "138": {
        "output": "Based on the patient note provided, the 58-year-old African-American woman presents with symptoms that are suggestive of angina pectoris: episodic pressing/burning anterior chest pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea. These symptoms seem to match the first inclusion criterion of the clinical trial which requires symptoms of angina pectoris.\n\nHowever, the inclusion criteria also specify the need for angiographic evidence of epicardial coronary artery stenosis referred for PCI, a flow-limiting lesion with a Fractional Flow Reserve \u22640.80, and an existing beta blocker prescription. It is not mentioned in the patient note that the woman has undergone angiography, has a documented flow-limiting lesion, or is on beta blocker therapy. Furthermore, there is no mention of an echocardiogram being performed in the preceding 12 months, which is another requirement for the trial. Lastly, we do not have information regarding the patient's consent, which is essential for participation in the trial.\n\nConsidering the missing information and the fact that the patient does not currently meet several of the explicit inclusion criteria, it would be premature to refer her to this clinical trial without further diagnostic workup to confirm the presence of flow-limiting coronary artery stenosis and to fulfill the other requirements. Therefore, at this stage, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "139": {
        "output": "To determine the patient's eligibility for the PACIFIC clinical trial, we need to review the patient's note against the inclusion criteria:\n\nInclusion Criteria Analysis:\n1. Age 18-65: The patient is 58 years old, which fits the age criterion.\n2. Overweight, with a BMI between 25 and 45: The patient is described as obese, which suggests a BMI over 30, so this criterion is likely met.\n3. English language skills at the 5th grade reading level: There is no information provided regarding the patient's language skills.\n4. Free of major medical conditions: The patient has hypertension, which is not listed among the exclusions, but she presented with chest pain, which might suggest underlying coronary heart disease or angina, conditions that would exclude her.\n5. No bulimia, anorexia, significant cognitive impairment, psychotic disorder, or unstable psychiatric illness: There is no information on these conditions, so we have to assume she does not have them.\n6. Not moving out of the San Diego area for the duration of the study enrollment: The location of the patient is not specified.\n7. Not pregnant, planning to get pregnant, or lactating: There is no information provided on this.\n8. Not taking medication for weight loss or that may impair physical activity tolerance or performance: The patient is not currently taking any medications.\n9. No medical or psychological problems, or taking medications that could make adherence with the study protocol difficult or dangerous: The patient's hypertension and episode of chest pain could potentially make adherence to the study protocol difficult or dangerous.\n10. No history of bariatric surgery: There is no information provided on this.\n11. Not currently enrolled in an organized weight control program: There is no information provided on this.\n\nSince the patient presents with episodic chest pain that could suggest underlying coronary heart disease or recent symptoms of angina, it is imperative to further investigate these symptoms before referring her to a clinical trial focusing on weight control and physical activity. Without more information on her medical clearance for physical activity, her language skills, location, pregnancy status, and other potential medical exclusions, the decision to refer her is not straightforward.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "140": {
        "output": "Given the patient's characteristics and the inclusion criteria for the clinical trial titled \"Anti-hypertensive Effect of Mycelia of Antrodia Cinnamomea,\" let's determine the patient's eligibility:\n\nPatient characteristics:\n- Age: 58-year-old woman\n- Known hypertension\n- No current medication for hypertension\n- SBP and DBP not specified\n\nClinical trial inclusion criteria:\n- Untreated hypertensive men or women\n- Age between 20 and 80 years old\n- SBP between 130 and 179 mmHg\n- DBP between 85 and 109 mmHg\n\nThe patient is within the age range required for the trial and has a known history of hypertension. However, the specific blood pressure values (SBP and DBP) for this patient are not provided. Since the patient is described as having hypertension and no current medication for it, she could potentially meet the criteria of \"untreated hypertensive.\" Therefore, further investigation is needed to determine her specific blood pressure measurements to confirm eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "141": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 58-year-old African-American woman.\n- She presents with episodic pressing/burning anterior chest pain that started while walking, radiates to the back, and is accompanied by nausea, diaphoresis, and mild dyspnea.\n- She has a history of hypertension and obesity.\n- No current medications are mentioned.\n- No prior heparin or low molecular weight heparin (LMWH) treatment is mentioned.\n- She has not mentioned if she has agreed to participate in a study or signed an informed consent, but this can typically be addressed at the time of recruitment.\n\nClinical Trial Inclusion Criteria:\n- Subjects with compatible symptoms with an acute coronary syndrome, for at least 15 minutes and not older than 3 hours.\n- Both men and women are eligible.\n- Patients who did not receive heparin or LMWH before the initial blood sample.\n- Patients agreeing to participate in the study and who signed an informed consent.\n\nComparison:\n- The patient's age fits the criterion of being over 18 years old.\n- The symptoms described could be compatible with an acute coronary syndrome, which is part of the inclusion criteria.\n- There is no mention of the patient receiving heparin or LMWH, so it's assumed that she has not.\n- The informed consent part is procedural and can be obtained if the patient agrees to participate.\n\nGiven that the patient presents with symptoms that may be related to acute coronary syndrome and other criteria (such as not having received heparin/LMWH) seem to be met, it is reasonable to consider the patient for the clinical trial upon further investigation, such as confirming the timing and nature of the chest pain, as well as obtaining informed consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "142": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the clinical trial:\n\nThe clinical trial is focused on the effect of a meal replacement on weight loss in obesity patients with metabolic syndrome.\n\nInclusion Criteria for the trial:\n\n1. Body mass index (BMI) more than or equal to 25 kg/m^2\n2. Patients with metabolic syndrome\n3. Patients who are on anti-hypertensive drugs, oral hypoglycemic drugs, and lipid-lowering drugs.\n\nPatient information:\n\n1. The patient has obesity, as indicated by the mention of obesity in the note.\n2. The patient has hypertension, which is a component of metabolic syndrome.\n3. The patient is not currently taking any medications, which includes the absence of anti-hypertensive drugs, oral hypoglycemic drugs, or lipid-lowering drugs.\n\nFrom the patient's description, while she does have obesity and hypertension, she does not meet all the criteria listed for the trial. Specifically, she is not currently taking any medications for her hypertension, which does not fulfill the criteria of being on anti-hypertensive drugs. Additionally, there is no mention of her having other components of metabolic syndrome, such as dyslipidemia or insulin resistance.\n\nGiven that the patient does not currently meet all of the inclusion criteria, particularly the requirement for medication, the assessment for eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "143": {
        "output": "After evaluating the patient note against the inclusion criteria of the clinical trial titled \"Study Of Angiomax In Infants Under Six Months With Thrombosis,\" it is clear that the patient does not meet the age requirement of being less than 6 months old. The patient is a 67-year-old woman, which is well beyond the specified age range for the trial participants. Therefore, she is not eligible for this clinical study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "144": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Use of Activated Recombinant FVII in Spinal Surgery,\" the patient does not appear to be eligible for this clinical trial.\n\nThe patient note describes a 67-year-old woman with a complication likely related to a cardiac catheterization procedure, presenting with a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms suggest a vascular issue, possibly a femoral artery pseudoaneurysm or occlusion, which is unrelated to spinal surgery.\n\nThe inclusion criteria for the clinical trial specify that the study is looking for patients who are undergoing elective spinal fusion surgery. Since the patient described is not undergoing spinal fusion surgery, nor is there any indication that she has a condition that would require such surgery, she does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "145": {
        "output": "The patient described is a 67-year-old woman who underwent cardiac catheterization and is now presenting with signs of a possible vascular complication (cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the catheterization site). This suggests that she might be experiencing a vascular emergency, such as a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is looking at the safe and feasible use of an endovascular cooling device in patients with hypothermic cardiopulmonary resuscitation (CPR). The inclusion criteria specify non-traumatic collapsed patients with persistent pulsation more than 5 minutes after return of spontaneous circulation from cardiopulmonary resuscitation and a consciousness level of less than GCS 5 points.\n\nThe patient described does not meet the inclusion criteria for this trial, as there is no indication that she has experienced cardiac arrest or required CPR, nor is there any information provided about her level of consciousness or GCS score. Instead, she appears to be experiencing a post-procedural complication unrelated to cardiac arrest or the need for hypothermic CPR.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "146": {
        "output": "Given the patient note, we have a 67-year-old woman who underwent cardiac catheterization and is now presenting with a cool right foot and a pulsatile mass in her right groin. This clinical information indicates a potential complication from the catheterization, such as a femoral artery pseudoaneurysm or occlusion, but does not mention hypertension or its treatment.\n\nThe clinical trial in question is focused on the efficacy and safety of valsartan versus amlodipine in postmenopausal women with hypertension. The trial's inclusion criteria are:\n1. Postmenopausal women\n2. Mild to moderate hypertension\n3. Statin therapy or LDL \u2264 4.1 mmol/L\n\nThe patient note does not provide information on whether the patient is postmenopausal, has hypertension, or is on statin therapy or has an LDL level \u2264 4.1 mmol/L.\n\nBased on the information provided in the patient note, we do not have enough evidence to determine if the patient meets the inclusion criteria for the clinical trial. Thus, further investigation would be needed to assess her eligibility, particularly concerning her menopausal status, blood pressure, and cholesterol management.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "147": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Summary:\n- 67-year-old woman\n- Underwent cardiac catheterization earlier in the morning\n- Complains of a cool right foot after the procedure\n- Has a pulsatile mass in her right groin\n- Loss of distal pulses\n- Auscultation reveals a bruit over the femoral artery entry point\n\nClinical Trial Summary:\n- Title: Catheter Thrombectomy in Patients With Massive Pulmonary Embolism\n- Target population: Patients with massive pulmonary embolism suitable for mechanical thrombectomy\n- Age criteria: \u2265 18 years\n- Specific condition: Massive pulmonary embolism and cardiogenic shock\n- Inclusion criteria include specific requirements related to pulmonary embolism, cardiogenic shock, and contraindications to PE thrombolysis\n- Exclusion criteria include systemic embolism with certain heart defects, free-floating heart thrombi, and life expectancy less than one month due to underlying disease\n\nThe patient in the note does not mention any symptoms or diagnosis of pulmonary embolism or cardiogenic shock. Instead, the patient's symptoms suggest a potential complication from cardiac catheterization, possibly a femoral artery pseudoaneurysm or occlusion, as indicated by a cool foot, pulsatile mass, and loss of distal pulses. These symptoms do not align with the inclusion criteria for the clinical trial, which focus on massive pulmonary embolism.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial on catheter thrombectomy in patients with massive pulmonary embolism.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "148": {
        "output": "Based on the patient note and the clinical trial provided:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaints of a cool right foot after the procedure\n- Pulsatile mass in right groin\n- Loss of distal pulses\n- Bruit over the entry point of the right femoral artery\n\nClinical Trial:\n- Title: Evaluation of Residual Urine After Intermittent Catheterisation\n- Summary: Study to compare residual urine after using two different hydrophilic coated intermittent catheters in a randomized, single-blinded, crossover study including 24 healthy males.\n- Inclusion Criteria:\n  - Male\n  - 18 years and above\n  - A negative urine dip-stick\n  - Have signed informed written consent\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- The patient is female, while the trial is specifically including only males.\n- The trial is including healthy individuals, and the patient is currently experiencing a medical issue related to a cardiac catheterization procedure.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "149": {
        "output": "",
        "label": 0
    },
    "150": {
        "output": "The patient note describes a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is now presenting with symptoms that could be indicative of a vascular complication such as a pseudoaneurysm or occlusion, given the cool extremity, pulsatile mass, loss of distal pulses, and bruit.\n\nThe clinical trial in question is looking to recruit patients with critical limb ischemia, specifically those with Fontaine stage III or IV or Rutherford category 4, 5, or 6, who also have a stenotic or occluded infrapopliteal artery that meets certain specifications.\n\nThe patient's current condition must be critically evaluated against the inclusion criteria of the clinical trial:\n\n1. Age > 18 years - The patient is 67 years old, which meets this criterion.\n2. If female patient with childbearing potential, not pregnant, and using reliable birth control - This may not be applicable given her age, but it's not discussed in the patient note.\n3. Willing and able to comply with follow-up - This is not discussed in the patient note.\n4. Critical Limb Ischemia, Fontaine stage III or IV or Rutherford category 4, 5, or 6 - The patient note does not specify that the patient has critical limb ischemia or describe symptoms consistent with Fontaine stage III/IV or Rutherford categories 4-6 (such as ischemic rest pain, tissue loss, or gangrene).\n5. Stenotic or occluded infrapopliteal artery with a lesion length \u2264 60 mm - The patient note does not provide information about the presence of stenotic or occluded infrapopliteal arteries or the specifics of any such lesions.\n6. Artery to be treated with a diameter of \u22652mm and \u22644mm - The patient note does not provide this information.\n7. Patent common iliac, external iliac, superficial femoral, and popliteal artery on the ipsilateral side prior to randomization - The patient note does not provide this information.\n8. At least one patent crural artery with expected unobstructed runoff to ankle level after treatment - The patient note does not provide this information.\n\nGiven that the patient note does not provide evidence that the patient has critical limb ischemia or other specific conditions required by the trial's inclusion criteria, and there is insufficient information to determine her eligibility based on the vascular status required by the trial, the patient does not appear to be a match for the clinical trial as described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "151": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following cardiac catheterization, specifically a cool right foot and a pulsatile mass in her right groin with loss of distal pulses and a bruit over the point at which the right femoral artery was entered. This suggests the possibility of a femoral artery complication, such as a pseudoaneurysm or occlusion.\n\nThe clinical trial in question is assessing the efficacy of carotid artery stenting (CAS) versus best medical treatment for patients with asymptomatic high-grade carotid artery stenosis. The inclusion criteria for this trial are specifically focused on patients who have atherosclerosis as the underlying disease, with an asymptomatic stenosis greater than 80% in the carotid artery. Additionally, there needs to be neurologist's consent for the potential performance of CAS.\n\nBased on the information given, the patient in the note does not fit the inclusion criteria for the clinical trial. The patient's current medical issue is related to a complication from cardiac catheterization rather than asymptomatic carotid artery stenosis. There is no mention of carotid artery disease, nor is there any indication of the patient having asymptomatic high-grade carotid artery stenosis.\n\nTherefore, the patient would not be eligible for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "152": {
        "output": "Upon reviewing the patient note and the clinical trial information, it appears that the patient is a 67-year-old woman who has recently undergone cardiac catheterization via the right femoral artery and is now presenting with complications, specifically a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the catheter entry point. These signs suggest a possible vascular complication such as a pseudoaneurysm or arterial occlusion.\n\nThe clinical trial in question is focused on assessing the safety and feasibility of the 7F Ensure Medical Vascular Closure Devices in patients undergoing diagnostic or interventional coronary procedures. The patient's current condition seems to be a complication from a coronary procedure, which may require emergent vascular surgery. However, the inclusion criteria for the trial specifically mention patients who are scheduled for a coronary diagnostic or interventional procedure, not those who have already completed one and are experiencing complications.\n\nFurthermore, the trial requires that the participant has a 7F arterial puncture located in the common femoral artery and a femoral artery with a lumen diameter of at least 5 mm. There is no information provided in the patient note regarding the size of the femoral artery or whether the current complication would exclude the patient from participating in such a trial.\n\nBased on the available information, the patient does not meet the inclusion criteria as outlined for the clinical trial, as she is not scheduled for a new procedure but is rather experiencing complications from a procedure that has already taken place. Therefore, the patient is not a suitable candidate for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "153": {
        "output": "In this scenario, the 67-year-old woman in the patient note is presenting with a cool right foot and a pulsatile mass in the right groin after undergoing cardiac catheterization. The clinical trial in question is focused on monitoring tissue transfer flaps by Modulated Imaging (MI) Spectroscopy in patients who are undergoing reconstructive surgery using either a pedicle or free tissue transfer flap.\n\nThe patient in question does not seem to be a candidate for reconstructive surgery using tissue transfer flaps, which is the primary focus of the clinical trial. The issue she is experiencing is related to a complication from cardiac catheterization, not reconstructive surgery. Additionally, there are no indications in the patient note that she is planned to undergo the type of reconstructive surgery relevant to the study.\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, this patient does not meet the inclusion criteria for the study. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "154": {
        "output": "",
        "label": 1
    },
    "155": {
        "output": "Based on the patient note, the 67-year-old woman underwent cardiac catheterization via the right femoral artery and is now experiencing complications, specifically a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the femoral artery. These symptoms suggest a vascular complication from the procedure.\n\nThe clinical trial titled \"Prospective Registry on Vascular Access in Interventions in Lazio Region\" is looking to monitor outcomes of any percutaneous cardiovascular procedure, which includes cardiac catheterization.\n\nSince the inclusion criteria for the clinical trial are:\n- All patients undergoing any percutaneous cardiovascular procedure\n\nAnd the patient underwent cardiac catheterization, which is a percutaneous cardiovascular procedure, she meets the inclusion criteria for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "156": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"RISE: A Clinical Evaluation of the StarClose\u2122 Vascular Closure System\" involves comparing the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot after the procedure\n- Pulsatile mass in the right groin\n- Loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical trial inclusion criteria:\n- Age 18-85\n- Acceptable candidate for an elective, non-emergent diagnostic procedure performed percutaneously via the common femoral artery\n- Acceptable candidate for emergent vascular surgery\n- Agrees to follow-up evaluations\n- If part of the ultrasound sub-study, agrees to have a post-procedure ultrasound\n- Informed consent provided\n\nClinical trial exclusion criteria relevant to the patient's situation:\n- History of ipsilateral femoral arterial puncture within the previous three months or history of vascular closure device deployment in the ipsilateral femoral artery at any time\n- Presence or previous use of an intra-aortic balloon pump through the existing arterial puncture site\n- Subject has intra-procedural bleeding around the access site\n- Presence of clinically significant hematoma in ipsilateral femoral artery prior to arterial closure\n\nBased on the patient's recent cardiac catheterization, it is unclear whether a vascular closure device was used, which would exclude her if it had been deployed in the ipsilateral femoral artery. Additionally, the presence of a pulsatile mass could indicate a complication such as a hematoma or pseudoaneurysm, which would also potentially exclude her. Without more specific information about the details of her procedure and complications, a definite conclusion cannot be reached.\n\nGiven the potential complications and the lack of detailed information, further investigation is needed to determine her eligibility:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "157": {
        "output": "After reviewing the patient note and the clinical trial information, we can determine the trial-level eligibility for this patient as follows:\n\nThe clinical trial's inclusion criteria are:\n1. Significant pulmonary arterial hypertension (mean pulmonary artery pressure > 25 mm Hg)\n2. Patients aged 4-18 years\n3. Routine cardiac catheterization clinically indicated for deciding therapeutic treatment\n4. Informed assent/consent from patient/parent\n\nThe patient in the note is a 67-year-old woman who underwent cardiac catheterization, which does not align with the age range specified in the clinical trial inclusion criteria (4-18 years). Additionally, the trial is focused on children with pulmonary arterial hypertension, and there is no mention of this condition in the patient's note. The clinical trial also requires a routine cardiac catheterization to be clinically indicated for deciding therapeutic treatment, which we cannot confirm from the patient note, as it only mentions that she underwent a catheterization procedure.\n\nBased on the information provided, this patient does not meet the age criterion, and there is no information suggesting that she has pulmonary arterial hypertension. Therefore, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "158": {
        "output": "Based on the patient note, the 67-year-old woman had undergone cardiac catheterization and is now presenting with symptoms suggestive of a vascular complication, specifically a possible femoral artery pseudoaneurysm or occlusion, given the cool foot, loss of distal pulses, and a pulsatile mass with a bruit.\n\nFor the clinical trial in question, the inclusion criteria are:\n\n1. Sustained return of spontaneous circulation (ROSC) after cardiac arrest, for more than 30 min\n2. Patients aged between 18 to 80 years.\n3. Patients who are hemodynamically stable, with a systolic BP > 90 mmHg with or without inotropic support.\n4. Patients comatose or unresponsive post-resuscitation\n\nThe provided patient note does not mention a cardiac arrest or a sustained return of spontaneous circulation (ROSC). The focus of the note is on a vascular complication following a cardiac procedure. There is no indication that the patient has suffered a cardiac arrest or that she is comatose or unresponsive post-resuscitation. Therefore, she does not meet the specific inclusion criteria for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "159": {
        "output": "Based on the information provided, the patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery and is now experiencing complications potentially related to the procedure. The clinical trial in question is investigating the use of suture-mediated closure devices for femoral venous access and is seeking participants who are over the age of 18 and who have received suture-mediated femoral vein closure following catheterization.\n\nThe patient note does not explicitly state that the patient received a suture-mediated closure device; however, it is implied that she has undergone a procedure that involved femoral access. The complication described (a cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the access site) is relevant to the trial's focus on complications associated with femoral access and closure.\n\nGiven that the trial is interested in understanding predictors of success and complications with suture-mediated closure devices, and that the patient has a complication that is potentially related to femoral access, she may be of interest to the trial. However, further information would be required to confirm that she received a suture-mediated closure device as part of her procedure. If she did, she would meet the inclusion criteria based on her age and the fact that she received femoral vein catheterization.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "160": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we should evaluate the eligibility as follows:\n\nPatient Note:\n\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaining of a cool right foot after the procedure\n- Pulsatile mass in right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery\n\nClinical Trial Inclusion Criteria:\n\n- ROSC after SCA due to VF/VT or PEA/Asystole\n- GCS 3\n\nThe patient note does not mention a sudden cardiac arrest (SCA) or any details regarding a Glasgow Coma Scale (GCS) score. The patient is dealing with a complication from a cardiac catheterization, which does not align with the clinical trial's focus on post-cardiac arrest outcomes and therapeutic hypothermia.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "161": {
        "output": "Based on the provided patient note and the inclusion criteria for the PROTECT Continued Access Post Marketing Surveillance Trial, here is the assessment:\n\nPatient note summary:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Has a pulsatile mass in her right groin with loss of distal pulses\n- Bruit over the point at which the right femoral artery was entered\n\nClinical trial inclusion criteria:\n1. Patient is > 18 years of age (or minimum age as required by local regulations).\n2. The patient or patient's legal representative has consented to participate and has authorized the collection and release of his medical information by signing the Patient Informed Consent Form.\n3. All lesions requiring interventions (target lesions - one to a maximum of four) in one or more native coronary arteries are amendable for implantation of one or more Endeavor\u00ae Zotarolimus Eluting Coronary Stent System.\n4. Patient indication, lesion length, and vessel diameter of the target lesion(s) are according to the 'Indications for Use' as mentioned in the 'Instructions for Use' that comes with every Endeavor\u00ae Zotarolimus Eluting Coronary Stent System.\n5. The patient is willing and able to cooperate with study procedures and required follow-up visits.\n\nAssessment:\nThe patient is of appropriate age for the trial (>18 years). However, the patient note does not provide information about her consent, the specific nature of her coronary artery lesions, or whether they are amendable to the Endeavor\u00ae Zotarolimus Eluting Coronary Stent System. Additionally, the patient is currently presenting with complications potentially related to cardiac catheterization, which is not necessarily aligned with the trial's focus on safety information for patients treated with a specific drug-eluting stent system. There is no mention of coronary artery disease or lesions that would require stenting in the patient note.\n\nGiven the lack of information on several key inclusion criteria and the fact that the patient's current condition does not directly suggest a need for coronary artery stenting, it is not possible to conclude with certainty that the patient is eligible for this trial. Therefore, further investigation would be required to determine if the patient has coronary lesions amendable to stenting with the Endeavor\u00ae Zotarolimus Eluting Coronary Stent System and to obtain the patient's consent.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "162": {
        "output": "",
        "label": 0
    },
    "163": {
        "output": "Given the patient note, we have a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is experiencing complications potentially related to femoral artery access (a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point).\n\nNow, comparing the patient's situation with the inclusion criteria of the clinical trial:\n\n1. The patient must be at least 18 years old - The patient is 67 years old, which meets this criterion.\n2. Patients undergoing femoral access coronary angiography - The patient has undergone cardiac catheterization, which typically involves coronary angiography through femoral access.\n3. Patient must be competent for providing informed, written consent - There is no information provided about the patient's competence, but there is no indication that the patient is not competent.\n4. Only 6F sheath - There is no information regarding the size of the sheath used during the patient's procedure.\n\nThe patient meets most of the known inclusion criteria; however, the size of the sheath used is not specified in the patient note. Since this is a crucial part of the inclusion criteria and we lack this information, we cannot fully determine eligibility without further investigation.\n\nTherefore, the assessment for trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "164": {
        "output": "",
        "label": 0
    },
    "165": {
        "output": "Based on the patient note provided, the 67-year-old woman has recently undergone cardiac catheterization via the right femoral artery and is now experiencing symptoms suggesting a possible complication, such as a hematoma or pseudoaneurysm (cool foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery).\n\nThe clinical trial in question is assessing the safety and efficacy of the QuickClose Design 9 closure device in patients undergoing diagnostic or therapeutic angiogram procedures. The trial's inclusion criteria specify that the patient must provide informed consent, be scheduled for a coronary or peripheral diagnostic or interventional procedure, have a target vessel with a lumen diameter \u2265 6 mm, be willing to comply with follow-up requirements, and have a 5-7F arterial puncture located in the common femoral artery.\n\nGiven the patient's current condition, which appears to be a complication from the cardiac catheterization rather than her being scheduled for a new procedure, she does not meet the inclusion criteria for the trial. The trial is specifically looking for patients who are scheduled for a procedure, not those who have already undergone one and are experiencing complications.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "166": {
        "output": "Based on the information provided, the patient is a 67-year-old woman who underwent cardiac catheterization via the right femoral artery. The clinical trial in question is investigating the use of local anesthetic for pain control in pediatric cardiac catheterization patients.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Ages 7-18 years\n- Scheduled for cardiac catheterization through the femoral artery and/or vein under general anesthetic\n- Ability to speak and understand English\n- No apparent cognitive impairments\n\nThe patient in the note does not meet the age criterion, as she is 67 years old and the trial specifically includes pediatric patients aged 7-18 years. Therefore, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "167": {
        "output": "Based on the information provided in the patient note, the 67-year-old woman who underwent cardiac catheterization is now presenting with a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the right femoral artery entry point. These symptoms suggest the possibility of a vascular complication, potentially an arterial occlusion or a pseudoaneurysm, as a result of the cardiac catheterization procedure.\n\nThe clinical trial in question is focusing on the feasibility of peripheral angioplasty in diabetic patients with type C and D lesions as per the TASC II criteria, with a focus on chronic critical ischemia.\n\nTo determine the patient's eligibility for the clinical trial, we need to assess whether the patient meets the following inclusion criteria:\n\n1. Adult diabetic patients type 1 or 2\n2. Chronic critical ischemia as defined by TASC 2007 criteria (pain at rest, and/or ulcer or gangrene due to arteriopathy: transcutaneous oximetry < 30 mmHg or pressure on the ankle < 70 mmHg)\n\nThe patient note does not mention diabetes or chronic critical ischemia. The symptoms described are acute, following a procedure, while the trial is concerned with chronic conditions. Moreover, there is no information about the patient's diabetic status or whether she meets the criteria for chronic critical ischemia.\n\nTherefore, based on the available information, the patient does not meet the specified inclusion criteria for the clinical trial as she does not have confirmed diabetes, nor is there any mention of chronic critical ischemia as defined by the TASC 2007 criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "168": {
        "output": "",
        "label": 0
    },
    "169": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following a cardiac catheterization procedure. She is presenting with a cool foot, loss of distal pulses, and a pulsatile mass in the groin, which are signs that could suggest a vascular complication such as a pseudoaneurysm or occlusion.\n\nThe clinical trial is focused on comparing the safety and efficacy of sirolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents. It is aimed at patients with symptomatic coronary artery disease requiring percutaneous coronary intervention (PCI).\n\nBased on the provided information, the patient could potentially meet the following inclusion criteria for the clinical trial:\n\n- Age \u226518 years (the patient is 67 years old)\n- Symptomatic coronary artery disease (if the reason for cardiac catheterization was due to coronary artery disease, which is not uncommon)\n\nHowever, the patient note does not provide sufficient information to confirm the following:\n\n- Whether the patient has symptomatic coronary artery disease that includes conditions such as chronic stable angina, silent ischemia, or acute coronary syndromes\n- Presence of one or more coronary artery stenoses >50%\n- If the condition can be treated with a stent ranging in diameter from 2.25 to 4.0 mm and can be covered with one or multiple stents\n\nMoreover, there are no exclusion criteria that the patient note clearly satisfies to exclude the patient from the trial. Therefore, given the limited information available, the patient could be considered for the trial if further investigation confirms symptomatic coronary artery disease that requires PCI with stent placement. However, the current symptoms she is presenting (cool foot, loss of distal pulses, pulsatile mass in the groin) suggest a vascular complication that would likely need to be addressed before considering stent placement.\n\nTherefore, based on the information provided, and assuming the patient's cardiac catheterization was due to coronary artery disease that could be treated with stenting:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "170": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following a cardiac catheterization procedure via the right femoral artery. The patient has a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery. This scenario suggests the patient is facing an issue related to the catheterization procedure, possibly a vascular complication such as a pseudoaneurysm or arteriovenous fistula.\n\nThe clinical trial in question is investigating the use of central venous catheters in the critical care setting and comparing the complications between different sites of catheterization (subclavian, internal jugular, and femoral). The inclusion criteria for the trial are quite straightforward:\n\n1. Patient admitted to the Intensive Care Unit (ICU).\n2. Requiring Central Venous Catheterization.\n\nBased on the patient note, there is no information to suggest that this patient is currently admitted to the ICU, nor is there any indication that the patient requires central venous catheterization for the management of her condition at this time. The complication she is experiencing is related to a previous catheterization procedure, not an indication for a new central venous catheter placement.\n\nGiven the lack of information connecting the patient's current situation to the inclusion criteria of the trial, it is unlikely that this patient would be referred for the clinical trial concerning the use of central venous catheters. The patient's current medical issue does not seem to align with the focus of the trial, which is on the initial placement of central venous catheters in ICU patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "171": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here is the analysis:\n\nPatient Note Summary:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Examination findings: pulsatile mass in the right groin, loss of distal pulses, bruit over the femoral artery entry point\n\nClinical Trial Summary:\n- Assessing the effect of acute inflammation on arterial stiffness and microcirculation\n- Patients with severe sepsis compared with matched controls\n- Inclusion criteria for controls: 18+ years, normal clinical examination and ECG, normal biological tests, BMI 18-27 kg/m\u00b2, informed consent\n- Inclusion criteria for patients group: 18+ years, severe sepsis with organ failure or tissue hypoperfusion, BMI 18-27 kg/m\u00b2, informed consent\n\nThe clinical trial is looking for two groups of participants: a control group and a patient group with severe sepsis. The patient in question has undergone a cardiac procedure and is experiencing symptoms that may indicate a vascular complication such as a femoral artery pseudoaneurysm or occlusion, but there is no mention of an infection or severe sepsis. Therefore, based on the information provided, this patient does not meet the inclusion criteria for either the control group or the patient group within the trial, as there is no indication of severe sepsis or the required matching with septic patients for the control group.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "172": {
        "output": "Considering the given patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 67-year-old woman, which fits within the age range of the inclusion criteria (19-90 years).\n- She underwent cardiac catheterization via the right femoral artery and is now presenting with a potential complication, as evidenced by a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit on auscultation over the right femoral artery entry point.\n\nClinical Trial Inclusion Criteria Analysis:\n- The clinical trial is investigating the use of an amplified stethoscope (AudioDoc) to detect the presence of bruits in the carotid and femoral arteries.\n- The inclusion criteria require participants to be between the ages of 19-90 and to be having a clinical ultrasound evaluation of the carotid or femoral artery.\n\nComparison:\n- The patient falls within the required age range.\n- The patient has signs suggestive of a femoral artery issue (specifically, a bruit over the femoral artery), which may warrant a clinical ultrasound evaluation. This could potentially make her a candidate for the study as the study aims to compare the detection of bruit using the AudioDoc with traditional auscultation and ultrasound.\n\nGiven the information provided, the patient could be considered for the clinical trial if a clinical ultrasound evaluation of the femoral artery is planned or deemed necessary due to her current presentation. However, an important factor is whether the trial is specifically looking for patients with potential arterial complications from procedures like cardiac catheterization or if it is more generally about detecting stenosis in asymptomatic patients.\n\nBased on the available information, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "173": {
        "output": "Based on the patient note, the 67-year-old woman has undergone cardiac catheterization via the right femoral artery and is now experiencing complications related to the procedure, indicated by a cool right foot, a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the access point.\n\nThe clinical trial in question is investigating the safety and efficacy of the CELT ACD\u00ae Vascular Closure Device, which is used to achieve hemostasis in the common femoral artery access site in patients who are undergoing percutaneous intervention (PCI) procedures with anticoagulation.\n\nTo determine trial-level eligibility, we must match the inclusion criteria with the patient's situation:\n\n1. Over 18 years of age - The patient is 67 years old, which meets this criterion.\n2. Each patient, or his or her guardian or legal representative, is willing to give informed consent - There is no information provided about the patient's willingness or capacity to consent, but we can assume that if the patient is competent, she can provide consent.\n3. Clinically indicated for an intra-arterial procedure involving access through the common femoral artery and conducted through an access sheath size of between 6F and 7F inclusive - The patient has already undergone a procedure through the right femoral artery, which suggests she has met this criterion.\n\nAlthough the patient has undergone a procedure that would potentially involve the use of the CELT ACD\u00ae Vascular Closure Device, there are no details indicating the patient is currently on anticoagulation or scheduled for another procedure that would require the device.\n\nGiven that the patient has had a recent arterial procedure and is experiencing complications that could potentially be addressed by the CELT ACD\u00ae device, there is a possibility that she might be considered for the trial if she requires further intervention. However, without further information regarding her current anticoagulation status or whether additional intervention is planned, we cannot be certain that she would be eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "174": {
        "output": "Based on the information provided:\n\nThe patient is a 67-year-old woman who underwent cardiac catheterization and is now experiencing symptoms that suggest a possible complication of the procedure, such as a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is focused on the use of fibrin-based adhesive for the prevention of surgical complications in kidney transplantation patients.\n\nThe inclusion criteria for the clinical trial are:\n- Patients candidates to renal transplantation\n\nThe patient in question is not indicated as being a candidate for renal transplantation. Instead, she is currently dealing with a potential vascular complication from a cardiac catheterization. There is no mention of the patient requiring a kidney transplant or having any related conditions that would make her a candidate for such a procedure.\n\nTherefore, based on the information provided and the mismatch between the patient's current medical issue and the focus of the clinical trial, the patient would not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "175": {
        "output": "Based on the inclusion criteria provided for the clinical trial, the patient in the note appears to be eligible for the study. The trial is focused on patients who have undergone cardiac surgery. The patient described underwent cardiac catheterization, which is a common procedure related to cardiac care, and is experiencing post-procedural complications which may be of interest to the study. Although the trial's inclusion criteria are broad (\"All cardiac surgical patients\"), it is reasonable to assume that patients who have complications after a cardiac-related procedure, such as cardiac catheterization, would be relevant to the study objectives.\n\nTherefore, considering the information provided:\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "176": {
        "output": "Based on the patient note, the patient is a 67-year-old woman who underwent cardiac catheterization and is now experiencing complications potentially indicative of a vascular issue, such as a pseudoaneurysm or arteriovenous fistula, given the presence of a pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point.\n\nThe clinical trial in question is looking to recruit patients who are undergoing elective carotid endarterectomy, open or endovascular abdominal aortic aneurysm repair, or surgical lower limb revascularization. The patient in the note has undergone a cardiac catheterization, not any of the surgical procedures mentioned as part of the inclusion criteria for the trial.\n\nWhile the patient does meet the age criterion for inclusion (age greater than 18 years) and may be willing to give full informed consent (although this is not explicitly stated in the patient note), the patient is not currently undergoing any of the specific vascular operations listed in the trial's inclusion criteria.\n\nTherefore, based on the available information, this patient would not be a candidate for referral to the \"Preconditioning Shields Against Vascular Events in Surgery\" clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "177": {
        "output": "The patient note describes a 67-year-old woman who underwent cardiac catheterization and is now presenting with signs of a vascular complication, specifically a pulsatile mass, loss of distal pulses, and a bruit over the entry point of the right femoral artery. These symptoms suggest the possibility of a femoral artery pseudoaneurysm or occlusion rather than an acute ischemic stroke, which is the focus of the clinical trial described.\n\nThe clinical trial is focused on patients who have had a supratentorial acute ischemic stroke and are being considered for mechanical thrombectomy device treatment in addition to IV thrombolytic drug treatment. The inclusion criteria specify that the patient must have had a clinical diagnosis of supratentorial acute ischemic stroke, a neurological deficit with an NIHSS score \u22656, and eligibility for IV rtPA treatment within a certain time frame after stroke onset, among other specific criteria.\n\nBased on the information provided, the 67-year-old woman does not meet the inclusion criteria for this particular clinical trial as she does not have a diagnosis of acute ischemic stroke but rather a vascular issue related to a cardiac catheterization procedure.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "178": {
        "output": "Based on the provided patient note and the clinical trial information, the patient is a 67-year-old woman with a recent cardiac catheterization experiencing a complication that could suggest a femoral artery issue, such as an arteriovenous fistula or pseudoaneurysm. However, the clinical trial in question is focused on the timing of antiretroviral treatment (ART) and its effects on arterial stiffness in the context of HIV treatment.\n\nThe inclusion criteria for the trial are quite specific:\n\n1. Simultaneous co-enrollment in the START study\n2. Signed informed consent\n\nThere is no information given in the patient note regarding HIV status or enrollment in the START study. The complication the woman is experiencing is unrelated to the focus of the clinical trial, which is on HIV treatment and arterial stiffness.\n\nTherefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "179": {
        "output": "",
        "label": 0
    },
    "180": {
        "output": "Based on the provided patient note and the clinical trial information, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 67-year-old woman\n- Underwent cardiac catheterization\n- Complaining of a cool right foot\n- Pulsatile mass in right groin, loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical Trial Inclusion Criteria:\n- Women\n- Diagnosis of diabetes\n- Diagnosis of peripheral arterial disease (PAD)\n\nThe patient note indicates that the woman is experiencing symptoms that may be indicative of a complication from cardiac catheterization, such as a potential femoral artery injury or occlusion. However, there is no information provided in the note that the woman has been diagnosed with diabetes or peripheral arterial disease, which are required conditions for eligibility in the clinical trial.\n\nGiven the lack of information regarding a diagnosis of diabetes or PAD, it is not possible to definitively assess the patient's eligibility for the trial based solely on the provided patient note. Thus, further investigation would be needed to determine if the patient has the diagnoses required for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "181": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility:\n\nPatient Note Assessment:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization.\n- There is no mention of chronic heart failure or any details about her left ventricular function.\n- There is no information provided about her New York Heart Association (NYHA) class or Left Ventricular Ejection Fraction (LVEF).\n- There is no information on the patient's heart failure treatment or stability.\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years of age.\n- Patients with chronic heart failure (ischemic and non-ischemic etiology).\n- NYHA class II-IV.\n- LVEF \u2264 35%.\n- Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, stable for at least four weeks.\n- Informed consent must be given prior to enrollment.\n\nThe patient's eligibility cannot be definitively determined from the information provided. The patient note does not mention chronic heart failure or severe left ventricular dysfunction, nor does it provide any details that would allow us to infer her NYHA class or LVEF. Thus, we do not have enough information to determine if the patient meets the specific criteria for this trial. However, given that the patient does have a cardiac-related issue and is of the age group that often has heart failure, further investigation would be needed to assess her eligibility.\n\nTherefore, the assessment of eligibility for this patient, given the information provided, is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "182": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization via the right femoral artery earlier in the morning.\n- She is now complaining of a cool right foot, has a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery.\n\nClinical Trial Inclusion Criteria:\n- Over 18 years of age.\n- Willing to give informed consent.\n- Clinically indicated for an endovascular procedure involving access through the femoral artery, with an access puncture of 18 - 24 F.\n- Females who are not pregnant or lactating, and not planning to become pregnant \u2264 12 months.\n\nAssessment:\n- The patient is over 18 years of age (meets criteria).\n- There is no information regarding the patient's willingness to give informed consent, but this can typically be obtained if the patient agrees to participate (potential to meet criteria upon patient agreement).\n- The patient has recently undergone a procedure involving access through the femoral artery, but it is not stated whether the access puncture is in the range of 18 - 24 F. This information is crucial to determine eligibility (requires further investigation).\n- The patient's pregnancy status is not mentioned, so it would need to be confirmed that she is not pregnant, lactating, or planning to become pregnant in the next 12 months (requires further investigation).\n\nGiven that the patient has just had a procedure that could potentially align with the trial's requirements for a femoral artery access puncture, and assuming that the puncture size and pregnancy status can be confirmed to meet trial criteria, the patient could be considered for the trial. However, because there is not enough information on the puncture size and pregnancy status, I would lean towards further investigation before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "183": {
        "output": "Given the patient note and the clinical trial information provided, we must compare the patient's condition to the inclusion criteria of the clinical trial to assess eligibility.\n\nPatient note key points:\n- The patient is a 67-year-old woman.\n- She underwent cardiac catheterization earlier in the morning.\n- She is now experiencing symptoms suggestive of a vascular complication (cool right foot, pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery entry point).\n\nClinical trial key points:\n- The study focuses on patients who have been successfully resuscitated from cardiac arrest.\n- It aims to explore the benefits of total body cooling in patients with pulseless electrical activity (PEA) after cardiac arrest.\n- Inclusion criteria specify patients admitted to the ICU postcardiac arrest.\n\nFrom the available information, the patient in question does not appear to have suffered from cardiac arrest. Instead, she seems to be experiencing complications from a cardiac catheterization procedure. Therefore, she does not meet the primary reason for ICU admission required by the trial's inclusion criteria, which is postcardiac arrest.\n\nSince the patient's current medical situation does not align with the inclusion criteria, which specifically targets postcardiac arrest patients, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "184": {
        "output": "Based on the provided patient note and the clinical trial details:\n\nPatient note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot post-procedure\n- Presenting with a pulsatile mass in the right groin with loss of distal pulses\n- Bruit over the femoral artery entry point\n\nClinical trial:\n- Title: Immediate Mobilization After Cardiac Catheterisation\n- Purpose: Investigate frequency of bleeding and hematomas in patients mobilized immediately after the procedure vs. two hours post-procedure\n- Inclusion criteria:\n  - CAG or PCI performed via the femoral artery\n  - No hematoma in the groin (> 5 cm in diameter)\n  - Heparin reversed with protamine after PCI\n\nAssessment:\nThe patient underwent cardiac catheterization via the femoral artery, which aligns with the trial's inclusion criteria. However, the patient is showing signs of a possible post-procedure complication (cool foot, pulsatile mass, loss of distal pulses, and a bruit), which may indicate vascular complications such as an arterial occlusion or a forming hematoma. There is no information provided regarding the size of the hematoma, if present, or whether heparin was reversed with protamine. These are critical pieces of information needed to assess the patient's eligibility for the trial.\n\nGiven that the patient appears to be experiencing complications, which could be contraindications for immediate mobilization (not explicitly stated in the inclusion criteria but could be inferred as a safety concern), the patient would not be referred to the clinical trial until further investigation and stabilization of her condition. Therefore, the patient's eligibility for the trial is questionable without additional information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "185": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient described does not seem to be a good candidate for this specific trial. Here are the reasons:\n\n- The clinical trial is looking for patients who have undergone coronary artery bypass graft surgery (CABG) with cardiopulmonary bypass (CPB).\n- The inclusion criteria specify the use of the left internal thoracic artery and/or saphena, which indicates that the trial is focused on patients who have had specific types of grafts used in their cardiac surgery.\n- The patient must have remained in spontaneous ventilation on the first postoperative day, meaning they should not have required assisted ventilation.\n- The trial requires the absence of chronic or acute pulmonary disease.\n- Participants must give written informed consent.\n\nThe patient in the note underwent cardiac catheterization, not CABG surgery, and there is no indication of the patient having coronary artery disease confirmed by angiography or the use of the left internal thoracic artery and/or saphena as required by the trial. Additionally, there is no mention of the patient's respiratory status post-procedure or whether they have a pulmonary disease, which is an important part of the inclusion criteria. The main concern in the patient note is the development of a complication at the catheterization site (a pulsatile mass in the groin and cool foot suggesting a vascular complication), which is not related to the focus of the clinical trial on respiratory depression after CABG.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial on postoperative respiratory depression after cardiac surgery.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "186": {
        "output": "The patient note describes a 67-year-old woman who is experiencing complications following cardiac catheterization, specifically a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These findings suggest a vascular issue, possibly a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is investigating the effects of remote ischemic preconditioning (RIPC) on patients undergoing major vascular surgery. The inclusion criteria for the trial are:\n\n1. Age greater than 18 years\n2. Patient willing to give full informed consent for participation\n3. Patients undergoing elective carotid endarterectomy or\n4. Patients undergoing open abdominal aortic aneurysm repair or\n5. Patients undergoing endovascular abdominal aneurysm repair or\n6. Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)\n\nBased on the information provided in the patient note, the patient has not been described as undergoing any of the specific surgical procedures listed in the inclusion criteria. She has undergone cardiac catheterization, which is not mentioned in the trial's inclusion criteria. Therefore, it does not appear that this patient's current medical issue (complication post-cardiac catheterization) is related to the types of surgeries that are being studied in the trial (carotid endarterectomy, abdominal aortic aneurysm repair, or lower limb revascularisation).\n\nThus, based on the available information, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "187": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaints of a cool right foot after the procedure\n- Examination shows a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the entry point of the right femoral artery\n\nClinical Trial:\n- Title: Left vs. Right Radial Approach for Routine Catheterization of Heart Transplant Patients\n- Summary: Compares trans right radial versus trans left radial approach in orthotopic heart transplantation patients undergoing routine coronary angiography\n- Inclusion Criteria: Transplanted patients scheduled for routine coronary angiography, age >18 years old\n\nAssessment:\nThe patient in the note has undergone cardiac catheterization and is experiencing complications potentially related to the procedure. However, there is no indication in the patient note that she is a heart transplant patient or that she is scheduled for routine coronary angiography, which are the key inclusion criteria for the clinical trial in question. Therefore, based on the information provided, the patient does not meet the inclusion criteria of being a heart transplant patient scheduled for routine coronary angiography.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "188": {
        "output": "In the given patient note, a 67-year-old woman is experiencing complications following cardiac catheterization via the right femoral artery. The clinical trial in question is investigating the use of a radioprotective device during cardiac catheterization in patients with acute coronary syndromes.\n\nThe inclusion criteria for the trial include:\n- Unstable angina with an indication for invasive stratification\n- Acute coronary syndrome without ST-segment elevation\n- Acute coronary syndrome with ST-segment elevation\n- Patient informed of the nature of the study and have signed the Informed Consent\n- Patient suitable for coronary angiography and / or percutaneous coronary intervention either by radial access or the femoral\n\nThe patient note does not mention acute coronary syndrome or unstable angina, which are key components of the inclusion criteria for the trial. Instead, the note describes a complication following a cardiac catheterization procedure. Moreover, there is no indication whether the patient was informed about the study or has signed the Informed Consent, which is a requirement for participation.\n\nGiven that the current medical issue described (a cool right foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point) may not directly align with the acute coronary syndromes mentioned in the inclusion criteria, and there is no information about the patient's consent or suitability for the procedures as per the trial's requirements, the patient does not appear to fit the inclusion criteria based solely on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "189": {
        "output": "Based on the patient note provided, the 67-year-old woman presented with a cool right foot and a pulsatile mass in her right groin following cardiac catheterization. She also has a loss of distal pulses and a bruit is audible over the point at which the right femoral artery was entered. This clinical presentation is suggestive of a vascular complication related to the cardiac catheterization, potentially a femoral artery pseudoaneurysm or occlusion, but not related to hemorrhoids or their treatment.\n\nThe clinical trial in question is focused on comparing different treatments for symptomatic grade III or IV hemorrhoids. The inclusion criteria specifically mention patients with symptomatic grade III or IV hemorrhoids eligible for surgical treatment with HAL-RAR or excision hemorrhoidectomy.\n\nSince the patient's current medical issue is unrelated to hemorrhoids, she does not meet the inclusion criteria for this trial, which are symptomatic grade III or IV hemorrhoids. Therefore, the patient would not be eligible for this clinical trial focused on hemorrhoid treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "190": {
        "output": "Based on the patient note, the 67-year-old woman underwent cardiac catheterization and is now presenting with symptoms suggestive of a vascular complication, specifically a potential femoral artery pseudoaneurysm or occlusion as indicated by the cool foot, loss of distal pulses, pulsatile mass, and bruit.\n\nThe clinical trial in question is focused on comparing the MynxGrip Vascular Closure Device to manual compression for closure after femoral access angiography, which is relevant to the patient's current situation given she has just undergone a procedure involving femoral artery access.\n\nThe inclusion criteria for the clinical trial specify that participants must be over 18 years old, able to provide valid informed consent, and have undergone a coronary angiography (CAG), possibly including additional intracoronary measurements or imaging.\n\nThe patient note does not mention if the cardiac catheterization was specifically a coronary angiography (CAG) or if it involved any of the specialized intracoronary procedures listed (FFR, IVUS, OCT, NIRS). However, given the patient has recently undergone a procedure involving femoral artery access, it is possible that she could be a candidate for the study if the procedure aligns with the trial's specifics regarding angiography.\n\nTherefore, based on the available information, the patient could potentially be eligible for the trial pending confirmation that her cardiac catheterization procedure matches the type of procedure the trial is investigating (CAG with or without the listed intracoronary procedures). \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "191": {
        "output": "",
        "label": 1
    },
    "192": {
        "output": "Based on the information provided, the 67-year-old woman has undergone cardiac catheterization via the right femoral artery and is now experiencing symptoms that suggest possible complications from the procedure, such as a pulsatile mass in her groin and loss of distal pulses, which could indicate a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is investigating the duration and adverse events of non-cuffed catheters in patients with chronic renal failure requiring hemodialysis. The inclusion criteria for the trial are:\n\n1. Chronic renal failure requiring hemodialysis.\n2. No medical history of central vena catheterization.\n3. Maintenance hemodialysis after central vena catheterization.\n4. Signed informed consent.\n\nThe patient's current medical issue, as described in the note, does not appear to be related to chronic renal failure or the need for hemodialysis. Additionally, there is no mention of her having chronic renal failure or being on hemodialysis. Therefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "193": {
        "output": "Based on the patient note provided, the 67-year-old woman is presenting with symptoms suggestive of a vascular complication, possibly a femoral artery pseudoaneurysm or occlusion, following a cardiac catheterization procedure. There is no mention of carotid stenosis or any related conditions in the patient note. \n\nThe clinical trial in question is focused on individuals with carotid stenosis greater than 60% as per NASCET criteria and is comparing the thrombogenicity of different materials used in carotid endarterectomy. \n\nSince the patient's current medical issue does not align with the inclusion criteria of the clinical trial \u2013 which specifically requires participants to have carotid stenosis \u2013 she would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "194": {
        "output": "Based on the patient note provided, here is the assessment:\n\nPatient Note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot after the procedure\n- Has a pulsatile mass in her right groin\n- Loss of distal pulses\n- Bruit over the entry point of the right femoral artery\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18\n- Patient undergoing vascular surgery that includes a groin incision\n- Types of surgeries include infrainguinal bypass and femoral endarterectomy among others\n- Willingness to comply with protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent\n\nAssessment:\nThe patient is 67 years old, which satisfies the age criterion. However, the patient has just undergone cardiac catheterization and is experiencing complications that suggest the possible development of a femoral artery pseudoaneurysm or occlusion, rather than having had vascular surgery involving a groin incision. The trial specifies that patients must be undergoing vascular surgery that includes a groin incision.\n\nSince the patient is not currently scheduled for or recovering from vascular surgery that includes a groin incision, she does not meet the inclusion criteria for the trial based on the information provided. While vascular intervention may potentially be required due to her current complication, there's no indication that this is planned or that she would be undergoing the specific types of vascular surgery listed in the trial criteria.\n\nTherefore, based on the information available, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "195": {
        "output": "Based on the information provided, the 67-year-old woman who is experiencing complications post-cardiac catheterization does not meet the inclusion criteria for the clinical trial in question. The trial is specifically looking at the effects of surgical safety checklists on perioperative complications in children undergoing noncardiac surgery in Ontario, Canada. The inclusion criteria state that participants must be surgical patients aged between >28 days and <18 years on the day of the surgical intervention.\n\nSince the patient in question is 67 years old, she is well outside the specified age range for this study, which is focused on children. Additionally, her current medical issue is related to a cardiac intervention, not a noncardiac surgical intervention.\n\nGiven these discrepancies between the patient's characteristics and the trial's inclusion criteria, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "196": {
        "output": "Based on the information provided, the patient in question underwent cardiac catheterization and is now presenting with complications potentially related to the procedure, including a pulsatile mass in the right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms suggest a vascular complication, possibly a femoral artery pseudoaneurysm or occlusion.\n\nThe clinical trial in question is focused on patients indicated for typical atrial flutter ablation and is investigating the use of intracardiac echocardiography (ICE) in the ablation procedure. The only listed inclusion criterion is having an indication for atrial flutter ablation.\n\nThe patient's current condition does not indicate that she has atrial flutter or that she is a candidate for atrial flutter ablation. Therefore, she does not meet the inclusion criteria for this clinical trial, which specifically requires an indication for atrial flutter ablation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "197": {
        "output": "The patient note describes a 67-year-old woman who underwent cardiac catheterization and is now presenting with a cool right foot, a pulsatile mass in her right groin, loss of distal pulses, and a bruit over the femoral artery entry point. These symptoms are indicative of a vascular complication from the procedure, possibly a femoral artery pseudoaneurysm or occlusion, which requires immediate medical attention.\n\nThe clinical trial in question is focused on comparing the efficacy of continuous adductor canal blocks versus low dose femoral nerve blocks for early rehabilitation after total knee arthroplasty (TKA). The inclusion criteria specifically require patients who are able to consent to regional anesthesia and are having primary total knee arthroplasty/replacement.\n\nBased on the information provided, the patient in the note is not undergoing a total knee arthroplasty but is experiencing a complication from a cardiac procedure. Therefore, she does not meet the inclusion criteria for the clinical trial, which is specifically targeting patients undergoing TKA and assessing pain management strategies postoperatively.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "198": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, we need to assess whether the 67-year-old woman is a candidate for the clinical trial comparing modified Non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) to Brachiocephalic arteriovenous fistula (BCAVF) in hemodialysis patients.\n\nThe patient is a 67-year-old woman who has had a cardiac catheterization and is now experiencing issues with her right foot, suggestive of vascular complications such as a pseudoaneurysm or occlusion given the presence of a pulsatile mass and loss of distal pulses.\n\nThe inclusion criteria for the clinical trial are:\n1. Age from 18 to 75 years\n2. Radial artery diameter <2.0 mm or cephalic vein diameter in the forearm <2.5 mm\n3. Brachial artery diameter \u2265 2 mm\n\nThe patient falls within the age range specified (67 years old). However, the patient note does not provide information about the diameters of her radial or brachial arteries or the cephalic vein in her forearm. Additionally, there is no information indicating that she is a hemodialysis patient or that she requires an arteriovenous fistula for hemodialysis access.\n\nGiven the lack of information on her vascular measurements and hemodialysis status, we cannot conclusively determine her eligibility. The patient's current vascular issue following cardiac catheterization is also not directly relevant to the trial's focus, which is on vascular access for hemodialysis.\n\nTherefore, based on the available information:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "199": {
        "output": "The patient described in the note is a 67-year-old woman who has undergone cardiac catheterization via the right femoral artery and is experiencing complications potentially related to the procedure, such as a cool foot, pulsatile mass in the groin, loss of distal pulses, and a bruit over the femoral artery entry point.\n\nThe clinical trial in question is focused on patients with pulmonary arterial hypertension (PAH), specifically targeting those who have not had their condition controlled by optimal medical management, and are classified as NYHA class III or IV. The intervention being studied is pulmonary artery denervation.\n\nTo assess the patient's eligibility for the clinical trial, we must compare her condition and situation with the inclusion criteria stated for the trial:\n\n- Patients with pulmonary artery hypertension (group 1 of the Nice classification of pulmonary hypertension)\n- Aged over 18 years old\n- NYHA class III or IV\n- Not controlled by optimal medical management\n- Signed informed consent\n\nThe patient note does not mention pulmonary arterial hypertension, nor does it describe any symptoms or treatments related to PAH. The only condition mentioned is related to complications post cardiac catheterization. There's no indication that the patient has PAH, is in NYHA class III or IV for heart failure, or is on any relevant therapies for PAH.\n\nBased on the information provided, there is no indication that this patient would meet the criteria for the clinical trial focused on pulmonary arterial hypertension as her condition (complications post cardiac catheterization) does not align with the target disease (PAH) of the study.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "200": {
        "output": "Given the information provided in the patient note:\n\nA physician is called to see a 67-year-old woman who underwent cardiac catheterization via the right femoral artery earlier in the morning. She is now complaining of a cool right foot. Upon examination she has a pulsatile mass in her right groin with loss of distal pulses, and auscultation reveals a bruit over the point at which the right femoral artery was entered.\n\nAnd the clinical trial in question:\n\nTitle: Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment\n\nInclusion criteria are:\n- Minimum 18 years old\n- Diagnosed with PAH or non-operable CTEPH or operated CTEPH with persistent pulmonary hypertension\n- Diagnosis of PAH based on cardiac catheterization\n- Diagnosis of CTEPH confirmed by contrast-enhanced spiral chest CT, pulmonary angiography, and V/Q scintigraphy\n- Recent diagnosis of sleep-disordered breathing (polysomnography realized within 3 months before inclusion showing AHI above 15)\n- Stable clinical condition for at least 3 months before inclusion as defined by NYHA and a walking distance difference within 10% of the previous 3 months and no change in medical therapy during this 3 months\n\nThe patient in the note is not explicitly stated to have pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), or sleep-disordered breathing. The patient's issue seems to be related to a complication from a cardiac catheterization procedure, with no mention of pulmonary hypertension or sleep disordered breathing. Thus, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "201": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient note:\n- 67-year-old woman\n- Underwent cardiac catheterization via the right femoral artery\n- Complaining of a cool right foot\n- Pulsatile mass in her right groin with loss of distal pulses\n- Bruit over the point at which the right femoral artery was entered\n\nClinical trial inclusion criteria:\n- Newly healed leg or diabetic foot ulcer within past 7 - 14 days\n- Ankle brachial index 0.8- 1.3mmHg (rule out absence of arterial disease)\n- Willing to wear compression stockings and appropriate footwear\n- Working freezer\n\nThe patient in question is presenting with a cool right foot and a pulsatile mass in her right groin following cardiac catheterization, which are indicative of a possible vascular complication, such as a pseudoaneurysm or arterial occlusion, rather than a healed leg or diabetic foot ulcer. There is no mention of the patient having a leg or diabetic foot ulcer, let alone one that has healed within the past 7 - 14 days. Thus, the patient does not meet the study's specific inclusion criteria regarding the ulcer healing status.\n\nAdditionally, the presence of a pulsatile mass with a loss of distal pulses suggests that the patient may have arterial disease, which could potentially be contraindicated as per the trial's inclusion criteria that require an ankle brachial index between 0.8 and 1.3mmHg to rule out the absence of arterial disease.\n\nGiven this information, the patient does not meet the inclusion criteria for the clinical trial, and it would not be appropriate to refer her for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "202": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia\", let's compare the patient's characteristics with the inclusion criteria provided:\n\nPatient's Characteristics:\n- Age: 67-year-old woman\n- Condition: Complaints of a cool right foot after cardiac catheterization, pulsatile mass in right groin, loss of distal pulses, and bruit over the point at which the right femoral artery was entered.\n\nInclusion Criteria:\n1. Willing, able, and committed to participate in the procedures for the full length of the study.\n2. All ethnic groups, male or female above the age of 18 years.\n3. Diagnosis of non-reconstructable arterial disease and critical limb ischaemia (with a minimum of duplex ultrasound and an MDT discussion to have reached this diagnosis)\n4. Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device.\n5. Blood pressure currently under moderate control (< 160/100mmHg)\n6. History of uncomplicated cardiovascular events beyond 3 months.\n7. No current foot ulceration\n\nFrom the patient note, we do not have enough information to confirm that the patient has non-reconstructable arterial disease and critical limb ischaemia, which is a key criterion for this study. While the symptoms mentioned suggest a vascular problem, likely related to the catheterization procedure, they do not necessarily indicate critical limb ischaemia. Moreover, a diagnosis of critical limb ischaemia would typically require more detailed investigation such as duplex ultrasound and multidisciplinary team (MDT) discussion, which are not mentioned in the patient note.\n\nGiven the lack of information confirming a diagnosis of critical limb ischaemia, and the fact that the patient's current symptoms seem to be acute and related to a recent procedure, it is not clear that this patient would meet all the necessary inclusion criteria for this trial.\n\nTherefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "203": {
        "output": "After reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the patient's eligibility as follows:\n\nThe inclusion criteria for the trial are:\n1. Age 18-60 years\n2. Right-handed non-smokers\n3. Diagnosed with facial pain\n4. Continuous pain for more than 3 months\n5. Spontaneous pain greater than 3 of 10\n6. Allodynia to brush greater than 5 of 10\n\nThe patient in question is a 40-year-old woman, which fits the age criterion. However, there is no information provided about her being right-handed, a non-smoker, or having facial pain, specifically. The patient note indicates she has excruciating pain in her right arm, not her face. There is also no mention of the duration of her pain, whether it is continuous or not, or the presence of allodynia.\n\nGiven that the patient's condition does not match the specific requirements of the trial (which are focused on facial pain, not arm pain), she would not meet the necessary inclusion criteria for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "204": {
        "output": "Based on the patient note provided, the patient is a 40-year-old woman who presents to the ER with excruciating pain in her right arm that began an hour prior to admission. There is no indication of diabetic peripheral neuropathic pain or diabetes in the patient's history. In addition, the pain she is experiencing is acute, localized to her right arm, and there is no mention of it being present for at least 6 months as required by the clinical trial's inclusion criteria.\n\nThe clinical trial's target population is patients with pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes, with the pain beginning in the feet and present for at least 6 months. Additionally, participants need to score 4 or greater on the Brief Pain Inventory on the 24-hour average pain item.\n\nSince the patient does not exhibit the specific type of pain (diabetic peripheral neuropathic pain) described in the inclusion criteria and there is no mention of diabetes or chronic pain present for at least 6 months, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "205": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 40-year-old woman with no past medical history who presents with excruciating pain in her right arm. She is pale, in moderate discomfort, tachypneic, tachycardic, and hypotensive (blood pressure 80/60), but she does not have any discoloration or movement limitation in her right arm.\n\nThe clinical trial in question is looking to recruit asymptomatic subjects older than 40 years of age without any history of coronary artery disease (CAD) but one cardiovascular risk factor with documented silent ischemia. The patient does not have a history of CAD mentioned, but she is not asymptomatic as she presents with excruciating pain in her right arm. Additionally, there is no mention of documented silent myocardial ischemia type I or any cardiovascular risk factors.\n\nGiven the information provided, the patient does not meet the inclusion criteria of being asymptomatic or having documented silent ischemia. Thus, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "206": {
        "output": "Based on the patient note provided, the 40-year-old woman presents with excruciating pain in her right arm, which is an acute symptom rather than chronic or recurrent right lower abdominal quadrant pain. The clinical trial in question is specifically studying the effects of elective laparoscopic appendectomy on patients with persistent or recurrent lower abdominal quadrant pain, and this patient's symptoms do not align with the condition being studied.\n\nGiven that the patient's current complaint does not match the inclusion criteria of chronic or recurrent right lower abdominal quadrant pain and there is no mention of a history of such pain, it is not appropriate to refer this patient to the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "207": {
        "output": "The patient presented in the note is a 40-year-old woman with severe pain in her right arm. There is no indication of brain trauma or any mention of a head injury. The clinical trial in question is specifically seeking patients who have suffered acute moderate brain trauma, and the tools being used (MR spectroscopy and diffusion tensor imaging) are meant to assess brain injury and its correlation with clinical outcomes.\n\nSince there is no evidence in the patient note that suggests the patient has suffered from a brain injury, she does not meet the inclusion criteria for the clinical trial, which is focused on patients with moderate brain trauma. Therefore, based on the information provided, this patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "208": {
        "output": "Upon reviewing the patient's note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the necessary criteria for inclusion in the trial.\n\nThe patient is a 40-year-old woman with no past medical history of diabetes and currently presents with symptoms unrelated to Type 2 Diabetes Mellitus. The clinical trial is specifically looking for asymptomatic subjects with Type 2 Diabetes Mellitus and has an age range of 50-75 years for its participants.\n\nSince the patient does not have a diagnosis of Type 2 Diabetes Mellitus and is also below the age range specified in the inclusion criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "209": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial for Low Level Laser Therapy to Reduce Chronic Pain, let's compare the necessary elements:\n\nPatient Characteristics:\n- Age: 40 years old (Inclusion criteria: 18-65 years of age)\n- Pain: Excruciating pain in the right arm (Inclusion criteria: Muscular-skeletal pain in the neck/shoulder region)\n- Chronicity: No mention of the duration of pain (Inclusion criteria requires acute and chronic pain)\n- Range of motion: No movement limitation (Inclusion criteria: Restricted range of motion in the neck/shoulder region)\n- Location: Pain is in the right arm, not specified as neck/shoulder (Inclusion criteria specifically mentions neck/shoulder region)\n- VAS score: Not provided (Inclusion criteria: Rating of 30 or greater on the VAS pain scale)\n\nFrom the information given, the patient's pain is not specified to be in the neck/shoulder region, which is a requirement for the clinical trial. The chronicity of the pain is also not mentioned, and there is no information on the VAS score or any indication of fibrosis, scar tissue, inflammation, altered function, or muscle strains specifically in the neck/shoulder region.\n\nGiven the mismatch between the patient's presenting symptoms and the inclusion criteria for the clinical trial, particularly the location of the pain, and the lack of information on several other criteria, the patient does not appear to be a suitable candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "210": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the eligibility requirements for the trial. The trial is focused on patients who have had a second generation drug-eluting stent implanted due to angina pectoris or documented silent ischemia. The patient in the note is presenting with pain in her right arm, with no mention of angina, silent ischemia, or any stent implantation.\n\nThe patient note does not provide any information that aligns with the inclusion criteria of the clinical trial, such as the diagnosis of angina pectoris, unstable angina pectoris, or documented silent ischemia, nor does it mention the patient having undergone any stent implantation.\n\nTherefore, based on the available information, the patient does not qualify for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "211": {
        "output": "Based on the patient note provided, the 40-year-old woman presents with acute pain in her right arm, without any prior medical history that is mentioned. There is no indication in the patient note that she has been diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), nor are there any details suggesting a progressive or relapsing dysfunction from motor and sensory or symmetric motor nerve only in at least one limb, which is required for eligibility in the clinical trial.\n\nThe clinical trial in question is specifically looking for subjects with CIDP, either newly diagnosed or with a history of the condition with specific treatment criteria. Since the patient does not have a documented history of CIDP or treatment for CIDP, she does not meet the inclusion criteria for this clinical trial based on the information provided.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "212": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's analyze the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is a 40-year-old woman.\n- She presents with excruciating pain in her right arm without prior trauma.\n- She is pale, tachypneic, tachycardic, and hypotensive (blood pressure is 80/60).\n- There are no signs of discoloration or movement limitation in her right arm.\n\nClinical Trial Inclusion Criteria:\n- The patient must be ventilated and in sinus rhythm.\n- The patient must have septic shock requiring a hemodynamic assessment.\n\nThe patient note indicates that the woman is in moderate discomfort and shows signs of possible shock (evidenced by tachypnea, tachycardia, and hypotension), but there is no specific mention of septic shock or the need for mechanical ventilation.\n\nThe diagnosis of septic shock would typically require signs of infection along with the hemodynamic disturbances. The patient's presentation with excruciating pain, without fever or other signs of infection, does not specifically point to septic shock.\n\nThe patient is not described as being ventilated, which is a specific requirement for this trial's inclusion criteria. Additionally, there is no explicit mention of sinus rhythm, although there is no indication of arrhythmia either.\n\nGiven the information provided, the patient does not clearly meet the criteria for the clinical trial. She may require further assessment to determine if she is indeed experiencing septic shock and if mechanical ventilation is needed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "213": {
        "output": "",
        "label": 0
    },
    "214": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to compare the patient's characteristics and condition with the inclusion criteria for the clinical trial on palmar-plantar erythrodysesthesia (PPE) treatment with topical sildenafil.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Receiving capecitabine or sunitinib as part of routine standard care.\n- CTCAE version 4.0, grade 1-3 PPE.\n- Adults age \u2265 18\n- Karnofsky (KPS) performance status of \u226570%\n- Adequate organ and marrow function as defined in the criteria.\n- Not pregnant or lactating.\n- Use of adequate birth control (for women of childbearing potential).\n- Ability to understand and the willingness to sign a written informed consent document.\n\nThe patient note presents a 40-year-old woman with excruciating pain in her right arm, without any mention of cancer treatment or palmar-plantar erythrodysesthesia (PPE). There is no indication that she is receiving capecitabine or sunitinib, which are specific medications linked to the development of HFS/PPE and are required for inclusion in the study.\n\nBased on the information provided in the patient note, which does not mention any of the key inclusion criteria relevant to the clinical trial (e.g., no mention of cancer treatment, PPE, or relevant medications), the patient does not meet the inclusion criteria for the clinical trial on PPE treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "215": {
        "output": "Based on the information provided in the patient note, the 40-year-old woman presents with excruciating pain in her right arm, is pale, in moderate discomfort, tachypneic, tachycardic, with a low blood pressure of 80/60, but without discoloration or movement limitation in her arm. There is no mention of infection, fever, or other systemic signs that would suggest sepsis. The clinical trial in question is looking for patients with septic shock, which is defined by the presence of infection along with other systemic signs and the necessity of vasopressor treatment.\n\nThe patient in the note does not clearly fulfill the criteria for septic shock as defined by the inclusion criteria. While she has some signs that could be associated with sepsis, such as being pale, tachypneic, tachycardic, and hypotensive, there is no documented or strong suspicion of infection mentioned, nor is there any indication that she requires vasopressor treatment. Furthermore, the inclusion criteria specify that the patient must meet 2 or more SIRS criteria and have a shock that requires vasopressor treatment. The patient note does not provide enough evidence to confidently assert that this patient has septic shock or meets the specific SIRS criteria.\n\nGiven the lack of clear evidence of infection or septic shock, it would be inappropriate to refer this patient for the septic shock clinical trial based on the information provided. However, further investigation would be needed to fully assess for sepsis or other conditions, but as per the given scenario, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "216": {
        "output": "Based on the provided patient note and clinical trial inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Assessment:\n- The patient is a 40-year-old woman, which satisfies the age requirement of being \u2265 18 years of age.\n- The patient presents to the ER with excruciating pain in her right arm, with no mention of stable angina pectoris or silent ischemia (positive stress test without chest pain).\n- There is no mention of the patient being scheduled for coronary angiography or possible angioplasty, which is required for the trial.\n- The patient's current medication regimen is not mentioned, so we cannot confirm if she is on dual anti-platelet therapy with aspirin and clopidogrel.\n- The patient's willingness and ability to conform to the requirements of the study and whether she has signed an informed consent cannot be determined from the note.\n- There is no information on whether the patient has any illness or condition that would impair the results of the study.\n- It is not indicated whether the patient is of childbearing potential or if a pregnancy test has been performed.\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years.\n- Presents with stable angina pectoris, or silent ischemia.\n- Scheduled for coronary angiography, with possible angioplasty.\n- Able to tolerate and on dual anti-platelet therapy with aspirin and clopidogrel.\n- Able and willing to conform to study requirements and has signed an informed consent.\n- No illness or condition that would impair study results.\n- Women of childbearing potential must have a negative pregnancy test.\n\nGiven the information in the patient note, the patient does not clearly meet the specific disease condition criteria (stable angina or silent ischemia) for the clinical trial, nor is there any mention of the patient being scheduled for PCI or being on the specified medications. Therefore, we cannot conclude that the patient is eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "217": {
        "output": "Based on the provided patient note, the patient is a 40-year-old woman who presents with excruciating pain in her right arm without prior trauma. She is pale, in moderate discomfort, tachypneic, tachycardic, and hypotensive with a blood pressure of 80/60. While she does exhibit some signs that could be associated with shock (tachycardia and hypotension), there is no clear evidence from the note that she meets all the criteria for septic shock or acute respiratory distress syndrome (ARDS) as required by the clinical trial's inclusion criteria.\n\nThe inclusion criteria for the clinical trial specify that patients must be diagnosed with shock or ARDS. For shock, four criteria must be present, including a heart rate of at least 90/min, a respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower or the use of mechanical ventilation, the use of vasopressors to maintain a systolic blood pressure of at least 90mmHg despite fluid resuscitation, and at least one sign of hypoperfusion.\n\nFor ARDS, the criteria include an acute decrease in PaO2/FIO2 to 200mmHg or lower, bilateral pulmonary infiltrates or a chest radiograph consistent with edema, no clinical evidence of left atrial hypertension, and the requirement for positive pressure ventilation.\n\nFrom the patient note, we do not have enough information to confirm a diagnosis of shock or ARDS. There are no details about her heart rate, PaCO2 levels, urine output, neurological dysfunction, plasma lactate levels, PaO2/FIO2 ratio, or chest radiograph findings. Moreover, there is no mention of the use of vasopressors or positive pressure ventilation.\n\nTherefore, based on the information provided, we cannot conclusively determine that the patient meets the inclusion criteria for the clinical trial. Further investigation would be needed to ascertain whether she has shock or ARDS according to the trial's definitions.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "218": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not appear to meet the specified criteria for the study on PTSD. The patient note does not mention any diagnosis of PTSD or any related symptoms; instead, it describes acute pain in the patient's right arm with no clear cause. The inclusion criteria require a diagnosis of PTSD according to the DSM-IV criteria, as well as a certain severity of PTSD symptoms as measured by the CAPS score.\n\nWithout any indication of PTSD in the patient's described condition, there is no basis to refer this patient to the PTSD clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "219": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can assess that the patient:\n\n- Is a 40-year-old woman\n- Presents with acute pain in her right arm\n- Is pale, tachypneic, and tachycardic\n- Has normal body temperature\n- Has low blood pressure (80/60)\n- Her right arm has no discoloration or movement limitation\n- There is no mention of Chagas disease or any related diagnosis\n\nThe clinical trial's inclusion criteria specify that the patient must:\n\n- Have Chagas disease, confirmed by two serological tests\n- Show evidence of certain electrical disorders on diagnostic tests\n- Be asymptomatic or have minimal isolated unspecific symptoms not consistent with serious cardiac conditions\n- Have ejection fraction of left ventricle >35%\n- Be able to give written informed consent\n- Be > 21 years old\n- Be able to return for follow-up visits as required\n\nThe patient in the note does not meet the inclusion criteria for the clinical trial because there is no indication that she has Chagas disease or any of the specific cardiac conditions listed in the inclusion criteria. Since one of the primary inclusion criteria (having Chagas disease) is not met, it is clear that this patient would not be eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "220": {
        "output": "Given the patient note and the clinical trial's inclusion criteria:\n\nPatient Note:\n- 40-year-old woman\n- Presents with excruciating pain in her right arm\n- No history of trauma\n- Pale, moderate discomfort\n- Tachypneic and tachycardic\n- Normal body temperature\n- Low blood pressure (80/60)\n- Right arm has no discoloration or movement limitation\n\nClinical Trial:\n- Title: Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in Patients With Symptoms and Signs in Favor of PTE\n- Inclusion Criteria: Patients with signs or symptoms in favor of Pulmonary Thromboemboli (PTE) who come to the emergency department\n\nThe patient has presented with symptoms that could be suggestive of a serious condition, but the provided information does not specifically indicate signs or symptoms that are clearly in favor of Pulmonary Thromboembolism (PTE). Symptoms of PTE typically include shortness of breath, chest pain, cough, and sometimes symptoms like those of a heart attack. While the patient is tachypneic and tachycardic, which might occur with PTE, there is no clear evidence of respiratory symptoms or chest pain mentioned.\n\nSince the patient's presentation is not specific for PTE, but the low blood pressure and tachycardia could potentially be associated with some form of embolism, further investigation would be needed to ascertain the cause of her symptoms and whether they could be related to PTE. Therefore, additional diagnostic workup would be required before considering her for this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "221": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility appears to be as follows:\n\nThe patient is a 40-year-old woman who presents with excruciating pain in her right arm, which is not related to chest pain or symptoms consistent with possible Acute Coronary Syndrome (ACS). The inclusion criteria for the clinical trial require participants to be at least 21 years old and to have chest discomfort or other symptoms consistent with possible ACS. Additionally, the treating physician should feel that the patient could be discharged home if cardiac disease was excluded.\n\nSince this patient presents with arm pain and not chest pain, and there is no indication that the symptoms are consistent with possible ACS, she does not meet the inclusion criteria specified for the clinical trial. Therefore, she would not be referred for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "222": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient does not meet the criteria for the clinical trial.\n\nThe clinical trial is looking for primiparous women who have had a vaginal delivery, vacuum-assisted-vaginal-delivery (VAVD), or forceps-assisted-vaginal-delivery (FAVD) of a neonate of gestational age 27 completed weeks, who are also experiencing issues with anal incontinence as a result of obstetric trauma.\n\nThe patient note describes a 40-year-old woman presenting with excruciating pain in her right arm, with no mention of recent childbirth, anal incontinence, or obstetric trauma. Therefore, she does not match the population targeted by the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "223": {
        "output": "Based on the provided patient note, the 40-year-old woman presents to the ER with excruciating pain in her right arm that had started 1 hour prior to her admission. The intensity of her pain is described as excruciating, which suggests it would be greater than 3 out of 10 on any standardized pain scale, although the exact number is not provided in the note. This meets the inclusion criteria of the clinical trial, which requires patients to report pain greater than or equal to 3 out of 10. \n\nTherefore, considering the information given, the patient appears to meet the inclusion criteria for the clinical trial titled \"Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales.\"\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "224": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- A 40-year-old woman with excruciating arm pain, no mention of hand dystonia or any movement disorder.\n- She is right-handed, which fits one of the criteria.\n- No information is given about her caffeine or alcohol consumption, open scalp wounds, or drug use.\n- No information about any neurological abnormalities besides the arm pain she is presenting with.\n- No information is provided on her mental health status, other neurological disorders, history of head injury, implanted medical devices, hearing loss, or medication use.\n\nClinical Trial Inclusion Criteria:\n- Confirmed diagnosis of focal hand dystonia (patients only).\n- Between age 18 and 70 years.\n- Able to give informed consent.\n- Right-handed.\n- Agrees to not drink caffeine or alcohol for 48 hours before the study session.\n- No open scalp wounds or scalp infections.\n- No use of illegal drugs within the past 6 months, etc.\n\nThe patient note does not indicate that the patient has focal hand dystonia, which is a primary requirement for participation in the clinical trial. Although the patient's exact condition is not fully disclosed, the information given points to an acute event rather than a chronic movement disorder. Therefore, based on the information provided in the patient note, the patient does not meet the key inclusion criterion of having a confirmed diagnosis of focal hand dystonia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "225": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Details:\n- 40-year-old woman\n- No past medical history\n- Presenting with excruciating pain in her right arm\n- No trauma reported\n- Tachypneic and tachycardic\n- Blood pressure is 80/60\n- No discoloration or movement limitation of the arm\n\nClinical Trial Inclusion Criteria:\n- Written informed consent by patient or relative\n- Time in ICU < 48 hours\n- Septic shock\n- Pulmonary artery catheter and radial arterial catheter\n- Age 18 - 75 years\n- Sinus rhythm\n- Need for norepinephrine over 0.1 ug/kg/min but otherwise hemodynamically stable\n- Mechanical ventilation with sedation\n- Pwcp <18 mmHg\n\nAnalysis:\n- The patient's age fits within the trial's inclusion criteria (18 - 75 years).\n- There is no mention of the patient being in septic shock, having a pulmonary artery or radial arterial catheter, or being mechanically ventilated with sedation.\n- The low blood pressure (hypotension) may be indicative of a critical condition, but we do not have enough information to diagnose septic shock.\n- The symptom of excruciating pain without discoloration or movement limitation does not align with typical septic shock presentation.\n- The patient's cardiac rhythm is not mentioned, so we cannot confirm sinus rhythm.\n- There is no information on the patient requiring norepinephrine or being hemodynamically stable.\n- The patient does not appear to be in the ICU, which is another requirement for the trial.\n\nGiven the information provided in the patient note, there is insufficient evidence to suggest that the patient meets the inclusion criteria for the clinical trial, particularly the specific criteria related to septic shock and the interventions required (e.g., norepinephrine administration, mechanical ventilation). Therefore, the patient is not a suitable candidate for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "226": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note Summary:\n- A 40-year-old woman\n- No history of pulmonary hypertension mentioned\n- Presents with excruciating pain in her right arm\n- Tachypneic, tachycardic, hypotensive\n- No discoloration or movement limitation of the arm\n\nClinical Trial Inclusion Criteria:\n- Man or woman aged over 18\n- With suspicion or diagnosis of pulmonary hypertension\n- For the prospective arm: Scheduled to undergo right heart catheterization\n- Able and willing to give informed consent\n- For the retrospective arm: Diagnosis of pulmonary hypertension confirmed by right heart catheterization in the past\n\nAssessment of Eligibility:\nThe patient does not have a diagnosis of pulmonary hypertension, nor is there any mention of a suspicion of pulmonary hypertension or that she is scheduled to undergo right heart catheterization. Therefore, the patient does not meet the specific inclusion criteria related to pulmonary hypertension for either the prospective or retrospective arm of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "227": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, we can evaluate the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 40-year-old woman\n- Presents with excruciating pain in her right arm, no history of trauma\n- Signs of distress: pale, moderate discomfort, tachypneic, tachycardic\n- Hypotensive (80/60)\n- No discoloration or movement limitation in the right arm\n\nClinical Trial Inclusion Criteria:\n- Admitted to the hospital for care of injuries\n- Have a greater than minimal (moderate to highest) level of VTE risk\n\nThe provided patient note does not indicate that the woman has been admitted for care of injuries related to trauma. The patient presents with pain in her right arm without any trauma and the symptoms could suggest other medical conditions rather than injuries from trauma. There is no specific information given about a VTE risk level for this patient.\n\nGiven the lack of evidence from the patient note that the patient has been admitted for trauma-related injuries or has a documented moderate to highest level of VTE risk, she does not seem to meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "228": {
        "output": "",
        "label": 0
    },
    "229": {
        "output": "Given the patient note and the clinical trial information provided, here is the assessment:\n\nPatient Note Assessment:\n- The patient is a 40-year-old woman with acute pain in her right arm.\n- She presents with hypotension, tachycardia, and tachypnea but no trauma or discoloration, and movement is not limited in her right arm.\n\nClinical Trial Assessment:\n- The trial is focused on diagnosing pneumonia under low-resource conditions in children.\n- The inclusion criteria specify that participants must be children below 5 years old meeting the WHO age-dependent tachypnea criteria.\n\nComparison:\n- The patient in the note is a 40-year-old woman, which does not match the age criterion for the clinical trial, which is specifically for children below 5 years old.\n\nConclusion:\nThe patient does not meet the age inclusion criteria for the clinical trial, as she is well above the maximum age limit of 5 years. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "230": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient would not be eligible for the clinical trial. The trial is specifically looking for asymptomatic subjects between the ages of 18 and 30 years old. The patient is a 40-year-old woman who presents with excruciating pain in her right arm, which means she is symptomatic and also outside the age range specified in the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "231": {
        "output": "In the provided patient note, we have a 40-year-old woman who presents to the ER with excruciating pain in her right arm, without a history of trauma. She is pale, in moderate discomfort, tachypneic, and tachycardic, with normal body temperature and low blood pressure. There is no mention of chest pain, angina, or symptoms that would typically be associated with acute coronary syndrome (ACS). Additionally, there is no information provided about her GRACE risk score or levels of high-sensitivity cardiac troponin (hs-cTn).\n\nThe clinical trial is focused on patients presenting with typical angina pectoris, who have a low GRACE risk score, are at least 18 years old, and provide informed consent. The patient in the note does not present with typical angina pectoris, which is a requirement for the clinical trial's inclusion criteria. Without this information, we cannot determine whether the patient's condition is related to ACS, nor can we confirm that she meets other specific inclusion criteria such as the GRACE risk score.\n\nGiven that the patient does not present with symptoms of ACS and no further information is available to suggest a diagnosis of ACS or a low GRACE risk score, it would be inappropriate to refer her to this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "232": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, we can determine the eligibility of the patient:\n\nPatient Note:\n- A 40-year-old woman with severe pain in her right arm, tachypneic and tachycardic, with a blood pressure reading of 80/60.\n\nClinical Trial Inclusion Criteria:\n- Healthy Caucasian male subjects aged between 18 and 45 years (inclusive) at screening.\n- Subjects must be in good health with no clinically significant findings on physical examination, among other specific health criteria.\n\nThe patient in the note does not meet a number of key inclusion criteria for the clinical trial:\n\n1. Gender: The trial is specifically looking for male subjects, while the patient is a woman.\n2. Health status: The patient presents with severe pain and abnormal vital signs, which does not align with the requirement for healthy subjects with no clinically significant findings.\n3. The patient's current medical emergency (severe pain and abnormal vital signs) would require immediate attention and treatment, which is not compatible with the nature of a Phase 1 trial in healthy volunteers.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "233": {
        "output": "Assessing the eligibility of the presented patient for the clinical trial titled \"Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain\" requires a comparison of the patient's characteristics and medical condition with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- A 40-year-old woman\n- No past medical history mentioned\n- Presents with excruciating pain in her right arm\n- No mention of knee pain or osteoarthritis\n\nClinical Trial Inclusion Criteria:\n- Age 45 to 80 years old\n- Clinical diagnosis of osteoarthritis in one target knee\n- Knee pain and other specified criteria related to osteoarthritis\n- Symptoms associated with osteoarthritis of the knee for \u2265 6 months\n- Knee pain requiring NSAID or other therapy for \u2265 15 days in the prior month\n- Radiographic evidence of osteoarthritis by Kellgren-Lawrence classification Grade 2 or 3\n- Meets pain assessment entry criteria as defined by the study\n- No significant change in physical activity or therapy for the past 3 months\n- Able to provide written informed consent and comply with trial requirements\n\nThe patient in question does not meet the age criterion, as she is 40 years old and the trial requires participants to be between 45 and 80 years old. Additionally, the patient presents with pain in her right arm, not knee pain associated with osteoarthritis. There is no mention of a diagnosis of osteoarthritis, knee pain, or any treatment related to osteoarthritis, and no information provided about the patient's history that would suggest she meets the clinical diagnosis criteria for osteoarthritis of the knee as per the American College of Rheumatology (ACR) criteria.\n\nGiven the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial on osteoarthritis of the knee. She is not the right age, and there is no indication that she has osteoarthritis or knee pain, which are fundamental requirements for participation in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "234": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria provided, here's the assessment:\n\nPatient Note:\n- A 40-year-old woman\n- No past medical history\n- Presents with excruciating pain in her right arm\n- No discoloration or movement limitation in the arm\n- Tachypneic and tachycardic\n- Blood pressure is 80/60\n\nClinical Trial Inclusion Criteria:\n- Patients needing venous blood sampling or insertion of an intravenous cannula\n- Normal development according to parents\n\nIn this case, the patient is an adult who might need venous blood sampling or insertion of an intravenous cannula because she is in the emergency room with a medical condition that could require such procedures for diagnosis or treatment. However, the trial specifically mentions a \"medical clown in a pediatric emergency department,\" which implies that the trial is aimed at children. Furthermore, the assessment of development \"according to parents\" also suggests the trial is aimed at pediatric patients, not adults.\n\nGiven that the patient is 40 years old and the study seems to be specifically designed for pediatric patients (children), she does not meet the inclusion criteria for age and the context of the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "235": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 40-year-old woman.\n- She presents with excruciating pain in her right arm.\n- There is no mention of trauma.\n- Her vital signs indicate possible shock (pale, moderate discomfort, tachypneic, tachycardic, hypotension).\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is seeking 30 healthy volunteers.\n- Volunteers must not have consumed coffee or any other substances that could affect the autonomic nervous system.\n\nComparison:\n- The patient is not healthy as she presents with symptoms indicating a medical emergency, possibly hypovolemic shock.\n- The trial requires healthy volunteers, which the patient clearly is not, due to her current medical condition.\n\nConclusion:\nThe patient does not meet the inclusion criteria for the clinical trial as she is not a healthy volunteer, which is a primary requirement for participation in this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "236": {
        "output": "",
        "label": 1
    },
    "237": {
        "output": "It seems that the information about the clinical trial, including its title, target diseases, interventions, summary, and inclusion criteria, is incomplete. Without these details, I am unable to assess the eligibility of the 40-year-old woman for the clinical trial based on her presentation to the ER with excruciating pain in her right arm.\n\nTo determine the patient's eligibility, I would need to know the specific inclusion criteria of the clinical trial to compare against the patient's medical condition and characteristics. Since this information is not provided, I cannot establish a trial-level eligibility assessment for this patient.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "238": {
        "output": "Based on the information provided, the patient is a 40-year-old woman who presents to the ER with excruciating pain in her right arm, without any past medical history that mentions scoliosis or any related condition. There is no mention of adolescent idiopathic scoliosis (AIS), and the patient's age does not meet the specified range of 14 to 16 years old as required by the clinical trial. Moreover, there is no indication that the patient has any spinal deformity, let alone a specific right thoracic scoliosis with a Cobb angle between 20 and 40\u00b0.\n\nThe inclusion criteria for the clinical trial are quite specific:\n- Female (the patient meets this criterion)\n- Between 14 and 16 years old (the patient does not meet this criterion)\n- Normal neurological examination (no information provided)\n- Right handed (no information provided)\n- Informed consent (no information provided)\n- Informed consent form signed by a parent or a holder of parental authority (not applicable as the patient is an adult)\n- Affiliated to medical insurance (no information provided)\n- Negative urine pregnancy test (no information provided)\n- For patients (A-STD): right thoracic scoliosis with a Cobb angle between 20 and 40\u00b0 (the patient does not meet this criterion)\n- For healthy volunteers (A-N): no clinical scoliosis (no information provided, but the patient's age is not within the required range)\n\nGiven the information available and the mismatch between the patient's age and the specified age range in the inclusion criteria, as well as the lack of any mention of scoliosis, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "239": {
        "output": "",
        "label": 0
    },
    "240": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 40-year-old woman\n- No past medical history\n- Presents with excruciating pain in her right arm without trauma\n- Tachypneic and tachycardic\n- Hypotensive (BP 80/60)\n- No discoloration or movement limitation in the right arm\n\nClinical Trial Inclusion Criteria:\n- Trauma patients \u2265 18 years of all severity stages\n- Admitted through the emergency room\n\nAssessment:\nThe clinical trial is specifically looking for trauma patients. The patient presented in the note does not report any trauma but is experiencing excruciating pain in her right arm. Although she is clearly in an emergency situation, there is no indication that her condition is a result of trauma. Therefore, she does not meet the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "241": {
        "output": "Based on the patient note and the clinical trial information provided, the patient is a 40-year-old woman presenting with excruciating pain in her right arm, which is unrelated to any trauma. The clinical trial in question is focused on patients with ankle fractures and the effectiveness of a compression treatment regimen post-surgery. The inclusion criteria for the trial are patients operated on at Nordsj\u00e6llands Hospital's department of Orthopaedic surgery for mono-, bi-, and trimalleolar fractures and an age above 18 years.\n\nGiven that the patient's condition (excruciating pain in the right arm) does not match the target condition of the clinical trial (ankle fractures), she would not be eligible for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "242": {
        "output": "The patient in the note is a 40-year-old woman who presents with excruciating pain in her right arm, with no past medical history of trauma. The clinical trial in question is focused on preventing intrusive memories and posttraumatic stress symptoms after an emergency cesarean section.\n\nTo determine the eligibility of the patient for the clinical trial, we must match the patient's characteristics and situation with the inclusion criteria specified by the trial:\n\n1. Female, aged 18+ years - The patient is a 40-year-old woman, so this criterion is met.\n2. Had emergency caesarean section within the past 6 hours - There is no indication in the patient note that she has had an emergency cesarean section, let alone within the past 6 hours.\n3. Have given birth to a live baby at \u2265 37 weeks gestation - The patient note does not mention pregnancy, childbirth, or any related events.\n\nGiven that the patient does not meet two of the three critical inclusion criteria for the clinical trial, specifically having had an emergency cesarean section and giving birth to a live baby at \u2265 37 weeks gestation, she would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "243": {
        "output": "",
        "label": 0
    },
    "244": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- A 40-year-old woman with excruciating pain in her right arm\n- No past medical history mentioned\n- Presents with tachypnea and tachycardia, hypotension but no fever\n- Right arm has no discoloration or movement limitation\n- No mention of tuberculosis (TB) symptoms or diagnosis\n\nClinical Trial Inclusion Criteria:\n- TB patients or suspected TB patients with specific symptoms/signs\n- Non-TB participants with clear lung disease but excluding pulmonary tuberculosis\n- Suspected TB participants with lung disease showing certain respiratory symptoms\n- Age 18 to 65 years old, no gender limitation\n- Consent and signed informed consent forms (ICF)\n- Willing to comply with follow-up\n\nGiven the information presented:\n- The patient does not exhibit symptoms or a diagnosis of tuberculosis or lung disease. The symptoms described in the patient note (excruciating arm pain, tachypnea, tachycardia, hypotension) are not consistent with TB or respiratory system diseases.\n- The patient's age falls within the inclusion criteria (18 to 65 years old).\n- There is no information given about the patient's consent or willingness to comply with follow-up, but this is a standard process for all trial participants.\n\nSince there is no indication that the patient has TB or a lung disease based on the patient note, and since the symptoms that the patient is presenting with do not match the inclusion criteria for the clinical trial, she would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "245": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial described, we need to compare the patient's characteristics to the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 25-year-old woman\n- Complaints of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Presence of a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Women aged 25 through 44\n- Body mass index (BMI) of 21 through 30\n\nBased on the patient note provided, the patient is a 25-year-old woman, which fits within the age range of 25 through 44 years required by the trial. However, the patient's BMI is not provided in the note. The patient's complaints, such as weight gain, suggest that she may be experiencing symptoms related to thyroid dysfunction (e.g., hypothyroidism), which is characterized by symptoms such as fatigue, hair loss, voice changes, weight gain, cold intolerance, and sometimes a thyroid mass. The presence of a midline cervical mass could also suggest a thyroid-related condition.\n\nWhile the patient's symptoms could potentially relate to weight changes, the specific information about her BMI is not included in the patient note. The BMI is a requirement for the trial inclusion, and without this information, we cannot conclusively determine her eligibility.\n\nTherefore, based on the information provided, further investigation would be needed to calculate her BMI and to determine if she fits within the BMI range of 21 through 30 as required by the clinical trial. If her BMI falls within the specified range, she would be eligible based on the age and BMI criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "246": {
        "output": "Based on the patient note and the inclusion criteria provided for the Thyroxine Titration Study, the patient's eligibility for the trial is as follows:\n\nThe patient is a 25-year-old woman, which satisfies the first criterion of being older than 18 years of age. She presents with symptoms that could be suggestive of hypothyroidism such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance. She also has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology.\n\nHowever, to determine her eligibility for this trial, we would need additional information:\n- Confirmation of primary hypothyroidism of \u22656 months duration, arising from autoimmune hypothyroidism, thyroidectomy, or radioiodine treatment.\n- Current thyroxine dose, which needs to be \u2265100 mcg/day.\n- Stability of the thyroxine dose in the past 2 months.\n- Current serum TSH level, which should be between 0.1-4.8 mU/L.\n- Information on the use of adequate contraceptive measures if she is of childbearing age.\n\nSince this information is not provided in the patient note, it is not possible to definitively determine her eligibility for the clinical trial. Therefore, further investigation is needed to acquire this information before considering a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "247": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial.\n\nPatient Note:\n- A 25-year-old woman\n- Complains of prolonged fatigue\n- No difficulty sleeping reported\n- Sleeps an average of 8 hours a night\n- Notable hair loss, change in voice, weight gain, and cold intolerance\n- Presence of a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Patients aged 25 with insomnia\n- Stable sleep/wake schedule with a preferred sleep phase between 10:00 PM and 8:00 AM\n- Residence in the Greater Rochester NY area\n- Diagnosis of Psychophysiological Insomnia according to the ICSD, with specific symptoms and duration\n\nThe patient in the note is indeed 25 years old, which matches the age requirement of the trial. However, the patient denies difficulty sleeping and does not complain of insomnia, which is a primary requirement for the study. The patient's symptoms are more indicative of a thyroid dysfunction (e.g., hypothyroidism, given the hair loss, voice change, weight gain, cold intolerance, and presence of a cervical mass), rather than insomnia.\n\nSince there is no indication that this patient has insomnia or impaired daytime function due to sleep disturbances, as required by the trial's inclusion criteria, we would not refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "248": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder (fatigue, hair loss, change in voice, weight gain, cold intolerance, and a cervical mass). The clinical trial in question is looking at the effects of weight loss on sleep-disordered breathing in obese, type 2 diabetic patients with obstructive sleep apnea.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Enrollment in Look AHEAD.\n2. Type II Diabetes and Sleep Apnea.\n\nThe patient note does not mention that the patient has type II diabetes or sleep apnea, nor does it state her enrollment in Look AHEAD. Instead, it presents a different set of symptoms that are not related to the inclusion criteria of the clinical trial.\n\nBased on the available information and the lack of any mention of the patient's diabetes status, obstructive sleep apnea, or enrollment in Look AHEAD, the patient does not meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "249": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and conditions with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics from the patient note:\n- 25-year-old woman\n- Complaints of prolonged fatigue\n- Sleeps an average of 8 hours a night\n- Hair loss, voice change, weight gain, cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical trial inclusion criteria:\n- 18 to 50 year old obese men and premenopausal women\n- BMI between 29-55\n- Chronically (for more than 6 months) sleep-deprived, defined as sleeping on a regular basis less than or equal to approximately 6-1/2 hours/night by history and objective devices\n\nClinical trial exclusion criteria of relevance:\n- Diagnosed sleep disorders\n- Unstable weight (voluntary losses in BMI greater than 5% over the past 6 months)\n- Untreated or uncontrolled diabetes\n- Severe uncontrolled hypertension\n- Other chronic organ disease diagnosis including COPD, chronic cardiac arrhythmia requiring treatments, gastro-esophageal disorders associated with sleep-related symptoms\n- Chronic use of prescription or over-the-counter medications known to affect sleep\n- Chronic fatigue syndrome and fibromyalgia\n- Endocrine disorders known to affect sleep, such as acromegaly, hypothyroidism (unless on a stable replacement dose of thyroid hormone), Cushing disease\n- Poorly controlled major depression\n- Medication and substance abuse\n- Pregnancy and lactation\n- Menopause\n- Chronic excessive caffeine use\n\nBased on the patient note, the patient does not meet the inclusion criteria for the clinical trial as she does not complain of sleep deprivation (she sleeps 8 hours a night) and there is no mention of her being obese (BMI between 29-55) or chronically sleep-deprived.\n\nMoreover, the patient's symptoms such as hair loss, voice change, weight gain, cold intolerance, and the presence of an anterior cervical mass suggest that she may have an underlying thyroid disorder, possibly hypothyroidism, which is listed as an exclusion criterion unless the patient is on a stable replacement dose of thyroid hormone. However, there is no information provided about her thyroid hormone levels or whether she has been diagnosed or is under treatment for hypothyroidism.\n\nGiven the available information, this patient does not meet the inclusion criteria for obesity and chronic sleep deprivation and potentially has an excluding condition (possible thyroid disorder), and thus would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "250": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, such as fatigue, hair loss, voice change, weight gain, cold intolerance, and a noticeable anterior cervical mass. These symptoms and physical findings do not align with the inclusion criteria specified for the clinical trial, which is focused on individuals diagnosed with type 2 diabetes and involves treatment with basal insulin therapy.\n\nThe inclusion criteria for the trial involve:\n- A diagnosis of type 2 diabetes\n- HbA1C <= 12.0% within the past 12 months\n- BMI <= 45.0 kg/m2\n- Initiation, addition of, change to, or continuation of basal insulin therapy with insulin detemir\n\nThere is no indication from the patient note that this woman has been diagnosed with type 2 diabetes, nor are there any details about her HbA1C levels, BMI, or any insulin therapy. Therefore, based on the information provided, she does not meet the inclusion criteria for the diabetes clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "251": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that could be suggestive of a thyroid disorder, such as prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms align with common manifestations of autoimmune thyroiditis (e.g., Hashimoto's thyroiditis).\n\nThe clinical trial in question is focusing on Selenium Treatment in Autoimmune Thyroiditis (AIT). The inclusion criteria for this trial are clinically approved AIT patients who do not use any medication other than LT4 (levothyroxine) to keep TSH in the lower half of the normal range.\n\nThe patient note does not provide enough information to determine with certainty whether the patient has AIT or whether she is taking LT4. Furthermore, it does not mention her thyroid-stimulating hormone (TSH) levels or whether she has been clinically approved as having AIT.\n\nGiven the absence of this critical information, an assessment of eligibility cannot be definitively made. However, the symptoms presented are suggestive of a thyroid condition that could potentially be AIT. Therefore, it would be prudent to consider referring the patient for further investigation to confirm the diagnosis and treatment status before making a final decision about her eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "252": {
        "output": "The patient note describes a 25-year-old woman with symptoms that are suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance, as well as a notable anterior cervical mass. These symptoms and examination findings could indicate primary hypothyroidism, but there's no clear evidence of secondary hypothyroidism (central hypothyroidism), which involves the pituitary gland.\n\nThe clinical trial is investigating treatment in patients with central hypothyroidism, specifically looking at body weight-adjusted doses of thyroxin and triiodothyronine supplementation. \n\nThe inclusion criteria for the clinical trial are:\n1. Hypopituitarism of at least 3 axes (TSH plus gonadotropin, somatotropin, corticotropin, or ADH deficiency)\n2. Termination of surgical or radiation treatment of pituitary tumors at least six months before study entry\n3. BMI of 20 - 39.9 kg/m2\n4. Non-smoking status\n\nBased on the information provided in the patient note, we cannot confirm that the patient meets any of the inclusion criteria. There is no mention of hypopituitarism, history of pituitary tumors, or the patient's BMI or smoking status.\n\nFor these reasons, the patient does not appear to meet the inclusion criteria for the clinical trial, and additional information would be required to determine her eligibility. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "253": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that are suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance. Additionally, she has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology.\n\nThe inclusion criteria for the clinical trial are focused on patients with manifest hypothyroidism or subclinical hypothyroidism, with specific TSH and T3/T4 levels defining each condition. However, the patient note does not provide any laboratory results to confirm a diagnosis of hypothyroidism or subclinical hypothyroidism. Without this information, we cannot definitively determine whether the patient meets the trial's inclusion criteria based on TSH and T3/T4 levels.\n\nGiven the symptoms described in the patient note, there is a suspicion of hypothyroidism, which makes the patient potentially relevant for the clinical trial. However, to confirm eligibility, further investigation is required to obtain the necessary thyroid function test results.\n\nTherefore, the trial-level eligibility for this patient would be:\n\n`Trial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.`",
        "label": 2
    },
    "254": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the trial.\n\nThe patient is a 25-year-old woman presenting with symptoms like fatigue, hair loss, voice change, weight gain, cold intolerance, and a noticeable cervical mass. These symptoms suggest she may have a thyroid disorder, possibly hypothyroidism. However, the clinical trial in question is specifically for preterm infants with hypothyroxinemia, which is not relevant to the adult patient described.\n\nThe inclusion criteria for the trial are:\n- Birth weight: less than 1500g\n- Gestation: 22 weeks 0 day \u2264\n- Serum free thyroxine level lower than 0.8 ng/dl\n- Serum thyrotropin lower than 10 \u03bcU/ml\n- Age of between 2 and 4 weeks after birth\n- Informed consent\n\nThe patient being an adult does not meet the criteria related to birth weight, gestation age, age after birth, or the specific condition being studied (hypothyroxinemia in VLBW infants).\n\nTherefore, the patient is not eligible for the clinical trial described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "255": {
        "output": "",
        "label": 0
    },
    "256": {
        "output": "Based on the patient note provided, the 25-year-old woman is experiencing symptoms such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance, as well as a noticeable anterior cervical mass. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the signs mentioned.\n\nComparing this patient's situation to the inclusion criteria of the clinical trial titled \"Weight Gain Prevention,\" we can see the following matches:\n\n1. Age 18-35: The patient is 25 years old, which fits within the specified age range.\n2. Interested in preventing weight gain: While the patient does report weight gain, there is no explicit statement of her interest in preventing further weight gain. However, given that weight gain is a concern, it could be inferred that she might be interested.\n\nThe only criterion that we do not have information on is her Body Mass Index (BMI). The trial requires a BMI between 23 and 30. Without knowledge of her height and weight, we cannot calculate her BMI and thus cannot confirm her eligibility based on this criterion.\n\nGiven that the patient fits two of the three known inclusion criteria but lacks information on BMI, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "257": {
        "output": "The patient is a 25-year-old woman presenting with symptoms of prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a uniform anterior cervical mass at the midline. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the presence of a thyroid mass and classic symptoms of low thyroid hormone levels.\n\nThe clinical trial in question is focused on the treatment of Essential Tremor (ET) using Pregabalin. The inclusion criteria for the trial specify that participants must have a diagnosis of ET based on the TRIG criteria, be aged between 18 and 80, be in generally good health, and meet certain other conditions, including medication restrictions and methods of contraception for women of childbearing age.\n\nBased on the information given, the patient does not present with symptoms of Essential Tremor and instead has symptoms that suggest a thyroid disorder. There is no mention of tremor, ET, or any related condition in the patient's note. Therefore, this patient does not meet the inclusion criteria for the clinical trial on Pregabalin in the treatment of Essential Tremor.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "258": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note:\n- A 25-year-old woman\n- Complaining of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- BMI 30-39.9 kg/m2\n- Age 25-50 years\n- No more than 3 kg weight loss during the past three months\n- Negative pregnancy test at entry; requirement for contraception if of childbearing potential\n\nAssessment:\n- The patient's age (25 years) fits within the trial's age criteria (25-50 years).\n- The trial requires participants to have a BMI between 30-39.9 kg/m2. There is no information provided about the patient's weight or height to calculate her BMI.\n- There is no mention of weight loss or gain specifics in the past three months, only that there has been weight gain over the previous 6 months.\n- There are no details provided about the patient's pregnancy status or contraception use.\n- The patient's symptoms suggest a possible thyroid disorder, which could be unrelated to the trial's focus on weight maintenance and the role of dairy.\n\nGiven the information provided, it is not possible to definitively determine the patient's BMI or other factors that would confirm eligibility for the trial. Therefore, further investigation would be needed to assess BMI and other relevant details such as pregnancy status and detailed weight history.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "259": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance. Additionally, she has a physical examination finding of a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of a thyroid gland abnormality.\n\nThe clinical trial in question is looking for premenopausal women with overt primary hypothyroidism, characterized by reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis who have not received thyroid hormones.\n\nWhile the patient's symptoms are suggestive of hypothyroidism, the patient note does not explicitly confirm the diagnosis of primary hypothyroidism with laboratory values (reduced T4 and increased TSH concentrations). Furthermore, it does not mention the menopausal status of the patient, nor does it indicate whether the patient has received thyroid hormone treatment in the past.\n\nBecause the patient note lacks specific laboratory confirmation of hypothyroidism, as well as details on the patient's menopausal status and prior thyroid hormone treatment, we cannot definitively determine if she meets the inclusion criteria based solely on the information provided.\n\nTherefore, the patient may potentially be a candidate for the clinical trial, but further investigation is needed to confirm the diagnosis of hypothyroidism and other inclusion criteria. Thus, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "260": {
        "output": "Let's assess the eligibility of the 25-year-old woman for the clinical trial \"Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units\" based on the inclusion criteria provided:\n\n1. The patient must be between 18 and 64 years of age (this patient is 25, so she meets this criterion).\n2. The patient must be English-speaking (the patient note does not specify language proficiency, so we would need more information).\n3. The patient must be currently receiving a serotonergic agent or scheduled to receive a new or change in serotonergic psychotropic agents for their psychiatric condition, or have been on a stable regimen without any weight gain in the last 3 months (the patient note does not mention any psychiatric condition or serotonergic medication usage, so we cannot determine eligibility based on this criterion without further information).\n4. The subject must have capacity to obtain and give informed consent (we would need more information to determine this).\n5. The subject must express concern about weight gain as a potential serotonin side effect (the patient note mentions weight gain, but not in the context of serotonergic medication side effects, so we would need more information).\n6. The patient must be in good health as determined by a medical and psychiatric history, medical examination, and cannot have major medical illness (the patient note mentions symptoms that may suggest a thyroid disorder, e.g., hair loss, voice change, cold intolerance, and a cervical mass, which could be indicative of a medical illness; thus, we would need more information).\n7. Women must meet certain criteria regarding contraception, pregnancy, and childbearing potential (the patient note does not provide information on this, so we would need more information).\n8. The patient must be willing and able to comply with study restrictions and remain at the clinic for the required duration, and willing to return for follow-up (we would need more information to determine this).\n9. The patient must be a voluntary admission inpatient at SUNY Upstate Medical University's Psychiatric department to enroll in the study (the patient note does not mention any current hospitalization, so we would need more information).\n\nBased on the information provided, we cannot determine whether the patient is currently receiving serotonergic medication, is concerned about weight gain due to these medications, is in good health without major medical illness, meets the contraception requirements, or is a voluntary inpatient at the specified institution. Therefore, further investigation would be needed to determine if this patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "261": {
        "output": "",
        "label": 0
    },
    "262": {
        "output": "Based on the patient note provided, the 25-year-old woman is complaining of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and has a prominent, soft, uniform anterior cervical mass at the midline. These symptoms are suggestive of a thyroid disorder, possibly hypothyroidism, given the presence of a cervical mass (likely the thyroid gland), fatigue, weight gain, and cold intolerance.\n\nThe clinical trial in question is focused on patients with fibromyalgia, and the inclusion criteria specifically require a diagnosis of fibromyalgia using ACR (American College of Rheumatology) criteria. There is no mention in the patient note of musculoskeletal pain, tender points, or other symptoms consistent with fibromyalgia. Furthermore, fibromyalgia is a diagnosis of exclusion, and symptoms of thyroid dysfunction would likely need to be addressed and ruled out before considering a fibromyalgia diagnosis.\n\nGiven that the patient's symptoms do not align with the inclusion criteria of the clinical trial, and there is no information to suggest that the patient has been diagnosed with fibromyalgia, the patient would not be eligible for this specific study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "263": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She presents with symptoms suggestive of a thyroid disorder (prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and anterior cervical mass).\n\nClinical Trial Analysis:\n- The title of the clinical trial is \"Overnight Weight Loss and Sleep Structure.\"\n- The study aims to evaluate overnight weight loss in relation to sleep structure, compare weight loss during sleep versus awake rest, and compare night weight loss profiles between normal and obese volunteers.\n- The inclusion criteria for the clinical trial are not very detailed but mention \"normal and obese volunteers.\"\n\nAlthough the patient presents with symptoms that may indicate a thyroid disorder and not specifically related to sleep or weight concerns, the trial does not specify any exclusion criteria that would prevent her from participating based on these symptoms. Given that the trial is accepting \"normal and obese volunteers,\" and no other specific characteristics are required, the patient's current health status does not appear to disqualify her.\n\nHowever, without additional information on the patient's weight status (normal or obese) and without any specific exclusion criteria provided from the trial, it is not possible to determine with high certainty whether this patient should be referred. Therefore, further investigation would be needed to assess the patient's weight status and other potential factors that may affect her eligibility for the trial in question.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "264": {
        "output": "The patient in question is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder, given the complaints of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms and findings are not consistent with the diagnosis of rheumatoid arthritis (RA).\n\nThe clinical trial provided is investigating the role of sleep and immunity in patients with rheumatoid arthritis and is specifically targeting those who meet the American College of Rheumatology revised criteria for RA, which include joint-related symptoms and findings, presence of serum rheumatoid factor, and radiographic changes, among others. The patient described in the note does not mention any joint complaints, rheumatoid nodules, serum rheumatoid factor, or radiographic changes that suggest RA. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nBased on the information provided, this patient does not have a diagnosis of rheumatoid arthritis and does not meet the inclusion criteria specified for the clinical trial focused on sleep and immunity in RA patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "265": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She is presenting with symptoms of fatigue, hair loss, voice change, weight gain, and cold intolerance.\n- She has a prominent, soft, uniform anterior cervical mass at the midline.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking for obese and morbidly obese women (BMI 30 - 50).\n- The women must be 25 years and older.\n- They must be undergoing laparoscopic gastric bypass surgery.\n- They must present with at least either metabolic syndrome or diabetes.\n\nComparison:\n- The patient's age matches the inclusion criteria (25 years and older).\n- There is no information provided about the patient's BMI or obesity status.\n- The trial specifically targets patients undergoing laparoscopic gastric bypass surgery, which is not mentioned in the patient note.\n- The patient does not mention having metabolic syndrome or diabetes, and the symptoms described may suggest a thyroid issue rather than the conditions required for the trial.\n\nGiven the information available, the patient does not seem to meet the key inclusion criteria for the clinical trial, particularly regarding the requirement for laparoscopic gastric bypass surgery and having metabolic syndrome or diabetes.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "266": {
        "output": "Based on the patient note, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, possibly hypothyroidism, given the fatigue, hair loss, voice change, weight gain, cold intolerance, and the presence of a cervical mass. There is no mention of lung cancer or any details that would suggest a diagnosis of stage IIIB/IV lung adenocarcinoma with EGFR mutations.\n\nThe clinical trial in question is specifically for patients who have been diagnosed with stage IIIB/IV lung adenocarcinoma with EGFR mutations and who have not received any prior treatment for lung adenocarcinoma. The inclusion criteria for the trial are quite clear, and the patient described does not fit these criteria, as there is no information provided about a lung adenocarcinoma diagnosis or EGFR mutations.\n\nSince the patient's condition and the inclusion criteria for the clinical trial do not match, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "267": {
        "output": "The patient note describes a 25-year-old woman with symptoms suggestive of hypothyroidism, such as prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a noticeable anterior cervical mass. The clinical trial in question is an observational study on the initial treatment of hypothyroidism in France.\n\nThe inclusion criteria for the clinical trial are:\n1. Recently diagnosed hypothyroid subject (either during the inclusion period, or within the 6 previous months)\n2. Subject who has given his/her oral consent for participation\n\nBased on the information provided in the patient note, this patient seems to meet the criteria for the clinical trial, assuming her symptoms and the cervical mass lead to a diagnosis of hypothyroidism, and that this diagnosis is recent (within the last 6 months). However, the note does not explicitly state that she has been diagnosed with hypothyroidism, only that she presents with symptoms that could indicate this condition.\n\nGiven that the patient's symptoms are highly suggestive of hypothyroidism and align with the focus of the clinical trial, and assuming the diagnosis is confirmed and recent, there is potential for the patient to be eligible for the trial. However, further investigation is needed to confirm the diagnosis and recency before she can be referred.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "268": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms suggestive of hypothyroidism rather than major depressive disorder (MDD). The symptoms include prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent anterior cervical mass, which could indicate a thyroid issue.\n\nThe clinical trial in question is specifically looking at the utilization of Desvenlafaxine Succinate Sustained-Release (Pristiq) among psychiatrists and primary care physicians in the treatment of patients with major depressive disorder (MDD). The inclusion criteria for patients in this trial are quite clear: patients must be diagnosed with MDD and treated with pharmacotherapy.\n\nSince the patient described does not have a diagnosis of MDD, she does not meet the inclusion criteria for this clinical trial. Therefore, it would not be appropriate to refer her to this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "269": {
        "output": "",
        "label": 0
    },
    "270": {
        "output": "The patient note describes a 25-year-old woman presenting with symptoms suggestive of hypothyroidism (fatigue, hair loss, change in voice, weight gain, cold intolerance) and a physical finding of an anterior cervical mass, which could suggest a thyroid origin of her symptoms. However, there is no specific mention of pituitary surgery or radiotherapy, nor is there laboratory documentation provided to confirm central hypothyroidism or other hormonal deficiencies.\n\nThe clinical trial is looking for patients with clinical evidence of central hypothyroidism, specifically those who have undergone pituitary surgery and/or radiotherapy, along with laboratory confirmation of central hypothyroidism. The trial also includes patients with concurrent hormonal deficiencies in other axes.\n\nSince there is no evidence in the patient note to suggest that the patient has undergone pituitary surgery or radiotherapy, nor is there laboratory evidence of central hypothyroidism provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "271": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of thyroid dysfunction (fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass). There is no mention of melanoma or any form of cancer, let alone metastatic melanoma which is the target disease for the clinical trial in question.\n\nThe inclusion criteria for the clinical trial explicitly require:\n- Histologically confirmed melanoma with evidence of metastatic disease\n- Measurable disease by physical examination or radiologic assessment\n- Specific requirements related to prior treatments, blood counts, organ function, HLA typing, agreement to undergo biopsy, and willingness to use contraception if of child-bearing potential\n\nGiven that there is no indication that the patient has melanoma, much less metastatic melanoma, she does not meet the fundamental inclusion criteria for the clinical trial. Therefore, it would not be appropriate to refer this patient to the trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "272": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the study. The clinical trial is focused on male patients aged 18 to 70 years old with androgenetic alopecia, as determined by the Hamilton-Norwood Scale. The patient in the note is a 25-year-old woman presenting with symptoms that suggest a thyroid issue (fatigue, hair loss, voice changes, weight gain, cold intolerance, and a cervical mass), which is not related to androgenetic alopecia.\n\nTherefore, the patient does not meet the gender and condition-specific inclusion criteria of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "273": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of a thyroid disorder: fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms could be consistent with autoimmune thyroiditis, such as Hashimoto's thyroiditis, but there is no explicit mention of her having positive antibodies against thyroid peroxidase or sonographic evidence, which are required according to the inclusion criteria of the clinical trial.\n\nThe clinical trial is focused on subjects with autoimmune thyroiditis and specifically mentions the need for positive antibodies against thyroid peroxidase and sonographic evidence consistent with Hashimoto's thyroiditis.\n\nSince we do not have information regarding her antibodies status or sonographic findings, further investigation would be necessary to determine if she has autoimmune thyroiditis and meets the specific inclusion criteria of the trial.\n\nTherefore, the trial-level eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "274": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms that are suggestive of hypothyroidism, such as prolonged fatigue, hair loss, a change in voice, weight gain, and cold intolerance. Additionally, she has a prominent, soft, uniform anterior cervical mass at the midline, which could be indicative of thyroid pathology. However, the clinical trial in question is focused on central hypothyroidism, a specific form of hypothyroidism due to insufficient stimulation by thyroid-stimulating hormone (TSH) from the pituitary gland, typically in the setting of pituitary insufficiency.\n\nThe inclusion criteria for the trial specify that all patients must have pituitary hypopituitarism. The patient note does not mention pituitary hypopituitarism or any other signs of pituitary dysfunction. The symptoms mentioned could suggest primary hypothyroidism, but there is no clear indication of central hypothyroidism or pituitary involvement.\n\nWithout further information confirming a diagnosis of pituitary hypopituitarism, we cannot assume that this patient would meet the inclusion criteria based solely on the symptoms described. Therefore, additional investigation, such as hormone level testing and imaging, would be needed to determine if the patient has central hypothyroidism due to pituitary insufficiency.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "275": {
        "output": "Based on the information provided in the patient note, the patient is a 25-year-old woman presenting with symptoms that may suggest hypothyroidism, such as prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance. The clinical examination finding of a prominent, soft, uniform anterior cervical mass at the midline could also be related to thyroid pathology. However, there is no mention of Down syndrome or any karyotype analysis in the patient's note.\n\nThe clinical trial in question is specifically targeting young children with Down syndrome and aims to assess the efficacy of treatment with L-thyroxine and folinic acid on their psychomotor development. The inclusion criteria also specify the need for a karyotype demonstrating trisomy 21 and an age range of 6 to 18 months, among other things.\n\nGiven that the patient described does not fit the age criterion (25 years old vs. the required 6 to 18 months), does not have a diagnosis of Down syndrome, and the trial is specifically for a very different patient population (young children with Down syndrome), this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "276": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it appears that the patient may have symptoms suggestive of hypothyroidism, such as fatigue, hair loss, voice change, weight gain, and cold intolerance, along with a notable anterior cervical mass. However, there is no mention in the patient note of a confirmed diagnosis of primary hypothyroidism or that the patient has been on levothyroxine treatment for at least 6 months, which are part of the inclusion criteria for the clinical trial.\n\nGiven the information provided:\n\n- The patient is within the age range of 18 to 65 years old, meeting that aspect of the inclusion criteria.\n- The symptoms presented could be consistent with hypothyroidism, and the presence of an anterior cervical mass might suggest thyroid pathology which could be related to her symptoms.\n- There is no confirmation of a hypothyroidism diagnosis or levothyroxine treatment history in the patient note.\n\nWe would need additional information to definitively assess the patient's eligibility, such as confirmation of a hypothyroidism diagnosis and details of any current or past treatments. Therefore, based on the available information, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "277": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Trastuzumab & Pertuzumab Followed by T-DM1 in MBC\", we need to compare the patient's information with the inclusion and exclusion criteria of the trial.\n\nPatient Information:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria for First-Line Therapy:\n- Histologically confirmed breast cancer with distant metastases\n- HER2-positive tumor according to central pathology testing\n- Women aged \u226518 years\n- WHO performance status 0 to 2\n- Adequate organ function with specified laboratory results\n- LVEF \u226550%\n\nClinical Trial Exclusion Criteria for First-Line Therapy:\n- Prior chemotherapy for inoperable locally advanced or metastatic breast cancer (exceptions apply)\n- Prior anti-HER2 treatment for metastatic or inoperable breast cancer (exceptions apply)\n- More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month (exceptions apply)\n- Known leptomeningeal or CNS metastases\n- Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion)\n\nBased on the patient note, there is no mention of breast cancer or HER2-positive status, which are critical inclusion criteria for the clinical trial. The patient's symptoms and the presence of an anterior cervical mass suggest a possible thyroid issue rather than breast cancer. Therefore, there is no indication that this patient would be eligible for a clinical trial focusing on HER2-positive metastatic breast cancer treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "278": {
        "output": "Based on the given patient note and the inclusion criteria of the clinical trial, we can analyze the patient's eligibility:\n\nPatient Note Summary:\n- 25-year-old woman\n- Presents with prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance over the past 6 months\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Summary:\n- Focus on differentiated thyroid cancer (DTC) follow-up\n- Aims to induce TSH elevation by decreasing the L-thyroxin dose\n\nInclusion Criteria for the Clinical Trial:\n- Differentiated thyroid cancer\n- Treated by thyroidectomy and at least 1 ablation with 131-I > 5 months ago\n- TSH < 4 imU/L\n\nComparison:\n- The patient presents with symptoms that could be indicative of a thyroid issue (fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass), which might suggest thyroid cancer, but there is no explicit mention of a diagnosis of differentiated thyroid cancer.\n- There is no information provided regarding treatment history, such as thyroidectomy or radioiodine treatment.\n- The patient's TSH levels are not provided.\n\nConclusion:\nThe information given does not confirm that the patient has been diagnosed with differentiated thyroid cancer, nor does it provide any details about treatments she may have undergone (such as thyroidectomy or radioiodine ablation), or her current TSH levels. Therefore, based on the information provided, we cannot definitively determine if the patient has met the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation. \n\nFurther investigation into the patient's medical history, specifically regarding the presence of differentiated thyroid cancer, treatment received, and current TSH levels, would be necessary to accurately determine eligibility.",
        "label": 1
    },
    "279": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Ages 40\u201375 years old\n- Diagnosis of overt or subclinical hypothyroidism on two occasions with a minimum interval period of three months\n\nThe patient in question is 25 years old, which does not meet the age criterion of the clinical trial that requires participants to be between 40 and 75 years old. Although the symptoms and the presence of an anterior cervical mass suggest the possibility of hypothyroidism, which is relevant to the clinical trial, the age mismatch alone is sufficient to determine that the patient is not eligible for this particular trial.\n\nTherefore, the trial-level eligibility for this patient is:\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "280": {
        "output": "Based on the patient note provided, the patient is a 25-year-old woman presenting symptoms that are suggestive of a thyroid disorder, indicated by fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent cervical mass. The clinical trial in question is specifically targeting emergency physicians to study the effect of stress and work shifts on biomarkers.\n\nThe patient described does not meet the inclusion criterion for the clinical trial, as she is not an emergency physician. Therefore, there is no relevance of her symptoms or potential diagnosis to the objectives of the clinical trial, and she would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "281": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism: prolonged fatigue, hair loss, voice change, weight gain, and cold intolerance, along with a noticeable anterior cervical mass, which could be indicative of a thyroid issue such as a goiter.\n\nThe clinical trial in question is focused on the prevention of chemotherapy-induced alopecia in women with breast cancer undergoing certain types of neoadjuvant or adjuvant chemotherapy. To be eligible for this trial, a patient must meet the following inclusion criteria:\n\n1. New diagnosis of breast cancer stage 1-2.\n2. Planning to undergo neoadjuvant or adjuvant chemotherapy with a curative intent.\n3. Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or taxane-based chemotherapy regimen.\n4. The patient must meet specific chemotherapy regimen requirements.\n5. Concurrent use of trastuzumab and/or pertuzumab at standard doses is allowed.\n6. TSH within normal range collected within 1 year prior to treatment.\n7. If the patient has a history of diabetes, Hemoglobin A1c must be drawn within 3 months prior to treatment and be within normal limits.\n8. CBC and CMP should be done within 4 weeks prior to treatment and found to be within acceptable limits.\n\nThe patient in the note does not mention a diagnosis of breast cancer or any plan to undergo chemotherapy. Therefore, based on the available information, this patient would not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "282": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms consistent with hypothyroidism (prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a prominent thyroid mass). There is no mention of a cancer diagnosis, let alone advanced stage III or IV cancer, which is a requirement for the clinical trial in question.\n\nGiven that the inclusion criteria for the clinical trial specifically require participants to have a stage III or IV cancer diagnosis, and there's no indication that the patient has cancer, she would not meet the criteria for this particular study. Additionally, the trial requires participants to have a Karnofsky Performance Status score and to have been cleared for physical activity, neither of which is addressed in the patient note.\n\nTherefore, based on the information given, the patient does not meet the trial's inclusion criteria. The assessment of eligibility for this patient for the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "283": {
        "output": "To determine the trial-level eligibility for this patient, we need to compare the patient's characteristics with the inclusion criteria of the clinical trial:\n\nPatient Characteristics:\n- 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical Trial Inclusion Criteria:\n- Men and women between 25 and 65 years of age\n- Overweight or Class I or Class II BMI\n- Walk without assistance\n- Commit to a schedule of assessment visits\n\nThe patient is a 25-year-old woman, which fits the age criterion. However, there is no information provided about her being overweight or about her BMI classification, which is a crucial piece of information necessary to meet the clinical trial's inclusion criteria. Furthermore, there is no mention of her ability to walk without assistance or her willingness to commit to a schedule of assessment visits. \n\nThe patient's symptoms (prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance, along with a thyroid mass) suggest a possible thyroid disorder, which is not related to the purpose of the clinical trial focused on obesity and lifestyle changes. \n\nGiven the lack of information on her BMI and the fact that the patient's presenting symptoms do not align with the focus of the trial on preventing long-term weight gain in overweight and obese adults, I would not refer this patient for this clinical trial without further information confirming her BMI status.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "284": {
        "output": "Based on the patient note provided:\n\nThe patient is a 25-year-old woman who presents with symptoms suggestive of a thyroid disorder: prolonged fatigue, hair loss, voice changes, weight gain, cold intolerance, and a anterior cervical mass, which could indicate a thyroid condition such as hypothyroidism.\n\nNow, let's compare this to the clinical trial inclusion criteria:\n\n1. 18 years of age or older - The patient meets this criterion.\n2. Known Asthma - There is no mention of asthma in the patient's note.\n3. The exacerbation is defined as moderate or severe - Since asthma is not mentioned, there is no exacerbation.\n4. Not currently enrolled as an active participant in another clinical trial - There's no information provided about participation in other clinical trials.\n5. The patient or first degree family relative (in cases where the patient is intubated) has authorized his/her consent to participate in this trial - Consent can be obtained if the patient agrees to participate.\n\nThe key eligibility factor that is not met is the diagnosis of asthma and specifically an asthma exacerbation. The patient's presentation does not suggest asthma or an exacerbation; instead, her symptoms point towards a possible thyroid disorder.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on Thyroid Hormones Treatment in Asthma Exacerbation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "285": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient in question does not meet the specific requirements for this clinical trial. The trial is focused on pregnant women with hypothyroidism who are being treated with levothyroxine (L-T4). The patient note does not mention pregnancy or a confirmed diagnosis of hypothyroidism being treated with L-T4, although symptoms such as fatigue, hair loss, voice changes, weight gain, cold intolerance, and a cervical mass could suggest hypothyroidism. However, without confirmation of both pregnancy and a hypothyroidism diagnosis being actively treated with L-T4, the patient does not meet the inclusion criteria as listed.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "286": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms suggestive of a thyroid disorder: prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent anterior cervical mass. These symptoms could be indicative of Hashimoto's thyroiditis (HT), but the note does not confirm a diagnosis of HT nor does it mention the presence of positive serum anti-TPO antibody or anti-thyroglobulin antibody, which are required for the diagnosis according to the trial's inclusion criteria. Additionally, there is no information provided about the patient's thyroid function tests (free T4 and TSH levels) to confirm a euthyroid state.\n\nGiven the lack of specific diagnostic information and thyroid function test results, I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis of HT and ensure she meets the euthyroid criteria. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "287": {
        "output": "Based on the patient note, the 25-year-old woman is presenting with symptoms that are suggestive of a thyroid disorder, including fatigue, hair loss, change in voice, weight gain, cold intolerance, and the presence of an anterior cervical mass. These symptoms could potentially indicate hypo- or hyperthyroidism, which is relevant to the clinical trial in question.\n\nThe clinical trial is looking to study the prevalence of thyroid disorders in Malaysia, including hypo- and hyperthyroidism, and its association with different ethnicity and iodine status. The inclusion criteria for the clinical trial are quite broad: participants must be aged 18 years or older at the time of sampling and be Malaysian citizens.\n\nGiven that the patient is 25 years old, she meets the age criterion. However, the patient note does not specify her ethnicity or citizenship. Assuming the patient is a Malaysian citizen (since the patient presents to a clinic and the trial is a nationwide multicentre study in Malaysia), she would meet the criteria based on age and potentially the presenting symptoms suggestive of a thyroid disorder.\n\nHowever, without confirmation of the patient's citizenship, it is not possible to definitively determine her eligibility for the trial. Therefore, further investigation is required to ascertain her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "288": {
        "output": "Based on the information provided, the patient is a 25-year-old woman who presents with symptoms of prolonged fatigue, hair loss, change in voice, weight gain, cold intolerance, and a noticeable anterior cervical mass. These symptoms suggest an endocrine disorder, possibly related to thyroid function, but there is no indication that the patient has been referred by a primary care physician for health coaching, nor is there any information regarding inadequate sleep, poor diet, physical inactivity, or the need for weight loss as per the recommendation of a health care provider. Additionally, the patient falls short of the inclusion criteria regarding age, as she is 25 years old and the study requires participants to be 21 years and over. \n\nHowever, the patient does meet the criteria of being an adult and presumably speaks English, given she is presenting to the clinic and communicating her symptoms. There is no information provided about whether she has a telephone for follow-up, but this is a common possession and could easily be confirmed.\n\nGiven the lack of explicit referral for health coaching, the age discrepancy, and the absence of information about whether a telephone is available for follow-up, this patient does not clearly meet all of the stated inclusion criteria for the clinical trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "289": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 25-year-old woman.\n- She presents with prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass.\n- There is no mention of insomnia or sleep-related issues.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 21 and 80 years. (The patient is 25 years old, which meets this criterion.)\n- Must have a diagnosis or meet the Research Diagnostic Criteria for insomnia disorder. (The patient note does not mention insomnia or difficulty sleeping.)\n- Score > 14 on the Insomnia Severity Index. (There is no information on whether the patient has been evaluated with this index.)\n- Report insomnia for > 3 months. (There is no mention of insomnia duration in the patient note.)\n- Have sleep difficulties > 3 nights per week. (The patient denies difficulty sleeping.)\n- Score < 3 on the Epworth Sleepiness Scale (ESS). (There is no information on the patient's ESS score.)\n- Score > 40 on the Hyperarousal Scale and report an inability to nap in the daytime. (There is no information on the patient's Hyperarousal Scale score or her ability to nap.)\n\nGiven that the patient does not present with insomnia or related sleep issues, she does not appear to meet the inclusion criteria for a trial focused on the impact of hyperarousal on cognitive task performance among insomnia sufferers. There is no evidence in the patient note that would align with the requirements of the trial, particularly the need for a diagnosis of insomnia disorder and related sleep difficulties.\n\nTherefore, the patient is not a match for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "290": {
        "output": "The patient is a 25-year-old woman presenting with symptoms of prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent cervical mass. These symptoms and clinical findings suggest that the patient may have a thyroid disorder, such as hypothyroidism, rather than androgenetic alopecia (female pattern hair loss), which is the target condition for the clinical trial.\n\nThe inclusion criteria for the clinical trial titled \"Hairstetics\u2122 Anchoring System in Female Pattern Hair Loss (HAS-FPHL)\" are as follows:\n\n- Age \u2265 19 yrs.\n- Female patients with androgenetic alopecia (FPHL).\n- Specific pre-treatment hematology and coagulation values within the stated limits.\n- A life expectancy of at least the duration of the trial.\n- Signed informed consent and post-implantation protocol.\n\nThe patient note does not mention androgenetic alopecia, nor does it provide the necessary hematology and coagulation values. Furthermore, the symptoms described do not align with FPHL but rather suggest a different medical issue. Therefore, based on the information provided, the patient does not meet the inclusion criteria specified for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "291": {
        "output": "Given the patient note:\n\n- The patient is a 25-year-old woman.\n- She presents with symptoms suggestive of hypothyroidism (fatigue, hair loss, voice changes, weight gain, cold intolerance, and a midline anterior cervical mass).\n\nGiven the clinical trial:\n\n- The trial is looking for participants who are:\n  - \u226518 years old\n  - In a low-risk singleton pregnancy\n  - Entering the last trimester of pregnancy (in the range of 26-30 weeks of gestation)\n  - Residing in the Greater Accra Metropolitan Area or area served by the Korle Bu Teaching Hospital\n  - Fluent in either English, Twi, or Ga.\n\nThe patient note does not indicate that the woman is pregnant, let alone in her last trimester of pregnancy. Therefore, she does not meet the essential inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "292": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note summary:\n- A 25-year-old woman\n- Complains of prolonged fatigue, hair loss, change in voice, weight gain, and cold intolerance\n- Has a prominent, soft, uniform anterior cervical mass at the midline\n\nClinical trial summary:\n- Title: The GlasVEGAS Study\n- Focus: Investigating fat storage and metabolic risk factors associated with weight gain and loss in South Asians and Europeans\n- Inclusion criteria: Men of European or South Asian origin, BMI <25 kg/m^2, weight stable for >6 months\n\nThe patient in the note is a 25-year-old woman with symptoms suggestive of a thyroid condition, given the presence of a cervical mass and symptoms like fatigue, hair loss, and cold intolerance. The clinical trial is specifically looking for men of European or South Asian origin with a BMI <25 kg/m^2 who have been weight stable.\n\nThe patient does not meet the gender requirement (the study is looking for men) nor the ethnic background criteria specified for the study (European or South Asian origin).\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "293": {
        "output": "The patient note describes a 25-year-old woman with symptoms suggestive of a thyroid disorder, such as fatigue, hair loss, voice changes, weight gain, and cold intolerance. She also has a notable anterior cervical mass, which could be indicative of a thyroid enlargement or goiter.\n\nThe clinical trial aims to analyze DNA methylation status in patients with autoimmune thyroid diseases, specifically Hashimoto Thyroiditis (HT) and Graves Disease (GD). The inclusion criteria for HT include positive titers of anti-TPO or anti-Tg antibodies and at least one of the following: abnormal thyroid function requiring substitution treatment, increased volume of thyroid gland, or morphological changes on ultrasound of the thyroid gland. For GD, the criteria include positive titers of anti-TSI antibodies, decreased TSH levels, and increased levels of fT4 or fT3.\n\nTo determine the eligibility of this patient for the trial, we would need additional information regarding her thyroid function tests (including TSH, fT4, fT3) and antibody status (anti-TPO, anti-Tg for HT, and anti-TSI for GD). An ultrasound could also provide evidence of morphological changes in the thyroid gland.\n\nGiven the patient's symptoms and the presence of a thyroid mass, she is a candidate for further testing to confirm a diagnosis of an autoimmune thyroid disease. If such a diagnosis is made and meets the trial's inclusion criteria, she could potentially be a candidate for the study. However, based on the information provided in the patient note alone, we do not have enough information to determine whether she meets the specific inclusion criteria for this trial, particularly the laboratory and ultrasound findings.\n\nTherefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "294": {
        "output": "Based on the patient note provided, the 25-year-old woman is presenting with symptoms that may suggest hypothyroidism, such as fatigue, hair loss, voice change, weight gain, cold intolerance, and a notable anterior cervical mass. However, the clinical trial in question specifically targets patients with subclinical hypothyroidism following head and neck surgery for cancer, treated with curative intent.\n\nThe patient note does not mention any history of head and neck cancer, surgery, or any indication that she has been treated for such conditions. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which requires a diagnosis of head and neck cancer treated with surgery, and a subsequent diagnosis of subclinical hypothyroidism.\n\nGiven the information provided, the patient does not appear to be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "295": {
        "output": "",
        "label": 0
    },
    "296": {
        "output": "Based on the patient note provided, the 25-year-old woman presents with symptoms suggestive of hypothyroidism, such as prolonged fatigue, hair loss, voice change, weight gain, cold intolerance, and a prominent, soft, uniform anterior cervical mass at the midline, which could possibly be an enlarged thyroid gland.\n\nThe clinical trial in question is looking for patients aged 20 to 80 years scheduled to receive neck dissection due to head and neck cancer. The patient described does not have a diagnosis of head and neck cancer, and there is no indication that she is scheduled to receive neck dissection.\n\nTherefore, this patient does not meet the inclusion criteria of the clinical trial, which specifically requires patients to have head and neck cancer and be scheduled for neck dissection.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "297": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient does not meet the key criteria for this clinical study. The patient is a 25-year-old woman presenting with symptoms suggestive of a thyroid disorder (fatigue, hair loss, voice change, weight gain, cold intolerance, and a cervical mass), which is not related to pediatric obstructive sleep apnea/hypopnea syndrome (OSAHS). Additionally, the trial specifically targets children between 2 and 18 years old with confirmed OSAHS, which is not applicable to this patient.\n\nTherefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "298": {
        "output": "Based on the patient note provided, the 30-year-old woman presents with shortness of breath, but there is no indication that she has been diagnosed with breast or lung cancer, which are the target diseases for the clinical trial in question. The inclusion criteria for the trial clearly state that patients must have a diagnosis of local or metastatic breast or lung cancer and that the shortness of breath must have started after the cancer diagnosis. Given that the patient does not meet these key inclusion criteria, she would not be eligible for the acupuncture for shortness of breath in cancer patients clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "299": {
        "output": "The patient described in the note is a 30-year-old woman presenting with shortness of breath. To determine if she is eligible for the clinical trial titled \"BNP Testing in Patients With SOB on Presentation to ED,\" we need to compare her characteristics to the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are:\n\n1. Patients presenting to the ED with shortness of breath.\n2. Patients who are over 40 years old.\n3. Patients with an emergency department triage category of 3 or higher.\n\nThe patient in the note does meet the first criterion, as she presents with shortness of breath. However, she does not meet the second criterion because she is only 30 years old. The third criterion regarding the emergency department triage category is not mentioned in the patient note.\n\nBased on the information provided, the patient does not meet one of the key age criteria for the trial. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "300": {
        "output": "",
        "label": 1
    },
    "301": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 30-year-old woman presents with shortness of breath that started 2 hours before admission.\n- She is tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%.\n- Chest X-ray and CBC are normal.\n- She recently gave birth 3 weeks prior.\n- There is no mention of pulmonary hypertension (mean PA > 35 mmHg), ARDS, or signs of heart failure.\n\nClinical Trial Inclusion Criteria:\n- Patients admitted to the ICU with pulmonary hypertension (mean PA > 35 mmHg).\n- Patients in ICU with postoperative pulmonary hypertension (mean PA > 35 mmHg).\n- Patients with ARDS (PaO2/FiO2 < 200, bilateral infiltrates on chest X-ray, and a wedge < 20 mm Hg).\n\nThe patient in the provided note does not directly meet any of the specified inclusion criteria for the clinical trial. There is no indication that the patient has pulmonary hypertension or ARDS, nor is there information on any postoperative conditions or the specific pulmonary arterial pressure. Additionally, the chest X-ray is noted as normal, which would not fit the criteria for ARDS that requires bilateral infiltrates.\n\nGiven the information provided, the patient does not appear to have the conditions being studied in the clinical trial (pulmonary hypertension or ARDS). Therefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "302": {
        "output": "",
        "label": 0
    },
    "303": {
        "output": "After reviewing the patient note and the clinical trial information, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 30-year-old woman\n- Gave birth 3 weeks prior\n- Presenting with shortness of breath\n\nClinical Trial Inclusion Criteria:\n- Must be 18 years or older\n- Must have been pregnant and enrolled by 10 weeks of gestation\n- Planned to carry pregnancy to term\n- No plans to move before delivery\n- English speaking\n- Found to have fibroids at either their 7-week or 22-week ultrasound examination during pregnancy\n\nClinical Trial Exclusion Criteria for MRI (if relevant to the patient's participation):\n- Weight greater than 250 pounds\n- Currently pregnant\n- Certain types of metal in the body\n- History of claustrophobia\n- Previous severe reaction to MRI contrast\n- Chronic kidney disease\n\nBased on the information provided:\n- The patient is 30 years old and English speaking, which meets two of the trial's inclusion criteria.\n- The patient has recently given birth, which suggests she carried a pregnancy to term.\n\nHowever, the clinical trial specifically requires participants who were found to have fibroids during their pregnancy. There is no mention of the patient having fibroids or being part of the Right From The Start Study during her pregnancy. Without evidence that she has fibroids, she does not meet one of the key inclusion criteria for the postpregnancy study.\n\nGiven this information, the patient does not meet the necessary inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "304": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial titled \"Family Spirit Study,\" let's review the patient's eligibility:\n\nPatient Note:\n- The patient is a 30-year-old woman.\n- She recently gave birth to a healthy child 3 weeks before.\n- No mention of Native American heritage or tribal membership.\n- No information about pregnancy at the time of conception (as the patient has recently given birth).\n- No mention of residing in the Reservation Service Unit Catchment Area or within 60 miles of the Indian Health Service Unit Headquarters.\n\nClinical Trial Inclusion Criteria:\n- Native American pregnant teens or young women ages 12-22 years old at the time of conception.\n- Women ages 20-22 years at the time of conception must be pregnant for the first time.\n- Partners of pregnant teens must be between the ages of 12-24.\n- Pregnant <28 weeks gestation and able to meet the requirements for completing the program in a timely way.\n- An enrolled tribal member.\n- Reside in the Reservation Service Unit Catchment Area and within 60 miles of the Indian Health Service Unit Headquarters.\n\nGiven the information provided in the patient note, the patient does not meet the specific demographic requirements (Native American heritage, tribal membership, residency requirements) nor the pregnancy-related inclusion criteria for the \"Family Spirit Study.\" Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "305": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods,\" the patient does not meet the specific inclusion criteria. The criteria require participants to be in the first trimester of a normal pregnancy and to have a normal baseline echocardiogram. The patient in question is postpartum, having given birth 3 weeks prior, and is thus not in the first trimester of pregnancy.\n\nIn addition, the patient is presenting with shortness of breath, tachypnea, and tachycardia, which may not align with being considered \"healthy,\" another requirement of the study's inclusion criteria. While the patient's chest x-ray and CBC are normal, her current symptoms could be indicative of a condition that warrants further investigation and may exclude her from being considered healthy at this time.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "306": {
        "output": "Upon reviewing the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the inclusion criteria for the study.\n\nThe inclusion criteria specify:\n1. Gestational age at birth of the infant: 23 0/7 - 27 6/7 weeks\n2. Enrollment in the COT trial at specified locations\n3. Postnatal age of the infant: between 21 days and 70 days\n4. Informed written consent obtained from at least one of the parents\n\nThe patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. The inclusion criteria are specifically for very preterm infants, and there is no indication that the woman's child was very preterm or enrolled in the COT trial. Therefore, the patient herself is not applicable for the trial, and the information provided does not indicate that her child is a candidate either.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "307": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Long-term Oxygen Treatment Trial,\" the patient does not appear to be eligible for this trial. Here's the breakdown:\n\n- The patient is a 30-year-old woman, which does not meet the trial's age criterion of at least 40 years.\n- There is no mention of COPD in the patient's note. Instead, the patient presents with shortness of breath postpartum, which is not necessarily indicative of COPD.\n- Dyspnea is present, but there is no indication that it's related to COPD, nor is there a mention of the MMRC scale in the patient note.\n- There are no lung function test results (FEV1, FVC) provided in the patient note to assess COPD severity.\n- The patient's oxygen saturation levels are mentioned (92%), but without evidence of COPD, this is not relevant to the trial's criteria.\n- There is no mention of the patient's smoking history, which is a requirement for the trial (at least 10 pack-years of tobacco cigarette smoking).\n- The patient does not appear to be on supplemental oxygen, which is a condition for part of the trial's inclusion criteria.\n- Lastly, there is no indication that the patient is a Medicare beneficiary with both Part A and Part B coverage or willing to personally cover costs, another criterion for the trial.\n\nBased on this analysis, the patient does not meet several key inclusion criteria for the clinical trial. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "308": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 30-year-old woman who presents with shortness of breath and was recently admitted presenting symptoms like being apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. She has had a chest x-ray that was noted to be normal.\n\nThe clinical trial in question is focused on the effects of X-ray computed tomography (CT) on blood reactive oxygen species (ROS) levels. The inclusion criteria for the trial are quite specific: the participants must be part of a health check program at the hospital conducting the study and are scheduled to receive an X-ray CT examination for either lung or heart health as part of that health check.\n\nThe patient note does not mention that the woman is part of a health check program or that she is scheduled for an X-ray CT examination for her lungs or heart. The fact that she has had a chest x-ray does not meet the criterion of having a scheduled CT examination. Without any information suggesting that she is part of the health check program or scheduled for a CT scan, this patient does not meet the inclusion criteria as stated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "309": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether the patient would be eligible for the clinical trial.\n\nPatient note:\n- 30-year-old woman\n- General health is good\n- Presenting with shortness of breath\n- History of 2 natural abortions\n- Gave birth to a healthy child 3 weeks prior\n- Normal chest x-ray and CBC\n\nClinical trial:\n- Title: Postpartum Anemia and Postpartum Depression\n- Focus: Relationship between postpartum anemia and postpartum depression\n- Participants: Women delivered by elective term cesarean section\n- Inclusion criteria: Women after term elective cesarean section\n\nThe inclusion criteria for the clinical trial specify that participants must be women who have undergone a term elective cesarean section. The patient presented has recently given birth but there is no information to suggest that she underwent a cesarean section, let alone an elective term one. Therefore, based on the information provided, the patient does not meet the inclusion criteria of having had an elective term cesarean section.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "310": {
        "output": "Based on the patient note provided, the 30-year-old woman has presented with shortness of breath, which is not necessarily indicative of asthma but rather could be related to a postpartum condition, given she gave birth 3 weeks before. Her physical examination is otherwise unremarkable, which includes normal blood pressure and a normal chest x-ray. The oxygen saturation is 92%, which is below the normal threshold set by the trial's inclusion criteria (> 94%).\n\nThe clinical trial is comparing responses to an inhalational challenge in individuals with allergic asthma and normal volunteers. To qualify as a normal volunteer, the trial specifies that participants must have normal lung function, normal oxygen saturation, and pass a methacholine inhalation challenge, among other criteria. For allergic asthmatics, the criteria include a history of asthma, positive methacholine test, and allergic sensitization confirmed by positive AST.\n\nWhile the woman's oxygen saturation is slightly below the normal threshold for the trial and she has shortness of breath, there is no indication she has asthma or a history of allergic reactions, both of which are necessary for the allergic asthmatics group. Additionally, since she's recently given birth, the cause of her symptoms may be related to other postpartum conditions not related to the objectives of the trial.\n\nGiven the information, it's not clear whether she would meet the normal lung function criteria or pass a methacholine inhalation challenge. Without further investigation to clarify her lung function and a negative methacholine test, she would not immediately qualify for the healthy control group either.\n\nTherefore, the assessment of trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be required to determine if her shortness of breath is indicative of an underlying condition that would exclude her from the study. Additionally, her recent childbirth and the fact that there was no mention of an asthma diagnosis or allergic sensitization in her history suggest that she may not meet the inclusion criteria for either the healthy controls or the allergic asthmatics groups.",
        "label": 0
    },
    "311": {
        "output": "To determine the patient's eligibility for the clinical trial, we need to assess whether the patient fits the inclusion criteria based on the patient note provided.\n\nInclusion Criteria for the Clinical Trial:\n1. Diagnosis of acute pulmonary embolism (PE) with symptoms present <14 days and confirmed by CT angiography.\n2. Initial evaluation for PE based on new or unexplained cardiopulmonary or chest-related clinical features consistent with PE.\n3. Systolic blood pressure (SBP) > 89 mm Hg at the time of enrollment (or a history of low blood pressure without symptoms of shock if SBP < 90 mm Hg)\n4. Oxygen saturation (SaO2%) > 80% at the time of enrollment.\n5. Borg score greater than 4/10.\n\nPatient Note Assessment:\n1. The patient presents with shortness of breath, which could be consistent with PE.\n2. The onset of shortness of breath was 2 hours before admission, fitting the criteria for recent onset.\n3. The patient's blood pressure is 110/70, which is above the threshold of 89 mm Hg.\n4. The patient's oxygen saturation is 92%, which is above the threshold of 80%.\n5. The patient is described as tachypneic and tachycardic, which can be clinical features associated with PE.\n6. However, there is no mention of a confirmed diagnosis of PE with CT angiography.\n7. The Borg score is not mentioned, so we do not have information on the severity of dyspnea according to the patient\u2019s subjective assessment.\n\nGiven that the patient presents with symptoms that could be consistent with PE (shortness of breath, tachypnea, tachycardia) and meets some of the physiological criteria (SBP and SaO2%), they could potentially be eligible for the trial. However, without confirmation of PE through CT angiography and the absence of a documented Borg score, we cannot conclusively determine eligibility. Therefore, the patient may require further evaluation to confirm the diagnosis and assess the severity of dyspnea before a referral can be made.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "312": {
        "output": "The patient in question is a 30-year-old woman who recently gave birth and is presenting with shortness of breath. This patient does not fit the inclusion criteria for the clinical trial provided, which is specifically seeking to enroll preterm very low birth weight infants with shock, in a specific gestational week range, and with specific birth weight criteria.\n\nThe clinical trial is not applicable to the woman in the patient note because she is not an infant, she is not within the specified gestational week range, her birth weight is not mentioned (and is obviously not within the specified range for very low birth weight infants), and there is no indication that she is experiencing shock or requires vasopressor therapy. Additionally, the trial is looking to enroll infants born at a specific institution (AIIMS), which has no bearing on the adult patient.\n\nBased on the information provided, the patient note is completely unrelated to the target population for the clinical trial, and therefore, the patient would not be eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "313": {
        "output": "Given the patient's presentation and the clinical trial's inclusion criteria, we need to determine if the patient is eligible for the trial. Let's assess the patient against the criteria:\n\n1. The patient is a 30-year-old woman, which meets the age requirement (age \u2265 18 years).\n2. She has recently given birth, which places her in the postpartum period.\n3. The patient presents with shortness of breath, which could be a symptom related to venous thromboembolism (VTE), but there is no direct indication that she has VTE or has been treated for it.\n4. The patient has had two natural abortions, which is mentioned in the inclusion criteria as a consideration for the study (history of abortion).\n\nHowever, the inclusion criteria specifically state that patients should have been treated with fondaparinux pre-, peri- and/or postpartum for more than 7 days for VTE prophylaxis or treatment. There is no information provided in the patient note that suggests the patient has been treated with fondaparinux or has a diagnosed VTE.\n\nGiven the information provided, we do not have evidence of fondaparinux treatment or VTE diagnosis. Therefore, based on the available information, we would not refer the patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "314": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient:\n\nPatient Note:\n- The patient is a 30-year-old woman.\n- She presented with shortness of breath that started 2 hours before admission.\n- She had given birth to a healthy child 3 weeks prior.\n- She shows signs of being apprehensive, tachypneic, and tachycardic, with oxygen saturation at 92%.\n- Her chest x-ray and CBC are normal.\n- There is no mention of the patient being mechanically ventilated or in the process of weaning from mechanical ventilation.\n\nClinical Trial Inclusion Criteria:\n- The trial is focused on the safety, feasibility, and efficacy of a computerized protocol integrated into a ventilator for patients during the weaning phase from mechanical ventilation.\n- The patient must be ready to begin weaning from mechanical ventilation as determined by the attending physician.\n- The patient must be able to breathe spontaneously or already be breathing spontaneously.\n- No vasopressor or inotropic medication, unless in small doses of specific medications.\n- Specific requirements related to mechanical ventilation settings and blood gas parameters.\n\nGiven that the patient in the note is not described as being mechanically ventilated nor in the process of weaning from mechanical ventilation, she does not meet the key inclusion criteria of the clinical trial. The trial specifically requires patients who are undergoing weaning from mechanical ventilation, and there is no information to suggest that this patient is in that clinical situation. Therefore, this patient would not be eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "315": {
        "output": "",
        "label": 1
    },
    "316": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Oxygen Saturation Monitoring During Surgery,\" the assessment of the patient's eligibility is as follows:\n\n- The patient is a 30-year-old woman, which does not meet the age criterion of \"Age greater than 21 years.\" However, she is only short by one year, which may be considered a minor discrepancy depending on the strictness of the trial's screening process.\n- The patient presents with shortness of breath that started 2 hours before admission, but there is no information suggesting she is scheduled for a procedure that requires analgesia or sedation.\n- There is no indication of the patient having Obstructive Sleep Apnea (OSA), which seems to be a focus of the study, nor is there any information about her ASA classification.\n- The trial appears to be focused on patients who are at risk for OSA during surgery, and this patient's current medical issue does not seem to align with the study's objectives.\n\nGiven the information provided, it is unlikely that this patient would be considered for referral to this particular clinical trial based on the mismatch of her current medical situation with the study's focus and lack of information fulfilling the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "317": {
        "output": "Based on the information provided, the patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. The clinical trial in question is aimed at identifying risk factors for fetomaternal hemorrhage (FMH) and is seeking to enroll women admitted for term delivery at the Mount Sinai Medical Center.\n\nSince the patient has already delivered her child and is not currently admitted for term delivery, she does not meet the inclusion criteria for the clinical trial, which specifically seeks women who are admitted for term delivery.\n\nTherefore, the assessment of the patient's eligibility for the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "318": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the patient's eligibility for the clinical trial titled \"Carbetocin at Elective Cesarean Delivery.\"\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman.\n- She recently gave birth to a healthy child 3 weeks prior.\n- She presents with shortness of breath, which is not related to the clinical trial's focus.\n- There is no mention of her undergoing an elective cesarean delivery or planning one.\n\nClinical Trial Inclusion Criteria Analysis:\n- All patients planned for elective cesarean delivery under spinal anesthesia.\n- All patients who gave written informed consent to participate in this study.\n\nAssessment:\nThe patient in the note does not meet the inclusion criteria for the clinical trial as there is no indication that she is planning to have an elective cesarean delivery. The trial is specifically looking for patients who are planned for an elective cesarean delivery under spinal anesthesia, and the patient just gave birth 3 weeks ago through what is presumed to be a vaginal delivery since cesarean delivery is not mentioned.\n\nGiven the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "319": {
        "output": "",
        "label": 0
    },
    "320": {
        "output": "Based on the patient note provided, the 30-year-old woman recently gave birth and is experiencing shortness of breath, tachypnea, and tachycardia. However, there is no mention of her delivery method, be it cesarean section or vaginal delivery. To determine eligibility for the clinical trial focused on \"Venous Thromboembolism Prophylaxis Post Cesarean Section,\" we must consider the inclusion criteria:\n\n1. Age > 18 years old - The patient is 30 years old, which meets this criterion.\n2. Delivered by cesarean section (emergency or planned) - There is no information provided about the delivery method.\n3. Signed, informed consent - This is a procedural aspect that the patient can fulfill if eligible.\n4. Ready access to a local health service - There is no information provided that contradicts this criterion.\n5. Capable of using Tinzaparin - There is no information provided against this, but it is also not confirmed.\n\nGiven that the critical inclusion criterion regarding delivery method is not addressed in the patient note, it is not possible to definitively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "321": {
        "output": "Given the patient note, the patient is a 30-year-old woman who has recently given birth to a healthy child 3 weeks prior and is now presenting with shortness of breath. There is no indication that the patient is currently planned for an elective cesarean delivery, which is a specific inclusion criterion for the clinical trial in question. The clinical trial is looking to recruit patients who are planned for elective cesarean delivery under spinal anesthesia, and the patient does not fit this description.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "322": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression,\" we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nPatient characteristics:\n- A 30-year-old woman\n- Recently gave birth to a healthy child 3 weeks ago\n- Planning to breastfeed (implied since she recently gave birth, however, not explicitly stated)\n- Experiencing shortness of breath, tachypnea, and tachycardia but otherwise generally healthy\n\nClinical trial inclusion criteria:\n- Age > 18 years old\n- > 24 0/7 weeks pregnant at the time of enrollment\n- Planning to deliver at Magee-Womens Hospital and to breastfeed\n- Plans to use DMPA for postpartum contraception for at least 6 months\n- Willing and able to provide informed consent in English and to comply with study protocol\n\nAssessment:\n- The patient is over 18 years old, which meets the first criterion.\n- The patient has already delivered, which does not meet the second criterion as it specifies being more than 24 0/7 weeks pregnant at the time of enrollment.\n- It is not specified whether the patient plans to deliver at Magee-Womens Hospital, which is a requirement.\n- There is no information provided about the patient's intention to use DMPA for postpartum contraception.\n- The ability to provide informed consent in English and comply with the study protocol cannot be assessed from the given information.\n\nGiven that the patient has already given birth, she does not meet the criterion of being pregnant at the time of enrollment. Additionally, there is insufficient information regarding the patient's intentions to use DMPA and whether she was planning to deliver at Magee-Womens Hospital.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "323": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess whether this patient is eligible for the trial based on the inclusion criteria.\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman.\n- She presents with shortness of breath that started 2 hours before admission.\n- She has had no significant health problems in the past besides 2 natural abortions and recently gave birth to a healthy child.\n- She is currently experiencing tachypnea (rapid breathing), tachycardia (rapid heart rate), and has a slightly reduced oxygen saturation at 92%.\n- Her chest x-ray and CBC are normal.\n\nClinical Trial Analysis:\n- The title of the study is \"Change in Peripheral Oxygen Saturation by Using Different Breathing Procedures in High Altitude.\"\n- The aim is to explore whether different types of breathing procedures can improve peripheral oxygen saturation to reduce the risk of acute mountain sickness or high altitude pulmonary edema.\n- The inclusion criteria mentioned are not detailed, but there is a note on exclusion criteria regarding \"acute clinically significant inter-current diseases.\"\n\nAssessment:\n- The patient appears to be suffering from an acute condition, as indicated by the sudden onset of shortness of breath, tachypnea, tachycardia, and reduced oxygen saturation.\n- There is no indication that the patient is at high altitude or that she is suffering from acute mountain sickness or high altitude pulmonary edema.\n- The exclusion criteria specifically mention acute clinically significant inter-current diseases, which could potentially include the patient's current condition (acute shortness of breath).\n\nGiven the lack of information connecting the patient's condition to high altitude illnesses and the fact that her acute symptoms may potentially fall under the exclusion criteria, it seems that this patient would not be a candidate for the trial. However, without explicit confirmation that the patient's current condition is considered an \"acute clinically significant inter-current disease\" within the context of the trial, there is some uncertainty.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "324": {
        "output": "Based on the information provided:\n\nThe patient in question is a 30-year-old woman presenting with shortness of breath, tachypnea, tachycardia, and a slightly lowered oxygen saturation. There are no indications of bronchiolitis, which is typically a condition affecting infants and young children. Furthermore, the patient's chest x-ray and CBC are normal, suggesting no apparent respiratory infection, which is common in bronchiolitis.\n\nThe clinical trial in question is targeting children under 18 months of age with a clinical diagnosis of bronchiolitis, requiring hospital admission for observation and oxygen therapy. Since the patient is an adult and there is no mention of bronchiolitis or any other criteria that would match the inclusion criteria of the trial, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "325": {
        "output": "",
        "label": 0
    },
    "326": {
        "output": "Based on the information provided in the patient note, the 30-year-old woman does not meet the inclusion criteria for the clinical trial. The inclusion criteria specify that the patient must have given birth to a premature child (less than 36 weeks of gestation and/or less than 2 kg birthweight) and there must have been a separation of the child and mother since birth. The patient note does not mention that the child was premature or that there has been a separation since birth. In fact, the only information about her recent childbirth is that she had given birth to a healthy child 3 weeks before. Without information to suggest that the child was premature or that there was a separation, the patient does not meet the specified criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "327": {
        "output": "Based on the information provided, the patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks before. The clinical trial in question is evaluating the effectiveness of a program to support breastfeeding after short-term hospitalization.\n\nThe inclusion criteria for the clinical trial is very specific: it requires pregnant women who are in gestational weeks 35-36. Since the patient has already given birth and is not currently pregnant, she does not meet the inclusion criteria for participation in the study.\n\nTherefore, the trial-level eligibility assessment for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "328": {
        "output": "In order to determine the patient's eligibility for the clinical trial titled \"Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men,\" we need to compare the patient's characteristics with the inclusion criteria of the study.\n\nHere are the relevant inclusion criteria for the trial:\n\n- Men of ages 18 and 30 (Dates of birth 1973-1985) or 55-92 years old (Dates of birth 1911-1948).\n- Must not currently be a cigarette smoker. If an ex-smoker then has not smoked for at least 10 years and consumption were no more than 10 pack years.\n- Agrees to volunteers for the study and willing to sign the informed consent form.\n- Negative/normal screening tests for respiratory diseases and cardiac conditions.\n- Normal spirometry and impedance oscillometry measurements.\n- Negative physical examination of the chest.\n- Exhaled nitric oxide concentration within specified limits for age groups.\n\nThe patient note gives us the following information:\n\n- The patient is a 30-year-old woman.\n- The patient presents with shortness of breath, which is a respiratory complaint.\n- There is no information on smoking history or willingness to volunteer and sign an informed consent form.\n- There is no information on spirometry, impedance oscillometry, or exhaled nitric oxide concentration.\n\nBased on the information provided, the patient does not meet the following inclusion criteria:\n\n- The patient is not a man (the trial specifically states men of certain ages).\n- The patient has a current respiratory complaint (shortness of breath), which is against the criteria that deny current respiratory complaints.\n\nGiven that the patient is a woman, which is not within the specified gender inclusion criteria, and she has a respiratory complaint, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "329": {
        "output": "Based on the patient note and the inclusion criteria of the given clinical trial, let's assess the eligibility:\n\nPatient Note Summary:\n- 30-year-old woman\n- Presents with shortness of breath\n- Gave birth 3 weeks prior\n- Tachypneic and tachycardic, with a blood pressure of 110/70 and oxygen saturation 92%\n- Normal chest x-ray and CBC\n\nClinical Trial Inclusion Criteria Summary:\n- Healthy males within the age range of 18 to 50 years\n- Body mass index within 18-25 Kg/m^2\n- Various health and lifestyle requirements (no significant diseases, normal ECG and chest X-Ray, no history of certain conditions, no recent participation in other clinical studies, etc.)\n\nEligibility Assessment:\n- Gender: The trial requires male participants, and the patient is a female.\n- Health status: The trial requires healthy participants, and the patient presents with shortness of breath, which may not be considered a healthy condition.\n- Postpartum: The patient recently gave birth, which may influence her health status and could be a factor in her current condition.\n\nGiven the patient is female and the trial explicitly requires male participants, along with the additional health concerns present, this patient would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "330": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient is not eligible for this clinical trial. The patient is a 30-year-old woman who has just given birth, which puts her in the immediate postpartum period, not the first or second trimester of pregnancy as required by the trial's inclusion criteria. Additionally, there is no information provided that suggests she has a history of tobacco use or nicotine dependence in the past 90 days or year, which are also part of the inclusion criteria for the trial.\n\nTherefore, this patient would not be referred for this clinical trial since she does not meet the necessary inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "331": {
        "output": "Based on the provided clinical trial inclusion criteria and the patient note, let's assess the patient's eligibility:\n\n1. Healthy pregnant females > 18 years of age - The patient is 30 years old.\n2. Singleton pregnancies (either nulliparous or multiparous) - The patient recently gave birth to a healthy child, so she is not currently pregnant.\n3. Less than 17 weeks gestation - Not applicable as the patient is not pregnant.\n4. A pre-pregnancy BMI < 40 kg/m^2 - The note does not provide information on the patient's pre-pregnancy BMI.\n5. Plans to deliver at a Hamilton or London regional hospital or by home birth - Not applicable as the patient is not currently pregnant.\n6. Able to tolerate dairy foods - The note does not provide information on this.\n7. Approval of primary care provider - The note does not provide information on this.\n8. Able to provide signed informed consent - The patient is an adult and likely capable of providing consent, but this is not explicitly stated.\n\nGiven that the patient is not currently pregnant, she does not meet the fundamental requirement of the clinical trial, which is targeting healthy pregnant females. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "332": {
        "output": "Given the patient note, we can assess the eligibility of the patient for the clinical trial based on the inclusion criteria provided.\n\nInclusion criteria for the clinical trial:\n1. Men and women aged between 18 and 35 years.\n2. Nonsmokers.\n3. Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.\n4. Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant.\n5. Normal ophthalmic findings, ametropy < 3 Dpt.\n\nPatient characteristics from the note:\n- A 30-year-old woman.\n- Generally healthy.\n- Non-smoker status is not mentioned.\n- Normal findings in the medical history and physical examination, except for shortness of breath, tachypnea, and tachycardia.\n- Normal laboratory values (CBC is normal).\n- Normal ophthalmic findings are not mentioned; ametropy status is unknown.\n\nThe patient is within the age range of 18 to 35 years, which meets the first criterion. However, there is no information provided about her smoking status, which is required by the second criterion. The presence of shortness of breath, tachypnea, and tachycardia might be considered clinically relevant abnormalities, and we do not have information on whether the investigator would consider these abnormalities irrelevant. Additionally, there is no information on her ophthalmic findings or ametropy, which are relevant to the fourth and fifth criteria.\n\nBased on the available information, the patient meets some of the inclusion criteria (age and normal CBC), but there is insufficient information to determine her eligibility regarding non-smoker status, clinical relevance of her current symptoms, and ophthalmic findings. Therefore, further investigation is needed to assess these areas before a referral can be considered.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "333": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Summary:\n- 30-year-old woman\n- Shortness of breath started 2 hours before admission\n- Recent childbirth 3 weeks prior\n- No past health problems except for 2 natural abortions\n- Apprehensive, tachypneic, tachycardic\n- Blood pressure: 110/70, oxygen saturation: 92%\n- Normal chest x-ray and CBC\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Caval filtration clinically indicated for prevention of pulmonary embolism in patients with venous thromboembolic disease or at high risk for venous thromboembolic disease, including patients with:\n  - Issues with anticoagulant therapy (contraindications, failures, complications, high risk, etc.)\n  - Specific conditions such as pulmonary embolus, iliocaval DVT, severe trauma, high-risk surgeries, etc.\n\nAssessment:\nThe clinical trial is focused on patients who require an inferior vena cava filter for the prevention of pulmonary embolism, specifically in the context of venous thromboembolic disease or high risk for such disease. The patient in the note presents with shortness of breath soon after childbirth, which could be a sign of various conditions, including a possible pulmonary embolism. However, there is no mention of venous thromboembolic disease or a high risk for it in the patient's note. The normal chest x-ray and CBC do not support an immediate diagnosis of pulmonary embolism or DVT, and there is no information about any contraindications to anticoagulant therapy that the patient might have.\n\nGiven the information provided, the patient does not clearly meet the inclusion criteria for the clinical trial. There is a potential for venous thromboembolic disease given her recent childbirth (a risk factor for thromboembolic events), but this is not confirmed, and further investigations would be needed to establish a diagnosis. Therefore, on the three-point scale, the assessment for this trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "334": {
        "output": "",
        "label": 0
    },
    "335": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient described is a 30-year-old woman presenting with shortness of breath. The trial is focused on the treatment of Transient Tachypnea of the Newborn (TTN), a condition affecting late preterm and term infants. \n\nThe patient in question is not a newborn nor is there any indication that her newborn child is experiencing TTN. Moreover, the inclusion criteria specifically mention that the trial is for late preterm and term infants diagnosed with TTN, and there is no mention of the mother's health status being a factor for inclusion.\n\nGiven these facts, the patient does not meet the inclusion criteria for the clinical trial because she is not a newborn, the actual subject of the study. Therefore, we would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "336": {
        "output": "Based on the information provided, the patient presented with shortness of breath, which started 2 hours before admission. The patient is a 30-year-old woman who recently gave birth and has no history of chronic health problems mentioned, other than natural abortions. The physical examination findings include tachypnea, tachycardia, normal blood pressure, and slightly reduced oxygen saturation, but no mention of chronic obstructive pulmonary disease (COPD) or residence at a low altitude.\n\nThe clinical trial in question is focused on patients with chronic obstructive pulmonary disease (COPD) of GOLD grade 2-3 who reside at low altitude (<800 m). As there is no mention of COPD in the patient's history or current symptoms indicative of COPD, the patient does not meet the inclusion criteria for the clinical trial.\n\nTherefore, the patient is not eligible for the trial based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "337": {
        "output": "Based on the patient note provided, the patient is a 30-year-old woman presenting with symptoms that could be suggestive of a pulmonary embolism, such as shortness of breath, which started 2 hours before admission, and she is also noted to be tachypneic and tachycardic. The clinical trial in question is assessing the efficacy of low-dose versus full-dose contrast CT pulmonary angiography in detecting emboli.\n\nThe inclusion criteria for the trial are patients referred for CT pulmonary angiogram to exclude pulmonary embolus. Since the patient's symptoms could be indicative of a pulmonary embolism, and she may be referred for a CT pulmonary angiogram to exclude this diagnosis, she fits the inclusion criteria for the clinical trial.\n\nTherefore, the patient is eligible for the clinical trial and it is highly likely that she would be referred for this clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "338": {
        "output": "The patient in question is a 30-year-old woman who has recently given birth and is presenting with symptoms of shortness of breath, which could be indicative of several possible conditions but is not explicitly related to any neonatal issues that would require ventilation support, as per the information provided.\n\nThe clinical trial in question is focused on infants at 24-36 weeks corrected gestational age who are already on high frequency oscillatory ventilation. The patient herself is not the subject of the clinical trial, rather her newborn infant could potentially be a subject if they met the specific inclusion criteria. However, there is no information given in the patient note that suggests her 3-week old child is experiencing any issues requiring ventilation, much less high frequency oscillatory ventilation.\n\nBased on the information provided, the patient and/or her infant do not meet the inclusion criteria for the clinical trial, which requires infants already ventilated with high frequency ventilation, and requiring a certain range of FiO2 to maintain oxygen saturation.\n\nTherefore, the patient (and by extension, her child) does not appear to be eligible for the clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "339": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet the criteria for participation in the clinical trial. The trial is designed for premature infants born less than 30 completed weeks gestation, whereas the patient is a 30-year-old woman who recently gave birth to a healthy child. Therefore, she is not eligible for a study focused on premature infants.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "340": {
        "output": "Based on the information provided:\n\nThe patient is a 30-year-old woman who recently gave birth to a healthy child 3 weeks ago. She presents with shortness of breath that started 2 hours before admission, and she is experiencing symptoms such as being apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. \n\nThe clinical trial in question is investigating the effect of a father inclusive psychoeducation program on postnatal depression. The inclusion criteria for this trial are:\n\n1. Aged 18 or above;\n2. First-time parents;\n3. Able to speak and read the Chinese language; and\n4. Hong Kong residents.\n\nThe patient fits the age criterion and is a first-time parent. However, there is no information provided about her ability to speak and read the Chinese language, nor whether she is a Hong Kong resident. These two criteria are crucial for determining eligibility for this specific trial. Without this information, we cannot definitively say whether she would be eligible or not.\n\nGiven the information gap regarding language and residency status, I would rate the eligibility as:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "341": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient does not seem to fit the requirements of the study. The clinical trial is focused on the effects of postpartum maternal vitamin A supplementation, and the inclusion criteria mention pregnant women of >18 years of age with low-risk obstetrics, but there is no clear indication that the patient is either pregnant or has a low-risk obstetric profile at the time of presentation. Moreover, the patient presented with symptoms of shortness of breath, for which she is seeking medical attention, and this symptom does not appear to be related to the focus of the clinical trial.\n\nGiven these discrepancies, the patient described in the note does not meet the inclusion criteria for the clinical trial provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "342": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the criteria for participation. The clinical trial is focused on neurocognitive and immunological development in infants fed a new infant formula compared to a standard formula or breastfeeding. The inclusion criteria are specific to newborns and infants in terms of gestational age at birth, birth weight, age at inclusion, breastfeeding status, Apgar score, and umbilical pH.\n\nThe patient is a 30-year-old woman and, as such, does not fit the demographic of the study participants, which are infants. Therefore, this patient would not be eligible to participate in the study based on the inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "343": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not appear to be eligible for the study. The clinical trial is looking for patients with precapillary pulmonary hypertension or interstitial lung disease, who are in the New York Heart Association class 2-3, and who reside at low altitude (<800m).\n\nThe patient note describes a 30-year-old woman presenting with shortness of breath, tachypnea, and tachycardia, with a recent childbirth history. There is no indication that she has pulmonary hypertension or interstitial lung disease, nor is there any mention of her residing at a low altitude or her NYHA class. The patient's symptoms could be related to a number of different causes, and without further information indicating a diagnosis of either precapillary pulmonary hypertension or interstitial lung disease, she would not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "344": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the patient note and the inclusion and exclusion criteria provided:\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman, which fits within the age range of 18-45 years specified in the inclusion criteria.\n- She has recently given birth to a healthy child 3 weeks prior, which aligns with the trial's inclusion of postpartum women.\n- The patient presents with shortness of breath, which started 2 hours before admission. This may suggest an acute condition but is not directly related to postpartum depression or sexual functioning.\n- The patient's blood pressure is within normal limits, and there's no indication of any of the exclusion conditions such as thrombophlebitis, thromboembolic disorders, diabetes mellitus, etc.\n- The patient is not described as breastfeeding, which is one of the exclusion criteria.\n- There is no mention of the patient's desire for contraception postpartum, which is a requirement for the medication groups. However, since there's also a control group that chooses not to use oral contraceptives postpartum, she could potentially fit into that group.\n- The patient has no history of depression, mood disorders, or psychiatric disorders mentioned, which satisfies both the medication and control group exclusion criteria.\n- There is no information provided about whether the patient had a cesarean section, her smoking status, or any history of alcohol or drug use.\n\nGiven the information presented in the patient note, the patient fits the age criteria and is in the postpartum period, which are key inclusion criteria for the clinical trial. However, there are some uncertainties:\n\n1. It is not clear if the patient desires contraception postpartum, which is necessary for the medication groups.\n2. The patient's method of delivery (cesarean section or not) is unknown.\n3. There is no information on the patient's smoking status, history of alcohol or drug use, or her opinion on using hormonal contraception.\n\nDue to these uncertainties and the lack of explicit information on some of the inclusion and exclusion criteria, further investigation is required before making a definitive decision on her eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "345": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 30-year-old woman, which meets the age criterion.\n- She gave birth to a healthy child 3 weeks before, meeting the criterion of having delivered at an estimated gestational age (EGA) \u226537 weeks.\n- She is within the postpartum period as she is 3 weeks postpartum, which adheres to the inclusion criteria.\n- The intent to breastfeed is not explicitly stated, but since breastfeeding rates are being studied, it can be inferred that the patient intended to breastfeed.\n- Breastfeeding initiation within the first 48 hours of delivery is not mentioned, so this is not verifiable from the note.\n- The infant's rooming-in status is not mentioned.\n- The patient's ability to speak English and complete surveys is not mentioned.\n- There's no information about the patient's military system affiliation or plans to move in the upcoming 6 months.\n- Willingness to render informed consent is typically assessed at the time of recruitment and is not something that can be determined from the note.\n\nClinical Trial Inclusion Criteria Checklist:\n- Age 18 or above at the time of delivery \u2714\ufe0f\n- Delivery of live born infant at EGA \u226537 weeks \u2714\ufe0f\n- Postpartum primiparous patients within the first 48 hours after delivery (the patient is 3 weeks postpartum, which does not strictly meet this criterion) \u274c\n- Patient intent to breastfeed (not explicitly stated but implied) \u2753\n- Breastfeeding initiated within the first 48 hours of delivery and/or prior to hospital discharge (not mentioned) \u2753\n- Infant is continuously rooming in with the mother from the time of delivery (not mentioned) \u2753\n- English-speaking (not mentioned) \u2753\n- Able to read and complete surveys (not mentioned) \u2753\n- No anticipated discharge from military system, Tricare benefits, or move planned in the upcoming 6 months (not mentioned) \u2753\n- Willing to render informed consent (assumed for every patient but not explicitly mentioned) \u2753\n\nBased on this analysis, the key piece of information missing is whether the patient meets the criterion of being a \"postpartum primiparous patient within the first 48 hours after delivery.\" Since the patient is 3 weeks postpartum, she does not meet this inclusion criterion. There is also a lack of information on several other criteria, which would require further investigation to determine eligibility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "346": {
        "output": "To determine the patient's eligibility for the \"nuMoM2b Heart Health Study\" clinical trial, we must assess whether she meets the inclusion criteria outlined for the study. Let's review the given patient note against the inclusion criteria:\n\nPatient Note Review:\n- The patient is a 30-year-old woman.\n- She has recently given birth to a healthy child 3 weeks prior.\n- She has had two natural abortions in the past.\n- She is presenting with shortness of breath, tachypnea, tachycardia, and reduced oxygen saturation.\n\nInclusion Criteria for the Clinical Trial:\n- Agreed to contact for future studies during nuMoM2b and not subsequently withdrawn from the cohort.\n- Have pregnancy outcome data from the nuMoM2b study.\n- At least 18 years of age.\n- Consented for participation in interval contacts and not subsequently withdrawn.\n- Between 2 and 3.5 years after the nuMoM2b pregnancy ended.\n- Self-report at least 6 months postpartum from any subsequent pregnancy.\n- Self-report not currently pregnant.\n- Participation in the in-clinic visit.\n- Participation in the sleep breathing substudy of nuMoM2b with at least one sleep breathing assessment providing valid data.\n- Not currently using positive airway pressure (PAP) therapy or other treatments for sleep apnea.\n- Not on continuous oral steroid therapy for asthma, or using oxygen supplementation for a medical condition.\n\nComparison:\n- The patient is of eligible age (\u2265 18 years).\n- However, there is no information provided that indicates whether the patient was part of the nuMoM2b cohort or that she consented for interval contact.\n- The patient has given birth 3 weeks ago, which is well within the 2 to 3.5 years postpartum period required by the study. However, participants must be at least 6 months postpartum from any subsequent pregnancy, which she is not.\n- The patient is not currently pregnant, which aligns with the study requirements.\n\nGiven the available information, there is no indication that the patient was part of the previous nuMoM2b study, which is a crucial requirement for participation in this follow-up study. Additionally, the patient is not at least 6 months postpartum from any subsequent pregnancy, which is another requirement for the study.\n\nBased on the patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet several key criteria for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "347": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion and exclusion criteria, it is clear that this patient does not meet the specific requirements for inclusion in the clinical trial. The trial is focused on patients undergoing major lung resection for malignancies and evaluating the incidence of VTE after such surgeries. \n\nThe patient in the note presents with shortness of breath and a history of recent childbirth but does not have any mention of lung cancer or the need for lung resection surgery. Therefore, this patient is not eligible for the clinical trial in question, which requires the patient to have a diagnosis of resectable lung cancer or metastatic lung disease eligible for complete metastasectomy and to be undergoing specific lung surgeries.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "348": {
        "output": "",
        "label": 1
    },
    "349": {
        "output": "The patient in question is a 30-year-old woman who recently gave birth and is presenting with shortness of breath, which started 2 hours before admission. There is no mention of preeclampsia in her medical history, and she has not been described as having been treated with magnesium sulfate before delivery.\n\nThe clinical trial is specifically looking for women with severe preeclampsia or severe preeclampsia aggregated to chronic hypertension who were treated with 4-6 grams of magnesium sulfate for impregnation with a minimum of 8 hours continuous of magnesium sulfate before delivery.\n\nGiven that the patient's condition does not match the inclusion criteria (which specifically mentions severe preeclampsia and treatment with magnesium sulfate), she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "350": {
        "output": "Given the patient note, we have a 30-year-old woman who has recently given birth. The clinical trial's inclusion criteria require participants to be either aged 16-18 and married or aged 18+ and in a co-habiting relationship. Furthermore, participants need to be pregnant within 24-36 weeks, have no obstetric risk factors requiring hospital delivery, live no more than one hour away on foot from the city, not planning to move from the city, and give informed consent.\n\nThe patient in the note is not currently pregnant, as she gave birth three weeks prior, and there is no information about her marital status or whether she is co-habiting. Even if she met the marital or co-habitation criteria, she does not meet the pregnancy criteria as she is not currently within the 24-36 weeks of pregnancy required by the trial.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "351": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, we can determine the patient's eligibility. \n\nThe patient is a 30-year-old woman presenting with shortness of breath, which began 2 hours before admission. She is also described as apprehensive, tachypneic, tachycardic, with a blood pressure of 110/70 and an oxygen saturation of 92%. The physical examination is otherwise unremarkable, and her chest x-ray and CBC are normal. \n\nThe clinical trial in question is focused on children with fast breathing pneumonia and is comparing amoxicillin with placebo. The inclusion criteria specify that the trial is for children with a history of cough or difficult breathing for less than 14 days and with a respiratory rate above a certain threshold specific to their age group. Additionally, informed consent by a legal guardian is required.\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n1. The patient is a 30-year-old woman, not a pre-school child (2-59 months old).\n2. There is no mention of the patient having a history of cough or difficult breathing for less than 14 days.\n3. The patient's respiratory rate is not mentioned, and even if it were, the criteria are specific to young children.\n4. The patient is not being presented as part of a legal guardian and is capable of providing consent herself.\n\nTherefore, this patient would not be eligible for the clinical trial based on the mismatch of age and the absence of specified symptoms and conditions related to the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "352": {
        "output": "Based on the patient note provided, the patient is a 30-year-old woman who has recently given birth to a healthy child and is currently experiencing shortness of breath. There is no mention of her breastfeeding status or whether she is experiencing pain during breastfeeding, which is the focus of the clinical trial.\n\nThe clinical trial is investigating the use of a dental support device (Leboride) during breastfeeding as a means for pain control. The inclusion criteria for the trial are:\n\n1. Maternal age 18-45 years.\n2. Normal vital signs.\n\nThe patient fits the age criterion (30 years old). However, the patient's vital signs are not entirely normal as she presents with tachypnea and tachycardia, and her oxygen saturation is slightly below the normal range (92% instead of the normal range of 95-100%). Since the trial specifically requires normal vital signs, this could be a point of concern.\n\nAdditionally, there is no information provided about pain during breastfeeding, which is a key aspect of what the trial is studying. Therefore, we cannot conclude that she is experiencing an issue that the trial aims to address. It's important to note that clinical trial referrals should consider not only the eligibility criteria but also the relevance of the trial to the patient's condition.\n\nGiven this information, the patient does not fully meet the inclusion criteria due to her abnormal vital signs, and there is no information about her experiencing pain during breastfeeding, which is the focus of the trial. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "353": {
        "output": "Based on the information provided, the patient in question is a 30-year-old woman who presents with shortness of breath that started 2 hours before admission. She has a recent history of childbirth and has experienced two natural abortions. Her current vital signs show tachypnea, tachycardia, and an oxygen saturation of 92%, but her chest x-ray and CBC are normal.\n\nThe clinical trial in question is studying the effects of sound energy on pulmonary gas exchange and is seeking healthy male or female volunteers. However, the inclusion criteria for the clinical trial are not fully detailed in the information provided. If \"healthy\" is defined as having no active medical issues, the patient's current presentation with shortness of breath would potentially exclude her from being considered healthy at this time. Furthermore, the shortness of breath could be a sign of an underlying condition that needs to be addressed before she can participate in a study.\n\nGiven the lack of detailed inclusion criteria, but considering the patient's current symptoms, it is not clear whether she would be an ideal candidate for a study on healthy volunteers without further information on her condition and the specific requirements of the trial. Therefore, I would lean towards:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "354": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, we need to assess whether the patient is eligible for the trial focusing on using sodium lactate Ringer's injection to resuscitate septic shock patients.\n\nPatient Note Summary:\n- 30-year-old woman\n- Presents with shortness of breath, tachypnea, tachycardia\n- Blood pressure is 110/70, oxygen saturation 92%\n- Chest x-ray and CBC are normal\n- Recently gave birth (3 weeks prior)\n- No other health problems except for 2 natural abortions\n\nClinical Trial Inclusion Criteria:\n- Diagnosis in patients with septic shock\n\nAnalysis:\nThe patient presents with symptoms that could be associated with a variety of conditions, including but not limited to postpartum complications, pulmonary embolism, or other cardiopulmonary issues. However, the normal chest x-ray and CBC, as well as a lack of information on fever, infection, or organ dysfunction, do not support a clear diagnosis of septic shock at this time. To be considered for inclusion in the trial, the patient would need a definitive diagnosis of septic shock.\n\nGiven the information at hand, the patient does not meet the inclusion criteria for the clinical trial, as there is no indication of septic shock from the patient note. Additional information and further medical evaluation would be necessary to determine if the patient's condition aligns with septic shock. Therefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "355": {
        "output": "Based on the information provided in the patient note, the woman is 30 years old and has recently given birth, which makes her potentially relevant to the clinical trial concerning the treatment of postpartum anemia. The clinical trial's inclusion criteria specify that participants must be women above 18 years old after giving birth, which fits the patient's profile.\n\nHowever, the inclusion criteria also specify that participants must suffer from iron deficiency anemia, defined as hemoglobin < 9.5 g/dl. The patient note does not provide any information regarding the patient's hemoglobin levels or a diagnosis of iron deficiency anemia. The patient presents with shortness of breath, which can be a symptom of anemia, but her CBC is normal, suggesting that her hemoglobin level may not be below the threshold required for the trial.\n\nSince the patient's eligibility regarding the specific criteria of iron deficiency anemia (hemoglobin < 9.5 g/dl) cannot be confirmed with the information provided, further investigation would be needed to determine her hemoglobin level and confirm the diagnosis of iron deficiency anemia.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "356": {
        "output": "",
        "label": 1
    },
    "357": {
        "output": "Given the patient note:\n\n- The patient is a 30-year-old woman.\n- She has given birth to a healthy child 3 weeks before.\n- She presents with shortness of breath but has no history of health problems other than 2 natural abortions.\n\nThe clinical trial's inclusion criteria are:\n\n- Women who are more than 28 weeks pregnant OR up to 9 months post-birth.\n\nBased on the provided information, the patient is within 9 months post-birth, which aligns with the clinical trial's inclusion criteria concerning the time frame post-birth.\n\nHowever, there is no indication in the patient note that the woman is experiencing symptoms of postnatal depression, which is the focus of the clinical trial. The trial is specifically about the impact of creative interventions on symptoms of Postnatal Depression (PND), and without information on whether the patient is experiencing PND, we cannot conclusively determine her eligibility.\n\nGiven the lack of information regarding PND symptoms in the patient's note but considering she is within the post-birth timeframe, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "358": {
        "output": "Given the patient note, the 30-year-old woman who presented with shortness of breath had given birth 3 weeks prior to admission. She is no longer pregnant, which is a key criterion for the clinical trial in question. The clinical trial is specifically targeting pregnant women who are hospitalized.\n\nSince the patient is not currently pregnant, she does not meet the inclusion criteria of being a hospitalized pregnant woman. Therefore, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "359": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question does not meet the inclusion criteria for the clinical trial.\n\nThe clinical trial is specifically targeted at pediatric patients between one and 18 years of age who require an endotracheal tube and are classified as ASA class I to III. The patient described in the note is a 30-year-old woman, which immediately disqualifies her from the study, as she is not within the specified age range for pediatric patients.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "360": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient's characteristics:\n- A 30-year-old woman\n- Generally healthy\n- Presented with shortness of breath, tachypneic, tachycardic, blood pressure 110/70, oxygen saturation 92%\n- Gave birth 3 weeks prior\n- No signs of severe PE (shock, hypotension)\n- No mention of any contraindications to iodinated contrast medium\n- Age > 18 years\n- No mention of health insurance status\n- No mention of the ability to give informed consent or the possibility of a 3-month follow-up\n\nClinical Trial Inclusion Criteria:\n- Women with clinically suspected pulmonary embolism (PE) during the first 6 weeks postpartum, without any sign of severe PE\n- No contraindications to iodinated contrast medium injection\n- Age > 18 years\n- Health insurance\n- Possibility to have a 3-month follow-up\n- Obtention of written informed consent (ability to give consent)\n\nThe patient appears to meet the following criteria:\n- She is within the first 6 weeks postpartum.\n- She is presenting with symptoms that could be indicative of PE (shortness of breath, tachypnea, tachycardia), though no diagnosis of PE is mentioned.\n- She is older than 18 years.\n- No severe PE is indicated in the note.\n- There is no mention of a previous allergic reaction to iodinated contrast medium, renal insufficiency, or uncontrolled hyperthyroidism.\n\nHowever, the following information is not provided or confirmed in the patient note:\n- Whether she has health insurance.\n- Whether she can be followed up for 3 months.\n- Whether she is capable and willing to give informed consent.\n\nGiven that the patient aligns with several of the inclusion criteria but there is missing information regarding health insurance, the possibility of a 3-month follow-up, and the ability to give informed consent, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "361": {
        "output": "Based on the provided information, the patient in question is an 85-year-old man with a gradual decrease in his level of consciousness and a recent decline in mobility and self-feeding abilities. The clinical trial in question is investigating the relationship between vitamin D, fingernail thickness, and bone density.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Females 25-75 years of age with no known bone disorders\n\nThe patient does not meet the inclusion criteria for the following reasons:\n- Gender: The trial is looking for female participants, and the patient is male.\n- Age: The trial is looking for participants between the ages of 25-75, and the patient is 85 years old.\n\nGiven these discrepancies, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "362": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Biomarkers and Early Alzheimer's Disease,\" we need to compare the patient's characteristics with the inclusion criteria of the trial.\n\nThe inclusion criteria are as follows:\n1. Individuals of either sex, with a high school education, and between the ages of 60 and 80 years living in the New York City metropolitan area.\n2. Minimum of 12 years of education.\n3. Participants will be classified as within normal limits on medical, psychiatric, and neuropsychological examinations (performance that is better than -1.5 sd of the NYU norm-based WMS-R delayed memory index).\n4. Participants will have a global deterioration scale (GDS) = 1 or 2. Those enrolled in the High-Risk group will have a GDS = 2 and have a score of >25 on the Memory Complaint Questionnaire (MCQ). In high-risk memory loss cases, an informed family member or caregiver will be interviewed to confirm that the participant can perform specific tasks.\n\nNow, let's assess the patient's eligibility based on the provided patient note:\n\n1. The patient is an 85-year-old man, which exceeds the maximum age limit of 80 years set by the trial.\n2. There is no information provided about the patient's level of education.\n3. The patient is experiencing a gradual decrease in his level of consciousness, and he has stopped walking and eating by himself, which may indicate that his performance on neuropsychological examinations would be outside the normal limits required by the trial.\n4. There is no information provided about the patient's GDS or MCQ scores, but the acute change in his level of consciousness and the inability to walk or eat independently suggest that he may not be within the GDS = 1 or 2 requirement.\n\nBased on the provided information, the patient does not meet the age criterion and likely does not meet other criteria regarding neuropsychological performance and the global deterioration scale. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "363": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial titled \"Donepezil in Preventing Delirium in Hospitalized Elderly,\" let's consider the eligibility of the patient:\n\nPatient note:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No fever, cough, rash, or diarrhea reported.\n- History of a car accident 3 weeks prior with a normal head CT at that time.\n- He is brought to the ER, but we do not have information about a hip fracture or any surgical repair plans.\n\nClinical trial inclusion criteria:\n- Community-dwelling individuals aged 65 or older.\n- Admitted to Methodist Hospital for surgical repair of hip fracture.\n- No evidence of delirium at admission to the hospital.\n- MMSE total score below 24 points after adjustment for education and age.\n- Consent to participate in the study.\n\nBased on the patient note, the patient is within the age range for the clinical trial. However, there are several points that need to be clarified to determine eligibility:\n\n1. It is not specified if the patient is community-dwelling.\n2. There is no information on whether the patient is admitted for surgical repair of a hip fracture; the reason for ER admission seems to be related to decreased consciousness rather than a hip fracture.\n3. The patient has a decreased level of consciousness, which could be indicative of delirium, making the criteria of \"no evidence of delirium at admission\" questionable.\n4. We do not have the patient's MMSE score, which is required to meet the inclusion criteria.\n5. There is no mention of whether the patient or his legal representative has given consent to participate in any study.\n\nWithout further information, especially regarding the patient's mental status (MMSE score), evidence of delirium, and the specific reason for ER admission (whether it's related to a hip fracture requiring surgical repair), we cannot confidently refer this patient to the trial. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "364": {
        "output": "",
        "label": 0
    },
    "365": {
        "output": "The patient in question is an 85-year-old man who was brought to the ER due to a gradual decrease in his level of consciousness. He stopped walking and eating by himself over the last three days but had no fever, cough, rash, or diarrhea. He was involved in a car accident 3 weeks prior, after which a head CT was performed and was normal at that time. \n\nThe clinical trial in question is studying the use of beta-blockers in elderly trauma patients. The inclusion criteria for the trial are:\n- All trauma patients admitted to the ICU \n- >55 years of age \n- With a primary diagnosis of injury\n\nThe patient is 85 years old, which fits the age criterion of being over 55 years of age. He was involved in a car accident, which could be considered a traumatic event. However, the patient note does not specify that the patient was admitted to the ICU with a primary diagnosis of injury. The decrease in the level of consciousness and the cessation of walking and eating could be related to many causes and do not necessarily confirm a direct link to the prior car accident or suggest a primary diagnosis of trauma.\n\nGiven that the patient was involved in a car accident recently, it is possible that he could fit the study's criteria, but there is not enough information in the patient note to confirm his eligibility based solely on the information provided. The note does not explicitly state that his current condition is due to the trauma from the car accident, nor does it mention an ICU admission with a primary diagnosis of injury as a result of the trauma.\n\nThus, referring this patient to the clinical trial would require further investigation into his medical records, particularly to understand the cause of his current symptoms and whether he was indeed admitted to the ICU with a primary diagnosis related to the trauma. Without this information, it's not possible to definitively determine his eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "366": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial titled \"Characteristics of Blood-Brain Barrier Permeability in Neurological Patients.\"\n\nPatient's Characteristics:\n- 85-year-old man\n- Gradual decrease in consciousness over the last 3 days\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at the time of the car accident\n\nClinical Trial Inclusion Criteria:\n- One week following: Traumatic Brain Injury or Cerebro-Vascular Accident\n- Subsequent brain CT showing cerebral cortex injury\n\nThe patient does not meet the inclusion criteria as specified for the clinical trial. There is no mention of a traumatic brain injury or cerebro-vascular accident occurring one week prior to the potential study enrollment. Additionally, there is no information about a subsequent CT showing cerebral cortex injury post the car accident. The patient had a normal head CT at the time of the accident, and the decrease in consciousness started much later (about 3 weeks after the accident).\n\nGiven the lack of alignment with the inclusion criteria, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "367": {
        "output": "Based on the information provided, the patient in the note is an 85-year-old man, which does not meet the inclusion criteria for age in the clinical trial mentioned. The trial specifically includes all asymptomatic trauma patients from 0 to 15 years old, and the patient is well beyond this age range. Additionally, the patient is not asymptomatic; he presents with a gradual decrease in his level of consciousness and has stopped walking and eating by himself.\n\nTherefore, this patient would not be eligible for the described clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "368": {
        "output": "Based on the patient note provided, the 85-year-old man brought to the ER due to a gradual decrease in his level of consciousness, with recent changes in mobility and eating, could potentially be experiencing symptoms related to dementia. However, there is no explicit mention of a dementia diagnosis by a physician in the patient note. Moreover, his Mini-Mental State Examination (MMSE) score is not provided in the note, which is a requirement for inclusion in the clinical trial.\n\nGiven the information provided:\n\n- The patient meets the age criterion (65 years of age or older).\n- There is no clear diagnosis of dementia stated, which is an essential inclusion criterion.\n- The MMSE score is not mentioned, which is needed to determine eligibility.\n- There is no information about the patient's ability to participate in the therapy sessions once a week for 6 weeks.\n\nDue to the absence of a clear diagnosis of dementia and the lack of an MMSE score, we cannot definitively determine the patient's eligibility. Therefore, further investigation would be needed to obtain this information before a referral could be made. The patient's ability to participate consistently would also need to be assessed given his recent decline.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "369": {
        "output": "Based on the provided information, the 85-year-old man does not meet the inclusion criteria for the clinical trial titled \"Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults.\" The inclusion criteria specify that participants must be healthy, male between 65-75 years old, have a valid Ontario driver's license, be an active driver (driving greater than or equal to three times per week), provide written, informed consent, and live in Toronto/Thunder Bay.\n\nThe patient in question is 85 years old, which is above the age range specified in the trial's inclusion criteria. Additionally, the patient has experienced a gradual decrease in the level of consciousness and has stopped walking and eating by himself, which suggests that he is not healthy, and therefore, does not meet the \"healthy\" criterion. There is also no information to confirm if he meets the other criteria such as having a valid Ontario driver's license, being an active driver, being able to provide informed consent, and living in Toronto/Thunder Bay.\n\nGiven these discrepancies, the patient does not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "370": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Delirium Recall in Advanced Cancer Patients,\" we must compare the patient's characteristics and condition with the inclusion criteria of the trial.\n\nThe inclusion criteria for the trial are as follows:\n1. Presence of advanced cancer, defined as local recurrent and/or metastatic.\n2. History of an episode of delirium during the patient's current inpatient admission; diagnosis of delirium will be made by one of the palliative care specialists according to DSM-IV-TR criteria.\n3. Complete recovery from the episode of delirium if it occurred, with the patient being approached within 3 days for the possibility of inclusion in the study.\n4. Ability to communicate in the English language.\n5. Caregiver who is 18 years of age or older, is able to communicate in English and comprehend the assessment questionnaire, and is at the bedside for a significant length of time each day during the delirium episode. Both the patient and their caregiver must agree to participate for inclusion in the study.\n6. Written informed consent signed by the patients and the participating caregivers.\n7. MDAS < 13 (Scores of 13 or above likely reflect the presence of delirium).\n8. Recruitment from the palliative care mobile team or the inpatient palliative care unit.\n\nThe patient note mentions:\n- An 85-year-old man with a gradual decrease in the level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No fever, cough, rash, or diarrhea reported.\n- He had a car accident 3 weeks prior and a normal head CT at that time.\n- There is no mention of advanced cancer, delirium, or recovery from delirium.\n\nBased on the provided patient note, the following points are noted:\n- There is no mention of the patient having advanced cancer, which is a primary requirement for the trial.\n- The patient has had a decrease in consciousness, but there is no explicit mention of an episode of delirium or a diagnosis of delirium made by a palliative care specialist.\n- There is no information on whether the patient has had a complete recovery from delirium, nor is there a timeline that matches the criteria of being approached within 3 days post-recovery.\n- There is no information on the patient's ability to communicate in English, the presence of a caregiver, or the caregiver's ability to communicate in English.\n- There is no indication that written informed consent has been provided by the patient or a caregiver.\n- The patient's MDAS score is not provided.\n- There is no information regarding the patient's recruitment from the palliative care mobile team or the inpatient palliative care unit.\n\nGiven the lack of information about advanced cancer, delirium, and other specific inclusion criteria, the patient does not appear to meet the requirements for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "371": {
        "output": "The patient is an 85-year-old man who has experienced a gradual decrease in his level of consciousness, cessation of walking and eating by himself, and no fever, cough, rash, or diarrhea. It's noted that he was involved in a car accident 3 weeks prior and had a normal head CT at that time.\n\nNow, let's compare the patient's situation to the inclusion criteria for the clinical trial:\n\n1. At least one fall in the last 6 months: The patient note does not mention any falls, so we cannot confirm this criterion is met based on the provided information.\n\n2. Living in their own home or in a home for the aged: There is no information provided about the patient's living situation.\n\n3. Availability of a primary caregiver caring for the patient at least once a week: The patient's daughter is mentioned, which might imply she could be a primary caregiver, but the frequency of care is not specified.\n\n4. Ability to walk 15 meters independently (use of a walking aid is permitted): The patient has stopped walking, meaning he currently does not meet this criterion.\n\n5. Life expectancy of more than 6 months, as judged by their geriatrician: There is no information provided about the patient's life expectancy.\n\nBased on the available information, the patient does not clearly meet several of the inclusion criteria, specifically the ability to walk 15 meters independently and the documented history of at least one fall in the last 6 months. Furthermore, other criteria such as living situation and life expectancy are not addressed in the patient note. Therefore, we would not refer this patient for this clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "372": {
        "output": "Based on the patient note provided, the 85-year-old man has experienced a gradual decrease in the level of consciousness and stopped walking and eating by himself. There is no mention of urinary incontinence, walking difficulties specifically in both legs, or mental impairment. Furthermore, there is no information provided regarding brain imaging results (CT or MRI) that show enlarged ventricles, nor is there an MMSE score available to determine the level of mental impairment.\n\nGiven the lack of detailed information in the patient note that matches the specific inclusion criteria for the clinical trial on normal pressure hydrocephalus (NPH), such as specific walking difficulties, mental impairment, urinary incontinence, and brain imaging findings, it is not possible to confidently refer this patient for the trial. More information would be needed to make an accurate assessment of his eligibility.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "373": {
        "output": "To determine the patient's eligibility for the clinical trial based on the provided inclusion criteria, we need to compare the patient's characteristics with those criteria.\n\nInclusion Criteria for the trial:\n1. Adults, 18-65 years old\n2. One or more mild-moderate TBI's characterized by loss of consciousness due to blast injury that is a minimum of one year old and occurred after 9/11/2001\n3. Absence of acute cardiac arrest or hemorrhagic shock at time of TBI.\n4. Absence of intracranial neurosurgery post-TBI\n5. Disability Rating Scale of 0-3\n6. Negative Michigan Alcohol Screening Test (MAST)\n7. Negative Drug Abuse Screening Test (DAST)\n8. Negative urine toxicology screen for drugs of abuse\n9. Negative pregnancy test in females\n10. Otherwise good health\n11. Less than 90% on the Percent Back to Normal Rating Scale\n\nPatient's Characteristics:\n- An 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at that time\n\nThe patient's age (85 years old) does not meet the age criterion of the clinical trial (18-65 years old). Additionally, there is no information provided about a TBI due to a blast injury or the absence of acute cardiac arrest or hemorrhagic shock at the time of the TBI. Furthermore, the patient's recent history does not suggest a TBI that occurred after 9/11/2001. The other criteria such as the Disability Rating Scale, MAST, DAST, and urine toxicology screen cannot be assessed from the given patient note, but the patient's age alone is a clear exclusion factor.\n\nBased on the information provided, the patient is not eligible for the clinical trial due to not meeting the age criterion.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "374": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical trial:\n- Title: Analysis of Balance in the Aging Process\n- Objective: To evaluate the functional balance in the aging process\n- Inclusion criteria: Absence of the basic pathology that interferes directly in the balance\n\nThe patient is an 85-year-old man experiencing a decline in his level of consciousness and functional abilities, which could be indicative of an underlying pathology not yet diagnosed. While the trial focuses on analyzing balance in older individuals and the patient falls within the age range, the inclusion criteria specify that participants should not have a basic pathology that directly interferes with balance.\n\nGiven the patient's recent changes in consciousness and abilities, it's possible that there may be an underlying condition affecting his balance. Therefore, further investigation would be required to determine whether the patient's current health status is related to a basic pathology that would interfere with balance assessments in the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "375": {
        "output": "Based on the patient note provided, the patient is an 85-year-old man who was brought to the ER due to a gradual decrease in his level of consciousness. He has had a recent decline in his ability to walk and eat by himself. Importantly, there is no mention of the patient being on vitamin K antagonists (VKA), having an increased INR, or having a spontaneous intracerebral hemorrhage (ICH) or subdural hematoma (SDH) diagnosed by CT scanning within 12 hours of symptom onset. Therefore, we cannot determine based on the information provided whether any of the inclusion criteria for the clinical trial titled \"International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage\" are met.\n\nSince we do not have evidence that the patient meets the specific inclusion criteria of being on VKA therapy and having an INR \u2265 2, or that he has a spontaneous ICH or SDH diagnosed by CT scanning within the required timeframe, we cannot refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "376": {
        "output": "Based on the information provided in the patient note, the 85-year-old man was brought to the ER due to a gradual decrease in his level of consciousness and had stopped walking and eating by himself. There is no mention of him being a veteran, having PTSD, or meeting the DSM-IV criteria for PTSD. The clinical trial in question is specifically looking for veterans who meet the DSM-IV criteria for PTSD and aims to study the neural correlates of cognitive rehabilitation in such individuals.\n\nGiven that the patient note does not indicate that the patient is a veteran or has PTSD, there is no basis for referring this patient to the clinical trial mentioned. Therefore, the trial-level eligibility for this patient for the clinical trial titled \"Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)\" is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "377": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient in question is an 85-year-old man who has experienced a gradual decrease in his level of consciousness and has stopped walking and eating by himself. It is noted that the patient was involved in a car accident 3 weeks prior to admission and had a normal head CT at that time.\n\nFor the clinical trial titled \"Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder,\" the inclusion criteria are as follows:\n\n1. At least 18 years of age and non-active duty.\n2. Either normal (no history of head injury) -OR- TBI (injury since Jan. 1, 2002).\n\nThe patient meets the age criterion as he is 85 years old and there is no information that suggests he is on active duty. However, the patient's head CT was normal following the car accident, and there is no clear indication from the provided note that he has a traumatic brain injury. The clinical trial is specifically interested in individuals with a normal brain or a history of TBI. Since the patient does not have a documented TBI but experienced a car accident which could potentially lead to late-onset symptoms not yet diagnosed, there may be a possibility of TBI that has not been identified by the normal CT scan done immediately after the accident.\n\nBased on the information provided and considering the potential for undiagnosed TBI due to the recent car accident, I would say:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "378": {
        "output": "Based on the patient note provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and recent changes in mobility and feeding behavior could be exhibiting signs of delirium. The patient's age and current location in the emergency department appear to meet the inclusion criteria for the clinical trial, which are:\n\n1. 65 years of age or greater\n2. In the Emergency Department for less than 12 hours at the time of enrollment\n\nSince the patient note does not specify the exact time the patient has been in the ER, it is assumed that, given he is currently being described as in the ER, he falls within the 12-hour window.\n\nGiven these considerations, the patient is a match for the age criterion and is currently in the ER, which makes him a likely candidate for the trial on delirium screening.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "379": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 85 years old (meets the age criteria of 65-85 years)\n- Independent in activities of daily living: Unknown\n- Able to walk without assistance for at least 10 minutes: As of the last 3 days, the patient stopped walking, which suggests he may not meet this criterion currently.\n- Cognitively intact (Mini Mental State Exam \u226524): The gradual decrease in the level of consciousness could indicate cognitive impairment; however, the actual MMSE score is unknown.\n- Reported 2 or more falls within 6 months prior to the beginning of the study: There is no information provided about previous falls.\n\nGiven the information from the patient note, the patient does not clearly meet all of the inclusion criteria for the clinical trial. Specifically, the criteria related to walking without assistance and cognitive integrity are not met based on the provided information. Additionally, there is no information about the patient's history of falls, which is a critical inclusion criterion for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "380": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Imaging of Traumatic Brain Injury,\" let's assess the patient's eligibility:\n\n- Age: The patient is 85 years old, which meets the criterion of being \"Age 18 or older.\"\n- Evidence of external head injury or facial trauma, or mechanism of injury consistent with brain trauma: The patient was involved in a car accident 3 weeks prior to admission, which could be consistent with brain trauma. However, the patient note indicates that he had a normal head CT at that time.\n- Residence and attendance: There is no information provided about the patient's residence or willingness to attend follow-up appointments at the University of Maryland Medical Center.\n\nGiven the patient's age meets the criteria and there is a history of a car accident, there could be potential for TBI despite the normal head CT. However, we lack information about the patient's residence and their ability or willingness to attend follow-up appointments, which are part of the inclusion criteria. Additionally, the gradual decrease in the level of consciousness may or may not be related to the car accident, as no direct evidence of head injury is provided.\n\nConsidering the above, the patient could potentially be eligible for the trial if further investigation confirms a mechanism of injury consistent with brain trauma and if the patient resides within the required distance and agrees to follow-up appointments. Thus, further information would be needed to make a definitive referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "381": {
        "output": "Based on the provided patient note and the clinical trial information, let's evaluate the patient's eligibility for the trial:\n\nPatient characteristics:\n- 85-year-old man\n- Brought to the ER because of a gradual decrease in the level of consciousness\n- Stopped walking and eating by himself recently\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical trial inclusion criteria:\n- Elderly patient (\u2265 75 years)\n- Patient with planned hip fracture surgery within 48 hours after the hip fracture\n- Patient willing and able to complete the requirements of this study including the signature of the written informed consent\n\nComparing the patient's characteristics with the clinical trial inclusion criteria:\n- The patient is 85 years old, which meets the age criterion of being an elderly patient (\u2265 75 years).\n- However, there is no mention of the patient having a hip fracture or planning to undergo hip fracture surgery. The patient's decreased level of consciousness and cessation of walking and eating by himself could be due to various other medical conditions and not necessarily related to a hip fracture.\n- There is also no information indicating that the patient is willing and able to complete the requirements of the study, including providing written informed consent, as his level of consciousness is decreased.\n\nGiven the information provided, the patient does not meet the inclusion criteria related to hip fracture surgery, and there is insufficient information to determine his ability to consent. Therefore, this patient would not be eligible for the clinical trial as described.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "382": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER due to a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea is reported.\n- He was involved in a car accident 3 weeks prior to admission and had a normal head CT at that time.\n\nClinical Trial Criteria:\n- Involved in or witnessed a car accident at least 6 months ago.\n- PTSD or distress or impairment in important areas of functioning following the car accident.\n\nAssessment:\n- The patient was involved in a car accident, which aligns with the trial's focus on individuals who have experienced an MVA trauma.\n- However, the inclusion criteria specify that the car accident must have occurred at least 6 months ago, and the patient's accident occurred only 3 weeks prior.\n- There is no mention of PTSD, distress, or impairment in important areas of functioning after the car accident in the patient note. The current symptoms (decrease in the level of consciousness, stopped walking and eating) may or may not be related to posttraumatic stress.\n\nGiven that the patient's accident did not occur at least 6 months ago and there is no clear indication of PTSD or related distress or impairment, the patient does not meet the inclusion criteria of the clinical trial at this time.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "383": {
        "output": "The patient is an 85-year-old man who is experiencing a gradual decrease in his level of consciousness. He has been brought to the ER because he stopped walking and eating by himself. There is no mention of surgery or any upcoming surgical procedure. The patient's current condition does not seem to be related to a postoperative state.\n\nThe clinical trial in question is focused on preventing postoperative delirium in the elderly, specifically in those who are admitted for scheduled surgery. The inclusion criteria state that the subject must be aged over 75 years, which fits the patient's age. However, the patient has not been admitted for a scheduled surgery, which is a critical requirement for participation in the trial.\n\nGiven that the patient does not meet the requirement of being admitted for a scheduled surgery, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "384": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Information:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- Involved in a car accident 3 weeks prior\n- No fever, cough, rash, or diarrhea\n- Had a normal head CT after the accident\n\nClinical Trial Inclusion Criteria:\n- Age 65 years and older (patient meets this criterion)\n- Must reside in Greve in Chianti or Bagno A Ripoli, Italy (no information provided regarding the patient's residence)\n- Subjects with moderate cognitive problems can be included if consent can be provided by a first-degree relative or another relative living with or close to the participant (patient has a decrease in consciousness, so this may apply if he has cognitive issues and if the daughter can consent)\n\nExclusion Criteria:\n- Children (patient does not meet this exclusion criterion as he is 85 years old)\n\nConsidering the information provided, the patient meets the age criterion. However, there is no information on whether the patient is an original participant in the InChianti Mobility Study or whether he resides in the specified Italian regions, which are both critical inclusion criteria for this study. Additionally, the patient's current medical condition and the fact that he is in the ER with decreased consciousness may impact the ability to participate in the study, depending on the nature and extent of his medical issues.\n\nGiven the lack of information on the patient's residence and participation in the original study, and the current acute medical condition, it is not possible to determine with certainty whether the patient would be eligible without further investigation. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "385": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man, which matches the age criterion of the trial (\u226565 years old).\n- There is no mention of the patient's nationality; however, the trial specifies Japanese volunteers. Since the patient's nationality is not stated, we cannot assume he is Japanese.\n- The patient is currently not healthy as he has been brought to the ER due to a decrease in his level of consciousness and inability to walk or eat by himself. The trial requires healthy volunteers.\n- There is no information on the patient's BMI or weight, but given his current health condition, it is likely irrelevant to the inclusion criteria.\n- The patient's ability to comply with the requirements of the study is in question due to his decreased level of consciousness.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is looking for healthy elderly male and female Japanese volunteers who are \u226565 years old.\n- Participants need to have a BMI of \u226518 and \u226427 kg/m^2 and weigh \u226545 kg.\n- Participants must be able to understand and comply with the requirements of the study.\n\nThe patient does not meet the inclusion criteria for being a healthy volunteer, and there is no information confirming his nationality as Japanese or his ability to understand and comply with the study requirements. Therefore:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "386": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we must determine if the patient is eligible for the trial. The patient note describes an 85-year-old man with a recent decrease in his level of consciousness, but there is no mention of a current olecranon fracture or any related symptoms. The clinical trial is specifically for patients aged 75 years or older who present with an isolated olecranon fracture within two weeks of the incident.\n\nSince the patient note does not indicate that the patient has an olecranon fracture or that the patient's condition is related to such a fracture, the patient does not meet the specified inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "387": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?\", we must compare the patient's characteristics and circumstances with the inclusion criteria of the trial.\n\nPatient Characteristics:\n- 85-year-old man\n- Brought to ER due to a gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- History of a car accident 3 weeks prior, with a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Completion of informed consent by the patient or a legally appointed guardian\n- Age \u2265 50 years\n- Sustained mild head trauma with a visit to the emergency department of the Hadassah-Hebrew University Medical Center within 24 hours after trauma\n- Low-dose aspirin therapy (75-100 mg) at the time of head trauma\n- Admission non-contrast head CT with no evidence of intracranial hemorrhage or skull fracture, as assessed by the neurosurgical resident on call and confirmed by an attending neuroradiologist\n\nAssessment:\n- The patient is 85 years old, which satisfies the age criterion.\n- The patient had a car accident, which could be considered mild head trauma, but there is no mention of low-dose aspirin therapy at the time of the head trauma, which is a specific requirement.\n- There is no information indicating that the patient visited the emergency department at Hadassah-Hebrew University Medical Center within 24 hours after the trauma, which is another specific requirement.\n- The patient had a head CT that showed no intracranial hemorrhage or skull fracture, which aligns with one of the criteria.\n- It is unclear if informed consent can be obtained due to the patient's decreased level of consciousness.\n\nGiven the information provided, the patient does not meet all the explicit inclusion criteria, specifically regarding the timing of the emergency department visit and the low-dose aspirin therapy at the time of trauma. Without additional information confirming these criteria, we cannot assume eligibility. Furthermore, the patient's decreased level of consciousness may impede the ability to obtain informed consent, unless a legally appointed guardian is available.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "388": {
        "output": "Based on the patient note provided:\n\nAn 85-year-old man is brought to the ER because of gradual decrease in his level of consciousness. In the last 3 days he stopped walking and eating by himself. He has had no fever, cough, rash or diarrhea. His daughter recalls that he had been involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nAnd comparing it with the inclusion criteria of the clinical trial:\n\nInclusion Criteria:\n\n- Subjects of 18 years old or older\n- CKD stage 3 according to GFR-MDRD equation.\n- Two consecutive stable plasma Creatinine levels during the last 2 months.\n- Elective computed tomography (CT) with a nonionic low-osmolality radiographic contrast agent.\n\nThe patient does not seem to meet the specific inclusion criteria for the clinical trial. There is no information provided that the patient has CKD stage 3, nor is there any mention of stable plasma Creatinine levels or an upcoming elective CT scan with contrast. His current medical issue seems unrelated to the focus of the clinical trial on contrast media-induced nephropathy (CIAKI).\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "389": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man.\n- He has a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself in the last 3 days.\n- No mention of fever, cough, rash, or diarrhea.\n- Was involved in a car accident 3 weeks prior.\n- Had a normal head CT after the accident.\n- No information provided about undergoing spine surgery or having a history of spine issues.\n\nClinical Trial Inclusion Criteria:\n- The participant must be \u2265 70 years old.\n- The participant must be undergoing lumbar spine surgery, posterior cervical spine surgery, or anterior cervical spine surgery > 2 levels.\n\nAssessment:\n- The patient meets the age requirement of being \u2265 70 years old.\n- However, there is no information provided that indicates the patient is undergoing or has undergone any lumbar spine surgery, posterior cervical spine surgery, or anterior cervical spine surgery > 2 levels. Thus, we cannot confirm their eligibility based only on the age criterion.\n\nBased on the available information, we do not have sufficient evidence to determine if the patient meets all the necessary inclusion criteria for this clinical trial. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThe further investigation would be to clarify whether the patient is planned for or has undergone spine surgery, as indicated by the trial's inclusion criteria. If the patient is scheduled for or has had spine surgery, then their eligibility might be reconsidered.",
        "label": 0
    },
    "390": {
        "output": "The patient in the note is an 85-year-old man who has experienced a gradual decrease in his level of consciousness. He also has a recent history of being involved in a car accident, however, his head CT was normal at that time. The clinical trial is looking for patients with different types of traumatic brain injury (TBI), and the inclusion criteria simply state \"all patients with traumatic brain injury.\"\n\nGiven that the patient had a normal head CT after the car accident, there is no specific indication from the patient note that he has a traumatic brain injury at this time. The decrease in the level of consciousness could be due to numerous other causes that are not necessarily related to TBI. Without evidence of TBI in the patient's history or presentation, this does not meet the inclusion criteria as specified by the clinical trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 2
    },
    "391": {
        "output": "",
        "label": 2
    },
    "392": {
        "output": "Based on the information provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and a recent history of stopping walking and eating by himself may be experiencing symptoms consistent with delirium. The lack of fever, cough, rash, or diarrhea, combined with the timeline of symptom development and the recent car accident, suggest a possible acute change in his mental status, which could fit the criteria for delirium.\n\nThe clinical trial in question is investigating the use of donepezil for the treatment of delirium in the elderly. The inclusion criteria for this trial are:\n\n1. Over 60 years old\n2. Delirium according to the CAM-ICU\n3. Informed consent (legal representatives)\n\nGiven that the patient is 85 years old, he meets the age criterion. The patient's symptoms may suggest delirium, but we do not have information that a CAM-ICU assessment has been conducted. Since the patient's level of consciousness is decreased, informed consent would need to be obtained from legal representatives, which seems possible given that the patient's daughter is involved in his care.\n\nWhile the patient's presentation is suggestive of delirium, further assessment using the CAM-ICU is necessary to confirm the diagnosis and thus his eligibility for the trial. Based on the information given, the assessment of this patient's eligibility for the clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "393": {
        "output": "",
        "label": 0
    },
    "394": {
        "output": "Based on the patient note and the clinical trial information provided, we need to assess the eligibility of an 85-year-old man who has experienced a gradual decrease in his level of consciousness, with recent changes in his ability to walk and eat by himself, and no fever, cough, rash, or diarrhea. This patient was also involved in a car accident 3 weeks prior to his admission but had a normal head CT at that time.\n\nThe clinical trial is focused on the incidence, severity, and treatment of delirium in cardiac surgery patients and is looking specifically to include:\n\n- Adult patients admitted for cardiac surgery at the department of cardiothoracic surgery, Rigshospitalet, Denmark\n\nGiven the information provided:\n\n- The patient's current medical issue (decreased level of consciousness and recent functional decline) could be related to delirium, but there is no specific mention of delirium or cardiac surgery in the patient note.\n- The trial specifically requires patients who are admitted for cardiac surgery, and there is no indication that this patient is undergoing or has undergone cardiac surgery.\n- The location of the trial is specified as Rigshospitalet in Denmark, and there is no information given about the patient's location or whether he could be transferred to this facility.\n\nWithout evidence that this patient is undergoing cardiac surgery, we cannot assume that he is eligible for the trial based on the provided inclusion criteria. However, considering that the patient is experiencing a decline in mental status, which could potentially be delirium, and if he were to undergo cardiac surgery, there might be a scenario where further investigation is warranted to determine if he could eventually be eligible.\n\nTherefore, the patient's eligibility based on the information provided is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "395": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial titled \"Hair Cortisol Level as a Predictor of PTSD Development,\" the patient does not meet the eligibility criteria for the following reasons:\n\n1. Age: The trial specifies that participants must be between the ages of 18 and 50. The patient is 85 years old, which is well beyond the age limit.\n2. Timing of ER visit: The trial requires participants to be brought to the ER within hours of the traumatic event, but the patient was brought to the ER 3 weeks after the car accident.\n3. Traumatic event criteria: The inclusion criteria specify that the participant must have experienced a traumatic event fitting certain criteria from the DSM-IV-TR related to Acute Stress Disorder (ASD). This is not detailed in the patient note, and considering the time elapsed since the event, it might not be applicable.\n\nGiven these discrepancies, the patient is not eligible to participate in the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "396": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 85-year-old man\n- Gradual decrease in his level of consciousness over the last 3 days\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Patients over 18 years\n- Onset of clinical symptoms of subarachnoid or intracranial hemorrhage or trauma suffered less than 72h\n- Indication for implanting a tissue oxygen and intracranial pressure probe\n- A signed informed consent by the patient or legal guardian\n\nAssessment:\n- The patient is over 18 years old, which meets one of the inclusion criteria.\n- However, the onset of clinical symptoms, as described in the patient note, does not mention any subarachnoid or intracranial hemorrhage or trauma within the past 72 hours. Instead, the car accident occurred 3 weeks prior, and at that time, the head CT was normal.\n- There is no information given about the indication for implanting a tissue oxygen and intracranial pressure probe.\n- There is also no information about whether informed consent can be obtained from the patient or a legal guardian.\n\nGiven the information available, the patient does not meet the critical inclusion criterion regarding the onset of clinical symptoms related to subarachnoid or intracranial hemorrhage or trauma within the last 72 hours.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "397": {
        "output": "The patient note describes an 85-year-old man who has experienced a gradual decrease in his level of consciousness, has stopped walking and eating by himself, and has no fever, cough, rash, or diarrhea. It is also mentioned that he was involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nThe clinical trial in question is focused on patients who have had a cerebrovascular attack (ischemic or hemorrhagic) and involves continuous video-EEG monitoring to detect epileptiform discharges and their potential effect on functional outcomes.\n\nThe inclusion criteria for the clinical trial are:\n- Patients with ischemic arteria cerebri media infarct\n- Patients with spontaneous intraparenchymal bleeding\n\nBased on the patient note, there is no evidence provided that this particular patient has had an ischemic arteria cerebri media infarct or spontaneous intraparenchymal bleeding. The note only mentions a car accident and a decrease in the level of consciousness, without details that would suggest a stroke or cerebrovascular attack.\n\nGiven the absence of information suggesting that this patient has had a stroke or a cerebrovascular attack, we cannot assume that he meets the inclusion criteria for the clinical trial. Hence, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "398": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man with a gradual decrease in consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Normal head CT at the time of the accident\n\nClinical Trial:\n- Title: Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage\n- Inclusion Criteria: Patient at least 18 years of age presenting with a symptomatic chronic subdural hematoma, verified on cranial CT or MRI\n\nAssessment:\nThe clinical trial is focused on patients with a chronic subdural hematoma. The patient in question has experienced a recent decline in consciousness and was previously involved in a car accident. However, there is no mention of a chronic subdural hematoma diagnosis in the patient note. Furthermore, the patient had a normal head CT after the car accident, which suggests that at that time, there was no chronic subdural hematoma detected.\n\nGiven the lack of information regarding a chronic subdural hematoma diagnosis and the fact that the patient's symptoms could be attributable to other causes, it is not possible to determine from the patient note whether the patient has a symptomatic chronic subdural hematoma, which is a critical inclusion criterion for the clinical trial. Therefore, further investigation would be necessary to ascertain the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "399": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the patient in question does not meet the requirements for this clinical trial. The inclusion criteria specify that participants must be female, 50 years or older, have a diagnosis of overactive bladder (OAB), be English literate, able to swallow oral medication, and have the cognitive ability to give consent.\n\nThe patient note describes an 85-year-old man who was brought to the ER due to a decrease in consciousness and recent inability to walk and eat by himself. There is no mention of a diagnosis of OAB, and the patient's current state suggests that he may not have the cognitive ability to give consent due to the described decrease in his level of consciousness.\n\nGiven that the patient is male and there's no indication of OAB or the ability to consent, he would not be eligible for this clinical trial focused on the effect of anticholinergics on cognitive function in elderly women with OAB.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "400": {
        "output": "Based on the inclusion criteria provided for the clinical trial, which focuses on patients who have been prescribed Rivaroxaban for the first time compared to those who have been prescribed Phenprocoumon for the first time, there is no information given in the patient note regarding a prescription for either Rivaroxaban or Phenprocoumon. The patient's presentation with decreased level of consciousness and recent history of a car accident does not directly relate to the criteria for the study of Rivaroxaban use.\n\nSince the patient note does not mention any use of Rivaroxaban or Phenprocoumon, and there is no indication that the patient's condition is related to anticoagulant use, which is the focus of the trial, we cannot determine from the given information whether the patient would be eligible for the clinical trial. Therefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "401": {
        "output": "To determine the trial-level eligibility of the patient, we need to assess the patient's condition against the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients who meet the Peterson diagnostic criteria of MCI:\n   - memory complaints (preferably confirmed by an informant).\n   - memory impairment according to age and education.\n   - preserved general cognitive function.\n   - intact activities of daily living, absence of dementia.\n\nThe patient note provides the following information:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea is reported.\n- He had a car accident 3 weeks prior, with a normal head CT at that time.\n\nBased on the patient note, there is no direct information about memory complaints, memory impairment according to age and education, preserved general cognitive function, or intact activities of daily living. The patient's decrease in consciousness level and inability to walk or eat by himself in the past few days could suggest a more acute or severe condition than MCI. The recent head trauma and the absence of symptoms such as fever or rash point away from an infectious or inflammatory etiology but do not confirm a diagnosis of MCI.\n\nWhile the patient's age fits within a demographic that could experience MCI, the information provided does not allow us to confirm that the patient meets the specific Peterson diagnostic criteria of MCI required for inclusion in the clinical trial. Further investigation would be necessary to determine if the patient has memory complaints, memory impairment according to age and education, preserved general cognitive function, and intact activities of daily living.\n\nTherefore, based on the information provided, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "402": {
        "output": "Based on the patient note and the clinical trial information provided, let's evaluate the patient's eligibility step by step:\n\nPatient Note:\n- 85-year-old man\n\nClinical Trial Inclusion Criteria:\n- Adult patients \u2265 18 yrs of age, < 76 yrs of age\n- Admitted to MICU (3B and 3C) or SICU (8C, 8D, 11C)\n- Surrogate present to provide informed consent when patient is not able\n- RASS score of >-3, < +1\n- CAM positive\n- Enteral access\n\nThe patient does not meet the age criterion, as they are 85 years old and the clinical trial requires participants to be less than 76 years old. Therefore, this patient would not be eligible for the clinical trial based on the age criterion alone. Other aspects of the patient's condition or situation, such as the location of care, RASS score, CAM positivity, and presence of enteral access, have not been specified in the patient note, but the age exclusion is definitive.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "403": {
        "output": "Considering the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself.\n- No mention of fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior.\n- He had a normal head CT at that time.\n- There is no indication that the patient is currently intubated or expected to be on mechanical ventilation for more than 24 hours.\n\nClinical Trial Inclusion Criteria:\n- Endotracheally intubated\n- Expected time on ventilator > 24 hours\n- Age \u2265 18 years\n- Informed consent\n\nThe patient does not currently meet the inclusion criteria as there is no information suggesting that he is endotracheally intubated or expected to be on mechanical ventilation for more than 24 hours. Since the patient's condition does not match the key characteristics required for the trial, he would not be considered for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "404": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"An Investigation Into the Mechanism of Inhalation Cough Challenge,\" let\u2019s assess the patient\u2019s eligibility.\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in consciousness\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- Had a normal head CT at that time\n\nClinical Trial Inclusion Criteria:\n- Significant cough symptoms, score >20/70 on the Hull Airways Reflux Questionnaire\n- Current non-smokers\n- Stable medication for at least one month\n- Able to attend the trials unit on at least 3 occasions\n- Normal lung function\n- Able to give informed consent\n\nAssessment:\n- The patient note does not mention cough symptoms, which is a primary requirement for the clinical trial.\n- The patient\u2019s current medical condition (decreased level of consciousness) may impair his ability to give informed consent.\n- It is not specified if the patient is a non-smoker or if his medication is stable, as required by the trial criteria.\n- The patient\u2019s ability to attend the trial unit on at least 3 occasions is questionable given his recent decline in health and hospital admission.\n\nConsidering these points, the patient does not meet the key inclusion criteria of having significant cough symptoms and the ability to give informed consent. Thus, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "405": {
        "output": "Based on the patient note provided, the 85-year-old man is brought to the ER with a gradual decrease in his level of consciousness and has stopped walking and eating by himself. However, there is no mention of him being a nursing home resident, which is one of the inclusion criteria for the clinical trial titled \"Cognitive Impairment and Balance in Elderly.\"\n\nSince there is a lack of information regarding whether the patient resides in a nursing home, we cannot definitively determine his eligibility for the clinical trial. Therefore, further investigation is necessary to ascertain if he meets the criteria of being a nursing home resident.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "406": {
        "output": "Based on the information provided:\n\n- The patient is an 85-year-old man, which meets the age criterion of being 65 years and older for the clinical trial.\n- The patient was brought to the ER with a gradual decrease in the level of consciousness, which could be indicative of an acute medical condition or complication, potentially related to a trauma given his car accident history, even though the head CT was normal at that time.\n\nWhile there are no specific details provided about the medical condition leading to the hospital admission, the age of the patient alone meets the inclusion criteria for the study focused on Delirium in Elderly patients Admitted to Trauma. Since delirium is a common acute condition in the elderly, especially after trauma or during hospitalization, and the patient's presentation is consistent with a possible delirium (change in the level of consciousness, recent trauma), it is reasonable to consider the patient for the trial.\n\nHowever, without explicit confirmation that the patient has delirium or more details on his medical condition, the referral would be contingent on further clinical evaluation to confirm that delirium is indeed the issue being faced, as per the study's interest.\n\nTherefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "407": {
        "output": "Assessing the patient's eligibility for the \"Florbetapir Calibration to the Centiloid Scale\" clinical trial:\n\nPatient's characteristics:\n- 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself over the past 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior\n- No further information on cognitive status or MMSE score\n\nClinical Trial Inclusion Criteria:\n- Cognitively Normal Subjects: Males or females \u2265 21 and \u2264 45 years of age, MMSE \u2265 29\n- Clinically Diagnosed AD Subject: Males or females \u2265 50 years of age, meet clinical criteria for dementia due to probable AD, MMSE \u2265 16 and \u2264 26\n- Possible AD Subject: Males or females \u2265 50 years of age, meet clinical criteria for dementia due to possible AD, MMSE \u2265 16 and \u2264 26\n- MCI Subject: Males or females \u2265 60 years of age with cognitive impairment (not dementia), MMSE >24 and <29\n- At Risk Elderly Subject: Cognitively normal males or females that are known ApoE4 carriers and \u2265 75 years of age, MMSE \u2265 27\n\nGiven the information provided, the patient does not meet any of the specified inclusion criteria. The patient is 85 years old, which falls outside the age range for the \"Cognitively Normal Subjects\" category and there is no indication that he is a known ApoE4 carrier. Additionally, there is no information about a diagnosis of Alzheimer's disease or cognitive impairment, nor is there an MMSE score provided to determine cognitive status.\n\nBased on the information at hand, the patient does not seem to fit any of the inclusion criteria categories for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "408": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- No recent surgery mentioned\n- No mention of undergoing scheduled surgery or providing informed consent\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 60 years\n- American Society of Anesthesiologists (ASA) physical status 1-3\n- Undergoing scheduled surgery\n- Giving an informed consent\n\nWhile the patient meets the age inclusion criterion, there is no information provided about his ASA physical status, nor is there any indication that he is undergoing or has recently undergone scheduled surgery, which are required criteria for this clinical trial. Additionally, the patient's current state with a decreased level of consciousness may impair his ability to give informed consent.\n\nGiven the lack of information regarding scheduled surgery and ASA status, as well as the inability to give informed consent due to the decreased level of consciousness, the patient does not meet the inclusion criteria as stated.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "409": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's assess this patient's eligibility for the trial.\n\nPatient note assessment:\n- The patient is an 85-year-old man.\n- His current health status includes a gradual decrease in the level of consciousness and an inability to walk or eat by himself.\n- There is no mention of him being an athlete or involved in regular running activities.\n- The patient's recent health decline does not suggest that he is \"apparently healthy\" as classified by A-1, A-2, or A-3 according to the American Heart Association.\n\nClinical trial inclusion criteria assessment:\n- Healthy, non-pregnant subjects between 18 and 55 years of age.\n- Classified as A-1, A-2, or A-3 according to the American Heart Association.\n- Capable of running a 5-km race within the specified age-graded time.\n- Willing to abstain from taking any nutritional supplements for the duration of the study, with the exception of certain specified supplements.\n\nThe patient does not meet the inclusion criteria based on his age (85 years old, which is above the maximum age of 55 years for the trial) and current health status (not apparently healthy as per AHA classification). Additionally, there is no indication that the patient is capable of running a 5-km race, which is a requirement for the trial.\n\nTherefore, the assessment of eligibility for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "410": {
        "output": "",
        "label": 0
    },
    "411": {
        "output": "",
        "label": 0
    },
    "412": {
        "output": "Based on the information provided:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- He stopped walking and eating by himself over the past 3 days.\n- He has no recent fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior and had a normal head CT at that time.\n- There is no mention of the patient undergoing surgery or planning to undergo non-cardiac surgery.\n\nClinical Trial:\n- The study concerns factors affecting the incidence of postoperative delirium in frail elderly patients.\n- The inclusion criteria specify patients who are elderly (over 65 years), frail, and undergoing non-cardiac surgery under anesthesia lasting more than 60 minutes.\n- The patient must be willing and able to complete the study requirements.\n\nAssessment:\n- The patient is elderly (85 years old) which fits the age criteria.\n- There is no information provided that suggests the patient is frail or that he is scheduled to undergo non-cardiac surgery. Thus, we cannot confirm whether he meets the criteria of being frail or the requirement of undergoing surgery which is key for this clinical trial.\n- Since the patient's current condition is related to a decline in consciousness and there is no mention of surgery, we cannot assume he will undergo surgery, which is a requirement for the trial.\n- The patient's willingness and ability to complete the study requirements cannot be assessed from the information given, particularly due to his decreased level of consciousness.\n\nGiven the lack of information on the patient's frailty status, upcoming surgery, and ability to participate in the study, we cannot definitively conclude that he is eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "413": {
        "output": "Considering the patient note and the clinical trial's inclusion and exclusion criteria, let's determine the patient's eligibility:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself\n- No mention of PTSD or a diagnosis related to PTSD\n- Involved in a car accident 3 weeks prior, but no mention of trauma-related stress symptoms\n\nClinical Trial Inclusion Criteria for PTSD Patients:\n- Age 18-55 years old\n- Currently diagnosed with PTSD and symptomatic with a CAPS score > 50\n\nThe patient does not meet the age criteria as he is 85 years old, which is outside the specified age range of 18-55 years old for the trial. Also, there is no information provided in the patient note that the patient has been diagnosed with PTSD or is experiencing any symptoms of PTSD.\n\nTherefore, based on the available information, the patient would not be eligible for this clinical trial focused on PTSD.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "414": {
        "output": "Based on the information provided:\n\nThe patient is an 85-year-old man who presented to the ER with a gradual decrease in his level of consciousness, stopped walking and eating by himself, and has no fever, cough, rash, or diarrhea. The patient had been involved in a car accident 3 weeks prior to his admission and had a normal head CT at that time.\n\nThe clinical trial is looking for:\n\n- Males between 40 to 85 years of age\n- Individuals who participated in contact sports or other activities that could lead to concussions and have a memory or cognitive complaint\n- Individuals with Mild Cognitive Impairment (MCI) and no history of concussion or TBI\n- Healthy controls with no history of head injury and no current cognitive or memory problems\n- All participants require a study partner\n\nThe patient is within the age range required by the study (85 years old). However, the patient note does not mention participation in contact sports or other activities that could lead to concussions, nor does it mention any memory or cognitive complaints. It only mentions a recent car accident. Additionally, the presence of MCI or healthy control status is not clarified in the patient note.\n\nGiven the information provided, there is insufficient evidence to determine whether the patient fits the study's specific inclusion criteria regarding history of concussions and cognitive complaints or MCI status. Therefore, a more detailed investigation into the patient's medical history and current cognitive status would be necessary before considering a referral to this clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "415": {
        "output": "Based on the information provided, the 85-year-old man brought to the ER with a gradual decrease in his level of consciousness and recent history of cessation of walking and eating by himself does not fit the inclusion criteria of the clinical trial titled \"Dexmedetomidine and Delirium in Patients After Cardiac Surgery.\" The inclusion criteria specifically require patients who are 60 years or older and are planning to receive cardiac surgery (CABG and/or valve replacement surgery). There is no mention of the patient having undergone or planning to undergo cardiac surgery. Therefore, he would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "416": {
        "output": "Given the patient note and the clinical trial information provided, we need to assess the patient's eligibility for the trial based on the inclusion criteria.\n\nPatient Note:\n- An 85-year-old man\n- Brought to the ER because of a gradual decrease in his level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Was involved in a car accident 3 weeks prior\n- Had a normal head CT at that time\n\nClinical Trial:\nTitle: Postoperative Delirium in Hip Arthroplasty Patients\nInclusion Criteria:\n- Male or female, between 30 and 80 years of age\n- ASA I, II, or III\n- Capable and willing to consent\n- Participants literate in English language\n\nAssessment:\nThe patient does not meet the age criterion for the trial, as he is 85 years old and the trial requires participants to be between 30 and 80 years of age. Additionally, there is no information provided that indicates the patient is undergoing or has undergone hip arthroplasty, which is the context in which the study of delirium is being conducted.\n\nTherefore, the patient is not eligible for the clinical trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "417": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the two:\n\nPatient Note:\n- The patient is an 85-year-old man.\n- He was brought to the ER because of a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No fever, cough, rash, or diarrhea reported.\n- Involved in a car accident 3 weeks prior with a normal head CT at that time.\n- There is no mention of acute abdominal pain.\n\nClinical Trial Inclusion Criteria:\n- Elderly patients aged 75 years old and older.\n- Admitted to the emergency department with acute abdominal pain.\n- Able to provide informed consent.\n\nThe patient in the note is within the appropriate age range for the trial (85 years old) and has been admitted to the emergency department. However, the patient does not present with acute abdominal pain, which is a requirement for the trial. Additionally, the patient has had a decrease in the level of consciousness, which may impair his ability to give informed consent.\n\nConsidering the information provided, the patient does not meet all of the inclusion criteria for the clinical trial, particularly the presence of acute abdominal pain and the ability to provide informed consent. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "418": {
        "output": "Based on the patient note provided, the 85-year-old man was brought to the ER because of a gradual decrease in his level of consciousness and has stopped walking and eating by himself. There is no mention of delirium or any symptoms that would specifically indicate delirium, such as changes in attention, cognition, or a fluctuating course of mental status. Additionally, there is no indication that the patient has been diagnosed with delirium or is exhibiting signs of delirium. The clinical trial is specifically looking for patients with delirium as part of the inclusion criteria.\n\nSince the patient note does not explicitly mention delirium, it is not possible to determine if the patient fits the inclusion criteria of the clinical trial without further information. Therefore, I would consider referring this patient to the clinical trial upon further investigation to determine if the decreased level of consciousness is due to delirium. This would potentially involve a clinical assessment for delirium using tools such as the CAM-ICU scale mentioned in the summary of the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "419": {
        "output": "",
        "label": 0
    },
    "420": {
        "output": "The patient in the note is an 85-year-old man who has experienced a gradual decrease in his level of consciousness. He has stopped walking and eating by himself, but there is no mention of fever, cough, rash, or diarrhea. His recent history includes a car accident three weeks prior to admission, after which he had a normal head CT.\n\nThe clinical trial in question is focused on validating an EEG-based delirium monitor in frail elderly patients who are undergoing elective surgery and are expected to remain admitted for at least two postoperative days. The inclusion criteria are as follows:\n1. 60 years and older\n2. Frail\n3. Undergoing elective surgery\n4. Expected to remain admitted for at least 2 postoperative days\n\nThe patient in the note does not meet the inclusion criteria for several reasons:\n- There is no indication that the patient is frail as defined by the study's requirements.\n- The patient has not undergone elective surgery, nor is there any mention of an upcoming surgery.\n- The patient's current admission to the ER does not seem to be related to an elective surgery, and thus, the requirement of remaining admitted post-surgery is not applicable.\n\nGiven these discrepancies, the patient would not meet the specific inclusion criteria set by the clinical trial. Therefore, he would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "421": {
        "output": "Based on the patient note, the 85-year-old man has been brought to the ER due to a gradual decrease in his level of consciousness, stopped walking, and stopped eating by himself. There is no mention of him being admitted to the Intensive Care Unit (ICU); however, the circumstances suggest he may require critical care given his acute change in status.\n\nThe clinical trial in question is targeting ICU patients to test the feasibility of a delirium detection system. The inclusion criteria for ICU patients are straightforward: the patient must be in the ICU, 18 years of age or older, and able to wear a motion sensor watch (ActiGraph). There are no specific exclusion criteria that would immediately disqualify the patient based on the note provided.\n\nSince the patient appears to be a candidate for ICU admission given his decreased level of consciousness and the recent decline in his functional status, he would potentially meet the age criteria (>18 years old) and could possibly be able to wear a motion sensor watch unless there are contraindications not mentioned in the note.\n\nHowever, without explicit confirmation of the patient's admission to the ICU or further clinical details, there is some uncertainty. Therefore, further investigation would be required to confirm the patient's ICU status and his ability to participate in the trial (e.g., whether he is able to wear the ActiGraph watch).\n\nGiven this information, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "422": {
        "output": "Based on the provided patient note and the clinical trial information, the patient would not meet the inclusion criteria for the clinical trial. The key reasons are:\n\n1. The patient is 85 years old, which is outside the age range of the inclusion criteria, which specify children aged 2 through 17 years.\n2. The clinical trial is specifically for cases of suspected long bone fractures requiring morphine analgesia within the first 12 hours after the injury. The patient note does not mention a long bone fracture or the need for morphine analgesia.\n3. The patient's presentation is a decrease in the level of consciousness and not related to an acute injury that would be treated in an emergency department for pain management, as the trial is investigating.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "423": {
        "output": "Based on the information provided:\n\nPatient note:\n- An 85-year-old man with a decrease in the level of consciousness.\n- No recent fever, cough, rash, or diarrhea.\n- Past car accident with normal head CT.\n\nClinical trial:\n- Focuses on young children with disabilities utilizing modified ride-on cars.\n- Aims to advance mobility and socialization.\n- Inclusion criteria include children aged 12 to 36 months with motor delays and specific motor impairments.\n\nThe patient in the note is an 85-year-old man, which does not meet the age criterion of the clinical trial that targets children between 12 to 36 months old. Additionally, the patient's condition as described does not match the focus of the clinical trial, which is on motor delays in young children.\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "424": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial \"Clinical Relevance of Microbleeds In Stroke,\" we need to determine if the patient is eligible for the clinical trial.\n\nPatient Note:\n- An 85-year-old man\n- Brought to the ER because of a gradual decrease in his level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial Inclusion Criteria (Study I: CROMIS-2 (AF)):\n- Adult (\u226518y; no upper limit) patients\n- Clinical diagnosis of non-valvular AF (verified by ECG)\n- Intention to treat with best practice oral anticoagulants (e.g., warfarin)\n- Previous ischemic stroke or TIA diagnosed by treating clinician\n- Must be able to have GRE MRI before (or within 1 week) of starting best practice oral anticoagulant\n\nThe patient note does not mention a diagnosis of non-valvular atrial fibrillation (AF), nor does it indicate that the patient has had a previous ischemic stroke or transient ischemic attack (TIA). The note also does not mention if the patient has the intention to be treated with oral anticoagulants or the ability to have a GRE MRI.\n\nSince the patient's condition described in the note does not meet the specific inclusion criteria of having AF and a history of ischemic stroke or TIA, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "425": {
        "output": "",
        "label": 1
    },
    "426": {
        "output": "Based on the provided patient note and the clinical trial information, the patient in question would not be eligible for the clinical trial.\n\nThe patient is an 85-year-old man with a recent decrease in level of consciousness and mobility, which is not consistent with the population targeted by the clinical trial. The clinical trial is specifically looking for toddlers aged between 12 months to 36 months old with motor delays that prevent functional independent mobility and who are able to tolerate sitting with support for 30 minutes and able to reach for objects with one or both hands.\n\nThe inclusion criteria for the clinical trial clearly do not match the patient's age or clinical condition. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "427": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- The patient is an 85-year-old man, which meets the age criterion of \u2265 75 years.\n- He was brought to the ER because of a gradual decrease in his level of consciousness and has stopped walking and eating by himself.\n- No mention is made of acute dyspnoea, breathe rate, PaO2, SpO2, PacO2, pH level, or the state of the electrocardiogram at admission.\n\nClinical trial inclusion criteria:\n- Admission to the Emergency Department\n- Age \u2265 75 years\n- Criteria of acute dyspnoea (one of the following):\n  - Breathe rate \u2265 25 cycles/minute\n  - PaO2 \u2264 70 mmHg\n  - SpO2 \u2264 92% in room air\n  - PacO2 \u2265 45 mmHg and pH \u2264 7.35\n- Electrocardiogram in sinus rhythm at admission\n\nThe patient's age and admission to the ER align with the trial's inclusion criteria. However, the note does not specify that the patient has acute dyspnoea, nor does it provide the specific respiratory or blood gas measurements required. Additionally, there is no information on the patient's cardiac rhythm.\n\nGiven the information provided, the patient's eligibility cannot be confirmed because the clinical information necessary to determine the presence of acute dyspnoea and corresponding criteria is not available in the patient note.\n\nTherefore, additional information would be needed to make a complete assessment. Without this information, I would consider referring this patient to this clinical trial upon further investigation to determine if the criteria for acute dyspnoea and electrocardiogram status are met.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "428": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nPatient Note Analysis:\n- An 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself\n- No fever, cough, rash, or diarrhea\n- History of a car accident 3 weeks prior with a normal head CT\n\nClinical Trial Inclusion Criteria:\n- Patients with an age equal or older than 65 years\n- Hospitalized at the Acute Geriatric Unit of the Complejo Hospitalario Universitario of Albacete\n- Valid signed informed consent by the patient or legal representative\n\nBased on this information, the patient meets the age criterion for the clinical trial. However, there is no mention of the patient being hospitalized in the Acute Geriatric Unit of the Complejo Hospitalario Universitario of Albacete, which is a specific requirement for the trial. Additionally, the patient's decreased level of consciousness may impact the ability to provide valid signed informed consent unless a legal representative is available to do so on his behalf.\n\nWithout further information regarding the hospitalization location or the patient's or legal representative's ability to consent, the assessment for referring this patient to the clinical trial is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "429": {
        "output": "The patient note describes an 85-year-old man who has experienced a gradual decrease in his level of consciousness, stopping walking and eating by himself. There is no mention of fever, cough, rash, or diarrhea, and he had a normal head CT following a car accident three weeks prior to admission.\n\nThe clinical trial is a randomized controlled trial (RCT) focused on the prevention of delirium using ramelteon in hospitalized adults aged 65 and older.\n\nInclusion Criteria for the clinical trial:\n- Hospitalized adults aged 65 and older\n- Patients from designated nursing units\n\nBased on the information provided, the patient is 85 years old and has been brought to the ER, which aligns with the age requirement for the clinical trial. However, the inclusion criteria are not fully detailed. It mentions \"from designated nursing units\" but does not specify if being in the ER qualifies or if the patient needs to be admitted to a specific unit within the hospital.\n\nGiven the lack of specificity in the inclusion criteria regarding the nursing units and the current setting of the patient (ER), it would be prudent to seek further information about the trial's specific requirements for the nursing units involved.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "430": {
        "output": "Based on the presented patient note and the inclusion criteria of the clinical trial, let's assess the eligibility of the patient for the trial:\n\nPatient Note Summary:\n- 85-year-old man\n- Gradual decrease in the level of consciousness\n- Stopped walking and eating by himself in the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior to admission\n- Normal head CT after the accident\n\nClinical Trial Inclusion Criteria Summary:\n- Severe Trauma Population\n- All adults (age \u226518 to 54) with specific trauma and injury conditions\n- All adults (age 55 and older) with specific trauma and injury conditions, including long bone or pelvic fractures, hemorrhagic shock, or ISS \u2265 15\n- Ability to obtain Informed Consent prior to OR repair of injury\n\nExclusion Criteria Summary:\n- Patients not expected to survive greater than 48 hours\n- Prisoners\n- Pregnancy\n- Chronic corticosteroids or immunosuppression therapies\n- Previous bone marrow transplantation\n- End Stage Renal Disease\n- Pre-existing hematological disease\n- Elective Hip Repair Population with its own specific criteria\n\nAssessment:\nThe patient is an 85-year-old man, which fits within the age range of \"55 and older\" for the clinical trial. However, there is no indication in the patient note that he has suffered long bone or pelvic fractures, hemorrhagic shock, or has an ISS \u2265 15, which are required trauma-related inclusion criteria for the trial. Additionally, the patient's decrease in consciousness and inability to walk or eat by himself do not seem related to a trauma that would qualify him for this trial.\n\nThere is no mention of the patient's ability to consent, and we are not informed about his injury severity score or specific trauma details. The car accident mentioned occurred 3 weeks prior, and the normal head CT suggests that it did not result in severe trauma requiring ORIF or CRPP, or meet the shock or ISS criteria listed.\n\nConclusion:\nThe patient does not appear to meet the trauma-related inclusion criteria for the clinical trial. Without evidence of severe trauma, specific types of injury, or the required severity measures, the patient is not a suitable candidate for this trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "431": {
        "output": "",
        "label": 0
    },
    "432": {
        "output": "Based on the information provided:\n\nPatient Note:\n- An 85-year-old man\n- Gradual decrease in level of consciousness\n- Stopped walking and eating by himself over the last 3 days\n- No fever, cough, rash, or diarrhea\n- Involved in a car accident 3 weeks prior with a normal head CT at that time\n\nClinical Trial:\n- Title: Delirium at the Intensive Care Unit - a Retrospective Cohort Study\n- Seeks to describe the incidence of delirium in ICU patients and identify risk and preventive factors\n- Investigates if an imitated natural light/dark cycle influences the frequency of delirium\n- Inclusion Criteria: Patients >18 years of age admitted to the ICU at K\u00f8ge Hospital in the study period\n\nAssessment:\nThe patient is an 85-year-old man who has had a significant change in his level of consciousness and functional status, which could be indicative of delirium or another acute medical condition. Considering he's been brought to the ER and, given his symptoms, may be admitted to the ICU, he would potentially meet the age and admission criteria for the clinical trial.\n\nHowever, it is not explicitly stated that he is diagnosed with delirium or that he is admitted to the ICU at K\u00f8ge Hospital, which are necessary to determine his eligibility for this specific study.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "433": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's review the patient's eligibility:\n\nPatient note review:\n- The patient is an 85-year-old man.\n- He has experienced a gradual decrease in his level of consciousness.\n- In the last 3 days, he stopped walking and eating by himself.\n- No recent fever, cough, rash, or diarrhea.\n- He was involved in a car accident 3 weeks prior with a normal head CT scan at that time.\n- There is no mention of the patient being scheduled for cardiac surgery.\n\nClinical trial inclusion criteria review:\n- Written informed consent.\n- Age \u2265 65 years.\n- Scheduled to undergo elective cardiac surgery with the use of cardiopulmonary bypass (CPB).\n- Both genders are eligible.\n\nEligibility assessment:\n- The patient meets the age criterion (\u2265 65 years).\n- There is no information about the patient's consent, but it is assumed that it could potentially be obtained.\n- The patient is not mentioned to be scheduled for elective cardiac surgery, which is a critical criterion for the study.\n\nSince the patient is not scheduled for elective cardiac surgery, he does not meet one of the key inclusion criteria for the clinical trial. Therefore, the patient would not be eligible for this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "434": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the eligibility of the patient for this specific clinical trial.\n\nPatient Note Analysis:\n- The patient is a 36-year-old woman with 12 weeks of amenorrhea and symptoms suggesting a possible molar pregnancy (enlarged uterus with multiple cystic areas, vaginal spotting, lower abdominal tenderness).\n- A negative pregnancy test and ultrasound findings raise the possibility of gestational trophoblastic neoplasia, which includes conditions like a hydatidiform mole and choriocarcinoma.\n- There is no mention of beta HCG levels or histological confirmation of the type of gestational trophoblastic neoplasia.\n- The patient's current health status, including blood count and biochemical profile, is normal.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for patients with histologically proven low-risk gestational trophoblastic neoplasia.\n- Patients must have undergone at least one uterine curettage.\n- The trial requires specific beta HCG titer criteria to be met.\n- The patient must not be pregnant or nursing and must agree to use effective contraception.\n- The patient must not have had any prior chemotherapy for gestational trophoblastic neoplasia.\n\nComparison:\n- The patient's condition could potentially be gestational trophoblastic neoplasia, but there is no histological proof provided in the patient note.\n- There is no information about prior uterine curettage or specific beta HCG titer levels.\n- The patient's performance status is not mentioned, but given the presentation in the emergency department, she might not meet the required performance status (GOG 0-2).\n- The patient's organ function seems to be within the normal ranges based on the \"complete blood count and biochemical profile are normal\" statement, but specific values for WBC, granulocyte count, platelet count, bilirubin, SGPT, SGOT, alkaline phosphatase, and creatinine are not provided.\n- The patient's pregnancy status is uncertain due to the negative pregnancy test despite the enlarged uterus, which could be due to a molar pregnancy (part of the spectrum of gestational trophoblastic neoplasia).\n\nGiven the information provided, the patient may potentially have a condition relevant to the clinical trial (gestational trophoblastic neoplasia), but there is insufficient evidence (such as histological confirmation and specific beta HCG titer criteria) to definitively include her in the trial without further investigation. Therefore, the assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "435": {
        "output": "To determine the eligibility of the patient for the clinical trial, we must compare the patient's characteristics and medical history to the inclusion and exclusion criteria of the study.\n\nPatient Characteristics:\n- 36-year-old woman\n- Presents with 12 weeks of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting\n- Physical exam reveals an 18-week sized uterus and cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound reports an enlarged uterus with multiple cystic areas\n- Differential diagnosis includes vesicular mole vs fibroid degeneration\n\nClinical Trial Inclusion Criteria:\n- Female gender\n- In good health, chronic medication use is acceptable except for glucocorticoids\n- Menstrual cycles of 24 - 35 days (no information provided about this)\n- Hemoglobin greater than 10 g/dL (no information on hemoglobin level)\n- Willing and able to comply with study requirements\n- Age 33 to 50\n- Using mechanical contraception, sterilization, or abstinence\n- Negative pregnancy test\n- BMI less than or equal to 33 (no information on BMI)\n- Fluent in English\n- Normal glomerular filtration rate (no information provided)\n- Liver function tests within 130% of upper limit (no information provided)\n- History of uterine leiomyoma causing symptoms\n- Uterine leiomyoma(ta) of at least 2 cm size\n- No desire for fertility; willing to undergo hysterectomy\n\nClinical Trial Exclusion Criteria:\n- Significant abnormalities in history, physical or laboratory examination (possible due to differential diagnosis)\n- Pregnancy or lactation\n- Use of oral, injectable or inhaled glucocorticoids or megesterol within the last year\n- Unexplained vaginal bleeding (patient has vaginal spotting)\n- History of malignancy within the past 5 years\n- Use of estrogen or progesterone-containing compounds within 8 weeks of study entry\n- Use of agents known to induct hepatic P450 enzymes; use of imidazoles\n- Current use of GnRH analogs or other compounds that affect menstrual cyclicity\n- FSH greater than 20 IU/mL (no information provided)\n- Significant medical disorders (no clear indication beyond the presenting symptoms)\n- Cervical dysplasia (no information provided)\n- Need for interval use of narcotics (no information provided)\n- Abnormal adnexal/ovarian mass (no information provided)\n- Intrauterine device (no information provided)\n- Use of herbal medication having estrogenic or antiestrogenic effects within the past 3 months (no information provided)\n- Contraindication to anesthesia (no information provided)\n- Genetic causes of leiomyomata (no information provided)\n- Previous participation in the study (no information provided)\n- Known recent rapid growth of fibroids (no information provided)\n\nBased on the patient note and the clinical trial criteria:\n- The patient is the correct gender and age for the trial.\n- She presents with a negative pregnancy test, which is required.\n- The patient has an enlarged uterus with cystic areas, which could indicate fibroids, but this is part of a differential diagnosis, and a confirmed diagnosis of uterine leiomyomata causing symptoms is necessary for inclusion.\n- No information is provided about the patient's menstrual cycle regularity, hemoglobin levels, BMI, glomerular filtration rate, liver function tests, FSH levels, or desire for fertility.\n- The patient has vaginal spotting, which could be considered unexplained bleeding, potentially excluding her from the trial.\n- The patient's willingness to undergo a hysterectomy is not stated.\n- It is not clear if the patient fulfills the health criteria or if she is taking any excluded medications.\n\nGiven the information available, the patient could potentially have fibroids, which is the condition the trial is studying. However, there is not enough information to confirm her eligibility based on the inclusion criteria, and there are potential concerns regarding the exclusion criteria (such as unexplained vaginal bleeding).\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "436": {
        "output": "Given the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for the trial:\n\nPatient characteristics:\n- 36-year-old premenopausal woman\n- 12 weeks of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting\n- Physical exam reveals tender abdomen, 18-week sized uterus, cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound reports enlarged uterus with multiple cystic areas\n\nClinical trial inclusion criteria:\n- Premenopausal women, at least 18 years of age \u2713 (Patient is 36 years old and presumed premenopausal)\n- Diagnosis of uterine fibroid(s), confirmed by ultrasound ? (Differential diagnosis includes uterine fibroids, but not confirmed)\n- History of menstrual cycles between 17 and 42 days ? (Not enough information)\n- Otherwise in good health ? (The patient presents with several health issues, but it is not clear if they are related to a condition other than the uterine issue)\n- Scheduled for a hysterectomy at the end of the treatment period ? (Not mentioned whether a hysterectomy is scheduled)\n- Negative pregnancy test \u2713 (Patient has a negative pregnancy test)\n- Agrees to double barrier method of contraception ? (Not mentioned if the patient agrees)\n- Pap test with no evidence of malignancy or pre-malignant changes ? (No information provided)\n- Endometrial biopsy with no significant histological disorder ? (No information provided)\n\nThe patient's diagnosis of uterine fibroids is not confirmed, as the differential diagnosis includes vesicular mole vs fibroid degeneration. The clinical trial requires a confirmed diagnosis of fibroids by ultrasound for inclusion. Additionally, there is no information regarding her history of menstrual cycles, whether she is scheduled for a hysterectomy, her willingness to use contraception, or the results of a Pap test or endometrial biopsy.\n\nGiven the lack of confirmatory diagnosis and incomplete information on several other criteria, it is not possible to determine with certainty if the patient would be eligible for the trial based on the provided note.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "437": {
        "output": "Given the provided patient note and the inclusion criteria for the clinical trial, let's assess the eligibility of the patient:\n\nPatient characteristics:\n- A 36-year-old woman\n- Presents with 12 weeks of amenorrhea and vaginal spotting\n- Lower abdominal tenderness, nausea, and vomiting\n- Physical exam shows tender abdomen, 18-week sized uterus, cervical dilation of 2 cm\n- Negative pregnancy test\n- Ultrasound shows an enlarged uterus with multiple cystic areas\n- Differential diagnosis includes vesicular mole vs fibroid degeneration\n\nClinical trial inclusion criteria:\n- Women that have completed 6 months of treatment in study C02-037 with no more than a 7-day interruption in their treatment\n- Otherwise good health\n- Premenopausal based on Estrogen and Follicle Stimulating Hormone levels\n- Agrees to double-barrier method of contraception\n- Adequate endometrial biopsy with no significant histological disorder\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial as there is no mention of her having completed the 6-month study C02-037, which is a prerequisite for participation. Furthermore, the patient's current health condition (amenorrhea, vaginal spotting, and the presence of a possibly enlarged uterus due to either a vesicular mole or fibroid degeneration) does not clearly indicate that she is in otherwise good health as required by the trial.\n\nTherefore, the patient does not meet the inclusion criteria for the clinical trial on the safety of treatment of uterine fibroids with Asoprisnil.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "438": {
        "output": "Based on the patient note provided, the patient is presenting with signs and symptoms that could be indicative of a gestational trophoblastic disease (GTD), such as a vesicular mole, given the 12 weeks of amenorrhea, vaginal spotting, and an ultrasound report of an enlarged uterus with multiple cystic areas. The differential diagnosis includes a vesicular mole, which is a type of GTD. However, the patient's Beta-HCG test is negative, which is not typically expected in active GTD, as these conditions are usually associated with high levels of hCG.\n\nThe clinical trial in question is focused on the detection of human chorionic gonadotropin (hCG) by Dual Polarisation Interferometry (DPI) in cases of gestational trophoblastic disease. The inclusion criteria for this clinical trial are specific to individuals with a diagnosis of GTD, including hydatidiform mole, choriocarcinoma, and gestational trophoblastic neoplasms.\n\nGiven that the patient's Beta-HCG is negative and there is no confirmed diagnosis of GTD (only a differential diagnosis that includes vesicular mole), further investigation would be needed to confirm the presence of a GTD before considering referral to the clinical trial. As such, the patient's eligibility for this trial is not clear cut based on the information provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "439": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- A 36-year-old woman presents with 12 weeks of amenorrhea and vaginal spotting.\n- The physical exam reveals a tender abdomen and an 18-week sized uterus with cervical dilation.\n- The point of care pregnancy test is negative.\n- Ultrasound reports an enlarged uterus with multiple cystic areas, with a differential diagnosis of vesicular mole vs. fibroid degeneration.\n\nClinical Trial Inclusion Criteria:\n1. Subject with uterine fibroids, who desire pregnancy within 12 months and has the one of the following criteria:\n   - Women 20-40 age.\n   - Women age < 46 years old who plan to have egg donation.\n   - Women above 38 should test for normal ovarian function as judged by endocrinological evaluation.\n   - If the couple has failed to conceive for more than 1 year, the woman should test for normal ovarian function, and the male must have adequate sperm test.\n   - Women undergoing fertility treatment or plan to have sperm donation.\n2. Use or non-use of non-steroidal treatments for excessive vaginal bleeding maintained for the three months prior to the study procedure.\n3. Clinically normal PAP smear within the timing of National Guidelines in the country of the clinical site.\n4. Able and willing to give consent and able to attend all study visits.\n5. Able to communicate sensations during the MRgFUS procedure.\n6. Having uterine fibroids that are device accessible.\n7. Tumors are clearly visible on non-contrast MRI.\n8. Largest fibroid 8 cm in diameter or 12 cm if receiving GnRH.\n\nComparison:\n- The patient's age (36 years) falls within the age range specified in the inclusion criteria.\n- The patient has not expressed a desire for pregnancy within 12 months, which is not stated in the patient note but could be inferred given the concern over amenorrhea.\n- The enlarged uterus and cystic areas on ultrasound suggest the possibility of fibroids, which is part of the differential diagnosis.\n- The trial requires the fibroids to be visible on non-contrast MRI, and while the patient has had an ultrasound, MRI visibility is not mentioned.\n- It is not indicated whether or not the patient meets the other specific criteria such as the use of non-steroidal treatments, a normal PAP smear, or the ability to communicate sensations during the MRgFUS procedure.\n\nGiven this information, the patient may potentially have uterine fibroids and is within the age range, but there is insufficient information to determine her complete eligibility. Further investigation would be needed to clarify her desire for future pregnancy, the exact diagnosis of her condition, and other relevant inclusion criteria details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "440": {
        "output": "",
        "label": 2
    },
    "441": {
        "output": "Based on the provided information, the patient is a 36-year-old woman, which meets the age criterion of the clinical trial (age \u2265 18 years). However, the clinical trial in question is focused on skin self-examination and the use of mole mapping diagrams to increase accuracy in detecting changes in moles on the skin.\n\nThe patient presents with symptoms related to gynecological issues (amenorrhea, vaginal spotting, lower abdominal tenderness, and an enlarged uterus with multiple cystic areas). There is no mention of skin-related concerns or the need for mole mapping in the patient's note. The patient's condition does not seem to be relevant to the objectives of the skin examination clinical trial.\n\nTherefore, the patient does not meet the specific inclusion criteria related to the clinical trial's focus on skin health and mole mapping.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "442": {
        "output": "The patient in the provided note is a 36-year-old woman presenting with symptoms consistent with a gynecological issue (amenorrhea, vaginal spotting, lower abdominal tenderness, nausea, and vomiting). The ultrasound suggests a differential diagnosis of vesicular mole vs fibroid degeneration. There is no mention of herpes labialis, which is the focus of the clinical trial.\n\nThe inclusion criteria for the clinical trial are specific to adult patients with a history of recurrent herpes labialis, which is not indicated in the patient's note. The patient's current medical issues seem unrelated to herpes labialis or the effectiveness of famciclovir in treating it.\n\nTo evaluate the eligibility of the patient for the clinical trial on famciclovir for the treatment of recurrent herpes labialis, we have to compare the patient's condition with the trial's inclusion criteria:\n\n- The patient is 18 years or older (meets criteria).\n- There is no indication in the patient note of a history typical for recurrent herpes labialis (does not meet criteria).\n- General good health status is not clearly stated, and the patient appears to be experiencing a serious gynecological condition (unclear but likely does not meet criteria).\n- The patient's renal and hepatic function is not mentioned (unclear).\n- The patient's birth control methods are not discussed (unclear).\n- A negative pregnancy test is required, and the patient's pregnancy test is negative (meets criteria).\n- The informed consent document is not mentioned (unclear).\n\nAlthough the patient meets the age criteria and has a negative pregnancy test, the primary condition under investigation for the clinical trial (recurrent herpes labialis) is not mentioned in the patient note. Therefore, based on the information provided, the patient does not meet the specific disease-related inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "443": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, the patient is a 36-year-old woman presenting with symptoms of amenorrhea, vaginal spotting, lower abdominal tenderness, nausea and vomiting, and an enlarged uterus with multiple cystic areas, which may indicate the presence of uterine fibroids or a vesicular mole. The differential diagnosis includes vesicular mole vs. fibroid degeneration.\n\nThe clinical trial is looking to enroll women with symptomatic uterine fibroids. The primary endpoint of the study is menstrual bleeding reduction six months after treatment, with secondary endpoints such as symptom relief and volume reduction of fibroids.\n\nThe patient's negative pregnancy test and the presence of an enlarged uterus with cystic areas might suggest that she has uterine fibroids. However, since the diagnosis is not confirmed, and there is a differential diagnosis that includes a vesicular mole, which is not related to uterine fibroids, this creates uncertainty regarding her eligibility for the trial.\n\nGiven that the patient's diagnosis is not definitive for uterine fibroids and that further investigation (e.g., histopathological examination) would be needed to confirm the diagnosis, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "444": {
        "output": "",
        "label": 0
    },
    "445": {
        "output": "The patient is a 36-year-old woman who presents with symptoms suggestive of a gynecological condition, specifically with ultrasound findings of an enlarged uterus with multiple cystic areas and a differential diagnosis that includes vesicular mole vs fibroid degeneration. Importantly, her pregnancy test is negative.\n\nNow, comparing this patient's information with the inclusion criteria of the \"Fibroid Growth Study\" clinical trial, we find the following:\n\n- The patient is at least 18 years of age and is premenopausal, which meets the age and menopausal status criteria.\n- She speaks English (although not explicitly stated, this is often assumed in case studies unless otherwise noted).\n- The ultrasound report suggests an enlarged uterus, which is consistent with the requirement of the uterus being enlarged to the size typical during the 8th week of pregnancy.\n- There is a suspicion of uterine leiomyomas (fibroids) based on the ultrasound report, although it is not confirmed and is part of a differential diagnosis including vesicular mole. The trial requires a confirmed diagnosis of leiomyoma.\n\nGiven that the patient has not been confirmed to have a diagnosis of leiomyoma by ultrasound but is being considered for such a diagnosis, there is potential for her to be eligible for the trial. However, further investigation is required to confirm the diagnosis of leiomyomas before she can be definitively referred to the trial.\n\nTherefore, the assessment of the patient's eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "446": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial, let's go through the factors one by one:\n\n1. The patient is a 36-year-old woman, which fits within the age range of 30 to 50 years specified by the trial inclusion criteria.\n   \n2. The patient presents with symptoms that could potentially be caused by uterine fibroids, such as lower abdominal tenderness and an enlarged uterus, which fits the criterion of symptoms caused by uterine fibroids. However, the trial specifically mentions symptoms like heavy bleeding (menorrhagia) and/or bulk-related complaints, which are not explicitly mentioned in the patient note.\n\n3. A differential diagnosis of vesicular mole vs fibroid degeneration is mentioned. This indicates that uterine fibroids are a consideration in her diagnosis, but it is not confirmed. The inclusion criterion requires fibroids confirmed by MRI, which is not yet established in this patient.\n\n4. The patient's kidney function isn't mentioned, but the biochemical profile is noted as normal, which may suggest normal kidney function. However, this would need to be explicitly confirmed to meet the trial's inclusion criteria.\n\n5. It is not clear if the patient has chosen to participate, signed informed consent, or is willing and able to undergo follow-up imaging as required by the trial.\n\nConsidering the information provided, there is potential for the patient to be eligible for the clinical trial, but further investigation is required to confirm fibroid presence via MRI, obtain patient consent, and establish her willingness and ability to comply with follow-up procedures. Therefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "447": {
        "output": "Based on the information provided, the 28-year-old female patient is experiencing a range of symptoms including neck and shoulder pain, paresthesias, slight tremors, spasticity, and various other acute symptoms leading to hospitalization. It is not clear from the patient note whether the patient has an underlying disease affecting her movement, or if her symptoms are transient or part of an acute condition. Moreover, the symptoms such as difficulty swallowing, hydrophobia, and marked agitation suggest a potentially serious and acute neurological condition that requires immediate attention, which could be outside the scope of the clinical trial's intent to collect data on normal and adaptive movements.\n\nThe clinical trial in question is looking to develop a database on normal movements and adaptive movements of people with diseases that affect the way they move. The inclusion criteria for the trial are broad, allowing for any volunteer of any age who is medically fit to participate and willing to provide informed consent.\n\nGiven the patient's recent onset of symptoms and the fact that they have been hospitalized, we cannot determine from the information provided if she is medically fit to participate in the study, as her acute symptoms might preclude her from engaging in the movement tasks safely or as intended by the study. Moreover, since she is hospitalized, obtaining informed consent might be challenging, especially if her cognitive function is impaired due to her current condition.\n\nTherefore, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nFurther investigation would be required to assess the patient's medical fitness for participation, her ability to provide informed consent, and whether her movement issues are related to an underlying disease that affects movement in a way that is relevant to the study's aims.",
        "label": 2
    },
    "448": {
        "output": "The patient note describes a 28-year-old female presenting with neck and shoulder pain and paresthesias, along with symptoms that include tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia, and spastic arm movements. These symptoms are not directly related to voice disorders; rather, they suggest a neurological condition, potentially severe, considering the hydrophobia and difficulty swallowing (which could suggest something like rabies given her recent history with stray animals, although this is not explicitly stated).\n\nThe clinical trial is specifically looking for participants with idiopathic familial voice disorders, such as spasmodic dysphonia and vocal fold paralysis, with a genetic component. The inclusion criteria are focused on symptoms related to speech and voice, and the exclusion criteria rule out structural abnormalities of the larynx, history of airway obstruction, smokers, and individuals with certain psychiatric disorders.\n\nThe patient described does not exhibit symptoms that primarily relate to voice disorders. There is no mention of voice-related issues, familial history of voice disorders, or any other symptom that aligns with the focus of the clinical trial. Additionally, the patient's condition appears acute and possibly life-threatening, which would likely require immediate and specific treatment not related to the objectives of the voice disorder study.\n\nGiven the information provided, the patient does not meet the inclusion criteria for the clinical trial on idiopathic familial voice disorders, and none of the symptoms or history provided suggest eligibility.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "449": {
        "output": "Reviewing the patient note and the inclusion criteria for the clinical trial titled \"1-Octanol to Treat Essential Tremor,\" let's assess the patient's eligibility:\n\nPatient Note Summary:\n- 28-year-old female\n- Neck and shoulder pain, left-hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Prescribed NSAIDs and a topical muscle relaxant\n- Symptoms escalated to spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia\n\nClinical Trial Inclusion Criteria:\n- Patients with essential tremor affecting the upper limbs\n- 21 years of age or older\n- Not on medications for essential tremor or any other medical condition for at least 2 weeks\n- Not consumed alcohol or cold medications containing alcohol for at least 24 hours prior to the study\n- Not pregnant or lactating, with birth control for women of childbearing age\n- No neurological disease other than tremor\n- No evidence of thyroid, liver, kidney, or chronic lung disease\n\nEligibility Assessment:\n- The patient is within the age range (21 years or older).\n- The patient does have tremors, but it is not clear if these are diagnosed as essential tremors.\n- There is no information on the patient's use of medications, alcohol, or birth control which could impact the assessment.\n- The patient has been hospitalized with severe symptoms that might not align with essential tremor, including difficulty swallowing and hydrophobia, which are not typical for essential tremors and may suggest another neurological condition.\n\nGiven the information provided, it's not clear if the patient's tremors are diagnosed as essential tremor, and the patient's severe symptoms may suggest another neurological condition, which would disqualify her from the trial. Therefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "450": {
        "output": "Upon reviewing the given patient note and the inclusion criteria for the clinical trial on Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy, it is clear that the patient does not meet the specified criteria for this trial.\n\nThe patient is a 28-year-old female presenting with symptoms such as neck and shoulder pain, paresthesias, tremors, spasticity, and various other symptoms after a trip. These symptoms do not align with the diagnosis of hemiparetic cerebral palsy, which is a requirement for the clinical trial. Additionally, the trial is specifically designed for children with cerebral palsy, and the patient in question is an adult.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "451": {
        "output": "Given the patient note and the clinical trial information provided, let's determine the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- Recent hospitalization due to severe symptoms\n\nClinical Trial:\n- Title: Octanol to Treat Essential Tremor\n- Target disease: Essential tremor\n- Inclusion Criteria for the trial:\n  - Clinical diagnosis of essential tremor\n  - History of ethanol responsiveness\n  - Must be off any medications used to treat essential tremor for at least 2 weeks\n  - Must withhold ethanol and caffeine 24 hours prior to starting the treatment periods\n  - Age 21 years or older\n- Exclusion Criteria for the trial:\n  - Abnormalities on neurologic exam other than tremor\n  - History of chronic alcohol dependence\n  - Chronic medical conditions such as renal failure, hepatic failure, and chronic lung disease\n  - On medications that cannot be temporarily discontinued\n  - Women who are pregnant or lactating\n  - Patients under the age of 21\n  - Asians and Pacific Islanders\n\nAssessment:\n- The patient's age (28) fits within the age criterion of the trial.\n- The patient's symptoms include \"slight tremors,\" which may suggest the possibility of essential tremor, but this is not clear-cut as the patient also presents with other neurological symptoms that are not characteristic of essential tremor alone.\n- There is no information given about the patient's history of ethanol responsiveness.\n- The patient's recent hospitalization suggests that they may have a more complex neurological condition than just essential tremor.\n- It's also not stated whether the patient is on any medications to treat essential tremor, or whether she can withhold ethanol and caffeine as required.\n\nGiven that the patient's symptoms are not clearly indicative of essential tremor, and the lack of information on ethanol responsiveness, it is not possible to confidently refer this patient to the clinical trial based solely on the information provided. \n\nFurther investigation would be needed to determine if the tremors are indeed due to essential tremor and if the patient has a history of ethanol responsiveness. If further evaluation confirms essential tremor and ethanol responsiveness, and the other inclusion and exclusion criteria are met, the patient may become eligible.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "452": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, the patient's eligibility for the trial can be assessed as follows:\n\nThe patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, and subsequent neurological symptoms including spastic arm movements and difficulty swallowing. There is no mention of Essential Tremor (ET) in the patient's condition. Instead, the patient's symptoms, particularly hydrophobia and difficulty swallowing, are more suggestive of a possible neurological condition that could be unrelated to ET, such as an infection or other acute neurological issues.\n\nThe clinical trial is specific to adults with ethanol-responsive Essential Tremor. The inclusion criteria for the trial require patients to have a diagnosis of alcohol-responsive ET, with limb involvement being a prominent feature.\n\nBased on the patient note, the following points can be considered:\n- The patient\u2019s symptoms do not align with the characteristics of Essential Tremor.\n- There is no mention of the patient's tremors being responsive to alcohol, which is a specific requirement for the trial.\n- The patient's current symptoms of spastic arm movements and difficulty swallowing could indicate an exclusion criterion: \"Patients with abnormalities other than tremor on neurological exam.\"\n- The patient does not meet the specific inclusion criteria of having alcohol-responsive ET with limb involvement.\n\nGiven that the patient does not meet the core inclusion criteria of having alcohol-responsive Essential Tremor and presents with symptoms suggesting a different or more severe neurological condition, the patient would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "453": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, and various other symptoms including difficulty swallowing and marked hydrophobia.\n- The patient's symptoms started after a trip and there is no mention of a stroke, which is required for the clinical trial in question.\n- The note indicates recent onset of symptoms rather than a chronic or post-stroke condition.\n\nClinical Trial Inclusion Criteria:\n- Must be at least six months post-stroke.\n- 18 years of age or older with a clinical diagnosis of hemiparesis.\n- Voluntary control with a low to medium range of motion function.\n- Functionally stable with no significant changes in motor function over a week.\n- Able to tolerate being seated upright for 90 minutes.\n- No excessive pain in the impaired arm.\n- No severe left neglect or spasticity that interferes with task completion or wheel turning.\n- Not participating in other experimental therapies.\n- Not recently received chemical injections for spasticity.\n- Must have driven prior to stroke.\n- Not clinically depressed.\n\nThe patient in the note does not meet several key inclusion criteria:\n- There is no mention of the patient being post-stroke, which is a primary requirement for the trial.\n- The symptoms described do not align with hemiparesis, which is typically a result of stroke.\n- The patient's recent and acute symptoms suggest a condition other than stroke.\n\nGiven the information provided, the patient does not appear to have had a stroke, which is a fundamental inclusion criterion for the clinical trial. Therefore, the patient is not eligible for the trial based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "454": {
        "output": "Based on the patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility:\n\nPatient Note Analysis:\n- Age: 28 years old\n- Presenting symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, increased agitation, and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- No mention of a stroke, which is a specific condition required by the clinical trial for post-stroke spasticity\n\nClinical Trial Inclusion Criteria:\n- Male or female patients \u2265 18 years\n- \u2265 6 months since the last stroke, diagnosed by an appropriate health care professional\n- Focal spasticity with \u2265 2 points on the Ashworth Scale in the wrist and finger flexors\n- Specific patterns of spasticity (Flexed Wrist and Clenched Fist) are required\n\nClinical Trial Exclusion Criteria:\n- Spasticity of any other origin than stroke\n\nAssessment:\nThe patient's symptoms seem to be acute and potentially related to an infection (e.g., hydrophobia could suggest rabies) or other neurological issues, rather than post-stroke spasticity. There is no mention of a stroke in the patient's history, which is a critical inclusion criterion for the clinical trial. Since the origin of the patient's condition does not appear to be post-stroke, the patient does not meet the inclusion criteria for the trial.\n\nTherefore, the patient is not eligible for the clinical trial titled \"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb\".\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "455": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 28-year-old female.\n- She is experiencing neck and shoulder pain, left hand and arm paresthesias, slight tremors, and almost imperceptible spasticity.\n- She has recently exhibited spastic arm movements and other symptoms suggestive of a serious condition that required hospitalization.\n\nClinical Trial:\n- The study is looking at the efficacy of Functional Electrical Stimulation (FES) in persons with upper extremity spasticity who receive Botulinum Neurotoxin (Botox\u00ae).\n- It requires participants to be at least 6 months post injury/insult with unilateral upper limb spasticity.\n- Participants need to have certain levels of spasticity as measured by the Modified Ashworth scores and CMA Hand Impairment Scale.\n- Participants must have received at least two prior doses of Botulinum toxin A, with the first dose occurring at least 6 months prior to study enrollment.\n- The trial requires the ability to answer yes/no questions and follow 1-step instructions, as well as providing written informed consent.\n- Female participants of childbearing age must agree to use adequate birth control measures.\n\nThe patient in the note does not clearly meet the specific criteria related to upper extremity spasticity as defined by the Modified Ashworth scores or the CMA Hand Impairment Scale. Additionally, there's no indication that the patient has had an injury/insult to the brain or spinal cord that is at least 6 months old, nor is there any information suggesting that she has received prior doses of Botulinum toxin A. Furthermore, the patient's symptoms may suggest an acute condition, possibly related to rabies given the hydrophobia mentioned, rather than a chronic neurological issue that has been present for over six months.\n\nGiven the lack of information confirming the patient's alignment with the trial's inclusion criteria, it would not be appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "456": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient characteristics:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia\n- Recently hospitalized\n\nClinical trial inclusion criteria:\n- 18 to 70 years of age\n- Written informed consent\n- Medically stable condition\n- History of stroke (hemorrhagic or ischemic) that resulted in a unilateral, upper-limb focal spasticity pattern of the wrist and fingers\n- EMG evidence of volitional activation of wrist and finger extensor and flexor muscles\n- Active range of motion capabilities as defined\n- MMSE >24\n- Stable anti-spasticity medication regimen 1 month prior to enrollment\n- Ability to follow study instructions and likely to complete all required visits\n\nThe patient's age falls within the trial's age range. However, there is no mention of a history of stroke, which is a critical inclusion criterion for the trial. The patient's symptoms seem to be related to a different medical issue rather than post-stroke spasticity. There's no mention of EMG evidence or assessment of active range of motion that aligns with the trial's requirements. There's also no information about the patient's MMSE score or medication regimen.\n\nGiven the information provided, the patient does not meet the key inclusion criteria related to the history of stroke and associated spasticity patterns. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "457": {
        "output": "Based on the patient note, the 28-year-old female patient is presenting with neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia, and was hospitalized. There is no mention of alcohol use or withdrawal, and her symptoms do not clearly align with alcohol withdrawal syndrome (AWS). The symptoms described could be indicative of another neurological disorder.\n\nThe clinical trial in question is focused on treating alcohol withdrawal with oral Baclofen in addition to standard benzodiazepine therapy. The inclusion criteria for the trial specify that participants must meet the DSM-IV criteria for alcohol withdrawal syndrome, be an inpatient at specific medical centers at the time of study enrollment, have a measurable alcohol withdrawal score triggering benzodiazepine therapy, agree to abstain from alcohol for the duration of the study, and be able to provide informed consent.\n\nThe patient note does not provide evidence that this patient is experiencing alcohol withdrawal or meets the DSM-IV criteria for AWS. Therefore, she does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "458": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the patient's eligibility for the trial:\n\nPatient Characteristics:\n- A 28-year-old female (meets age criteria of \u226519 to \u226465 years)\n- Experiencing health problems (neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia)\n\nClinical Trial Inclusion Criteria:\n- Subjects free of obvious health-problems or with stable condition\n- Male or female subjects aged \u226519 to \u226465 years\n- BMI between \u226518 and \u226430 kg/m2\n\nThe patient's current health problems (spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing and marked hydrophobia) suggest that she is not free of obvious health-problems nor in a stable condition, especially considering that she was hospitalized.\n\nGiven the acute presentation and hospitalization, the patient does not meet the criterion of being free of obvious health problems or in a stable condition. Therefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "459": {
        "output": "After reviewing the patient note and the clinical trial information, the patient does not meet the inclusion criteria for the clinical trial. The trial is specifically looking for toddlers aged 12-18 months, while the patient is a 28-year-old female. Additionally, the patient's symptoms suggest a possible rabies exposure, which is not the focus of the trial. The trial is for pre-exposure rabies immunization and Japanese Encephalitis vaccination in healthy toddlers.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "460": {
        "output": "Based on the information provided about the patient and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the Malaria Vaccine for Children in Mali clinical trial.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Males or females aged greater than or equal to 1 to less than 4 years.\n- Known residents of the village of Bancoumana, Mali, or its surrounding area.\n- Good general health as determined by means of the screening procedure.\n- Available for the duration of the trial (24 months from enrollment).\n- Willingness to have the child participate in the study as evidenced by parents/legal guardians signing or fingerprinting the informed consent document.\n\nThe patient note describes a 28-year-old female with various symptoms that led to hospitalization. This patient does not meet the age requirement (as she is 28, not between 1 and 4 years old), nor is there any indication that she is a resident of Bancoumana, Mali, or its surrounding area. Furthermore, the trial is specifically for children and requires parental consent, which is not applicable to this adult patient.\n\nTherefore, the patient is not eligible for the clinical trial based on age, residency, and the nature of the trial being for children.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "461": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, the patient does not match the profile for this particular study. The patient is a 28-year-old female presenting with neurological symptoms such as tremors, spasticity, anxiety, difficulty swallowing, and hydrophobia. These symptoms do not align with the trial's focus on chronic functional constipation in children.\n\nThe inclusion criteria for the trial are specific to chronic functional constipation, which includes symptoms like less than two bowel movements per week, fecal incontinence, retentive behavior, pain at defecation, and hard stools. The patient's symptoms do not mention any of these gastrointestinal issues, nor is there any indication that the patient is a child, as the patient is clearly stated to be 28 years old.\n\nTherefore, based on the available information, this patient would not be eligible for the physiotherapeutic intervention trial for children with chronic functional constipation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "462": {
        "output": "Based on the patient note and the clinical trial inclusion and exclusion criteria provided, let's assess the patient's eligibility:\n\nPatient note:\n- 28-year-old female (meets age criterion: 18 to 60 years)\n- Neck and shoulder pain and left hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Hospitalized with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n\nClinical trial inclusion criteria:\n- Aged 18 to 60 years on the day of inclusion (patient meets this criterion)\n- Provision of a signed Informed Consent Form (assumed that the patient can provide if meeting other criteria)\n- Able to attend all scheduled visits and comply with all trial procedures (assumed that the patient can comply if meeting other criteria)\n- For a woman of child-bearing potential, use of an effective method of contraception or abstinence (assumed that the patient can comply if meeting other criteria)\n- Entitlement to national social security (not mentioned in patient note, assumed to be met)\n- No known pregnancy or breast-feeding (not mentioned in patient note, assumed to be met)\n- No participation in another clinical trial in the 4 weeks preceding or planned during the trial (not mentioned in patient note, assumed to be met)\n- No immunodeficiency, immunosuppressive therapy, or systemic hypersensitivity related to the trial (not mentioned in patient note, assumed to be met)\n- No chronic illness, alcohol abuse, drug addiction, or receipt of blood products that might interfere with the trial (not mentioned in patient note, assumed to be met)\n- No vaccination against rabies with any vaccine (in pre- or post-exposure regimen)\n\nHowever, the patient's symptoms (difficulty swallowing, marked hydrophobia) suggest a possible acute illness, potentially rabies given the recent contact with stray animals and the symptoms aligning with rabies infection. This would most likely exclude the patient from participating in the trial if confirmed to be rabies, as it would be a contraindication to receive a vaccine under these conditions.\n\nGiven the information provided, the patient's current symptoms may be indicative of a serious acute illness that could interfere with the trial. Without further information on the definitive diagnosis and the cause of her symptoms, there is uncertainty about her eligibility. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "463": {
        "output": "",
        "label": 0
    },
    "464": {
        "output": "After reviewing the provided patient note and comparing it to the inclusion criteria of the \"Positive Action for Today's Health\" clinical trial, we can determine the trial-level eligibility as follows:\n\nThe inclusion criteria for the clinical trial are:\n1. African American (must have 3 of 4 grandparents of African Descent)\n2. Lives in the designated census area\n3. No plans to move in the next two years\n4. Has no medical condition that would limit participation in moderate intensity exercise including life-threatening illness (e.g., immobile, severely disabled, or bedridden)\n5. Available and able to participate in measures and intervention activities over the next 2 years\n\nBased on the patient note, we do not have information about the following:\n- The patient's race or ethnicity (whether she is African American with 3 of 4 grandparents of African Descent)\n- Her residential status in the designated census area\n- Her plans regarding relocating in the next two years\n- Her availability and ability to participate in the study activities over the next 2 years\n\nHowever, we do know that the patient does not have a medical condition which would limit participation in moderate intensity exercise according to the note provided. The symptoms described (neck and shoulder pain, tremors, spasticity, agitation, and hydrophobia) do not indicate a life-threatening illness or a condition that would make the patient immobile, severely disabled, or bedridden.\n\nSince we lack information on several key inclusion criteria, we cannot definitely determine the patient's eligibility for the trial. Therefore, further investigation is required to ascertain the missing details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "465": {
        "output": "Based on the information provided, let's assess the patient's eligibility for the clinical trial titled \"Study of Intradermal Administration of PCEC Rabies Vaccine\":\n\nInclusion Criteria Breakdown:\n1. Laboratory personnel, epidemiologists, EISOs, veterinary students, interns, and other first responders at CDC; other CDC employees; and healthy volunteer adults.\n2. Persons who contact the study coordinator will be assessed for possible occupational exposure to rabies using the risk assessment form.\n3. Male or nonpregnant females (as indicated by a negative urine pregnancy test prior to the first dose of vaccine), aged 18 years and older.\n4. Women of childbearing potential must agree to practice adequate contraception for the entire study period.\n5. Be in good health, as determined by vital signs, medical history, and a targeted physical examination based on medical history.\n6. Able to understand and comply with planned study procedures.\n7. Provide informed consent prior to any study procedures and be available for all study visits.\n8. Have health insurance.\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which satisfies the age criterion.\n- The patient has presented with symptoms that could potentially be related to rabies exposure (difficulty swallowing, hydrophobia), and there is a mention of her returning from a trip where she attended a stray animal recovery campaign. This could imply a risk of rabies exposure, which might align with the study's focus on individuals with potential occupational exposure to rabies.\n- The patient's health status is not fully clear from the note, but she does have several health issues (spastic arm movements, increased agitation, anxiety, malaise, hydrophobia), which might be considered when determining \"good health.\"\n- There is no information about the patient's occupation, whether she is one of the specified professionals or first responders, or a CDC employee.\n- There is no information on her insurance status, understanding, and willingness to comply with the study procedures, or her consent availability.\n\nGiven the available information, it is not clear if the patient would meet all the inclusion criteria, particularly with respect to her occupation and her current health status. However, assuming she had potential occupational exposure to rabies and her symptoms could be assessed as part of the study's interest in rabies exposure, she might be a candidate for further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "466": {
        "output": "The patient in question is a 28-year-old female presenting with various neurological symptoms, including neck and shoulder pain, paresthesias, tremors, spasticity, and a range of symptoms that could suggest a serious neurological condition, such as difficultly swallowing, marked hydrophobia, and increased agitation. These symptoms are potentially severe, and no definitive diagnosis is mentioned in the patient note.\n\nThe clinical trial at hand is focused on the immunogenicity and safety of the Japanese Encephalitis Vaccine IC51 in children and adolescents in non-endemic countries. The inclusion criteria specify:\n\n1. Male or female healthy children and adolescents aged >=2 months to <18 years at the time of first vaccination\n2. Written informed consent by the subject's legal representative(s), and assent by the subject if applicable\n3. For female subjects, either no childbearing potential or a negative pregnancy test. For females after menarche, a willingness to practice a reliable method of contraception.\n4. The subject is planning to travel to an area where JE is endemic after completion of the vaccination schedule and can adhere to the study visit schedule.\n\nThe patient described does not meet the inclusion criteria for several reasons:\n\n1. Age: The patient is 28 years old, which is outside the specified age range for the trial of 2 months to <18 years.\n2. Health status: The trial requires healthy children and adolescents, while the patient is presenting with significant neurological symptoms that would likely exclude them from being considered healthy.\n3. Travel plans: There is no information about the patient planning to travel to JE endemic areas.\n\nBased on the above points, this patient does not meet the inclusion criteria for the described clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "467": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial for the vaccine against Enterotoxigenic Escherichia coli (ETEC), we need to analyze whether the patient meets the criteria for the study. Let's review the patient's information and the trial's criteria:\n\nPatient note:\n- A 28-year-old female, which fits the age criterion of 18-50 years.\n- Presents with neck and shoulder pain, left hand and arm paresthesias, slight tremors, spasticity, increased agitation, anxiety, malaise, difficulty swallowing, and marked hydrophobia.\n- No direct mention of general good health or clinically significant medical history.\n- No information provided about pregnancy status or contraception use.\n- No information on willingness to participate, training session attendance, or availability for the study duration.\n- No mention of any significant medical or psychiatric condition that would preclude participation.\n- No details on recent vaccinations or receipt of an investigational product.\n- No mention of working as a food handler, in child-care, or as a healthcare worker with direct patient contact.\n- No household contacts information provided.\n- No details on stool pattern, medication, or allergies.\n- The patient recently returned from California, but no information on symptoms consistent with Traveler's Diarrhea or travel to ETEC endemic countries.\n- No information on ETEC, cholera, or LT toxin vaccinations or ingestion.\n- No mention of antibiotic or proton pump inhibitor use before dosing.\n\nGiven the patient's current symptoms, including spastic arm movements, and the lack of detailed information regarding her overall health status, we cannot confirm general good health as required by the trial's inclusion criteria. Moreover, the patient's symptoms suggest an acute health issue, which may be a significant medical condition that could preclude participation in the trial, as per the exclusion criteria.\n\nWithout additional information to confirm her eligibility, particularly regarding her general health status, contraceptive use, willingness to participate, and absence of significant medical or psychiatric conditions, we cannot definitively determine her suitability for the trial.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "468": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to be a candidate for the trial. The patient note describes a 28-year-old female with symptoms that include neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia, and marked sweating. There is no mention of thyroid disease, let alone the specific conditions of follicular thyroid carcinoma or papillary thyroid carcinoma that are required for inclusion in the trial.\n\nThe clinical trial is specifically looking for candidates who have either:\n(a) a minimally invasive follicular thyroid carcinoma \u22644 cm in diameter, or\n(b) a papillary thyroid carcinoma \u22642 cm in diameter.\n\nSince the patient's symptoms and diagnosis do not match the inclusion criteria of the clinical trial, which is focused on thyroid carcinoma and surgical outcomes, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "469": {
        "output": "Based on the given patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility:\n\nPatient note:\n- 28-year-old female\n- Neck and shoulder pain, left hand and arm paresthesias\n- Recent spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia\n\nClinical trial inclusion criteria:\n- Diagnosis of non-relapsing multiple sclerosis (either primary progressive MS or secondary progressive MS)\n- Reduced use of one of the hands because of MS\n- Ability to pick up and release a small object with the more-affected hand when requested\n- Can travel to the treatment program at UAB\n- Can undergo treatment for 2 weeks (Monday-Friday), 3.5 hours per day\n- Can undergo MRI scan\n- Any medication for MS allowed except spasticity medicine\n\nAssessment:\n- The patient's symptoms do not clearly indicate a diagnosis of multiple sclerosis.\n- There is no mention of a diagnosis of MS in the patient note, let alone the specific type required by the trial (non-relapsing MS).\n- The symptoms described in the patient note could potentially be due to a number of conditions, and there is no explicit link to MS.\n- The symptoms started after a specific event (trip to California and participation in a stray animal recovery campaign), which could suggest other etiologies.\n- The severity of the patient's symptoms and the rapid progression to hydrophobia and difficulty swallowing are concerning and may suggest a more acute condition (such as rabies, given the hydrophobia and recent contact with stray animals).\n\nGiven the information in the patient note, there is no evidence that this patient has been diagnosed with multiple sclerosis, which is a primary inclusion criterion for the clinical trial. Therefore, the patient does not meet the eligibility criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "470": {
        "output": "Based on the patient note, the 28-year-old female is showing symptoms that could possibly be related to rabies, particularly given her recent contact with stray animals and symptoms like difficulty swallowing, hydrophobia, and spastic arm movements. The clinical trial in question is focused on the rabies virus neutralizing activity and safety of CL184, a monoclonal antibody cocktail, in simulated rabies post-exposure prophylaxis in healthy adults.\n\nTo determine the patient's eligibility for the clinical trial, let's review the inclusion criteria:\n- Male or female subject aged \u226518 to \u226455 years\n- Subjects free of obvious health-problems or with stable conditions or medications\n- Body mass index between \u226518 to \u226430 kg/m^2\n- Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90\n- Male subjects must agree that they will not donate sperm from the first check-in until Day 90\n- Subject signed written informed consent\n\nThe patient meets the age criterion (28 years old) and the gender criterion (female subject). However, the patient is not \"free of obvious health problems,\" as the symptoms presented are quite severe and indicative of a potential rabies infection, which is a serious and life-threatening condition.\n\nGiven the severity and acute nature of the patient's symptoms, she is not a healthy adult subject, which is a requirement for this clinical trial. Therefore, she would not be eligible to participate in this study focused on healthy adults in a simulated post-exposure prophylaxis scenario.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "471": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the criteria for participation in the trial. The patient is described as a 28-year-old female with symptoms that do not indicate a diagnosis of Angelman Syndrome (AS). Instead, she presents with neck and shoulder pain, paresthesias, tremors, spasticity, and other symptoms that seem unrelated to AS. Furthermore, there is no mention of a molecular confirmation of AS, which is a requirement for enrollment in the study.\n\nThe inclusion criteria for the clinical trial specifically require participants to be between 4 years and 12 years of age with a molecularly confirmed diagnosis of Angelman Syndrome and not on certain medications prior to participation. The patient in question is 28 years old, which is well outside the specified age range, and there is no evidence of an AS diagnosis.\n\nTherefore, this patient does not meet the age requirement, nor is there a confirmed diagnosis of AS, which are both critical inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "472": {
        "output": "Based on the patient note provided:\n\nA 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing and marked hydrophobia, and was immediately hospitalized.\n\nAnd the clinical trial's inclusion criteria:\n\n- HIV infected patients 18-60 years of age\n- Ever received primary rabies immunization\n\nThe patient note does not mention HIV infection or a history of rabies immunization. The patient's symptoms suggest a possible acute rabies infection, especially given the marked hydrophobia and recent contact with stray animals, but there is no information provided about their HIV status or whether they have ever received rabies vaccination (primary or booster).\n\nGiven the lack of information on two critical inclusion criteria (HIV status and history of rabies vaccination), we cannot refer this patient for the clinical trial based on the available data.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "473": {
        "output": "Given the patient note and the clinical trial information provided, let's assess the patient's eligibility for the trial:\n\nPatient Details:\n- 28-year-old female\n- Presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- No mention of malaria or travel to a malaria endemic area\n\nClinical Trial Details:\n- Title: AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area\n- Aim: Assess the safety and immunogenicity of candidate malaria vaccines\n- Inclusion Criteria: Consenting adult males aged 18-50 years in good health and healthy children aged 2-6 years with consenting parents\n\nAssessment:\n- The patient is an adult female, which does not match the gender specified in the inclusion criteria (male).\n- The health condition presented by the patient is not related to malaria, nor is there any information to suggest that she is a volunteer in a malaria-endemic region, or that she is in good health, as required by the trial's inclusion criteria.\n\nBased on the above, the patient does not meet the gender requirement and does not have a health condition relevant to the trial's focus on malaria vaccine evaluation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "474": {
        "output": "Given the information from the patient note and the inclusion criteria of the clinical trial, we can assess the patient's eligibility for this specific trial:\n\nPatient Characteristics:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity\n- Additional symptoms upon ER visit: spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- No mention of a stroke\n\nClinical Trial Inclusion Criteria:\n- Adult patients with upper limb spasticity following a stroke\n- Eligible to receive botulinum toxin Type A\n- No previous botulinum toxin Type A therapy\n\nThe patient in the note does exhibit some spasticity; however, there is no mention of her spasticity being the result of a stroke, which is a specific requirement for the trial's inclusion criteria. Additionally, there is no information regarding her eligibility to receive botulinum toxin Type A or whether she has previously received botulinum toxin Type A therapy. Given the lack of evidence that her spasticity is post-stroke, we cannot consider her a strong candidate for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "475": {
        "output": "After reviewing the patient note and the clinical trial information, the eligibility assessment can be determined as follows:\n\n- The patient is a 28-year-old female, which does not meet the age requirement of 40-80 years stated in the inclusion criteria for the clinical trial focused on upper limb stroke rehabilitation.\n- The patient's symptoms and diagnosis do not indicate that she has sustained a stroke, which is the primary condition under investigation in the clinical trial. The symptoms mentioned in the patient note, such as spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and hydrophobia, suggest a different medical condition.\n- The inclusion criteria specifically require a history of a single stroke leading to upper limb paresis, which is not present in the patient's condition as described.\n\nConsidering these points, the patient does not fit the inclusion criteria for the clinical trial focused on stroke rehabilitation. Therefore, the patient would not be referred to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "476": {
        "output": "",
        "label": 0
    },
    "477": {
        "output": "Given the patient note:\n\n- A 28-year-old female with symptoms suggestive of rabies (neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia) following participation in a stray animal recovery campaign.\n\nAnd the clinical trial:\n\n- Title: Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV\n- Inclusion Criteria: Healthy individuals who can visit according to the protocol.\n\nThe patient described in the note shows signs of a possible rabies infection, which is a serious and life-threatening condition. The clinical trial is looking for healthy individuals, which is typically defined as not having any significant acute or chronic illnesses that could impact the study outcome or the health of the participant. Given the patient's symptoms, she does not meet the \"healthy\" criterion set by the trial.\n\nTherefore, the assessment of eligibility for this patient to participate in the clinical trial would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "478": {
        "output": "Based on the information provided:\n\nPatient note: A 28-year-old female with various symptoms possibly unrelated to malaria, including neck and shoulder pain, paresthesias, slight tremors, spasticity, and a series of other acute symptoms leading to hospitalization.\n\nClinical trial: A Phase 1/2b study of an investigational malaria vaccination strategy for infants and children aged 5-17 months in Burkina Faso.\n\nInclusion criteria: Healthy infant/child aged 5-17 months at the time of first study vaccination, with informed consent of parent/guardian, and residency in the study area villages with availability for follow-up.\n\nThe patient in the note does not meet the age requirement (5-17 months) as she is 28 years old. Additionally, the trial is specifically targeting healthy infants and children for a malaria vaccination study, and the patient's symptoms suggest an acute condition unrelated to malaria. Furthermore, the patient is not located in the study area of Burkina Faso.\n\nTherefore, the patient is not eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "479": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient does not appear to meet the specific requirements for the trial. The patient's symptoms include neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. These symptoms do not clearly indicate that the patient has a spinal cord injury, which is a key requirement for the clinical trial. Additionally, the trial specifically targets individuals with incomplete traumatic spinal cord injury that occurred at least 18 months prior and has been stable for 6 months, with moderate to severe lower-limb spasticity.\n\nThe patient's condition does not mention a spinal cord injury, nor does it mention the duration or stability of any such injury. Furthermore, the spasticity mentioned is not described as moderate to severe lower-limb spasticity, which is a requirement for the trial. Therefore, based on the information provided, the patient does not meet the inclusion criteria and is not a suitable candidate for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "480": {
        "output": "Based on the provided patient note, the patient is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and various symptoms associated with increased agitation, difficulty swallowing, and hydrophobia. These symptoms and the timeline (three weeks after a trip) do not indicate a stroke; instead, they might suggest another neurological condition, possibly an infection given her recent exposure during a stray animal recovery campaign.\n\nThe clinical trial in question is focused on patients who have had a first episode of unilateral stroke within the past 3 months and have specific functional and cognitive criteria, including a motor part of the upper limb of FMA score ranging from 10 to 40 and no serious cognitive impairment.\n\nThe patient does not meet the inclusion criteria for the trial, as there is no information suggesting she has had a stroke, which is a critical requirement for participation in the trial. Furthermore, there is no provided FMA score or Mini Mental State Exam score, which are required to assess the severity of motor impairment and cognitive function, respectively.\n\nTherefore, the patient in the note does not match the inclusion criteria for the clinical trial focused on robot-assisted therapy in patients with subacute stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "481": {
        "output": "After reviewing the patient note and the clinical trial information, here is the assessment:\n\nPatient Note:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- Recent history: attended a stray animal recovery campaign in California\n\nClinical Trial:\n- Title: The Protection Effect of Speeda\u00ae Rabies Vaccine for Human Use\n- Summary: Post-marketing protective effect research of rabies vaccine\n- Inclusion Criteria:\n  - Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed\n  - Participant is considered to be in good health including the body and mental status based on reported medical history and limited physical examination and live in local area \u2265 12 months before injured\n  - The man-killer (animal) could be found and detect whether it carries the virus\n\nAssessment:\nThe patient presents with symptoms that are concerning for rabies (difficulty swallowing, hydrophobia, and history of potential exposure through a stray animal recovery campaign), although rabies is not explicitly mentioned. However, the clinical trial is for the post-marketing protective effect of a rabies vaccine, which generally would require participants to be vaccinated prior to any potential exposure to rabies. The presence of active symptoms suggests that the patient is already experiencing the disease and therefore would not be eligible for a preventative vaccine trial. Furthermore, the inclusion criteria specify that the participant should be in good health, which does not seem to align with the current medical condition of the patient.\n\nAdditionally, the trial requires that the man-killer animal can be found and tested for the virus, which is not mentioned in the patient note. Given this information, the patient does not meet the inclusion criteria for the clinical trial on the protective effect of the rabies vaccine.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "482": {
        "output": "After reviewing the patient note and the clinical trial information, it's clear that the patient does not meet the inclusion criteria for the clinical trial provided. The trial is specifically for children and adolescents aged 2 to 17 years as part of a pre-exposure regimen for rabies vaccination. The patient in the note is a 28-year-old female, which is outside the age range specified in the trial's inclusion criteria. Therefore, she is not eligible to participate in this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "483": {
        "output": "Upon reviewing the patient's note and the inclusion criteria of the clinical trial, the following points are critical to determining eligibility:\n\nPatient Note:\n- The patient is a 28-year-old female.\n- She has neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and other non-specific symptoms like agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n- The symptoms started three weeks after returning from a trip.\n- There is no mention of a diagnosis of Essential Tremor (ET), nor is there any indication that the tremors are refractory to medications.\n\nClinical Trial Inclusion Criteria:\n- Men and women between 18 and 80 years, inclusive.\n- A diagnosis of ET confirmed by a movement disorder neurologist.\n- Tremor refractory to medication trials.\n- Specific targeting requirements for the thalamus on MRI.\n- A tremor severity score requirement.\n- Significant disability due to essential tremor despite medical treatment.\n\nComparison:\n- The patient's age falls within the specified range.\n- There is no confirmation of a diagnosis of ET by a movement disorder neurologist.\n- There are no details suggesting that the patient's tremors are refractory to medication trials.\n- There is no evidence of significant disability due to tremors, nor is there any scoring based on the CRST rating scale provided.\n- It's not clear if the tremors are postural or intention tremors, which is necessary for the diagnosis of ET.\n- The patient's symptoms may suggest other neurological issues rather than Essential Tremor, particularly given the acute onset after a trip.\n\nBased on the available information, the patient does not meet several key inclusion criteria for this clinical trial, most importantly, a confirmed diagnosis of Essential Tremor and evidence of tremors being refractory to specific medications. Therefore, the patient is not eligible for the ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "484": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, let's assess the patient's eligibility for the trial:\n\nPatient Note:\n- 28-year-old female\n- Neck and shoulder pain and left hand and arm paresthesias\n- Slight tremors and almost imperceptible spasticity\n- Symptoms worsened to include spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- No mention of stroke or any history related to stroke\n\nClinical Trial:\n- Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke\n- Inclusion criteria focus on patients in the acute phase of stroke recovery (less than 12 months post-onset)\n- The patient must have experienced their first stroke episode\n- No history of peripheral nerve injury or musculoskeletal disease in the affected upper extremity\n- No contracture of the affected wrist or fingers\n- No history of invasive procedures for spasticity treatment\n- Differentiation between patients with residual active motion and those without\n\nThe patient in the note does not mention having had a stroke. Moreover, the symptoms described do not align with those typically associated with a post-stroke condition, but rather suggest some form of acute neurologic event or condition, which is not specified as a stroke. The clinical trial is specifically designed for patients who have had a stroke, which does not appear to apply to the patient described.\n\nBased on the information given, the patient does not meet the inclusion criteria for the clinical trial because there is no evidence of a recent stroke, which is a primary requirement for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "485": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not appear to meet the inclusion criteria for the \"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib\" trial. The trial is looking for healthy volunteers in general good health, while the patient is presenting with a number of symptoms (spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, marked hydrophobia). These symptoms suggest that the patient is not in general good health, which is a requirement for participation in the study.\n\nAdditionally, the trial is specific to malaria vaccine research, and there is no indication in the patient note that the patient has been exposed to malaria or is at risk for malaria, which could potentially be a focus of the Phase Ib criteria, despite that part being for African volunteers. The patient's current health issues do not seem to be related to malaria or the focus of the vaccine study.\n\nTherefore, the patient does not meet the inclusion criteria based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "486": {
        "output": "The patient in the note is a 28-year-old female presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and a range of other symptoms including difficulty swallowing and marked hydrophobia. The patient was hospitalized after her symptoms escalated.\n\nThe clinical trial in question is looking at the safety and efficacy of BOTOX (botulinum toxin Type A) in patients in Korea for treating primary axillary hyperhidrosis, focal spasticity, or moderate to severe glabellar lines.\n\nBased on the given patient note, there is a mention of \"slight tremors and almost imperceptible spasticity,\" which could potentially align with the \"focal spasticity\" mentioned in the inclusion criteria for the clinical trial. However, the patient's symptoms seem to be part of a broader and more acute clinical presentation, possibly not directly related to the conditions targeted by the clinical trial (primary axillary hyperhidrosis, focal spasticity related to a chronic condition, or cosmetic use for glabellar lines). \n\nFurthermore, it is not clear whether the patient's spasticity is a chronic condition or a transient response to another underlying issue. The trial seems to be directed towards patients with established conditions of hyperhidrosis, spasticity, or cosmetic concerns. \n\nGiven the limited information on the chronicity and cause of the patient's spasticity and the absence of a clear diagnosis of primary axillary hyperhidrosis or a need for treatment of glabellar lines, I would lean towards further investigation before making a referral. Thus:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "487": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"ASIS for Botox in Upper Limb Spasticity,\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 28-year-old female who presents with neck and shoulder pain and paresthesias in the left hand and arm.\n- Physical exam shows slight tremors and almost imperceptible spasticity.\n- The patient's symptoms have escalated to include spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia.\n\nClinical Trial Inclusion Criteria:\n- Adults with a history of stroke that resulted in unilateral, upper-limb focal spasticity.\n- Wrist flexor tone and finger flexor tone of more than 2 as measured by the Ashworth Scale.\n- Ability to understand and follow verbal directions.\n- At least 1 functional disability item with a rating of more than 2 on the Disability Assessment Scale (DAS).\n- At least 1 functional task score that meets specific criteria at Day 0.\n\nComparison:\n- There is no mention of the patient having a history of stroke, which is a required condition for the trial.\n- The level of spasticity as measured by the Ashworth Scale is not documented, nor is there any indication that the patient's spasticity is a result of a stroke.\n- The patient's ability to understand and follow verbal directions is not explicitly mentioned, but given her recent hospitalization for severe symptoms, her ability to participate in a trial may be compromised.\n- The note does not provide information about the patient's functional disability items or task scores as per the Disability Assessment Scale (DAS) and other functional criteria.\n\nGiven that the patient does not have a documented history of stroke and other necessary details are missing or do not match the trial's criteria, the patient does not appear to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "488": {
        "output": "After reviewing both the patient note and the clinical trial inclusion criteria, it is clear that the patient does not meet the inclusion criteria for this clinical trial.\n\nThe patient is a 28-year-old female, which does not meet the age requirement of \"over 40 years of age\" stated in the trial's inclusion criteria. Additionally, the patient's symptoms and conditions mentioned in the note do not indicate that she has Myopic Macular Degeneration (MMD). Instead, her symptoms suggest a neurological condition, possibly related to her recent trip and involvement in a stray animal recovery campaign.\n\nThe clinical trial is specifically targeting patients with MMD and has very specific requirements for visual acuity, axial myopia, and other ocular health parameters, none of which are mentioned in the patient's note. Therefore, based on the information provided, the patient does not qualify for referral to this particular clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "489": {
        "output": "",
        "label": 0
    },
    "490": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, the assessment of eligibility is as follows:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which meets the age criterion of the clinical trial (aged sixteen or older).\n- The symptoms described (spastic arm movements, tremors, and almost imperceptible spasticity) could suggest a neurological disorder, but there is no specific mention of cerebral palsy, which is a requirement for the trial.\n- There is no information provided regarding the patient's intelligence quotient (I.Q), speech troubles, or psychiatric health, which are also part of the inclusion criteria.\n- The patient's symptoms appeared to arise after a trip and are acute in nature, which does not align with cerebral palsy being a lifelong condition that typically arises in early childhood.\n\nClinical Trial Criteria Analysis:\n- The clinical trial is specifically aimed at patients with spastic cerebral palsy with a stable condition, which is not mentioned in the patient's note.\n- The trial requires motor disability to be unilateral or predominantly unilateral, which is not specified in the patient note.\n- The trial requires clinically evident speech troubles and normal or slightly sub-normal I.Q., none of which are mentioned in the patient note.\n- The trial excludes patients with psychiatric disorders, which could potentially include severe agitation and anxiety, though these symptoms in the patient note may be due to an acute condition rather than a psychiatric disorder.\n\nGiven the information provided, there is no indication that the patient has cerebral palsy, let alone the specific type of spastic cerebral palsy with the characteristics required for the trial. The patient's symptoms seem to be acute and related to a recent event rather than a stable, long-term condition like cerebral palsy. Thus, the patient does not meet the necessary criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "491": {
        "output": "Given the patient note and the inclusion criteria for the clinical trial, let's assess the patient's eligibility:\n\nPatient note summary:\n- 28-year-old female\n- Symptoms: neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Recent hospitalization\n\nClinical trial inclusion criteria:\n- Compliant with protocol procedures and availability for clinical follow-up\n- Physical examination and laboratory results without clinically significant findings\n- BMI between 18.0 and 32.0 kg/m^2\n- Reliable forms of contraception or true abstinence, and refrain from sperm donation during treatment and the follow-up period\n\nAssessment:\n- The patient's age fits the criteria of being over 18.\n- The patient's current medical condition, with symptoms such as difficulty swallowing and hydrophobia, suggests a possible acute neurological condition that may not be stable or without clinically significant findings. This would likely require further investigation before determining her eligibility.\n- The patient's BMI is not mentioned, so we do not have enough information to assess this criterion.\n- The patient's contraceptive use is not discussed in the note, but this is a criterion that could be easily assessed and managed if she were otherwise eligible.\n\nBased on the patient's current symptoms and the lack of information on some of the criteria, I would say that further investigation is needed to determine her eligibility for the clinical trial. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "492": {
        "output": "To determine the patient's eligibility for the RNActive\u00ae Rabies Vaccine (CV7201) in Healthy Adults clinical trial, we need to assess the patient's characteristics against the inclusion criteria provided.\n\nInclusion criteria for the trial:\n1. Healthy male and female volunteers aged 18 to 40 years inclusive\n2. Compliant with protocol procedures and available for clinical follow-up through the last planned visit (V9)\n3. Physical examination and laboratory results without clinically significant findings\n4. Body Mass Index (BMI) \u2265 18.0 and \u2264 32.0 kg/m2\n5. Females: Negative human chorionic gonadotropin (HCG) pregnancy test (serum) for women presumed to be of reproductive potential on the day of enrolment\n6. Females of childbearing potential must use acceptable methods of birth control during the trial and follow-up period\n7. Males must use reliable forms of contraception and must refrain from sperm donation during the trial and follow-up period\n\nPatient characteristics from the note:\n- 28-year-old female\n- Presenting with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia\n- Hospitalized after the onset of severe symptoms\n\nBased on the patient note, this individual is experiencing severe symptoms including spasticity, agitation, and marked hydrophobia, which may be indicative of a significant medical condition. The inclusion criteria specify that participants should not have clinically significant findings in their physical examination and laboratory results. Therefore, this patient does not meet the criteria of being a \"healthy volunteer\" due to her current medical state, and referring her to this clinical trial would not be appropriate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "493": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial provided, the patient is a 28-year-old female presenting with symptoms that could suggest possible rabies exposure (e.g., difficulty swallowing, hydrophobia, anxiety). The clinical trial is focused on the immunogenicity and safety of a post-exposure rabies intradermal regimen in children.\n\nThe inclusion criteria for the clinical trial specify that participants must be:\n1. 1-15 years old healthy children\n2. Able to give signed informed consent from their parents\n3. Willing to participate in the study and able to receive the vaccination and collect blood samples as planned.\n\nThe patient in the note is 28 years old, which is outside the specified age range for the trial (1-15 years). Therefore, she would not meet the inclusion criteria based on her age alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "494": {
        "output": "Based on the patient note provided, the 28-year-old female patient does not appear to be eligible for the clinical trial in question. The clinical trial is targeted towards individuals who have suffered a stroke and have specific sensorimotor impairments as a result. The inclusion criteria for the trial are:\n\n- First focal unilateral lesion, ischemic or hemorrhagic\n- Had a stroke 1-12 months prior to enrollment\n- Rated between stages 2-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory: Stage of Recovery of the Arm and Hand\n\nThe patient's symptoms of neck and shoulder pain, paresthesias in the left hand and arm, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, marked hydrophobia, and hospitalization do not indicate that she has had a stroke. Instead, her symptoms might suggest a different neurological condition, potentially related to an infection or other acute event, especially given the onset after a trip and exposure to stray animals. Her symptoms do not align with the inclusion criteria specified for the trial, which are specific to stroke recovery.\n\nTherefore, based on the information given in the patient note, this patient would not be referred for the clinical trial focused on robot-aided rehabilitation intervention for stroke patients.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "495": {
        "output": "Based on the patient note provided, the patient is a 28-year-old female who presented with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and later developed more severe symptoms including spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficulty swallowing, and marked hydrophobia. The patient was hospitalized after these symptoms developed.\n\nThe clinical trial in question is focused on the rehabilitation of sensory and motor impairments following a stroke. The inclusion criteria for the trial specify that participants must have had their first focal unilateral lesion, ischemic or hemorrhagic, less than a month prior to enrollment, and be rated between stages 1-4 on the Chedoke McMaster Stroke Assessment Impairment Inventory for both arm and hand recovery.\n\nThe patient's symptoms do not indicate that she has had a stroke. Instead, her symptoms could suggest another neurological condition. There is no mention of a stroke or focal unilateral lesion, which are critical for eligibility in this trial. Therefore, based on the information provided in the patient note, the patient does not meet the inclusion criteria of having had a stroke and the subsequent impairment ratings required for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "496": {
        "output": "Given the patient's symptoms of neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and severe symptoms including spastic arm movements, sweating, agitation, anxiety, malaise, difficulty swallowing, and marked hydrophobia after attending a stray animal recovery campaign, there's a high suspicion of rabies exposure especially considering the hydrophobia symptom which is characteristic of rabies infection.\n\nThe clinical trial in question is studying the immunogenicity of rabies vaccine for pre-exposure prophylaxis. The inclusion criteria for the trial are:\n- Male and non-pregnant females aged \u2265 18 to \u2264 60 years on the day of inclusion\n- Able to comprehend and give informed consent\n- Able to attend all scheduled visits and to comply with all trial procedures\n- Subject in good health, based on medical history and physical examination\n\nThe patient is a 28-year-old female, which fits the age criterion. There is no information provided about pregnancy, but assuming she is not pregnant based on the available information, she would meet the gender and age criteria. However, the trial is for pre-exposure prophylaxis, and the patient's symptoms suggest that she may have already been exposed to rabies, which could be considered post-exposure. Additionally, the presence of clinical symptoms would likely exclude her from being considered \"in good health\" as per the trial's requirements.\n\nTherefore, despite the patient's age and gender fitting the inclusion criteria, her current health status does not align with the \"good health\" requirement for the trial, which is focused on pre-exposure prophylaxis rather than post-exposure treatment.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "497": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor,\" I will determine the patient's eligibility for referral.\n\nPatient Note Summary:\n- A 28-year-old female with neck and shoulder pain and left hand and arm paresthesias.\n- Presented with slight tremors and almost imperceptible spasticity.\n- Symptoms worsened over time, leading to hospitalization with spastic arm movements and other severe symptoms such as hydrophobia.\n\nClinical Trial Inclusion Criteria:\n- Essential Tremor diagnosed by criteria listed in the Consensus statement of the Movement Disorders Society on Tremor\n- Age 18 - 85 years of age\n- Motor skills allowing for capability to complete evaluations\n- Medically cleared for undergoing anesthesia and DBS surgery\n\nAssessment:\nThe patient's symptoms include tremors, which could be relevant to the trial's focus on Essential Tremor (ET). However, the patient's diagnosis is not clear from the note provided. The severe symptoms and rapid progression, including hydrophobia and difficulty swallowing, are not typical of ET, which is generally characterized by action tremors and does not typically include hydrophobia or difficulty swallowing. These symptoms may suggest a different neurological condition or another acute medical issue.\n\nThe clinical trial specifically requires a diagnosis of Essential Tremor as per the Movement Disorders Society's criteria. Since the patient has not been diagnosed with Essential Tremor and the symptoms described do not clearly match the typical presentation of ET, she does not meet the inclusion criteria based on the information provided.\n\nBased on the information available, it is not appropriate to refer the patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "498": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Analysis:\n- The patient is a 28-year-old female, which fits within the age range of the inclusion criteria (2-100 years).\n- The patient presents with neck and shoulder pain, left hand and arm paresthesias, slight tremors, almost imperceptible spasticity, and later with spastic arm movements, among other symptoms.\n\nClinical Trial Inclusion Criteria:\n- Clinical diagnosis of cervical dystonia or spasmodic torticollis.\n- Age range 2-100 years.\n\nAssessment:\nWhile the patient's age fits the trial's inclusion criteria, the patient note does not mention a clinical diagnosis of cervical dystonia or spasmodic torticollis. Instead, the symptoms described indicate a potential neurological condition that could require immediate and possibly different medical attention (e.g., difficulty swallowing, marked hydrophobia could suggest something more acute like rabies, given the recent history of attending a stray animal recovery campaign).\n\nThere is not enough information to diagnose cervical dystonia or spasmodic torticollis based solely on the patient note provided. The slight tremors and spasticity noted could be related to a variety of neurological conditions and would require further investigation before confirming a diagnosis of cervical dystonia.\n\nTherefore, the patient would not currently be referred for this clinical trial based on the information provided. However, further investigation and a definitive diagnosis would be necessary to make a final determination.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "499": {
        "output": "The patient described in the note is a 28-year-old female presenting with symptoms such as neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia following a trip and involvement in a stray animal recovery campaign. Her symptoms do not seem to be related to pregnancy, childbirth, or perineal tears, which are the focus of the clinical trial in question.\n\nThe clinical trial titled \"Palestinian Perineum and Birth Complication Study\" is aimed at assessing complications associated with pregnancy and delivery, and interventions used during labor. The inclusion criteria are specifically targeting midwives and physicians working on the labor ward in the participating hospitals and all women giving birth in those hospitals. There is no mention of the patient's condition being relevant to the study.\n\nGiven these considerations, the patient described does not meet the inclusion criteria for the clinical trial, as her medical condition is unrelated to the focus of the study and she is not part of the specified groups (midwives, physicians, or women giving birth in the participating hospitals).\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "500": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 28-year-old female\n- Recently developed neck and shoulder pain, left hand and arm paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Hospitalized with symptoms suggestive of a possible neurological or infectious condition\n\nClinical Trial:\n- A Phase 3 study for a rabies vaccine (Vero Cell) for human use\n- Healthy Chinese subjects aged 10-60 years\n- Subjects must be in good health, as judged from medical history after the investigator's inquiry\n- Subjects with a temperature <=37.0\u00b0C on axillary setting\n\nAssessment:\nThe patient's recent symptoms, particularly marked hydrophobia and difficulty swallowing, are consistent with symptoms of rabies, a severe and often fatal viral infection. Given that the patient has been hospitalized with these symptoms and is exhibiting neurological signs, she would not be considered a \"healthy subject,\" which is a requirement for participation in the rabies vaccine trial. Additionally, the trial specifically mentions \"healthy Chinese subjects,\" and there is no information provided about the patient's ethnicity or nationality; thus, we cannot assume she meets this criterion.\n\nTherefore, based on the information provided and the inclusion criteria of the clinical trial, the patient would not qualify for the rabies vaccine study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "501": {
        "output": "Based on the patient note provided, the 28-year-old female presented with symptoms that could potentially be related to rabies, given her recent contact with stray animals and the subsequent development of hydrophobia, difficulty swallowing, and neurological symptoms. However, there is no mention of her HIV status or previous rabies immunization history in the patient note, which are both required inclusion criteria for the clinical trial in question.\n\nThe clinical trial is specifically for HIV-infected adults who have received primary rabies immunization and is designed to study the immune responses after a four-site intradermal rabies booster vaccination. Since the patient's HIV status and rabies vaccination history are not provided, we cannot determine her eligibility based on the inclusion criteria.\n\nTherefore, without additional information regarding the patient's HIV status and rabies immunization history, the assessment of her eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "502": {
        "output": "Given the patient note:\n\nA 28-year-old female with neck and shoulder pain and left hand and arm paresthesias three weeks after returning from a trip to California where she attended a stray animal recovery campaign. Her physical exam was unremarkable except for slight tremors and almost imperceptible spasticity. She was prescribed NSAIDS and a topical muscle relaxant. She was brought in to the ER three days later with spastic arm movements, sweating, increasing agitation and anxiety, malaise, difficultly swallowing and marked hydrophobia, and was immediately hospitalized.\n\nAnd the clinical trial:\n\nTitle: Immediate Effects Cervicothoracic Manipulation Versus Passive Upper Trapezius Stretch\n\nSummary: The proposed project seeks to evaluate the influence of cervicothoracic (CT) manipulation and passive stretching to the upper trapezius on pressure pain thresholds and range of motion (ROM) in individuals without recent complain of neck pain.\n\nInclusion criteria:\n1. No current history or past history of neck pain; able to lie on back or stomach without difficulty\n\nThe patient clearly does not meet the inclusion criteria as she has a current history of neck and shoulder pain, which disqualifies her from the trial which requires individuals without recent complaints of neck pain.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "503": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note Summary:\n- 28-year-old female\n- Presenting with neck and shoulder pain, paresthesias, tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, hydrophobia\n- Recent possible exposure to rabies (symptoms suggestive of rabies such as hydrophobia and difficulty swallowing)\n- Hospitalized for the symptoms\n- No mention of malaria or travel to malaria-endemic areas\n\nClinical Trial Summary:\n- Exploratory trial evaluating the effect of antimalarial drugs on the immune response to rabies vaccine\n- Inclusion criteria include being 18 to 60 years old, in good general health, and willing to comply with study procedures\n\nThe patient meets the age criterion for the trial. However, the trial is focused on the interaction between antimalarial drugs and the rabies vaccine. There is no indication that the patient has been exposed to malaria or is in need of antimalarial chemoprophylaxis. The patient appears to be presenting symptoms of rabies exposure, which is the focus of the vaccine portion of the study, but the main aspect of the study is the interaction with antimalarial drugs, not just the response to the rabies vaccine.\n\nGiven that the patient's medical condition (suspected rabies exposure) is not related to the primary focus of the clinical trial (antimalarial drugs' effect on rabies vaccine response), and there is no mention of a need for antimalarial drugs in her case, it would not be appropriate to refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "504": {
        "output": "Based on the information provided, the patient is a 28-year-old female with neck and shoulder pain and left hand and arm paresthesias that started after a trip. Her symptoms include tremors, spasticity, agitation, anxiety, malaise, difficulty swallowing, and hydrophobia. There is no mention of lateral elbow pain or tennis elbow (lateral epicondylitis), which is the specific condition being addressed in the clinical trial for Radial Extracorporeal Shockwave Therapy.\n\nThe inclusion criteria for the clinical trial are:\n- Aged > 18 years old\n- Lateral elbow pain lasting > 3 months\n- Pain induced by direct compression on the lateral epicondyle or common extensor tendon, resistant wrist extension and pronation in the elbow extension position, or static stretching of common extensor tendon through the palmer flexion in wrist pronation and elbow extension position\n\nThe patient does not appear to meet the inclusion criteria for lateral elbow pain lasting more than 3 months or specific pain induced by actions associated with tennis elbow. Therefore, based on the patient note and the inclusion criteria provided, this patient would not be eligible for the clinical trial focused on tennis elbow.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "505": {
        "output": "",
        "label": 2
    },
    "506": {
        "output": "Given the details provided in the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, tachycardia, hypotension, and was found to have a ruptured liver abscess that required surgical intervention.\n\nThe clinical trial in question is studying cystic hydatid disease in Peru, which is caused by the parasite Echinococcus granulosus. The inclusion criteria for the trial are quite broad, requiring participants to be living in the study area (Cooperative Tupac Amaru) and to be older than five years old.\n\nThe patient note does not mention cystic hydatid disease or Echinococcus granulosus infection; rather, it details an acute presentation of a ruptured liver abscess in a patient with CVID. Additionally, there is no information suggesting that the patient resides in the specific study area required for the trial (Cooperative Tupac Amaru).\n\nBased on the available information, there is no direct link between the patient's current medical condition and the focus of the clinical trial. Furthermore, the geographical requirement is not met unless additional information is provided confirming the patient's residence in the study area.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "507": {
        "output": "To determine the patient's eligibility for the STA-5326 Mesylate clinical trial based on the provided patient note, we need to compare the patient's information against the inclusion and exclusion criteria of the trial.\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- He experienced acute abdominal pain, fever, dehydration, elevated heart rate, and low blood pressure.\n- The patient underwent exploratory laparotomy for a ruptured liver abscess and was taken to ICU post-surgery.\n\nClinical Trial Inclusion Criteria:\n- Age between 18 and 75 years.\n- Diagnosed with CVID.\n- Documented, unintended loss of greater than 5% of body weight over the last year OR chronic diarrhea OR nutritional supplements required to maintain body weight.\n- If on oral antibiotics, a stable dose for at least 2 weeks.\n\nClinical Trial Exclusion Criteria:\n- Clinically significant diseases that could make the subject unsuitable.\n- Use of potential CYP3A4 inhibitors/inducers.\n- Abnormal clinical chemistry values including AST, ALT, serum bilirubin, serum creatinine, and alkaline phosphatase.\n- Abnormal blood cell counts and certain infection histories.\n\nBased on the provided patient note, we can see the following:\n\n- The patient is within the age range for inclusion.\n- The patient has a diagnosis of CVID.\n- The patient note does not mention unintended weight loss or chronic diarrhea or the need for nutritional supplements. More information would be needed to confirm this criterion.\n- The note does not provide information on the use of oral antibiotics or any chronic medication.\n- The patient has had a recent surgical emergency for a ruptured liver abscess, which may not disqualify him but does indicate a significant acute illness that could influence trial eligibility.\n- Given the patient's recent surgery and ICU admission, his clinical chemistry values might be outside the normal range, but we do not have specific values to confirm this.\n\nBased on the available information, we cannot definitively determine the patient's eligibility for the trial because of the following reasons:\n\n- We lack information about weight loss, diarrhea, and nutritional supplements.\n- The recent severe medical event (ruptured liver abscess) and ICU stay may impact his eligibility due to the potential for clinically significant diseases or abnormal clinical chemistry values.\n- We do not have information about potential CYP3A4 inhibitors/inducers usage.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "508": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess, which required surgical intervention\n- No mention of hyper-IgM syndrome or other disorders of immunoglobulin production besides CVID\n\nClinical Trial:\n- Investigates gene abnormalities in Primary Immune Deficiency (PID), including CVID\n- Aims to improve the diagnosis and treatment of patients with these conditions\n- Inclusion criteria specify patients with a known or suspected immune defect with hyper-IgM syndrome and/or disorders of immunoglobulin production\n- No age, sex, race, or disability limitations for patients with immune defects\n- Normal volunteers must be healthy adults between the age of 18 and 70 years\n- Participants must agree to allow the Principal Investigator (PI) to store research samples\n- Exclusion criteria include acquired abnormalities leading to immune defects such as HIV, chemotherapy, and malignancy\n\nThe patient has a history of CVID, which is one of the specific disorders mentioned in the summary of the clinical trial. Given that the patient's condition (CVID) is a focus of the study, and considering that the inclusion criteria do not restrict participation based on the patient's current complications (surgical intervention for a ruptured liver abscess), the patient appears to be a match for the trial's inclusion criteria.\n\nThe only potential consideration is the patient's current acute condition and whether it could interfere with the evaluation or pose an added risk for the patient as a study participant, which would be at the discretion of the Principal Investigator (PI) according to the exclusion criteria. However, based on the information provided, this does not seem to be a factor that would automatically exclude the patient from the trial.\n\nTherefore, it is reasonable to refer the patient to the clinical trial for further evaluation by the research team.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "509": {
        "output": "Based on the information provided for the patient and the clinical trial's inclusion criteria, let's examine the compatibility:\n\nPatient information:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Findings: Tenderness and positive Murphy sign, hepatomegaly, ruptured liver abscess\n- Intervention: Exploratory laparotomy and drainage in ICU\n\nClinical trial inclusion criteria:\n- Female or male, aged between 18 and 90 years.\n- Written informed consent.\n- Abscess formation or abdominal cyst scheduled for drainage.\n- Plasma creatinine <1.5 mg/dL\n\nComparison:\n- Age: The patient is 48 years old, which falls within the trial's age range of 18 to 90 years.\n- Gender: The trial accepts both female and male participants, so the patient's gender is appropriate.\n- Medical condition: The patient has a ruptured liver abscess and has undergone surgical drainage, fitting the criterion for abscess formation scheduled for drainage.\n- Plasma creatinine: The patient note does not mention the level of plasma creatinine. This would need to be confirmed to ensure it is below the <1.5 mg/dL required by the study.\n\nThe patient seems to match the majority of the inclusion criteria for the clinical trial. However, the plasma creatinine level is not mentioned, which is a necessary parameter to ascertain eligibility. Given this information, the patient would be considered for referral to the clinical trial upon confirmation of the plasma creatinine level.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "510": {
        "output": "Based on the provided patient note and the clinical trial information, we must assess the patient's eligibility for the clinical trial concerning biliary tract cancer treatment.\n\nPatient Note Summary:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Physical examination: tenderness and positive Murphy sign\n- Abdominal ultrasound: hepatomegaly and free intraperitoneal fluid\n- Diagnosis: ruptured liver abscess, surgically drained\n- Postoperative care in ICU\n\nClinical Trial Inclusion Criteria Summary:\n- Nonmetastatic biliary tract cancer diagnosis, confirmed histologically or by imaging (MRI, CT scan, or ECHO)\n- Unresectable disease amenable to radiotherapy\n- No visceral metastases by imaging\n- Hepatic adenopathies within radiation field allowed\n- No ampulla of Vater or pancreatic cancer involving the biliary tract\n- WHO performance status 0-2\n- Creatinine < 1.5 mg/dL\n- Absolute neutrophil count \u2265 1,500/mm^3\n- Platelet count \u2265 75,000/mm^3\n- Prothrombin time > 70%\n- Bilirubin \u2264 2.9 mg/dL (after hepatic draining if needed)\n- No significant comorbidities that would preclude study therapy\n- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix\n- Not pregnant or nursing\n- No recent biliary surgery\n- No hepatic intra-arterial chemotherapy\n- No prior anticancer therapy\n\nComparison:\n- The patient has a history of CVID and a current diagnosis of a ruptured liver abscess, not biliary tract cancer.\n- There is no information regarding nonmetastatic biliary tract cancer or the patient's WHO performance status, creatinine levels, blood counts, prothrombin time, or bilirubin levels.\n- The patient has had recent abdominal surgery, which could potentially exclude him from the trial as per the \"No recent biliary surgery\" criterion, depending on the timeframe considered as \"recent\" by the trial.\n- The patient's current condition (ruptured liver abscess) is not related to biliary tract cancer and does not meet the disease characteristics required for the trial.\n\nBased on the information provided, the patient does not meet the disease criteria for the clinical trial, as he has no diagnosis of biliary tract cancer, and he has recently undergone abdominal surgery. Therefore, he would not be eligible for the clinical trial focused on treating nonmetastatic biliary tract cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "511": {
        "output": "",
        "label": 0
    },
    "512": {
        "output": "Upon reviewing the patient note and the clinical trial information provided, let's determine the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 48 years\n- Gender: Male\n- Medical condition: Common variable immunodeficiency (CVID), acute abdominal pain, fever, dehydration, ruptured liver abscess\n- History of receiving treatment: The patient has undergone surgery (exploratory laparotomy and drainage of a ruptured liver abscess) and is currently in the ICU.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent, age-adapted\n- Male or female aged 1 to 70 years\n- Diagnosis of primary humoral immunodeficiency\n- No prior immunoglobulin substitution therapy\n- IgG level of <5 g/L at screening\n- Women of childbearing potential must use medically approved contraception and must have a negative urine pregnancy test at screening\n\nClinical Trial Exclusion Criteria:\n- Evidence of serious infection between screening and first treatment\n- Bleeding disorders that require medical treatments\n- Any medical disorder causing secondary immune disorders, autoimmune neutropenia, or a clinically significant defect in cell-mediated immunity\n- Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial\n\nAssessment:\n- The patient is within the age range required by the trial (48 years old).\n- The patient has a diagnosis of primary humoral immunodeficiency, which meets one of the trial's inclusion criteria.\n- No information is provided regarding previous immunoglobulin substitution therapy, so we cannot determine if the patient has had this treatment before. This will require further investigation.\n- The patient's IgG level is not mentioned; this would need to be confirmed to meet the inclusion criteria.\n- The patient has just undergone surgery for a ruptured liver abscess, which could be considered a serious infection. This might place the patient under the exclusion criteria due to the recent serious infection.\n\nBased on the available information, the patient's eligibility is uncertain due to the lack of detail on their previous immunoglobulin therapy and IgG levels. Moreover, the recent surgery for a ruptured liver abscess might exclude the patient from participation. Therefore, further investigation is needed to determine if the patient has had prior immunoglobulin therapy and to confirm their IgG levels. Additionally, the impact of the recent surgery and current ICU stay on the patient's eligibility needs careful consideration.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "513": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's examine the patient's eligibility for the clinical trial.\n\nPatient note:\n- 48-year-old white male (within age criteria of 18 to 75 years)\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, tachycardia, and hypotension\n- Abdominal ultrasound showed hepatomegaly and abundant free intraperitoneal fluid\n- Exploratory laparotomy revealed a ruptured liver abscess, which was drained surgically\n\nClinical trial inclusion criteria:\n- Patients between 18 and 75 years of age inclusive (patient meets this criterion)\n- Patients with at least one focal liver lesion, either identified or suspected by various imaging techniques within 2 months before entering the study (the patient had a ruptured liver abscess, which is one of the listed pathologies under 'focal liver lesions')\n- Patients willing to undergo study procedures including safety follow-up (not mentioned in the patient note but typically expected if a patient is referred for a trial)\n- Patients who have undergone or who are scheduled to undergo the defined procedure for SOR within one month before or after the study MRI (patient has undergone surgery for the liver abscess, which might be considered a procedure in the context of the study)\n- Women of child-bearing potential with negative urine pregnancy test result within 24 hours before contrast medium injection (not applicable to the patient as he is male)\n- Patients who are fully informed about the study and have signed the informed consent form (not mentioned in the patient note but is a standard procedure for trial enrollment)\n\nGiven that the patient is within the age range, has a focal liver lesion (ruptured liver abscess), and there's no information suggesting that they are unwilling to undergo study procedures or unable to consent, it seems that the patient could potentially be eligible for the clinical trial.\n\nHowever, there are a few considerations to take into account:\n- The study is specific to Chinese patients, and it is not mentioned if the patient is Chinese or not.\n- The patient's current medical stability post-surgery and ICU admission is not clarified, which might affect his immediate eligibility for MRI procedures.\n\nSince the key inclusion criteria appear to be met but there are still some uncertainties that would need to be clarified (such as the patient's current medical stability and whether the study's ethnic focus applies to the patient), I would rate this as:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "514": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the trial.\n\nPatient Note Summary:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presents with acute abdominal pain, fever, dehydration\n- Physical examination: tenderness, positive Murphy sign\n- Exploratory laparotomy reveals a ruptured liver abscess, which is surgically drained\n- Patient is taken to the ICU post-surgery\n\nClinical Trial Inclusion Criteria:\n- Adult patients (>18 years)\n- Surgical intervention within 24 hours of diagnosis for localized intra-abdominal infection (IAI) of mild to moderate severity\n- Specific conditions include:\n  - Acute appendicitis: Ruptured or perforated with abscess\n  - Acute diverticulitis with perforation and/or abscess\n  - Acute cholecystitis with either rupture or perforation\n  - Acute gastric and duodenal (>24 hours) perforation\n  - Traumatic (>12 hours) perforation of the intestines\n  - Secondary peritonitis due to perforated viscus\n  - Intra-abdominal abscess (including of liver and spleen)\n\nMatching Points:\n- The patient is an adult over 18 years of age.\n- The patient required surgical intervention due to a ruptured liver abscess, which matches the criteria for \"Intra-abdominal abscess (including of liver and spleen).\"\n- The trial requires intervention within 24 hours of diagnosis, which is not specified in the patient note but can be inferred as likely given the nature of the condition and immediate surgical intervention.\n\nBased on the information provided, the patient matches the trial's inclusion criteria regarding age, the requirement for surgical intervention, and the specific condition of intra-abdominal abscess. However, the severity of the infection (mild to moderate) and the timeline of intervention (within 24 hours of diagnosis) are not explicitly detailed in the patient note, which could influence eligibility.\n\nWithout further information, the patient seems to fit the trial's criteria, but we cannot be certain without additional details on the severity of the infection and the timing of the surgical intervention.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "515": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- 48-year-old white male (meets age criterion)\n- History of common variable immunodeficiency (CVID)\n- Presentation with acute abdominal pain, fever, dehydration\n- Positive Murphy sign, hepatomegaly, and free intraperitoneal fluid on ultrasound\n- Ruptured liver abscess surgically drained (indicates that the patient had a liver abscess)\n\nClinical Trial Inclusion Criteria:\n- Clinical, ultrasonographic and serologic diagnosis (ELISA) of amebic liver abscess\n- Both genders\n- Older than 15 years\n\nThe patient is a 48-year-old male which fulfills the age and gender criteria. However, the patient note does not specify that the liver abscess is amebic in nature, nor does it mention if serologic testing (ELISA) for amebiasis has been performed.\n\nGiven the patient has had a liver abscess, it would be reasonable to consider further investigation to determine if the abscess was caused by an amebic infection. If serologic testing confirms the diagnosis of an amebic liver abscess, the patient would meet the clinical trial's inclusion criteria.\n\nAs the information stands, there is not enough information to confirm the patient's eligibility for the clinical trial without further testing.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "516": {
        "output": "The patient described in the note is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, a rapid heart rate (HR of 132 bpm), and low blood pressure (BP 80/40). The physical examination showed tenderness and a positive Murphy sign, which often indicates gallbladder inflammation. However, an abdominal ultrasound revealed hepatomegaly and free intraperitoneal fluid, and exploratory laparotomy confirmed a ruptured liver abscess that was surgically drained.\n\nThe clinical trial in question is focused on determining the correlation between the region of abdominal tenderness as determined by a physical examination and the location of acute pathology diagnosed on abdominal CT in emergency department patients with non-traumatic abdominal pain and tenderness.\n\nBased on the inclusion criteria provided for the clinical trial, all consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled. The key requirement is that the abdominal pain and tenderness must be to direct palpation in the region anterior to the mid-axillary line bilaterally, and extending from the costal margins to the inguinal ligaments.\n\nGiven that the patient in the note was taken to the ICU after surgery for a ruptured liver abscess, it is unclear whether an abdominal CT for non-traumatic abdominal pain was performed or planned. However, the patient's clinical presentation and the findings from the ultrasound and surgery suggest that he would likely have met the criteria for abdominal pain and tenderness as defined by the trial.\n\nTherefore, I would consider referring this patient to the clinical trial upon further investigation into whether an abdominal CT was performed or indicated as part of the patient's evaluation in the emergency department. If the patient did undergo an abdominal CT for the evaluation of his abdominal pain and tenderness, he would meet the inclusion criteria for the study.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "517": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note:\n- The patient is a 48-year-old white male.\n- The patient has a history of common variable immunodeficiency (CVID).\n- The patient presented with acute abdominal pain, fever, dehydration, a high heart rate, and low blood pressure.\n- Physical examination showed tenderness and a positive Murphy sign, which is typically indicative of gallbladder inflammation.\n- Abdominal ultrasound showed hepatomegaly and free intraperitoneal fluid.\n- The patient had a ruptured liver abscess, not appendicitis, which was surgically drained.\n\nClinical Trial Inclusion Criteria:\n- The trial is studying laparoscopic operation for perforated appendicitis.\n- Patients admitted with pain other than the right lower abdominal quadrant, favoring the diagnosis of perforated acute appendicitis.\n- Clinical examination and abdominal computed tomography results must reveal signs of acute appendicitis and intra-abdominal fluid accumulation.\n- Perforated appendicitis must remain as the most likely diagnosis.\n- Age between 12 and 80 years old with informed consent.\n\nComparison:\n- The patient's age falls within the range specified by the trial (12 to 80 years old).\n- The patient's condition (ruptured liver abscess) is not consistent with the condition being studied (perforated appendicitis).\n- The diagnosis of the patient does not match the required diagnosis for the trial (perforated appendicitis).\n\nConclusion:\nThe patient's condition does not match the specific disease and condition that the clinical trial is investigating. The trial is focused on perforated appendicitis, and this patient has a ruptured liver abscess, which is a different condition. Therefore, based on the information provided, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "518": {
        "output": "Based on the information provided, the patient in the note has a history of common variable immunodeficiency (CVID) and has undergone surgery for a ruptured liver abscess. The clinical trial in question is investigating the effect of intraperitoneal local anaesthetic application on postoperative pain and fatigue in patients undergoing open colonic resection as part of an Enhanced Recovery After Surgery (ERAS) program.\n\nThe inclusion criteria for the clinical trial specifically mention \"Consecutive patients undergoing open colonic resection at MSC under the ERAS program.\"\n\nThe patient in the note does not fit the inclusion criteria because:\n- The patient underwent surgery for a ruptured liver abscess, not open colonic resection.\n- There is no indication that the patient's surgery was part of the ERAS program or that it was an open colonic resection.\n\nGiven this information, it would not be appropriate to refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "519": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient described does not appear to match the specific requirements for the clinical trial in question. The patient note describes a 48-year-old white male with a history of common variable immunodeficiency (CVID) and complications arising from a ruptured liver abscess, which was surgically drained. The clinical trial, however, is focused on patients who have had a laparoscopic cholecystectomy for gallbladder stones and is investigating the clinical impact of routine abdominal drainage after such surgery.\n\nThe patient in the note has not been described as having gallbladder stones or having undergone a laparoscopic cholecystectomy (surgery to remove the gallbladder). Instead, the patient had surgery for a ruptured liver abscess. Therefore, the patient does not meet the inclusion criteria for the clinical trial, which specifically requires patients who are undergoing or have undergone a laparoscopic cholecystectomy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "520": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, the patient does not appear to be eligible for the clinical trial. The trial is specifically looking for patients with gastric cancer to study the ultra-structure of the peritoneal surface by electronic microscopy. The patient described has a history of common variable immunodeficiency (CVID) and recently experienced a ruptured liver abscess, which is not related to gastric cancer.\n\nThe inclusion criteria for the trial are:\n- Patients with operable local gastric adenocarcinoma\n\nThe patient note does not mention gastric adenocarcinoma or any type of gastric cancer; instead, it describes a different medical condition involving a liver abscess and CVID. Hence, this patient would not meet the inclusion criteria for the trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "521": {
        "output": "The patient in the note has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, and signs of a ruptured liver abscess, which was surgically drained. The patient does not have a confirmed diagnosis of liver cirrhosis or a mention of symptomatic gall bladder stones, which are critical for inclusion in the clinical trial mentioned.\n\nThe clinical trial is specifically looking to include patients with liver cirrhosis who have symptomatic gall bladder stones for a study on clipless laparoscopic cholecystectomy using a harmonic scalpel. Since the patient's condition does not match the inclusion criteria of having liver cirrhosis and symptomatic gall bladder stones, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "522": {
        "output": "Based on the information provided:\n\nThe patient in the note is a 48-year-old white male with a history of common variable immunodeficiency (CVID). He presented with acute abdominal pain, fever, dehydration, tachycardia, hypotension, and signs consistent with a ruptured liver abscess, which was confirmed and treated surgically.\n\nThe clinical trial is focused on the prophylactic platelet transfusion in adults with dengue and severe thrombocytopenia without bleeding.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Age \u2265 21 years\n- Probable or confirmed dengue\n    - Confirmed dengue: laboratory confirmation of acute dengue by either positive PCR for viral RNA or positive NS1 antigen test with a compatible clinical syndrome\n    - Probable dengue: Positive acute dengue serology and clinical presentation fulfilling either WHO 1997 or 2009 criteria for probable dengue.\n- Platelets \u2264 20x10^3/\u03bcL\n\nComparing the patient's condition to the trial's inclusion criteria:\n- The patient is 48 years old, which meets the age criterion.\n- There is no mention of dengue or related symptoms, laboratory tests, or diagnostic criteria that would suggest probable or confirmed dengue.\n- The platelet count is not mentioned, so we cannot assess if the patient has severe thrombocytopenia as defined by the trial's inclusion criteria.\n\nGiven that the patient does not have a confirmed or probable diagnosis of dengue, which is a critical inclusion criterion for the trial, the patient does not appear to meet the trial's eligibility requirements.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "523": {
        "output": "Based on the patient note and the clinical trial information provided, let's assess the eligibility of the patient for the clinical trial:\n\nPatient Note:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- The patient presented with acute abdominal pain, fever, dehydration, tachycardia (HR of 132 bpm), and hypotension (BP 80/40).\n- The physical examination showed tenderness and a positive Murphy sign.\n- Abdominal ultrasound demonstrated hepatomegaly and free intraperitoneal fluid.\n- Exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained.\n- The patient was taken to the ICU post-surgery.\n\nClinical Trial:\n- The trial targets children with a delayed diagnosis of perforated appendicitis.\n- Inclusion criteria specify that participants must be children with symptoms of perforated appendicitis for 4 or more days.\n- The diagnosis must be confirmed with diagnostic imaging (CT scan or ultrasound) showing an established appendiceal abscess or phlegmon.\n- Consent to participate is required.\n\nAssessment:\n- The patient in question is not a child, therefore does not meet the age demographic targeted by the study.\n- The patient's diagnosis is a ruptured liver abscess, not perforated appendicitis.\n- There is no indication that the patient had appendicitis, delayed or otherwise.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial since the trial specifically targets children with perforated appendicitis and the patient has a different diagnosis. Therefore, it would not be appropriate to refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "524": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male, which fits the age criterion of the clinical trial (18 to 90 years of age).\n- The patient has had a ruptured liver abscess requiring surgical drainage, which aligns with one of the diagnoses specified in the inclusion criteria (intraabdominal abscess including liver).\n- The patient required surgical intervention (exploratory laparotomy and drainage), which fits the surgical intervention requirement within 24 hours of the first dose of the study drug.\n- There is no information provided that the patient would be unwilling or unable to comply with study procedures and restrictions, or that they would be unwilling or unable to provide written informed consent.\n\nClinical Trial Inclusion Criteria Review:\n- Age: 18 to 90 years (Patient is 48 years old)\n- Diagnoses: Intraperitoneal infection, including intraabdominal abscess (Patient had a ruptured liver abscess)\n- Surgical intervention required within 24 hours of the first dose of study drug (Patient had exploratory laparotomy)\n- Willingness and ability to comply with study procedures and to provide informed consent (Assumed, as there is no information suggesting otherwise)\n\nBased on the information given, the patient meets the age requirement, has a diagnosis that fits the inclusion criteria, and required surgical intervention in line with the trial's requirements. There is no clear information on renal function, but since this is not mentioned in the patient note, we will assume normal renal function unless otherwise indicated.\n\nGiven the above points, the patient appears to meet the inclusion criteria of the clinical trial.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "525": {
        "output": "Based on the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who has recently undergone surgery for a ruptured liver abscess. The patient has been in the ICU after the surgery.\n\nComparing this patient's situation to the inclusion criteria of the clinical trial, it is clear that the trial is specifically looking for adult recipients of kidney transplants from deceased donors. The patient note does not mention that the patient has received a kidney transplant, nor is there any indication that the patient is an eligible recipient for a kidney transplant. Thus, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "526": {
        "output": "Assessing the patient's eligibility for the clinical trial based on the inclusion criteria provided:\n\nInclusion Criteria Assessment:\nA) The patient does not have a history of histologically-proven colorectal adenocarcinoma, nor is there any indication of peritoneal carcinomatosis, ovarian metastases, or rupture of a primary colorectal tumor.\nB) The patient has not received the specified chemotherapy regimen (Folfox 4) for colorectal adenocarcinoma, as there is no mention of colorectal cancer or such treatment in the patient's note.\nC) Since the patient does not have colorectal adenocarcinoma, the criterion regarding the absence of tumor recurrence does not apply.\nD) The patient's age fits within the specified range (18-70 years), but there is no information on the patient's Performance Status, blood counts, liver and renal function, peripheral neuropathy, or operability to determine eligibility based on these points.\nE) The trial-specific procedures, including informed consent, are not relevant to assessing eligibility at this point since the patient does not meet the primary disease-related criteria.\n\nGiven the information provided in the patient note, the patient does not meet the core disease-related inclusion criteria for the clinical trial. The patient's condition (CVID with ruptured liver abscess) is not related to colorectal adenocarcinoma or the specific risk factors for peritoneal carcinomatosis mentioned in the trial's inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "527": {
        "output": "Given the patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), acute abdominal pain, fever, dehydration, and a ruptured liver abscess that was surgically drained. He does not meet the inclusion criteria for the clinical trial described, as the trial is specifically for pregnant women aged 14 years and over at \u2265 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans. Since the patient is male and not pregnant, he is not eligible for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "528": {
        "output": "Upon reviewing the patient's notes and the clinical trial's inclusion criteria, it is clear that this patient does not meet several of the specified criteria for the clinical trial on once-daily therapy for streptococcal pharyngitis.\n\nThe inclusion criteria for the trial are:\n- Age of 6 to 15 years old.\n- Clinical examination signs such as fever, erythema or exudate of tonsils, enlarged lymph nodes, sore throat, neck tenderness, abdominal pain, and pharynx petechiae.\n- No antibiotic use in the week before.\n- Positive throat culture for Group A \u03b2-hemolytic Streptococcus (GABHS).\n- No previous history of allergy to penicillin.\n\nThe patient in question is a 48-year-old male, which is outside the age range of 6 to 15 years old required by the trial. Furthermore, the patient's condition (common variable immunodeficiency with complications of a ruptured liver abscess) is not related to streptococcal pharyngitis, and there is no mention of a sore throat, fever, or any signs suggesting streptococcal infection. There is also no information on a throat culture being performed or results indicating GABHS.\n\nBased on this information, the patient does not meet the inclusion criteria for the clinical trial on once-daily therapy for streptococcal pharyngitis.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "529": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, the patient does not appear to meet the criteria for the Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease study. The inclusion criteria specifically require a patient to have polycystic liver disease with a liver volume of \u2265 4 liters and \u2265 20 liver cysts. The patient must also exhibit at least two out of five listed symptoms related to mass effect and be diagnosed with either ADPKD (Autosomal Dominant Polycystic Kidney Disease) or ADPLD (Autosomal Dominant Polycystic Liver Disease).\n\nThe provided patient note describes a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and signs of sepsis (tachycardia and hypotension). An abdominal ultrasound showed hepatomegaly and intraperitoneal fluid, and an exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained. There is no mention of polycystic liver disease, liver cysts, or any of the other specific symptoms required by the study's inclusion criteria.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "530": {
        "output": "Based on the provided patient note, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who presented with acute abdominal pain, fever, dehydration, and was found to have a ruptured liver abscess on exploratory laparotomy. The clinical trial in question is investigating the use of contrast-enhanced ultrasound for the evaluation of de novo focal liver lesions.\n\nComparing the patient's situation with the inclusion criteria for the clinical trial, the trial is specifically looking for:\n\n1. Patients diagnosed with de novo focal liver lesions (FLL) at standard ultrasound.\n2. Age > 18 years, male and female gender.\n3. Informed consent for the contrast-enhanced study.\n\nThe patient has a ruptured liver abscess, which is not described as a de novo focal liver lesion. However, since the patient has hepatomegaly, which could be related to his underlying condition (CVID), it is possible that focal liver lesions could be present or develop, but this has not been specifically mentioned in the patient note.\n\nGiven the information provided, the patient does not strictly meet the inclusion criteria as he is not described to have a de novo focal liver lesion that has been diagnosed at standard ultrasound. However, it is not clear whether the hepatomegaly observed might be related to such lesions, or if further ultrasound evaluation post-surgery could reveal de novo FLL.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "531": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- Age: 48 years old (meets age criterion of >18 years)\n- Condition: Ruptured liver abscess leading to severe intra-abdominal sepsis, managed with exploratory laparotomy and ICU care\n- Gender: Male (no gender-specific criteria mentioned)\n\nClinical Trial:\n- Title: Assessment of peritoneal immune response in patients with severe intra-abdominal sepsis managed with laparostomy and Vacuum Assisted Closure (VAC)\n- Inclusion Criteria: Patient > 18 years old, patients with severe abdominal sepsis, and informed consent\n\nThe patient in the note is a 48-year-old male who has severe intra-abdominal sepsis as a result of a ruptured liver abscess, which aligns with the clinical trial's patient population of interest (severe intra-abdominal sepsis). The clinical trial does not specify exclusions based on the type of sepsis or the origin (liver abscess), and the patient meets the age requirement. Additionally, there is no mention that the patient or relatives are unable or unwilling to sign the informed consent, which can be further investigated to ensure compliance with this criterion. Therefore, based on the available information:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "532": {
        "output": "Upon reviewing the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 48-year-old white male (meets age criteria)\n- Ruptured liver abscess (condition is not liver cirrhosis as specified in the trial criteria)\n- No mention of liver cirrhosis diagnosis or MELD score\n- No information on whether the patient has been refused by a liver transplant program or not a transplant candidate\n\nClinical Trial Inclusion Criteria:\n- Age >18 years (patient meets this criterion)\n- Clinically diagnosed liver cirrhosis by any of the following: ultrasound/MRI/CT + tissue biopsy (no evidence in patient note)\n- MELD score \u2265 18 and <35 (no MELD score provided in patient note)\n- Ability to sign an informed consent (assumed capable unless stated otherwise)\n- Refused by liver transplant program or labeled as not a liver transplant candidate, decided by at least 3 transplant physicians (no information provided)\n\nBased on the information provided, the patient does not meet the specific diagnosis of liver cirrhosis required for the clinical trial, nor is there any evidence of a MELD score or liver transplant candidacy status. Therefore, the patient would not be eligible for this specific trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "533": {
        "output": "Based on the patient note and the clinical trial information provided:\n\nPatient Note:\n- A 48-year-old white male with a history of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration\n- Physical examination showing tenderness and positive Murphy sign\n- Abdominal ultrasound indicating hepatomegaly and free intraperitoneal fluid\n- Exploratory laparotomy revealing a ruptured liver abscess, managed surgically\n\nClinical Trial:\n- Title: Antibiotics Versus Surgery in Acute Appendicitis\n- Target condition: Acute Appendicitis (AA)\n- Inclusion criteria:\n  - Patients between 18 and 65 years old\n  - First episode of suspected AA diagnosed by Andersson's score or combination with abdominal ultrasound\n\nAssessment:\nThe patient does not have acute appendicitis; instead, he has a ruptured liver abscess. The inclusion criteria for the clinical trial specify participants with a first episode of suspected acute appendicitis, which does not apply to this patient. Therefore, this patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "534": {
        "output": "Given the patient note:\n\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presenting with acute abdominal pain, fever, dehydration, etc.\n- Underwent surgery for a ruptured liver abscess\n\nAnd the clinical trial's inclusion criteria:\n\n- Female patients only\n- Patients undergoing controlled ovarian hyperstimulation (COH), transvaginal oocyte aspiration (TVA), and Saline Infused Sonography (SIS) with UL collection\n- Age <35 y/o at the time of in vitro fertilization (IVF) cycle\n- Various criteria related to ovarian function and menstrual cycles or PCOS diagnosis and BMI\n\nThe patient in the provided note is a 48-year-old male, and the clinical trial's inclusion criteria specify that only female patients are eligible. Furthermore, the trial is focused on ovarian function and fertility issues, which are not applicable to the male patient. Thus, the patient does not meet the basic demographic and gender requirements for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "535": {
        "output": "To determine if the patient is eligible for the clinical trial of Bilhvax, a vaccine candidate against schistosomiasis, we must compare the patient's characteristics and condition with the inclusion criteria provided.\n\nThe inclusion criteria for the clinical trial are:\n1. Caucasian volunteers\n2. No smoker\n3. Biological parameters (haematological, biochemical, renal and hepatic) in normal range\n4. Health Insurance\n5. Sign informed consent\n\nThe patient note provides the following information:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- The patient has recently undergone surgery for a ruptured liver abscess and is taken to the ICU.\n\nFrom the patient note, we can infer the following:\n- The patient is a Caucasian male, which matches the first criterion regarding ethnicity.\n- There is no information on whether the patient is a smoker or not.\n- Given the patient has a ruptured liver abscess and is in the ICU, it is unlikely that his biological parameters are within the normal range, especially considering the acute presentation with fever, dehydration, and unstable vital signs.\n- There is no information regarding the patient's health insurance status.\n- Whether the patient can sign informed consent is uncertain due to his acute condition and potential ICU stay.\n\nBased on the available information, the patient does not meet at least one of the key inclusion criteria (biological parameters in normal range) due to his recent surgery and current critical condition. Additionally, the trial seeks healthy volunteers, which the patient is not, given his acute illness and CVID history.\n\nTherefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "536": {
        "output": "Based on the information provided, the patient in the note has a history of common variable immunodeficiency (CVID), and the recent medical issue is related to a ruptured liver abscess. This patient does not have gastric cancer, which is the disease of interest for the clinical trial.\n\nThe inclusion criteria for the clinical trial specify that participants must be gastric cancer patients eligible for curative surgery. Since the patient in question does not have a diagnosis of gastric cancer, they do not meet the inclusion criteria for the clinical trial.\n\nTherefore, I would not refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "537": {
        "output": "Given the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Ruptured liver abscess, treated with surgery and taken to ICU\n\nClinical Trial Inclusion Criteria:\n- Patients of both sexes aged \u2265 18 years\n- Standard analytical parameters within certain ranges\n- Patients with liver space occupying lesion (LOE) that require extended hepatic resection\n- Different types of liver damage requiring specific interventions\n- Patients must give written informed consent\n\nComparison:\n- Age: The patient is 48 years old, which meets the age criterion (\u2265 18 years).\n- Sex: The trial includes patients of both sexes, so being male is not a disqualifying factor.\n- Standard analytical parameters: The patient's complete blood count and liver function tests are not provided, so we cannot assess this criterion.\n- Specific liver condition: The patient has a history of a ruptured liver abscess, which is not listed as one of the liver conditions for which the trial is recruiting (the trial mentions metastatic disease, hepatocarcinoma, and other specific liver lesions requiring resection).\n- Informed consent: The patient's ability to give informed consent is not clear from the note, as he is in the ICU after surgery, which may affect his capacity to consent.\n\nBased on the information provided, the patient does not appear to meet the inclusion criteria related to the specific liver conditions the trial is targeting. While he does have a liver-related issue (ruptured liver abscess), this is not the same as the liver space occupying lesions (LOE) that require extended hepatic resection mentioned in the inclusion criteria.\n\nTherefore, referring this patient to the clinical trial does not seem appropriate based on the provided information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "538": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, it is clear that the patient does not meet the criteria for this endometriosis study. The patient is a 48-year-old male with a history of common variable immunodeficiency (CVID) and a recent medical event involving a ruptured liver abscess. The clinical trial is specifically focused on patients with endometriosis, which is a condition exclusive to individuals with a uterus, typically females. Furthermore, the trial is looking for participants with adnexal findings or those requiring laparoscopic sterilization, which are also not applicable to the male patient in question.\n\nSince the patient's condition and gender do not match any of the inclusion criteria for the endometriosis trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "539": {
        "output": "Assessing the patient's eligibility for the clinical trial titled \"Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease\" involves matching the patient's characteristics and medical history with the inclusion and exclusion criteria provided for the trial.\n\nPatient characteristics:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Physical examination showed tenderness and positive Murphy sign\n- Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid\n- Exploratory laparotomy reveals a ruptured liver abscess, surgically drained\n- Patient was in the ICU post-surgery\n\nClinical trial inclusion criteria:\n- Has documented chronic granulomatous disease (CGD)\n- Age 18 - 75\n- Has a liver abscess infected with Staphylococcus aureus or other microorganism susceptible to RFA\n- Not an optimal candidate for curative surgical resection\n- Willing to return for imaging scans\n- Willing to undergo testing or procedures associated with the protocol\n- Has failed long term antibiotic treatment and abscess drainage if applicable\n\nClinical trial exclusion criteria:\n- Positive results for toxin-producing bacteria from liver biopsy\n- Good candidate for liver-curative open surgical resection\n- Not a candidate for RFA therapy due to lesion size or location\n- PT or PTT >1.5 times normal\n- Platelet count <50,000/mm(3)\n- Pregnancy\n- Any condition placing the patient at undue risk\n\nThe patient has a history of common variable immunodeficiency (CVID), not chronic granulomatous disease (CGD), which is a primary requirement for inclusion in the trial. Therefore, the patient does not meet one of the key inclusion criteria of having documented CGD. Additionally, there is no information about the patient refusing surgery or having failed long-term antibiotic treatment, which are other points of consideration in the inclusion criteria.\n\nBased on the information provided, the patient does not align with the specific disease and treatment history requirements for the clinical trial. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "540": {
        "output": "Based on the information provided, the patient in question has undergone exploratory laparotomy due to a ruptured liver abscess, which is different from an acutely inflamed gallbladder. The clinical trial is specifically interested in patients who have had a laparoscopic cholecystectomy for an acutely inflamed gallbladder. \n\nSince the patient did not have a laparoscopic cholecystectomy for an acutely inflamed gallbladder, but rather surgery for a ruptured liver abscess, they do not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "541": {
        "output": "Based on the patient note provided, the 48-year-old white male has a history of common variable immunodeficiency (CVID) and was diagnosed with a ruptured liver abscess, which was surgically drained. The inclusion criteria for the clinical trial are a radiologically and bacteriologically diagnosed pyogenic liver abscess.\n\nThe patient note confirms the presence of a liver abscess as it mentions a ruptured liver abscess found during exploratory laparotomy. However, the note does not specify whether the abscess is pyogenic, nor does it mention the results of any radiological or bacteriological tests that would confirm this diagnosis according to the trial's inclusion criteria.\n\nGiven the information provided, the patient has a liver abscess, which is relevant to the trial's focus. However, further investigation is required to determine whether the abscess is pyogenic and meets the trial's specific diagnostic criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "542": {
        "output": "Given the patient's note and the clinical trial inclusion criteria, we must determine if the patient is eligible for the trial. The patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID), who presented with acute abdominal pain, fever, dehydration, and a ruptured liver abscess. The clinical trial is investigating the efficacy of combining Pasireotide with aspiration sclerotherapy to improve the volume reduction of hepatic cysts.\n\nThe inclusion criteria for the clinical trial are:\n\n1. Age 18 - 70 years.\n2. Diagnosis of a dominant liver cyst with an indication for aspiration and sclerotherapy.\n3. Providing informed consent.\n\nThe patient note indicates a ruptured liver abscess rather than a simple or dominant liver cyst, which is the focus of the clinical trial. Therefore, based on the information provided, the patient does not meet the specific diagnosis required for the clinical trial, which is a dominant liver cyst needing aspiration and sclerotherapy.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "543": {
        "output": "The patient described in the note has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, tachycardia (heart rate of 132 bpm), hypotension (blood pressure 80/40), and positive Murphy sign, indicative of gallbladder inflammation. An abdominal ultrasound showed hepatomegaly and free intraperitoneal fluid. During exploratory laparotomy, a ruptured liver abscess was found and surgically drained, and the patient was then taken to the ICU.\n\nThe clinical trial in question is examining the significance of peritoneal washing cytology before and after neoadjuvant chemotherapy in patients with esophagogastric-junction (GEJ) cancer. The eligibility criteria for this trial are:\n\n- Patients with biopsy-verified GEJ-cancer referred to the department of surgical gastroenterology at Rigshospitalet, which is considered resectable at the multidisciplinary conference.\n- Patients must be over 18 years old.\n- Patients must provide informed consent.\n\nThe patient in the note does not have GEJ-cancer, nor is there any indication that they have been diagnosed with or treated for this type of cancer. Instead, the patient has been treated for a ruptured liver abscess. Therefore, based on the information provided, the patient does not meet the inclusion criteria for the clinical trial, which is specifically looking for patients with GEJ-cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "544": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration, tachycardia, and hypotension\n- Physical examination: tenderness and positive Murphy sign\n- Abdominal ultrasound: hepatomegaly and free intraperitoneal fluid\n- Exploratory laparotomy revealed a ruptured liver abscess, which was surgically drained\n- Post-surgery, the patient is in the ICU\n\nClinical trial:\n- Focused on gastric cancer patients\n- Requires T3 or T4 stage gastric cancer, any N staging, and M0 (no distant metastasis)\n- Open or laparoscopic gastrectomy with curative intent\n- Age limit of 21 to 80 years old\n- Ability to provide informed consent\n\nThe patient has a history of CVID and presented with a ruptured liver abscess, not gastric cancer. The trial is specific to patients with gastric cancer undergoing gastrectomy, and there is no information to suggest that the patient has gastric cancer or is undergoing gastrectomy. Therefore, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "545": {
        "output": "Based on the patient note provided, the 48-year-old white male patient has a history of common variable immunodeficiency (CVID) and presented with acute abdominal pain, fever, dehydration, and signs consistent with a ruptured liver abscess, which was confirmed by exploratory laparotomy and subsequently drained. The patient was then taken to the ICU.\n\nThe clinical trial in question is focused on the management of hypersplenism in patients with liver cirrhosis and aims to compare the effectiveness of microwave thermal coagulation and partial splenic embolization.\n\nThe inclusion criteria for the clinical trial are:\n1. Liver Cirrhosis\n2. Hypersplenism\n\nFrom the patient note, there is no mention of liver cirrhosis or hypersplenism. The patient does have a liver-related condition (ruptured liver abscess), but this is not the same as liver cirrhosis, and there is no indication of splenomegaly or hypersplenism. Therefore, based on the information given, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "546": {
        "output": "",
        "label": 2
    },
    "547": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial, we can determine the eligibility as follows:\n\nPatient Note:\n- 48-year-old white male\n- History of common variable immunodeficiency (CVID)\n- Presented with acute abdominal pain, fever, dehydration\n- Surgical intervention for a ruptured liver abscess\n- No mention of breast cancer or oligometastatic disease\n\nClinical Trial:\n- Requires patients with histologically or cytologically confirmed breast cancer\n- Patients must have evidence of 1 to 5 metastases, suitable for SABR treatment\n- Requires a certain level of performance status and adequate organ function\n- Life expectancy > 12 months\n- Specific requirements for reproductive health and consent\n\nThe patient in the note does not have a diagnosis of breast cancer or any mention of metastatic disease. The trial specifically targets individuals with oligometastatic breast cancer and requires confirmation of this diagnosis. Therefore, the patient does not meet the trial's inclusion criteria based on the available information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "548": {
        "output": "Given the patient's condition and the clinical trial's specifics, the patient does not meet the inclusion criteria for the trial. The trial is focused on the use of Buckypaper for surgical procedures and treatment of solid cancers and hematopoietic system tumors, as well as abdominal wall hernias in humans. Furthermore, the inclusion criteria specifically mention an animal model using New Zealand female rabbits.\n\nThe patient in the provided note has a history of common variable immunodeficiency (CVID) and recently experienced a ruptured liver abscess, treated surgically. There is no mention of solid cancer, hematopoietic system tumors, or abdominal wall hernias, and certainly, the patient is not a New Zealand female rabbit.\n\nTherefore, it is clear that the patient does not fit the criteria for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "549": {
        "output": "",
        "label": 0
    },
    "550": {
        "output": "Based on the provided patient note, the patient has a history of common variable immunodeficiency (CVID) and has been treated for a ruptured liver abscess. There is no mention of an intracranial aneurysm, which is a requirement for eligibility in the clinical trial for the Codman Enterprise\u00ae 2 Vascular Reconstruction Device.\n\nThe inclusion criteria for the clinical trial are:\n1. Subject \u2265 18 years old.\n2. Subjects with non-ruptured or ruptured intracranial aneurysm that is referred for endovascular treatment.\n3. Parent vessel with a diameter of \u2265 2.0 mm and \u2264 4 mm.\n4. Subject understands the nature of the procedure and provides voluntary written informed consent in accordance with the requirements of this study protocol.\n5. Subject is willing to participate in the telephone follow-ups and to return to the investigational site for the post-procedure follow-up evaluations.\n\nThe patient in the note does not meet the second key inclusion criterion as there is no indication of an intracranial aneurysm needing endovascular treatment. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "551": {
        "output": "After reviewing the patient note and the clinical trial details, here's the assessment:\n\nThe patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and signs of a ruptured liver abscess, which was surgically drained.\n\nThe clinical trial in question is studying the natural history of Noncirrhotic Portal Hypertension (NCPH). The inclusion criteria for this trial state that participants should be age 12 years or above and have a known diagnosis of NCPH or be at risk for NCPH due to underlying disease processes such as CVID. The patient in the note has CVID, which is specifically listed in the inclusion criteria as an underlying disease that puts him at risk for NCPH.\n\nWhile the patient has not been explicitly diagnosed with NCPH in the provided note, his condition of CVID makes him eligible to be considered at risk for NCPH, which is one of the criteria for inclusion in the study.\n\nNone of the exclusion criteria listed in the clinical trial seem to apply to this patient based on the information provided in the patient note. However, further investigation would be needed to confirm that none of the exclusion criteria apply, such as ensuring there are no other forms of liver disease that typically result in cirrhosis, no evidence of active chronic hepatitis B or C, and no evidence of hepatocellular carcinoma, among others.\n\nGiven the information available, the patient's CVID status places him at risk for NCPH, making him a potential candidate for the clinical trial upon further investigation to rule out any exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "552": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy,\" let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 48-year-old white male.\n- He has a history of common variable immunodeficiency (CVID).\n- He presented with acute abdominal pain, fever, dehydration, hepatomegaly, and a ruptured liver abscess.\n- He underwent exploratory laparotomy and surgical drainage.\n- He is currently in the ICU.\n\nClinical Trial Inclusion Criteria Analysis:\n- Aged > 18 years old (Patient is 48, meets this criterion)\n- Capable of providing informed consent (No information provided about the patient's ability to consent)\n- Histologically confirmed peritoneal carcinomatosis from specific origins, with no systemic metastases (The patient has a history of CVID and a ruptured liver abscess; there's no mention of peritoneal carcinomatosis or its origin)\n- Evidence of low-volume peritoneal disease (No information provided about peritoneal disease)\n- ECOG performance status of 0-2 (Patient is in the ICU, which suggests a performance status higher than 2)\n- Medically fit for surgery with specific requirements including no hepatic metastases, no biliary obstruction, no significant small bowel involvement, and no distant metastasis (Patient has a ruptured liver abscess, which could complicate surgical fitness)\n- Certain lab values and adequate hepatic and renal function (No lab values provided)\n- Satisfactory cardiopulmonary function (No information on cardiopulmonary function)\n- No significant history of a medical problem or co-morbidity that would preclude surgery (The patient has CVID, which may affect his eligibility)\n- No concurrent second malignancy or psychiatric/addictive disorders (No information provided on these aspects)\n\nGiven the provided information, the patient does not meet the inclusion criteria for the clinical trial. The trial is looking for patients with specific types of peritoneal carcinomatosis and the patient's current medical issues do not align with the trial's focus. Furthermore, the patient's current condition in the ICU suggests a performance status that would likely exclude him from the trial. There is no indication that the patient has peritoneal carcinomatosis or that he would be medically fit for the surgical procedure described in the trial, given his recent surgery and ICU stay.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "553": {
        "output": "Based on the patient note provided, the patient is a 48-year-old white male with a history of common variable immunodeficiency (CVID) who presented with acute abdominal pain, fever, dehydration, and complications including a ruptured liver abscess which required surgical intervention and ICU care.\n\nThe clinical trial in question is focused on the consequences of DNA Repair and Telomere Defects on the Function of the Immune System with a specific application to CVID and immune deficiencies with dysmorphic syndromes. Given that the patient has a documented history of CVID, he meets one of the key inclusion criteria for the trial, which is having a diagnosis of Common Variable Immunodeficiency (CVID).\n\nThe trial does not specify additional inclusion criteria such as age limits or specific stages of CVID. Therefore, based on the information provided, the patient appears to be a good candidate for the clinical trial because he has a diagnosis that is directly relevant to the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 1
    },
    "554": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient's eligibility can be assessed as follows:\n\nPatient note:\n- The patient is a 48-year-old white male, which meets the age criterion (\u226518 yrs old).\n- The patient has been diagnosed with a ruptured liver abscess, not a perianal abscess.\n- No information is provided about any perianal abscess or its characteristics.\n\nClinical trial:\n- The trial is focused on the treatment of perianal abscesses.\n- Inclusion criteria specify the patient must have a perianal abscess larger than 2 cm in diameter that has not spontaneously ruptured.\n- Patient must provide signed informed consent.\n\nSince the patient has a ruptured liver abscess, not a perianal abscess, he does not meet the specific condition criteria for the clinical trial. Therefore, the patient would not be eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "555": {
        "output": "Upon reviewing the patient note and the inclusion criteria for the clinical trial titled \"Cyclophosphamide and Fludarabine to Treat Lupus Nephritis,\" we can determine the following:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient is post-major surgery with low urine output, generalized edema, and abnormal kidney function tests (blood urea nitrogen and serum creatinine levels).\n- The initial urinalysis shows RBC and granular casts, pointing towards renal involvement.\n\nClinical Trial Analysis:\n- This trial is designed for patients who are 18 years of age or older.\n- Patients must meet at least 4 criteria for Systemic Lupus Erythematosus (SLE) as defined by the American Rheumatism Association.\n- The trial is specifically for patients with active glomerulonephritis due to lupus nephritis with a renal biopsy within 1 year showing class III or class IV active lupus nephritis.\n- There are specific requirements for abnormal urine analysis and proteinuria levels, as well as exclusion criteria regarding previous treatments and other health conditions.\n\nThe patient in the note is a 6-month-old infant, which immediately disqualifies him from the clinical trial as the inclusion criteria specify that participants must be 18 years or older. Additionally, there is no mention of the patient having SLE, nor is there any indication that the patient meets the other specific criteria required for the study, such as having lupus nephritis.\n\nTherefore, based on the patient note and the clinical trial inclusion criteria, this patient would not be eligible to participate in the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "556": {
        "output": "Based on the patient note and the inclusion criteria provided for the clinical trial titled \"Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure\", let's evaluate the patient's eligibility.\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery and is experiencing a reduced urine output of less than 0.2 mL/kg/hr.\n- The patient has generalized edema.\n- Blood pressure, pulse, and respirations are listed, with elevated blood pressure for an infant.\n- Laboratory results indicate a blood urea nitrogen of 33 mg/dL and a serum creatinine of 1.3 mg/dL.\n- Urinalysis shows specific gravity of 1.017 with some white and red blood cells, and granular casts present.\n- The patient's fractional excretion of sodium is 3.3%.\n\nClinical Trial Inclusion Criteria Analysis:\n- Group 3 criteria seem the most relevant to the patient, as they address acute renal failure (ARF) due to surgery or trauma.\n- Group 3 inclusion criteria specify:\n  - ARF severity index 20-60%\n  - Creatinine clearance 12-14 mL/min\n  - Rising creatinine of at least 0.5 mg/dL per day for 2 days without evidence of recovery despite standard supportive care\n  - No drug or contrast-induced renal failure\n  - Baseline creatinine greater than 2.5 mg/dL (males) or 2.0 mg/dL (females)\n\nEligibility Assessment:\n- The patient is an infant, which may not align with the typical demographic considered for this study (this is not explicitly stated in the inclusion criteria, but the baseline creatinine levels suggest adult participants).\n- The patient's current creatinine level is 1.3 mg/dL, which is below the specified baseline level for inclusion in the study.\n- The patient does not meet the creatinine clearance specified for Group 3, and there is no information on a rising creatinine level or ARF severity index.\n- It is unclear if the patient's condition is due to hypotension, surgery, or trauma as required by Group 3.\n- The patient does not appear to have chronic renal failure or other exclusions mentioned for Group 3.\n\nGiven the above analysis, the patient does not meet the specific inclusion criteria outlined for Group 3 participants, especially concerning age, baseline creatinine level, and creatinine clearance rate. Therefore, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "557": {
        "output": "To assess the patient's eligibility for the clinical trial titled \"Study of Morphine in Postoperative Infants to Allow Normal Ventilation,\" let's compare the patient's characteristics and condition with the inclusion criteria provided:\n\nInclusion Criteria:\n1. Infants scheduled for surgery with postoperative inpatient care.\n2. Must be born after 35 weeks or more gestational age.\n3. No prenatal opiate exposure.\n4. Part I patients: Less than 12 months of age undergoing surgeries involving major thoracic, abdominal, or cardiac procedures.\n5. No pneumonectomy, tracheal or bronchial stenosis reconstruction, diaphragmatic hernia repair, or surgeries resulting in high intraabdominal pressure.\n6. No hepatic or renal transplantation.\n7. Age: Part I: Less than 12 months. Part II: Less than 3 months.\n8. Normal hepatic function tests.\n9. Normal renal function tests.\n10. No pulmonary disease causing baseline hypercarbia.\n11. No pulmonary hypertension contraindicating the use of 5% CO2 in rebreathing studies.\n12. No allergy to morphine.\n13. No severe developmental delay that precludes analgesia scoring.\n\nPatient Characteristics:\n- Age: 6-month-old male infant, which fits within the age range for Part I of the study.\n- Underwent major surgery, which aligns with the requirement for postoperative inpatient care.\n- Urine output of less than 0.2 mL/kg/hr shortly after surgery may suggest renal impairment.\n- Generalized edema.\n- Blood pressure is 115/80 mm Hg, pulse 141/min, respirations 18/min.\n- Blood urea nitrogen is 33 mg/dL, and serum creatinine is 1.3 mg/dL, which may indicate abnormal renal function.\n- Specific gravity of urine is 1.017, with some RBCs and granular casts present in urinalysis.\n\nBased on the patient note, while the patient's age and the fact that they underwent major surgery fit the inclusion criteria, the note indicates potential renal impairment as evidenced by low urine output, elevated blood urea nitrogen, and serum creatinine levels. The inclusion criteria specifically require normal renal function tests, which the patient does not seem to meet.\n\nGiven this mismatch, the patient's eligibility for the clinical trial in question is not supported. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "558": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's assess the eligibility:\n\nPatient Note:\n- 6-month-old male infant\n- Post major surgery with low urine output\n- Generalized edema, elevated blood pressure, and high pulse\n- Blood urea nitrogen and serum creatinine levels elevated\n- Urinalysis shows specific gravity, WBCs, RBCs, and granular casts\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed IgA nephropathy, diagnosed within the past 3 years\n- Clinical presentation of either isolated hematuria/proteinuria for less than 3 years OR acute nephritic or nephrotic syndrome\n- No secondary forms of IgA nephropathy\n- No end stage renal failure\n- No systemic lupus erythematosus or systemic vasculitis\n- Healthy volunteers as control group\n- No concurrent medical or psychiatric illness that would preclude study\n\nThe patient note does not mention IgA nephropathy, which is a primary inclusion criterion for the clinical trial. The patient is a 6-month-old infant, whereas the inclusion criteria do not specify an age limit, but the diagnosis and clinical presentation specific to IgA nephropathy are critical for eligibility. Additionally, the patient has just undergone major surgery which could be considered a concurrent medical condition that may preclude study participation, although the trial does not specify post-surgical patients as an exclusion.\n\nGiven the information provided, the patient does not meet the key inclusion criterion of a confirmed diagnosis of IgA nephropathy. Therefore, this patient would not be eligible for the clinical trial based on the information given.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "559": {
        "output": "The patient is a 6-month-old male infant who has recently undergone major surgery. The clinical trial in question is studying the safety and efficacy of Triostat in infants with congenital heart disease during cardiopulmonary bypass surgery.\n\nTo determine trial-level eligibility, we need to compare the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nThe inclusion criteria for the clinical trial are:\n- Diagnosis of one of the following:\n  - Ventricular septal defect (VSD)\n  - Infant coarctation of the aorta\n  - Transposition of the great arteries\n  - Tetralogy of Fallot\n  - Complete atrioventricular canal defect\n  - Hypoplastic left heart, including patients who undergo a Norwood type procedure for aortic or mitral atresia\n- Patient must be scheduled for surgery.\n\nThe patient note does not mention any congenital heart disease or specify that the infant has any of the listed conditions that qualify for inclusion in the clinical trial. Additionally, the note does not indicate whether the infant is scheduled for heart surgery, which is a requirement for the trial.\n\nGiven the information provided, the patient does not meet the specified inclusion criteria, as there is no mention of a congenital heart defect or a scheduled surgery relevant to the study's focus.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "560": {
        "output": "Upon reviewing the patient's details and the inclusion criteria for the clinical trial titled \"Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery,\" we can determine the patient's eligibility as follows:\n\nThe inclusion criteria for the clinical trial are:\n1) Scheduled cardiac surgery with hypothermic CPB to repair certain congenital heart defects or to palliate certain heart conditions.\n2) Age 1-45 days at surgery.\n3) Birth weight > 2.3 kg.\n4) A cranial ultrasound < 1 week prior to enrollment showing at most grade II hemorrhage in high-risk patients.\n\nThe patient is a 6-month-old infant, which translates to approximately 180 days old. This is beyond the age range specified in the inclusion criteria, which is 1-45 days at surgery. Therefore, based solely on the age criterion, the patient does not meet the eligibility requirements for the clinical trial.\n\nFurthermore, the patient note does not mention any congenital heart defects or conditions that would qualify for the trial's specific cardiac surgical interventions. The patient's condition appears to be related to renal issues following major surgery, not cardiac issues that would require hypothermic cardiopulmonary bypass.\n\nTherefore, this patient would not be a candidate for the clinical trial based on both age and the condition not matching the specified inclusion criteria.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "561": {
        "output": "Based on the information provided, the patient in question is a 6-month-old male infant, which does not meet the age requirement of the clinical trial. The clinical trial's inclusion criteria specify that participants must be children aged 8-12 years.\n\nTherefore, given that the patient's age does not fall within the specified range for the clinical trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "562": {
        "output": "Based on the patient note and the clinical trial's inclusion criteria, the patient in question would not be eligible for this trial. The trial is focused on healthy infants aged 0 to 3 years, who are free of medication. The patient described is a 6-month-old male infant who has undergone major surgery, has generalized edema, and is showing signs of renal impairment, as indicated by low urine output, elevated blood urea nitrogen, and serum creatinine levels. This patient is not healthy and free of medication as required by the trial's inclusion criteria.\n\nTherefore, the assessment of eligibility is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "563": {
        "output": "Assessing the patient note against the inclusion criteria for the clinical trial:\n\nPatient Note:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery.\n- The patient has oliguria (urine output of less than 0.2 mL/kg/hr).\n- The patient is not currently described as being on hemofiltration.\n- There is no mention of mechanical ventilation or written informed consent.\n\nClinical Trial Inclusion Criteria:\n- Cessation of hemofiltration.\n- Mechanical ventilation.\n- Written informed consent.\n\nBased on the patient note and the inclusion criteria provided for the clinical trial:\n\n- The infant is not currently described as being on hemofiltration, which is a requirement to meet the inclusion criteria.\n- There is no mention of the infant requiring mechanical ventilation.\n- It is not possible for an infant to provide written informed consent, and the note does not mention consent provided by a guardian or parent.\n\nGiven the information provided, the 6-month-old patient does not meet the explicit inclusion criteria for the clinical trial. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "564": {
        "output": "Given the patient note and the clinical trial information, we can evaluate the eligibility of the 6-month-old male infant for the clinical trial.\n\nPatient Note Details:\n- Age: 6-month-old male infant\n- Condition: Post-major surgery with low urine output, generalized edema, and changes in blood urea nitrogen and serum creatinine levels\n- Other Relevant Information: Blood pressure, pulse, respirations, urinalysis results\n\nClinical Trial Inclusion Criteria:\n- Age: Greater than 18 years of age\n- Referral for coronary angiography\n- Type 1 or type 2 diabetic requiring insulin or oral hypoglycemic agents\n- Specific serum creatinine concentration parameters for diabetics and non-diabetics\n- Stable renal function\n\nUpon comparing the patient's characteristics with the inclusion criteria of the clinical trial, it is clear that the patient does not meet the age criterion (greater than 18 years of age) as he is only a 6-month-old infant. Additionally, the trial is focused on patients referred for coronary angiography, which is not applicable to the infant. There is also no mention of diabetes, which is a requirement for the trial participants.\n\nTherefore, the 6-month-old patient does not fulfill the inclusion criteria for this clinical trial, and the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "565": {
        "output": "In assessing the eligibility of the 6-month-old male infant for the clinical trial involving Enteroaggregative E. coli (EAEC), we must compare the patient's characteristics to the inclusion criteria of the study.\n\nThe inclusion criteria for the EAEC study are as follows:\n1. Age between 18 and 40 years at the time of enrollment.\n2. Otherwise healthy individuals with a stable address and telephone.\n3. Ability to read and write English.\n4. Possession of a social security number.\n5. Negative serum pregnancy test for females and use of effective birth control.\n6. Seronegative for antibodies to dispersin.\n7. Normal laboratory screening values including WBC count, hemoglobin, hematocrit, platelets, BUN, glucose, creatinine, ALT, AST, quantitative immunoglobulins, T cell subsets (CD4 and CD8), urinalysis.\n8. Normal chest x-ray and electrocardiogram.\n9. Negative serologies for HIV, HBV, HCV, and a negative RPR.\n10. Negative stool examination for pathogenic ova and parasites, and bacterial enteropathogens (EAEC, Salmonella, Shigella, Campylobacter).\n11. Having the -251 AA IL-8 genotype.\n\nThe patient note describes a 6-month-old male infant, which immediately disqualifies him based on the age criterion alone, as the study requires participants to be at least 18 years of age. Moreover, the patient does not meet the criterion of being otherwise healthy, as he is currently experiencing medical issues (low urine output, generalized edema, abnormal blood urea nitrogen and serum creatinine levels) shortly after undergoing major surgery.\n\nGiven that the patient does not meet the age requirement and is not in a healthy state as required by the study, he is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "566": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, the 6-month-old male infant does not meet the inclusion criteria for the trial on \"Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis.\" The inclusion criteria specify that the trial is for infants diagnosed with Gastroschisis, which is not a condition mentioned in the patient note. Instead, the patient note describes an infant with post-surgical complications related to urine output and kidney function, which is unrelated to Gastroschisis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "567": {
        "output": "The patient note presents a 6-month-old male infant who has undergone major surgery and is experiencing a low urine output, generalized edema, and abnormal laboratory findings including increased blood urea nitrogen and serum creatinine levels, alongside urinary findings indicative of renal impairment or injury.\n\nThe clinical trial in question is investigating the prophylactic use of Levosimendan versus Milrinone in open heart surgery in infants. The inclusion criteria for this trial are specifically:\n\n- Age younger than one year\n- Corrective open heart surgery with biventricular repair, except tetralogy of Fallot\n\nWhile the patient note does indicate that the infant is of the appropriate age for the clinical trial (younger than one year), there is no mention in the patient note of the infant having undergone open heart surgery or requiring biventricular repair. Without information confirming that the infant meets the surgical criteria for this clinical trial, it is not possible to determine eligibility based on the provided patient note.\n\nGiven the lack of information on the type of major surgery the infant underwent, we cannot assume it was open heart surgery with biventricular repair. Therefore, based on the available information, we cannot refer this patient for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "568": {
        "output": "Considering the patient note and the inclusion criteria of the clinical trial for belatacept in liver transplant recipients, we can determine the following:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- He has undergone major surgery and now has low urine output, generalized edema, and abnormal values in blood urea nitrogen and serum creatinine.\n- The patient has not been described as a liver transplant recipient.\n\nClinical Trial Inclusion Criteria Analysis:\n- The trial is for first-time recipients of a deceased donor liver transplant.\n- Age range for participants is 18-70 years.\n- Participants must be Hepatitis C virus (HCV) positive recipients.\n- Certain exclusion criteria apply, including known intrinsic renal disease with a GFR < 40 ml/min/1.73 m^2 BSA.\n\nBased on the patient note, it is clear that the infant does not meet the age criteria for the clinical trial (the infant is 6 months old, while the trial requires participants to be aged between 18 and 70 years). Additionally, there is no mention of the infant being a liver transplant recipient or being HCV positive, both of which are required for participation in the trial.\n\nGiven these discrepancies between the patient's characteristics and the trial's inclusion criteria, the patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "569": {
        "output": "Given the patient note and the clinical trial inclusion criteria, here's the assessment:\n\nPatient Note:\n- 6-month-old male infant\n- Underwent major surgery\n- Low urine output\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Pulse 141/min\n- Respirations 18/min\n- Blood urea nitrogen 33 mg/dL\n- Serum creatinine 1.3 mg/dL\n- Initial urinalysis shows specific gravity of 1.017, 1 WBC/HPF, 18 RBCs/HPF, and 5 granular casts/HPF\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial Inclusion Criteria:\n- Age over 18 years\n- Planned CABG or valvular surgery with cardiopulmonary bypass\n- Serum creatinine available (within 30 days)\n- Estimated GFR 15-90 ml/min using the abbreviated MDRD formula (CKD stages 2-4)\n\nThe patient in question is a 6-month-old infant, which does not meet the age criterion (over 18 years) of the clinical trial. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "570": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, we can determine the following:\n\nThe patient is a 6-month-old male infant who has undergone major surgery and is experiencing a urine output of less than 0.2 mL/kg/hr, which indicates oliguria. The patient also presents with generalized edema, elevated blood pressure for an infant, tachycardia (pulse of 141/min), and abnormal laboratory findings indicative of renal impairment (blood urea nitrogen of 33 mg/dL and serum creatinine of 1.3 mg/dL).\n\nThe clinical trial in question is investigating the effect of fenoldopam and ketanserin on preventing acute kidney failure after cardiac surgery. The inclusion criteria for the clinical trial specify that participants must have undergone cardiac surgery and must exhibit at least one risk factor for acute renal failure, which includes oliguria < 0.5 ml/kg/hour for over 3 hours despite adequate blood volume and furosemide administration.\n\nThe patient note does not mention cardiac surgery specifically; it only mentions \"major surgery.\" Moreover, the patient note does not mention the administration of furosemide or the maintenance of diuresis at a rate greater than 1 ml/kg/hour.\n\nGiven the lack of specific information about the type of surgery the infant underwent and the absence of details regarding furosemide treatment, we cannot conclusively determine that the patient fits the inclusion criteria. However, the patient does exhibit a risk factor for acute renal failure (oliguria), which might make him a potential candidate for the trial if the surgery was indeed cardiac in nature and if other inclusion criteria are met upon further investigation.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "571": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial titled \"Acute Kidney Injury in Neonates,\" we can evaluate the patient's eligibility.\n\nPatient Note Review:\n- The patient is a 6-month-old male infant, which fits the neonate category.\n- The patient has undergone major surgery and is experiencing a reduced urine output indicative of renal issues.\n- The patient has generalized edema, which can be associated with renal function impairment.\n- The laboratory results show elevated blood urea nitrogen and serum creatinine levels, as well as abnormal findings in the urinalysis, which may indicate acute kidney injury (AKI).\n\nClinical Trial Inclusion Criteria Review:\n- The trial is focused on infants in a neonatal intensive care unit.\n- The study aims to investigate acute kidney injury in neonates.\n- The inclusion criteria specify that families of infants with a birthweight over 1500g are to be asked to participate.\n\nThe patient appears to meet the trial's age range (neonate) and is experiencing renal issues, which is the focus of the study. However, the trial's inclusion criteria do not provide a detailed age range or specify the severity of renal dysfunction required for eligibility. The inclusion criteria also do not mention postoperative patients explicitly.\n\nGiven the information, the patient fits the general profile of the study population (neonates with potential acute kidney injury), but we lack some specifics such as birthweight and whether the study is looking at postoperative AKI cases exclusively or not. Therefore, further investigation would be required to determine the full eligibility of this patient for the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "572": {
        "output": "Based on the information provided in the patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant, which satisfies the age criterion (\u2265 18 years is not specified, so we can assume pediatric patients are eligible).\n- The patient is experiencing renal issues shortly after major surgery, with low urine output, generalized edema, high blood pressure, and abnormal blood and urine test results.\n- The patient's condition seems to be acute, given the context of recent surgery.\n\nClinical Trial Inclusion Criteria Analysis:\n- Proteinuria over 0.25 g/mmol of creatinine with hypoalbuminemia below 30g/L for the case: The patient note does not provide information on the proteinuria or albumin levels, so we cannot confirm if this criterion is met.\n- No history of renal disease: The patient note does not indicate a history of renal disease, but the current acute situation does not necessarily imply a history of chronic or idiopathic conditions.\n- Normal C3 and negativity for hepatitis B and C: The patient note does not provide information on C3 levels or hepatitis status.\n\nGiven that the patient note lacks information on proteinuria, albumin levels, C3, and hepatitis B and C status, we cannot definitively determine the patient's eligibility for the trial based on the information provided. Moreover, the trial seems to be focused on idiopathic nephrotic syndrome, which may not apply to the post-surgical acute condition of the patient.\n\nTherefore, the assessment of eligibility leans towards not referring this patient to the trial due to the lack of information and the acute context of the patient's condition, which does not clearly align with the idiopathic nature of the condition being studied in the trial. However, if additional information becomes available that aligns with the inclusion criteria, the assessment may change.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "573": {
        "output": "Given the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the clinical trial.\n\nPatient note:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery.\n- The patient is experiencing a low urine output, generalized edema, and abnormal blood and urine test results.\n\nClinical trial inclusion criteria:\n- Infants aged 6 to 36 months.\n- Admitted to the Intensive Care-Sophia after craniofacial surgery.\n\nBased on the information provided, the patient is a 6-month-old infant, which fits the age range specified in the clinical trial's inclusion criteria. However, the trial specifically requires infants admitted to the Intensive Care-Sophia after craniofacial surgery. The patient note does not mention craniofacial surgery; instead, it refers to major surgery, with postoperative complications suggestive of renal issues.\n\nSince we do not have evidence that the patient underwent craniofacial surgery, we cannot definitively conclude that this patient meets the inclusion criteria based solely on the age match. Therefore, further investigation would be needed to determine if the patient's surgery was craniofacial and if they are admitted to the Intensive Care-Sophia.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "574": {
        "output": "The patient in the note is a 6-month-old male infant with complications following major surgery, characterized by low urine output, generalized edema, and abnormal lab findings. The clinical trial in question is studying the absorption and excretion of zinc and copper in infants with ostomies, particularly focusing on those with ileostomies who are undergoing various nutritional support stages, including total parenteral nutrition (TPN) and enteral nutrition.\n\nThe inclusion criteria for the clinical trial are:\n1. Presence of ileostomy due to any disease or condition.\n2. Minimum birth weight of 500g.\n3. Likely to survive.\n\nThe patient note, however, does not mention the presence of an ileostomy or any related conditions such as necrotizing enterocolitis, intestinal atresias, gastroschisis, or intestinal perforations. Instead, the note focuses on the patient's postoperative state, with no information provided that would directly relate to the trial's focus on zinc and copper metabolism in the context of an ileostomy.\n\nGiven the available information, we cannot establish that this patient meets the inclusion criteria of the clinical trial. Therefore, the patient would not be referred for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "575": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant who has experienced a decrease in urine output following major surgery, along with other symptoms including generalized edema, elevated blood pressure, and changes in blood urea nitrogen and serum creatinine. The clinical trial in question is investigating the relationship of gestational age and urine concentration of S100B in preterm and term infants during the first week of life.\n\nThe inclusion criteria for the clinical trial specify that infants born at >28 weeks gestation are eligible for enrollment. However, the patient note does not provide any information about the gestational age at birth of the 6-month-old infant in question. Additionally, the study is focused on infants in their first week of life, which does not apply to the patient in the note who is already 6 months old.\n\nGiven this information, the 6-month-old patient does not meet the inclusion criteria based on the age requirement specified by the clinical trial, as the patient is well beyond the first week of life. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "576": {
        "output": "",
        "label": 0
    },
    "577": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, it appears that the patient is a 6-month-old male infant who has undergone major surgery and is now showing signs that could be indicative of acute kidney injury (AKI). The clinical trial is examining new diagnostic tests for AKI after heart surgery.\n\nThe inclusion criteria for children in the clinical trial state that the child must be undergoing open heart surgery. The patient note does not specify that the infant had open heart surgery; it only mentions \"major surgery.\" Without this specific information, it is not clear whether the child meets the inclusion criteria for the trial. Furthermore, the exclusion criteria for children mention pre-existing acute kidney failure (greater than 50% decline in creatinine clearance), but the patient note does not provide enough information to determine the percentage decline in creatinine clearance for this patient.\n\nGiven the information provided, and the lack of specifics regarding the type of surgery the infant underwent, I would consider further investigation to determine if the major surgery was in fact open heart surgery and to clarify whether the infant's current kidney condition meets the definition of pre-existing acute kidney failure as per the trial's exclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "578": {
        "output": "",
        "label": 0
    },
    "579": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient in question is not eligible for referral to the clinical trial. The clinical trial is looking for healthy adult subjects between the ages of 18 and 45, while the patient is a 6-month-old male infant. Additionally, the trial requires subjects to be of normal health, and the infant is currently experiencing health issues following major surgery, as indicated by low urine output, generalized edema, and abnormal lab results.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "580": {
        "output": "Based on the information provided:\n\nPatient note:\n- A 6-month-old male infant\n- Post-major surgery\n- Acute kidney injury indicators (low urine output, edema, elevated blood urea nitrogen, elevated serum creatinine)\n- No mention of heart surgery or cardiopulmonary bypass\n\nClinical trial:\n- Investigating the influence of remote ischemic preconditioning on acute kidney injury after cardiac surgery\n- Inclusion criteria specify patient undergoing heart surgery on cardiopulmonary bypass\n\nGiven that the patient is a 6-month-old infant who has undergone major surgery and there's no mention of the surgery being related to the heart or involving cardiopulmonary bypass, the patient does not meet the inclusion criteria specified for the clinical trial. The trial is specifically looking for patients who are undergoing heart surgery on cardiopulmonary bypass, which does not seem to apply to the infant described in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "581": {
        "output": "In this scenario, the patient is a 6-month-old male infant who recently underwent major surgery and is now presenting with a low urine output, generalized edema, and abnormal blood and urine test results. The clinical trial in question is studying the efficacy and safety of eltrombopag in pediatric patients with chronic idiopathic thrombocytopenic purpura (ITP).\n\nBased on the inclusion criteria provided for the clinical trial, the patient must meet several requirements to be eligible:\n\n1. Subjects between 1 year and <18 years of age at Day 1.\n2. Confirmed diagnosis of chronic ITP.\n3. Subjects who are refractory or have relapsed after at least one prior ITP therapy or are not eligible, for a medical reason, for other treatments.\n4. Day 1 (or within 48 hours prior) platelet count <30 Gi/L.\n5. Additional criteria related to previous treatments, stable doses of concomitant ITP medication, blood test results within a certain range, and specific criteria for kidney and liver function tests.\n\nThe patient note does not mention chronic ITP, instead it describes a post-surgical condition with complications related to kidney function, specifically mentioning findings of edema and abnormal blood and urine tests. There is no mention of thrombocytopenia or any previous treatment for ITP.\n\nGiven that the patient does not have a diagnosis of chronic ITP, and the fact that the patient is under 1 year of age, he does not meet the key inclusion criteria for the clinical trial. Therefore, this patient is not eligible for the clinical trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "582": {
        "output": "The patient described in the patient note is a 6-month-old male infant. According to the inclusion criteria stated for the clinical trial titled \"Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass,\" the participants must:\n\n- Be neonates aged \u2264 1 month\n- Be scheduled to undergo cardiac surgery involving Cardiopulmonary Bypass (CPB) (reparative or palliative procedures)\n- Have an inpatient status at MUSC a minimum of 8 hours prior to planned surgery\n\nThe patient in question does not meet the age criterion as he is 6 months old, and the trial specifically requires neonates who are 1 month old or younger. There is no information provided about whether the patient is scheduled to undergo cardiac surgery involving CPB or his inpatient status. However, the age criterion alone is sufficient to determine that this patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "583": {
        "output": "Considering the provided inclusion criteria for the clinical trial and the patient's information:\n\nInclusion Criteria Analysis:\n- The patient must be \u2265 18 years of age. The patient in the note is a 6-month-old infant, which does not meet this criterion.\n- The patient must be in general good health without a history of any of the conditions listed in exclusion criteria (not provided, but the infant has just undergone major surgery, indicating they are not in general good health).\n- Screening laboratory values must meet certain criteria. The patient's serum creatinine is 1.3 mg/dL, which is likely above the upper limit of normal (ULN) for an infant, and also does not meet the requirement of <1.1 x ULN for the study.\n- The study is designed for healthy adult volunteers, and this patient is a 6-month-old infant with health issues secondary to major surgery.\n\nGiven this information, the patient does not meet the age requirement, is not in general good health, and has laboratory values that do not meet the specified criteria for the clinical trial. \n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "584": {
        "output": "In this scenario, we are given a patient note for a 6-month-old male infant and a clinical trial that is focused on preterm very low birth weight infants with shock.\n\nThe inclusion criteria for the clinical trial are as follows:\n- Preterm infants born between 28 to 34 weeks gestation.\n- Very low birth weight infants with a birth weight of 750 to 1500 grams.\n- Infants who exhibit shock in the first week of life requiring vasopressor therapy or stable preterm infants matched for gestational age, birth weight, and postnatal age.\n\nThe patient note describes a 6-month-old male infant with a low urine output post-surgery, generalized edema, abnormal blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, and urinalysis findings. The infant does not fit the gestational age or birth weight criteria mentioned in the trial inclusion criteria. Furthermore, the patient's condition does not seem to be related to the trial's focus on relative adrenal insufficiency in the context of shock in the first week of life.\n\nGiven the information provided, this patient would not meet the inclusion criteria for the clinical trial because:\n- The patient is not within the 28 to 34 week gestation range.\n- The patient's current age is 6 months, which is beyond the first week of life.\n- The birth weight of the patient is not specified, but given the age, it is unlikely that the current weight would fall within the very low birth weight category.\n- There is no mention of shock requiring vasopressor therapy in the first week of life in the patient's history.\n\nTherefore, the assessment for this patient's eligibility for the clinical trial in question is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "585": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, the patient is a 6-month-old male infant, which means he is beyond the neonatal period and does not fit the inclusion criteria of the clinical trial that specifically targets premature infants with a gestational age of less than 32 weeks. The trial aims to define normal citrulline levels as a diagnostic tool for gastrointestinal disease in the premature population. Since the patient is not a premature infant and does not fall within the specified gestational age range for the trial, he would not qualify for participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "586": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, we can determine the eligibility of the patient as follows:\n\nPatient Note Analysis:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery.\n- No mention of minimal change nephritic syndrome or a kidney biopsy.\n- Urine output, blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, and urinalysis results are provided.\n- Fractional excretion of sodium is 3.3%.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age from 18 years to 80 years.\n- Minimal change disease diagnosed by kidney biopsy.\n- Urine protein/creatinine ratio over 3.0.\n- Serum albumin below 3.0g/dL.\n- Consent form signed by the patient.\n\nComparing the two:\n- The patient is a 6-month-old male infant, which does not meet the age criterion of the clinical trial (18 to 80 years).\n- There is no mention of minimal change nephritic syndrome or evidence of a kidney biopsy.\n- The specific levels of urine protein/creatinine ratio and serum albumin are not provided in the patient note.\n- An infant cannot sign a consent form; a parent or guardian would have to provide consent.\n\nBased on the above, the patient does not meet the inclusion criteria for the clinical trial due to age, lack of diagnosis of minimal change disease, and no provided urine protein/creatinine ratio or serum albumin levels. The patient also cannot sign the consent form due to being an infant.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "587": {
        "output": "Considering the patient note and the clinical trial's inclusion criteria, the 6-month-old male infant does not meet the age criteria, as the trial requires participants to be 18 years or older. Since the patient is significantly younger, they are not eligible to participate in this clinical trial.\n\nTherefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "588": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial:\n\nPatient Note:\n- The patient is a 6-month-old male infant.\n- The patient has undergone major surgery.\n- The patient has a urine output of less than 0.2 mL/kg/hr.\n- The patient has generalized edema, increased blood pressure, and altered renal function tests.\n- The patient does not have a diagnosis of cirrhosis or ascites mentioned.\n- The patient's serum creatinine is 1.3 mg/dL which is below the inclusion criterion of the trial.\n\nClinical Trial Inclusion Criteria:\n- Written informed consent by subject or legally authorized representative.\n- At least 18 years of age.\n- Cirrhosis and ascites.\n- Rapidly progressive reduction in renal function characterized by a serum creatinine (SCr) \u2265 2.5 mg/dL and a doubling of SCr within 2 weeks.\n- No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion with albumin.\n\nThe patient does not meet the following inclusion criteria:\n- Age: The patient is 6 months old, whereas the study requires participants to be at least 18 years of age.\n- Diagnosis: The study is for patients with cirrhosis and ascites, which is not mentioned in the patient's note.\n- Serum creatinine: The patient's serum creatinine is 1.3 mg/dL, which does not meet the study's requirement of \u2265 2.5 mg/dL.\n\nGiven these discrepancies, the patient would not be eligible for the clinical trial aimed at evaluating the treatment of type 1 hepatorenal syndrome in participants with cirrhosis and ascites.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "589": {
        "output": "",
        "label": 0
    },
    "590": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- 6-month-old male infant\n- Underwent major surgery\n- Postoperative findings suggesting acute kidney injury (AKI): low urine output, edema, elevated blood urea nitrogen and serum creatinine, abnormal urinalysis\n\nClinical Trial:\n- Title: NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants\n- Focus: Observational study on urinary NGAL as an early marker of AKI post-cardiac surgery\n- Inclusion Criteria: Term neonates and infants undergoing heart surgery with cardiopulmonary bypass, parental consent\n- Exclusion Criteria: Preoperative documented kidney injury, lack of parental consent\n\nThe patient is a 6-month-old infant, which aligns with the age group of the trial (neonates and infants). The patient has undergone major surgery, and the clinical trial specifically is looking at patients undergoing cardiac surgery with cardiopulmonary bypass. However, the patient note does not specify that the recent surgery was cardiac or involved cardiopulmonary bypass. Without this specific information, we cannot definitively say the patient meets all the inclusion criteria.\n\nThe trial aims to observe the postoperative kinetics of urinary NGAL in neonates and identify thresholds for predicting severe AKI requiring renal replacement therapy. The patient's condition suggests the possibility of AKI, which is relevant to the study's aim. However, the patient would only be eligible if the major surgery they underwent was indeed cardiac surgery with cardiopulmonary bypass.\n\nThe patient note does not mention any preoperative kidney injury, which is part of the exclusion criteria. It also does not mention whether the parents have been informed as required for inclusion.\n\nGiven the information provided, the patient might be eligible for the trial if the surgery was cardiac with cardiopulmonary bypass and parental consent can be obtained. However, since these details are missing, further investigation is required to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "591": {
        "output": "",
        "label": 0
    },
    "592": {
        "output": "Upon reviewing the patient note and comparing it with the inclusion and exclusion criteria of the clinical trial titled \"High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infants,\" the following observations are made:\n\nPatient note observations:\n- The patient is a 6-month-old male infant.\n- The patient has a urine output of less than 0.2 mL/kg/hr.\n- The patient's serum creatinine is 1.3 mg/dL.\n\nClinical trial inclusion criteria:\n- Gestational age <29 weeks.\n- Echocardiographic evidence of significant PDA.\n- Age of 12 to 24 hours.\n- RDS necessitating respiratory support.\n\nClinical trial exclusion criteria:\n- Major congenital anomalies.\n- Life-threatening infection or hydrops fetalis.\n- Pulmonary hypertension.\n- Death before the conclusion of the first course of ibuprofen.\n- Urine output below 1 ml per kilogram of body weight per hour during the preceding 12 hours (with the exception of the first dose).\n- A serum creatinine concentration of >1.5 mg/dL.\n- A platelet count of <50,000/mm3.\n- A tendency to bleed, as revealed by various clinical signs.\n\nBased on the patient note, the patient's age (6-month-old) does not meet the inclusion criteria, which specify an age of 12 to 24 hours. Additionally, the urine output of less than 0.2 mL/kg/hr is lower than the exclusion criteria threshold of 1 ml per kilogram of body weight per hour. Moreover, there is no information provided in the patient note about echocardiographic evidence of significant PDA or RDS necessitating respiratory support.\n\nTherefore, based on the available information, this patient would not meet the inclusion criteria for the clinical trial, and it is not possible to determine if the patient would meet any of the exclusion criteria because some of the necessary information, such as platelet count and presence of major congenital anomalies, is not provided in the patient note.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "593": {
        "output": "Based on the information provided, the patient is a 6-month-old male infant who recently underwent major surgery. The clinical trial is investigating the effects of Remote Ischemic Preconditioning (RIPC) on post-operative acute kidney, myocardial, and lung injury in patients undergoing cardiac surgery with planned cardiopulmonary bypass.\n\nThe inclusion criteria for the trial are:\n1. Age birth to 18 years\n2. Cardiac surgery with planned cardiopulmonary bypass\n\nThe patient note indicates that the infant is within the age range specified by the inclusion criteria (birth to 18 years). However, there is no mention of the infant undergoing cardiac surgery or having planned cardiopulmonary bypass. Therefore, we do not have sufficient information to determine if the infant meets all the inclusion criteria for the clinical trial.\n\nGiven the information provided, we cannot ascertain whether the infant has undergone cardiac surgery with planned cardiopulmonary bypass. Thus, at this point, further investigation is needed to determine if the infant meets the second inclusion criterion.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "594": {
        "output": "Assessing eligibility based on the patient note and the clinical trial inclusion criteria:\n\nPatient note:\n- 6-month-old male infant\n- Post major surgery\n- Specific clinical findings (urine output, edema, blood pressure, pulse, respirations, blood urea nitrogen, serum creatinine, urinalysis results)\n\nClinical trial:\n- Title: Ketorolac in Postoperative Infants: Pharmacokinetics and Safety\n- Target population: Non-prematurely-born infants admitted to hospital following surgery ages 2-18 months, studied by age group 12-18 months, 6-12 months, < 6 months\n\nThe patient is a 6-month-old male infant which fits the age group for the clinical trial (6-12 months). The patient is also postoperative, a requirement for the trial. There is no indication that the patient was born prematurely, hence we would assume he meets this criterion as well.\n\nThe clinical trial is designed to analyze the pharmacokinetics and safety of ketorolac in infants, with a particular focus on kidney and liver function. The patient note indicates a concern for renal function (low urine output, elevated blood urea nitrogen and serum creatinine), which would be a particular point of interest for the safety aspect of the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "595": {
        "output": "",
        "label": 0
    },
    "596": {
        "output": "",
        "label": 1
    },
    "597": {
        "output": "",
        "label": 0
    },
    "598": {
        "output": "Based on the provided patient note and the clinical trial information, this patient would not be a candidate for the clinical trial titled \"Plasma and Hemodynamic Markers During Hepatectomy.\" The inclusion criteria for the trial specify that the patient must have a neoplastic liver tumor and be undergoing elective hepatectomy. The patient note describes an infant who has developed renal issues post-major surgery, not specified as hepatectomy, nor is it mentioned that the patient has a neoplastic liver tumor.\n\nThe patient in question is a 6-month-old male infant with postoperative complications potentially related to acute kidney injury, as indicated by oliguria, increased blood urea nitrogen, and serum creatinine levels. The trial is assessing the impact of portal venous pressure on the kidney following liver resection and the effect of circulating growth factors on liver regeneration post-hepatectomy in patients with neoplastic liver tumors.\n\nSince the patient does not meet the critical inclusion criteria of having a neoplastic liver tumor and undergoing elective hepatectomy, they are not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "599": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant who has undergone major surgery and is experiencing issues with urine output and has generalized edema, among other symptoms.\n\nThe clinical trial in question is focused on the effects of sodium supplementation in very low birth weight infants, specifically those born at less than 32 weeks postmenstrual age.\n\nThe only inclusion criterion provided for this clinical trial is:\n\n- infants born at less than 32 weeks postmenstrual age\n\nThe patient's age (6 months old) is not directly relevant to the inclusion criterion, which is based on gestational age at birth rather than current age. There is no information provided in the patient note regarding the infant's gestational age at birth. Without this information, we cannot determine if the patient meets the inclusion criterion based on gestational age.\n\nGiven the lack of information on the birth gestational age of the patient, I cannot confirm eligibility. Further investigation would be needed to determine if the patient was born at less than 32 weeks postmenstrual age. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "600": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, the patient does not meet several key eligibility requirements for the study:\n\n1. Age: The trial requires participants to be over 18 years of age, and the patient is a 6-month-old male infant.\n2. Health status: The trial is designed for healthy human subjects, and the patient has just undergone major surgery, indicating that he is currently not in a state of general health.\n3. Serum creatinine levels: The inclusion criteria specify normal clinical laboratory profiles with no clinically significant values. The patient's serum creatinine is elevated at 1.3 mg/dL, which may be considered clinically significant, especially for an infant.\n4. Urinalysis: The patient's urinalysis shows abnormalities (18 RBCs per HPF, and 5 granular casts per HPF), whereas the trial requires normal urinalysis with no clinically significant values.\n\nGiven the mismatch between the patient's profile and the trial's inclusion criteria, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "601": {
        "output": "Based on the information provided, the patient in question is a 6-month-old male infant who has undergone major surgery and is experiencing renal function issues. The clinical trial, however, is looking for adult deceased brain dead kidney donors and recipients scheduled for renal transplantation.\n\nThe patient does not meet the inclusion criteria for the clinical trial due to his age (infant vs. adult criteria) and the fact that he is not a deceased brain dead kidney donor or recipient. Therefore, I would not refer this patient for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "602": {
        "output": "Based on the provided patient note and the clinical trial information, the inclusion criteria for the clinical trial are:\n\n- Patients undergoing cardiac surgery (OPS 5-35 bis 5-37) between 2007 and 2011\n- Followed by postoperative observation on an ICU of the anaesthesiology department of the Charit\u00e9 hospital\n\nThe patient note describes a 6-month-old male infant who has recently undergone major surgery, not specifically cardiac surgery. Additionally, there is no mention of the surgery taking place between 2007 and 2011, nor is there any indication that the postoperative observation is taking place in the anaesthesiology department of the Charit\u00e9 hospital.\n\nGiven these mismatches between the patient's situation and the clinical trial's inclusion criteria, the patient would not be eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "603": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, it is clear that the patient does not meet the inclusion criteria for the study.\n\nThe inclusion criteria for the clinical trial specify that participants must be:\n1. Aged 18-65 years old.\n2. Comply with percutaneous nephrolithotomy lithotripsy indications for surgery (Group A/B) or have normal renal function and not associated with urinary calculi, or be cancer patients meeting radical nephrectomy indications for surgery, or be emergency trauma patients suffering from kidney resection surgical indications (Group C).\n\nThe patient in the provided note is a 6-month-old male infant, which does not meet the age requirement of 18-65 years old. Additionally, the patient's clinical presentation does not match any of the other criteria listed for the groups A, B, or C in the inclusion criteria.\n\nTherefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "604": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant with a post-operative condition that includes reduced urine output, generalized edema, and laboratory findings suggestive of kidney injury (elevated blood urea nitrogen and serum creatinine levels, and the presence of granular casts in the urine).\n\nThe clinical trial in question is focused on the incidence and spectrum of acute kidney injury (AKI) in individuals with cirrhosis. The inclusion criteria specify two groups:\n\n- Group A: Patients with cirrhosis and normal baseline renal function\n- Group B: Patients who present with AKI\n\nHowever, the patient in the note does not have a diagnosis of cirrhosis; the condition described is acute kidney injury likely resulting from major surgery. Since cirrhosis is not mentioned as an underlying condition for the infant, the patient does not meet the specified inclusion criteria for the clinical trial.\n\nTherefore, the assessment is:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "605": {
        "output": "",
        "label": 0
    },
    "606": {
        "output": "Based on the patient note provided and the clinical trial's inclusion criteria, it seems that the patient, a 6-month-old male infant, does not meet the specific inclusion criteria stated for the clinical trial. The clinical trial is focused on patients who underwent surgery for congenital heart disease, and there is no information in the patient note indicating that the infant's surgery was for congenital heart disease.\n\nTherefore, without additional information that connects the patient's surgery to a congenital heart disease, it would not be appropriate to refer this patient for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "607": {
        "output": "Given the patient note and the clinical trial information provided, the patient in question is a 6-month-old male infant who has had major surgery and is now exhibiting signs that could be consistent with acute kidney injury (low urine output, edema, elevated blood urea nitrogen, and serum creatinine).\n\nThe clinical trial is focused on predicting acute kidney injury after coronary artery bypass graft surgery. However, the inclusion criteria for the trial are very specific: patients must have undergone coronary artery bypass surgery at the Samsung Medical Center between 2010 and 2012.\n\nThe patient in the note does not fit the inclusion criteria for several reasons:\n- The patient is a 6-month-old infant, and coronary artery bypass surgery is not a procedure typically performed on infants.\n- There is no mention of the patient having undergone coronary artery bypass surgery, only \"major surgery.\"\n- The timeframe during which the patient must have had surgery (between 2010 and 2012) does not align with the age of the patient (6 months old at the time of the note).\n\nBased on the provided information, the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "608": {
        "output": "Given the patient note and the clinical trial information, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note:\n- 6-month-old male infant\n- Post-major surgery\n- Low urine output, generalized edema, high blood pressure for an infant, tachycardia, elevated blood urea nitrogen, and serum creatinine levels\n- Urinalysis with specific gravity, WBCs, RBCs, and granular casts\n- Fractional excretion of sodium is 3.3%\n\nClinical Trial:\n- Evaluating the effect of tidal volume on clinical outcome in pediatric patients after congenital heart surgery\n- Inclusion Criteria: Pediatric patients who underwent surgery for congenital heart disease with cardiopulmonary bypass between 2009 and 2013 at Samsung Medical Center\n\nAssessment of Eligibility:\n- The patient is a 6-month-old infant, which fits the pediatric category.\n- The patient has undergone major surgery; however, there is no mention of congenital heart disease or use of cardiopulmonary bypass, which are specific requirements for the trial.\n- The surgery and patient care occurred after 2013, given the real-time knowledge cutoff.\n- The trial is specific to a time period and location (Samsung Medical Center), which is not mentioned in the patient note.\n\nConsidering the information provided, the patient does not meet the specified inclusion criteria for the clinical trial, as there is no evidence that the patient underwent surgery for congenital heart disease with cardiopulmonary bypass, nor is there evidence that the surgery took place between 2009 and 2013 at Samsung Medical Center. Therefore, the patient is not eligible for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "609": {
        "output": "",
        "label": 0
    },
    "610": {
        "output": "The patient in the provided note is a 6-month-old male infant, which immediately disqualifies him from the clinical trial mentioned, as the inclusion criteria specify that the patient must be 18 years of age or older. Additionally, there is no mention of a burn injury in the patient note, which is another requirement for the trial as the inclusion criteria state that the burn injury must be between 20% and 80% of total body surface area (TBSA).\n\nGiven these two critical discrepancies between the patient's characteristics and the trial's inclusion criteria, it is clear that this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "611": {
        "output": "Upon reviewing the patient note and the clinical trial's inclusion criteria, we can determine the patient's eligibility for the clinical trial.\n\nPatient note review:\n- The patient is a 6-month-old male infant.\n- The patient has recently undergone major surgery and is experiencing low urine output, generalized edema, and elevated blood urea nitrogen and serum creatinine levels.\n- The patient's urinalysis shows 18 RBCs per high-power field, which indicates the presence of blood in the urine (microscopic hematuria).\n\nClinical trial inclusion criteria review:\n- The trial is focused on post-menopausal women.\n- The participants must have asymptomatic microscopic hematuria.\n\nThe patient in the note is a 6-month-old male infant, which does not meet the age or gender criteria for the clinical trial, which is specifically looking for post-menopausal women. Therefore, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "612": {
        "output": "",
        "label": 0
    },
    "613": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's evaluate the patient's eligibility step by step:\n\n1. Age: The patient is a 6-month-old male infant, which means he is less than 3 months postnatal age. This meets the first criterion of the clinical trial, which requires the patient to be a neonate less than 3 months postnatal age.\n\n2. Diagnosis: The patient note indicates that the infant has a urine output of less than 0.2 mL/kg/hr after surgery, generalized edema, elevated blood urea nitrogen, and elevated serum creatinine. These findings are consistent with acute kidney injury (AKI), which fits the second criterion of needing a diagnosis of AKI.\n\n3. Treatment: According to the trial criteria, the patient needs to be receiving aminophylline for AKI treatment as per local standard of care. The patient note does not specify if the infant is currently receiving aminophylline for AKI treatment.\n\nGiven the information available, the patient meets the age and diagnosis criteria but lacks specific information about the current treatment with aminophylline. To determine final eligibility, further investigation is required to confirm whether the infant is receiving aminophylline as part of the standard of care for AKI.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "614": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria of the trial.\n\nPatient characteristics and condition:\n- 6-month-old male infant\n- Urine output of less than 0.2 mL/kg/hr post-surgery\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Blood urea nitrogen is 33 mg/dL\n- Serum creatinine is 1.3 mg/dL\n- Initial urinalysis shows specific gravity of 1.017, 1 WBC per HPF, 18 RBCs per HPF, 5 granular casts per HPF\n- Fractional excretion of sodium is 3.3%\n\nClinical trial inclusion criteria:\n- Proteinuria > 1000 mg/24h despite ACEi/ARB therapy and blood pressure control for > 3 months\n- Creatinine clearance > 30 ml/min/1.73m2\n- Blood pressure < 130/80 mmHg at > 75% of readings\n- Biopsy-proven IgA nephropathy with clinical features of HSP\n- Ability to receive injections\n- Kidney biopsy slide on file\n\nThe patient's characteristics do not align with the inclusion criteria. The patient is a 6-month-old infant and there is no mention of IgA nephropathy or proteinuria levels. Additionally, the trial seems to be targeting adults due to the mention of blood pressure requirements and previous treatments that are not typically applicable to infants.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial, so:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "615": {
        "output": "The patient is a 6-month-old male infant who has recently undergone major surgery and is now presenting with symptoms consistent with acute kidney injury (AKI), such as low urine output, generalized edema, elevated blood urea nitrogen, and elevated serum creatinine. The clinical trial in question is focused on following up with neonates who experienced AKI during their stay in the NICU to learn more about the early signs of chronic kidney diseases in children who were born prematurely with low birth weight.\n\nThe inclusion criteria for the trial are:\n- Premature birth for Premature groups\n- UVA NICU admission prior to 2 days of life\n- Birth weight less than 1500 grams for premature groups\n- Premature AKI Study group: Acute Kidney Injury as defined by KDIGO modified criteria during NICU stay at UVA\n- Premature no AKI Control group: No AKI during NICU stay\n- Term no AKI Control group: No AKI and born at term\n- Parental or legal guardian consent obtained\n\nThe patient note does not specify that the infant was born prematurely or that he was admitted to the UVA NICU, nor does it provide information about the infant's birth weight or whether he meets the KDIGO criteria for AKI during his NICU stay. Without this information, we cannot definitively determine the infant's eligibility for the trial.\n\nGiven the lack of information on the patient's birth history, birth weight, and NICU stay at UVA, we cannot confidently refer this patient for the clinical trial based on the information provided. Additional information would be needed to determine if the patient meets the specific inclusion criteria related to prematurity, birth weight, and NICU admission. Therefore:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "616": {
        "output": "Based on the patient note provided, the patient is a 6-month-old male infant experiencing renal issues post-surgery, as indicated by low urine output, edema, and abnormalities in urinalysis. \n\nConsidering the inclusion criteria of the clinical trial, which are as follows:\n\n- Were in the age range of 18-45 years.\n- Were neither overweight nor underweight for their height as per the Life Insurance Corporation of India height/weight chart for non-medical cases.\n- Had voluntarily given written informed consent to participate in this study.\n- Were of normal health as determined by medical history and physical examination of the subjects performed within 21 days prior to the commencement of the study.\n- Had a non-vegetarian diet habit.\n\nThe patient does not meet the age criteria since he is a 6-month-old infant, and the trial specifically requires subjects to be aged between 18-45 years. Additionally, the trial is looking for healthy adult male human subjects, while the patient in question is currently experiencing health issues related to renal function. Therefore, the patient is not eligible for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "617": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient's Characteristics:\n- Age: 6 months old\n- Condition: Low urine output post-major surgery, not specified as a kidney transplant recipient\n- Other: Currently experiencing generalized edema, abnormal blood urea nitrogen and creatinine levels indicating renal dysfunction\n\nClinical Trial Inclusion Criteria:\n- Age \u2265 18 years\n- Patient with End-Stage Renal Disease (ESRD) on Renal Replacement Therapy (RRT)\n- Recipient of deceased donor kidney transplant\n- Urine output less than 0.5 mL/kg/h before transplant\n- Patient consents to the study\n- Patient is not allergic to furosemide or sulfa\n- English or Spanish speaking patient\n- Patient is oliguric or anuric in the first 6 hours post kidney transplant\n\nAssessment of Eligibility:\n- The patient is a 6-month-old infant, which does not meet the age requirement of \u2265 18 years.\n- There is no information suggesting that the patient has undergone a kidney transplant or has ESRD. The surgery mentioned is not specified as a kidney transplant.\n- The patient has low urine output, but this is post-major surgery, and there is no indication this was a kidney transplant.\n- No information is provided about the patient's ability to consent, language abilities, or allergies to furosemide or sulfa.\n\nGiven the patient's age and lack of information suggesting that they are a kidney transplant recipient with ESRD, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient is not eligible.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "618": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient does not meet the eligibility requirements for the clinical trial.\n\nThe patient is a 6-month-old male infant presenting with low urine output, generalized edema, and abnormal laboratory findings consistent with acute kidney injury post major surgery. This clinical presentation is not related to the focus of the clinical trial.\n\nThe clinical trial is specifically looking for patients undergoing flexible cystoscopy due to hematuria or a previous diagnosis of non-muscle invasive bladder cancer (NMIBC). The patient's age and clinical situation (post-operative pediatric patient with acute kidney injury) do not match the inclusion criteria, which are clearly targeted at an adult population with hematuria or a history of NMIBC.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "619": {
        "output": "Based on the provided patient note and the clinical trial information, we can determine the patient's eligibility for the trial by comparing the patient's characteristics and condition with the inclusion criteria of the clinical trial.\n\nPatient Note Summary:\n- 6-month-old male infant\n- Post-major surgery\n- Oliguria (urine output < 0.2 mL/kg/hr)\n- Generalized edema\n- Blood pressure 115/80 mm Hg\n- Pulse 141/min\n- Respiratory rate 18/min\n- Blood urea nitrogen 33 mg/dL\n- Serum creatinine 1.3 mg/dL\n- Urinalysis: Specific gravity 1.017, 1 WBC/HPF, 18 RBCs/HPF, 5 granular casts/HPF\n- Fractional excretion of sodium 3.3%\n\nClinical Trial Summary:\n- Title: Algorithm for Oliguria in Septic Shock\n- Focus: Acute Kidney Injury (AKI) in critically ill patients with shock, oliguria, and intervention with a goal-directed ultrasonographic protocol\n- Sample: Adult patients\n- Inclusion Criteria: Critically ill, adult patients with acute oliguric renal failure within 6 hours of presentation\n\nThe key inclusion criteria for the clinical trial are being critically ill, an adult patient with acute oliguric renal failure, and presentation within 6 hours. The patient described in the note does not meet the age criterion, as he is a 6-month-old infant, and the trial specifically states \"adult patients.\"\n\nTherefore, the patient is not eligible for the clinical trial based on the age criterion alone.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "620": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the 6-month-old male infant would not be eligible for the trial which is focused on old patients undergoing orthopaedic surgery. The patient does not meet the age criteria, nor the clinical scenario as he is post-major surgery, not specifically orthopaedic surgery, and the trial is looking for old patients with normal renal function.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "621": {
        "output": "Based on the provided patient note, the 6-month-old male infant has recently undergone major surgery and is experiencing a low urine output with generalized edema. There are no indications in the note that the infant has been diagnosed with pyloric stenosis or that the infant will undergo pyloromyotomy.\n\nThe clinical trial in question is focused on assessing optimal postoperative feeding regimens following pyloromyotomy, and the inclusion criteria specify that subjects must be infants with a diagnosis of pyloric stenosis who will undergo pyloromyotomy.\n\nSince the infant in the patient note does not fit the inclusion criteria of having a diagnosis of pyloric stenosis and there is no mention of an upcoming pyloromyotomy procedure, the infant would not be eligible for this specific clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "622": {
        "output": "Based on the information provided, the 6-month-old male infant appears to meet the inclusion criteria for the clinical trial titled \"Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates.\" The trial is focused on neonates admitted to NICU who develop acute kidney injury and the patient note indicates that the infant has signs consistent with AKI (low urine output, generalized edema, elevated blood urea nitrogen, and serum creatinine levels). Additionally, the infant would have received intravenous fluids post-surgery, likely for more than 48 hours, which fits the second inclusion criterion.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 0
    },
    "623": {
        "output": "The patient note describes a 6-month-old male infant with low urine output, generalized edema, and elevated blood urea nitrogen and serum creatinine levels. This suggests the infant is experiencing some form of renal impairment, possibly acute kidney injury (AKI), following major surgery.\n\nThe clinical trial in question is the REMEDIAL III trial, focused on the prevention of contrast-induced acute kidney injury (CI-AKI) in patients with pre-existing chronic kidney disease (CKD) who are undergoing imaging procedures that require contrast media. The trial is comparing two different hydration strategies to prevent CI-AKI.\n\nTo determine the patient's eligibility for this clinical trial, we need to compare the patient's characteristics to the trial's inclusion criteria:\n\nInclusion criteria for the trial:\n- Patients with chronic kidney disease (CKD) scheduled for coronary and/or peripheral angiography and/or angioplasty\n- An estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m^2\n- High risk for CI-AKI according to Mehran's score \u226511 and/or Gurm's score >7\n\nThe patient's note does not indicate that the infant has chronic kidney disease, nor is the infant scheduled for coronary or peripheral angiography/angioplasty procedures. The patient's eGFR is not provided, but given the age and the current medical problem (post-surgery), it is likely not a chronic condition but an acute one. Mehran's score and Gurm's score are specific to adults undergoing procedures with contrast media and do not apply to this infant.\n\nBased on the provided information, this 6-month-old infant does not meet the inclusion criteria for the REMEDIAL III trial, primarily because he does not have chronic kidney disease, is not scheduled for a procedure that involves contrast media, and is not within the age range typically studied for these scores or interventions.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "624": {
        "output": "Based on the information provided, the patient is a 6-month-old male infant, which fits within the age range specified in the inclusion criteria (1-12 months). The patient has recently undergone major surgery, but it is not specified whether this surgery is related to cataract surgery. However, since the inclusion criteria specifically mention infants undergoing elective cataract surgery, and there is no mention of the infant having cataracts or requiring cataract surgery, it is unlikely that this patient would be eligible for the trial focused on postoperative analgesia in infantile cataract surgery.\n\nThe patient's current condition involves low urine output and generalized edema, suggesting a focus on renal function rather than ophthalmic issues, which are not relevant to the clinical trial's focus on analgesia for cataract surgery.\n\nAdditionally, there is no mention of the infant's ASA physical status grade, which is a requirement for inclusion. Without this information, we cannot confirm that the patient meets the criteria of ASA physical status grade I or II.\n\nGiven the information provided, it is clear that the patient does not meet the specific requirements of the clinical trial in question. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "625": {
        "output": "",
        "label": 0
    },
    "626": {
        "output": "",
        "label": 0
    },
    "627": {
        "output": "Based on the information provided:\n\nPatient Note:\n- A 6-month-old male infant with post-surgical oliguria, generalized edema, and abnormal laboratory findings suggestive of kidney dysfunction or injury.\n\nClinical Trial:\n- The trial is focused on patients with bladder cancer in a surveillance setting, using blue light cystoscopy with Cysview.\n- Inclusion criteria specify patients with histologically confirmed bladder cancer at their first surveillance cystoscopy, with a history of multiple tumors, recurrent tumors, or high-grade tumors.\n\nAssessment:\n- The patient in the note is an infant with no mention of bladder cancer or any surveillance cystoscopy, let alone a histologically confirmed tumor.\n- The patient's age and condition do not match the inclusion criteria of the clinical trial, which is specifically for patients with a history of bladder cancer.\n\nBased on this information, it's clear that the patient does not meet the inclusion criteria for the clinical trial in question.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "628": {
        "output": "",
        "label": 1
    },
    "629": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial in question, we need to match the patient characteristics and history with the inclusion criteria of the trial.\n\nPatient Note Analysis:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- Difficulty swallowing that progressed from solids to liquids\n- Weight loss of 25 pounds\n- Obstruction felt at the lower end of his sternum\n\nClinical Trial Inclusion Criteria Analysis:\n- Age: 18 and over (Patient is 52 years old, so meets this criterion)\n- Histologically confirmed epidermoid carcinoma or adenocarcinoma of the esophagus (The patient's note does not confirm a diagnosis of esophageal cancer; further investigation is needed to determine if the dysphagia is due to epidermoid carcinoma or adenocarcinoma of the esophagus)\n- Disease eligible for potentially curative radiotherapy (Not confirmed from the patient note)\n- Performance status: Karnofsky 60-100% (Not specified in the patient note)\n- Adequate hematopoietic, hepatic, renal, and cardiovascular function (Not specified in the patient note)\n- No severe uncontrolled diabetes, uncontrolled infection, or other medical condition precluding treatment (The patient note does not indicate any of these conditions)\n- No mental status abnormality precluding comprehension or compliance with treatment (Not specified in the patient note)\n- No active cancer at another primary site (Not specified in the patient note)\n- No prior chemotherapy or radiotherapy (The patient note does not indicate any prior chemotherapy or radiotherapy)\n\nGiven the available information, the patient shows signs that could be consistent with cancer of the esophagus, such as progressive dysphagia and significant weight loss. However, without a confirmed diagnosis of epidermoid carcinoma or adenocarcinoma of the esophagus, as well as other necessary medical information, we cannot definitively determine eligibility for the clinical trial.\n\nTherefore, the patient should undergo further investigation to confirm the diagnosis and to assess other health parameters as per the trial's inclusion criteria. Only after obtaining a confirmed diagnosis and additional medical information can we properly assess the patient's eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "630": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. These symptoms are highly suggestive of esophageal cancer, although the note does not provide a specific diagnosis or staging.\n\nThe clinical trial in question is targeting patients with stage II or III esophageal squamous cell cancer that is stage T2-3 Nx M0. The inclusion criteria specify that the cancer must be histologically confirmed and that there should be no prior chemotherapy or radiotherapy.\n\nSince the patient note does not confirm a diagnosis of esophageal squamous cell cancer, nor does it provide staging information, it is uncertain whether this patient's condition matches the trial's inclusion criteria. Furthermore, the note does not mention whether the patient has had any prior treatments which would also affect eligibility.\n\nBased on the information at hand, the assessment of eligibility for this clinical trial would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.\n\nThis cautious approach is due to the absence of key diagnostic information and treatment history which are necessary to determine the patient's eligibility with certainty. Further investigation, such as a biopsy, would be needed to confirm the diagnosis and stage of cancer, as well as to determine any previous treatments before a definite referral could be made.",
        "label": 1
    },
    "631": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. These symptoms suggest that the patient may have esophageal cancer, but the note does not confirm a diagnosis of esophageal cancer nor does it mention any biopsy or histological confirmation.\n\nThe clinical trial in question is looking for patients with histologically confirmed esophageal or non-small cell lung carcinoma that is considered acceptable for curative esophageal resection or locally advanced lung cancer (Stages IA-IIIB, T(any)N(any)M0) without pleural effusion. The patient must be a candidate for induction chemotherapy followed by surgical resection.\n\nThe patient in the note does not have a confirmed diagnosis, which is a key inclusion criterion for the trial. However, the symptoms described are highly suggestive of esophageal carcinoma, and if this were confirmed with a biopsy, the patient could potentially be a candidate for the trial.\n\nGiven that we do not have confirmation of a histological diagnosis or information on whether the patient is considered acceptable for curative resection or if he is a candidate for induction chemotherapy followed by surgical resection, we cannot definitively assess his eligibility for the trial.\n\nTherefore, the most appropriate response would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "632": {
        "output": "",
        "label": 1
    },
    "633": {
        "output": "The patient note describes a 52-year-old African American man with a history of heavy smoking and drinking who is experiencing progressive dysphagia. He has noticed difficulty swallowing that has progressed from solids to liquids and has lost 25 pounds due to this condition.\n\nThe clinical trial in question is focused on smoking cessation or weight control programs. The inclusion criteria for the smoking cessation studies are:\n- between 18 and 60 years old,\n- a minimum 2-year history of smoking,\n- a current level of smoking > 10 cigarettes per day,\n- and agreement to participate in the study.\n\nThe patient fits the age range and has a history of heavy smoking, which likely indicates he meets the minimum 2-year history of smoking and the current level of smoking > 10 cigarettes per day. However, there is no direct information about the precise number of cigarettes the patient smokes per day, or if the patient agrees to participate in the study.\n\nThe exclusion criteria mention that smokers and overweight persons would be excluded if currently being treated by a physician for a serious physical or psychological disorder, such as heart disease, cancer, depression, etc. The patient's dysphagia and significant weight loss could be symptoms of a serious underlying condition, potentially cancer, given his history of heavy smoking and drinking, which are risk factors for esophageal cancer. This suspicion would need to be confirmed with further medical investigation.\n\nSince the patient's medical condition isn't clearly defined as serious in the note, but there is a potential for an underlying serious condition, this might warrant further investigation before determining eligibility.\n\nBased on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "634": {
        "output": "The patient note describes a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. The patient has noted difficulty swallowing that has progressed from solids to liquids and has localized the obstruction sensation to the lower end of his sternum. The patient has lost a significant amount of weight, which may suggest advanced disease.\n\nThe clinical trial is looking for patients with advanced oesophageal cancer to compare the treatment of gullet cancer with radiotherapy alone versus radiotherapy with the addition of chemotherapy. The trial's aim is to assess the relief of dysphagia and quality of life improvements.\n\nTo determine the patient's eligibility for this clinical trial, we need to compare the patient's condition with the inclusion criteria:\n\n1. Biopsy proven Carcinoma of the oesophagus: The patient note does not mention a biopsy or a confirmed diagnosis of carcinoma of the oesophagus.\n2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness: The patient note suggests advanced disease due to progressive dysphagia and weight loss, but without more information on the staging or presence of metastases, we cannot confirm this criterion.\n3. Symptomatic patients with dysphagia scores of \u2265 1: The patient has dysphagia, which has progressed from solids to liquids, indicating a dysphagia score of at least 1.\n4. Performance status ECOG \u2264 2: The patient's performance status is not mentioned, but given the progressive nature of his symptoms, it's possible he falls within this range.\n5. Patients must begin treatment within 2 weeks of randomization: This criterion is contingent upon acceptance into the trial.\n6. Patient is at least 18 years old: The patient is 52 years old.\n7. Adequate haematological function to undergo chemotherapy: The patient's haematological function is not mentioned.\n8. Adequate renal function: The patient's renal function is not mentioned.\n9. Patients capable of childbearing are using adequate contraception: Not applicable to this patient.\n10. Written informed consent of patient: This is obtainable if the patient agrees to participate.\n\nBased on the provided information, the patient appears to meet some of the inclusion criteria (age, dysphagia symptoms). However, there are several key pieces of information missing that are crucial to determine his eligibility fully, such as a confirmed diagnosis of carcinoma of the oesophagus through biopsy, performance status, haematological and renal function tests, and whether he is not a candidate for radical treatment. Therefore, further investigation is needed to determine if the patient is suitable for this trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "635": {
        "output": "Based on the inclusion criteria for the clinical trial, the 52-year-old African American man with a history of progressive dysphagia fits the profile of a potential participant. The criteria require patients aged 18-90 presenting with dysphagia or food impaction, and the ability to undergo esophagogastroduodenoscopy (EGD) with biopsies. There is no mention of exclusion due to a history of smoking and drinking, and the patient does not have significant cardiopulmonary disease or other contraindications to EGD as far as the information provided.\n\nGiven the information provided in the patient note, this patient meets the age requirement, is experiencing dysphagia, and there is no indication that he has contraindications to undergoing EGD and biopsies. Therefore, he appears to be eligible for the study.\n\nTrial-level eligibility: 2) Highly likely to refer this patient for this clinical trial.",
        "label": 2
    },
    "636": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Volitional Swallowing in Stroke Patients With Chronic Dysphagia,\" we need to compare the patient's characteristics and condition with the inclusion and exclusion criteria provided for the study.\n\nPatient Note Analysis:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He experiences progressive dysphagia (difficulty swallowing) that has worsened over time.\n- The patient has lost 25 pounds, possibly due to his difficulty in swallowing.\n- There is no mention of a stroke or brain injury, which is pertinent to the clinical trial's inclusion criteria.\n\nClinical Trial Inclusion Criteria Analysis:\n- Age between 20 to 90 years old.\n- History of brain injury (no specific localization or type required).\n- Evidence of pharyngeal phase dysphagia following brain injury that places the patient at risk for aspiration.\n- Duration of dysphagia of 4 months or greater post-onset of brain injury.\n- MMSE score greater than or equal to 23, indicating adequate cognitive skills.\n- Stable medical status.\n\nClinical Trial Exclusion Criteria Analysis:\n- History of epileptic seizure.\n- Certain cardiac conditions or pacemaker in place if participating in TMS.\n- History of progressive neurodegenerative disorders.\n- History of malignant brain tumor.\n- Severe oral phase swallowing deficits.\n- Esophageal motility disorder.\n- Current psychiatric disorder other than depression.\n- Presence of metal in the body incompatible with MRI/TMS.\n- Inability to coordinate button or switch press with swallow.\n\nBased on the patient note, the patient does not meet the main inclusion criteria for the study, which requires a history of brain injury and evidence of pharyngeal phase dysphagia due to brain injury. The patient's dysphagia could be related to other causes, such as esophageal conditions often associated with a history of heavy smoking and drinking, and not necessarily due to a brain injury.\n\nSince the patient's condition does not fit the criteria of chronic dysphagia due to brain injury, and there is no mention of a stroke or other brain injury, the patient would not be eligible for this clinical trial. Therefore, the assessment of eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "637": {
        "output": "The patient described in the note is a 52-year-old African American man with a history of progressive dysphagia and significant weight loss (25 pounds). \n\nComparing this patient's characteristics with the inclusion criteria of the clinical trial, which is aimed at evaluating the effect of a medicine on gastric functions in healthy volunteers, we can see the following discrepancies:\n\n1. Age: The trial is seeking participants between 18-45 years old, and the patient is 52 years old.\n2. Gender: The trial specifies non-pregnant, non-breastfeeding females, and the patient is male.\n3. No alarm indicators: One of the exclusion criteria for the trial is no alarm indicators like weight loss of more than 7kg, but the patient has lost 25 pounds, which is an alarm indicator for potential serious underlying conditions.\n4. Health status: The patient's history of heavy smoking and drinking, along with the progressive dysphagia, suggests that he may not be a \"healthy volunteer\" as required by the study.\n\nGiven these points, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the patient would not be referred for this trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "638": {
        "output": "The patient is a 52-year-old African American man with progressive dysphagia, which has worsened from difficulty swallowing meat to including other solid foods, soft foods, and then liquids. He has also experienced significant weight loss. These symptoms are indicative of esophageal obstruction, possibly due to esophageal cancer, although no specific diagnosis is mentioned in the patient note.\n\nThe clinical trial in question is an observational study looking at the risks and burden of mucositis in patients receiving chemotherapy and radiation therapy treatment for various cancer types.\n\nThe inclusion criteria for the clinical trial are:\n\n1. 18 years or older\n2. Ability to understand the protocol and willing to provide written informed consent\n3. Membership in one of the following sub-cohorts:\n   - Histologically proven oral cavity or oropharyngeal cancers planned to receive radiation therapy +/- chemotherapy\n   - Histologically proven laryngeal or hypopharyngeal cancers planned to receive radiation +/- chemotherapy\n   - Histologically proven adenocarcinoma of the colon or rectum planned to receive chemotherapy cycles\n   - Adenocarcinoma of the breast planned to receive chemotherapy cycles\n   - Histologically proven adenocarcinoma (any primary) planned to receive chemotherapy cycles\n   - Stage 3A or 3B non-small cell lung cancers planned to receive radiation +/- chemotherapy\n   - B-cell Non-Hodgkin's lymphoma (NHL) planned to receive chemotherapy cycles\n\nThe patient's symptoms are suggestive of an esophageal cancer, but there is no information provided about a histological diagnosis or planned treatment that matches the cancer types specified in the inclusion criteria. Without a matching diagnosis and planned treatment regimen, the patient does not meet the necessary criteria to be included in the mucositis study.\n\nTherefore, based on the information provided, the patient does not fit the trial's inclusion criteria as there is no indication of the patient having any of the specified cancers or planned treatments.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "639": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial, let's assess the patient's eligibility for the trial:\n\nPatient Note Assessment:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He describes progressive dysphagia (difficulty swallowing) that has progressed from meats to liquids.\n- The patient has lost 25 pounds, presumably due to his difficulty in swallowing.\n- There is no mention of any cancer diagnosis, stage, or treatment in the patient note.\n\nClinical Trial Inclusion Criteria Assessment:\n- Patients with either: \n  a) histologically proven stage I, II, IIIa NSCLC who have undergone a complete surgical resection of the primary tumor OR \n  b) stage I or II HNSCC who have undergone definitive local treatment (surgery or radiation therapy).\n- Definitive local treatment \u2264 12 months prior to trial enrollment for HNSCC patients. For NSCLC patients, surgery \u2264 12 months prior to trial enrollment.\n- No evidence of residual cancer.\n- Age \u2265 18 years.\n- Performance status of 0-2 (Zubrod).\n- No contraindications for undergoing bronchoscopy.\n- No active pulmonary infections.\n- Required blood levels (granulocyte count, platelet count, total bilirubin, creatinine).\n- Consent to bronchoscopy and endobronchial biopsy for biomarker studies.\n- Smoking history of at least 10 pack years. May be current or former smoker.\n- Legally capable of providing consent.\n- For HNSCC patients only: No contraindications for undergoing laryngoscopy.\n\nThe provided patient note does not indicate that the patient has been diagnosed with NSCLC or HNSCC, nor that they have undergone any treatment for such conditions. The patient's primary complaint is dysphagia, which can be associated with esophageal cancer or another non-cancerous condition, but there is no specific mention of lung or head and neck cancer, which are the target diseases for the clinical trial.\n\nGiven the lack of information regarding a cancer diagnosis or treatment, it would not be appropriate to refer this patient to the clinical trial based on the information provided. The patient does not meet the specific inclusion criteria relating to NSCLC or HNSCC diagnosis and treatment history.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "640": {
        "output": "To determine the eligibility of the patient for the clinical trial, we need to compare the patient's characteristics and condition to the inclusion criteria of the study.\n\nThe inclusion criteria for the clinical trial are as follows:\n1. 18 years or older\n2. Diagnosed with head and neck cancer including the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid\n3. All histological types of cancer\n4. All tumor stages according to American Joint Committee for Cancer (AJCC) Staging\n5. All forms of RT including standard or investigational and/or concurrent standard or investigational chemotherapy for head and neck cancers\n6. Alert and mentally competent\n7. English speaking\n\nThe patient note contains the following information about the patient:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, soft foods, and liquids\n- Sensation of obstruction at the lower end of the sternum\n- Significant weight loss (25 pounds)\n\nWhile the patient has symptoms that could be suggestive of a head or neck cancer (e.g., progressive dysphagia, significant weight loss), there is no explicit diagnosis of head or neck cancer mentioned in the patient note. Before this patient can be considered for the clinical trial, a diagnosis that fits the inclusion criteria (such as cancer of the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, or thyroid) would need to be confirmed. \n\nGiven the current information:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "641": {
        "output": "Based on the information provided:\n\nThe patient is a 52-year-old African American man with progressive dysphagia, initially with solids and now including liquids. He reports obstruction at the lower end of his sternum and has experienced significant weight loss.\n\nThe clinical trial aims to assess the analgesic effectiveness of celecoxib in patients with painful pharyngitis (sore throat).\n\nThe inclusion criteria for the clinical trial are:\n- The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis.\n- The patient is willing to abstain from taking anything by mouth except trial medication during specified times.\n\nThe patient described in the note does not have a diagnosis of pharyngitis; rather, he has dysphagia, which is difficulty swallowing and may indicate an esophageal disorder rather than a sore throat. Since the patient's symptoms and condition do not match the target condition for the clinical trial, which is pharyngitis, this patient would not meet the inclusion criteria for the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "642": {
        "output": "The patient described in the note has progressive dysphagia with a history of heavy smoking and drinking, and has experienced significant weight loss. There is no mention of ovarian cancer or primary peritoneal cancer, which are the target diseases for the clinical trial.\n\nThe clinical trial in question is specifically for patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer who have been previously treated with platinum and taxol compounds. The patient described does not meet the disease criteria as there is no mention of ovarian or primary peritoneal cancer. Therefore, they are not eligible for this trial based on the information provided.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "643": {
        "output": "Given the patient note, the patient is a 52-year-old African American man with a history of heavy smoking and drinking, experiencing progressive dysphagia which has worsened over time to include difficulty swallowing solids, soft foods, and liquids. The patient notes an obstruction at the lower end of his sternum and has lost a total of 25 pounds.\n\nNow, let's compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\n1. The patient is 52 years old, which satisfies the age criterion of being 18 years of age or older.\n2. The patient is able to communicate his symptoms, which likely means he can provide written informed consent.\n3. The clinical trial is looking for patients with a diagnosis of head and neck malignancy involving an oral cavity site. The patient's symptoms suggest a possible malignancy, but the location is not specified as an oral cavity site, and the symptoms could potentially indicate an esophageal rather than an oral cavity cancer.\n4. The patient has not been described as having undergone any previous treatment for his condition, which fits the criteria of no previous treatment.\n5. The trial requires the current treatment plan to include a surgical intervention, but we don't have information about the treatment plan for this patient.\n6. The patient note does not specify whether the patient is English speaking, but if the patient interaction took place in an English-speaking country, it is likely that he speaks English.\n\nThe patient appears to potentially meet some of the inclusion criteria. However, there are uncertainties regarding the exact diagnosis, the treatment plan, and the patient's ability to speak English. This patient might be eligible for the trial if further investigation confirms the diagnosis of a malignancy involving an oral cavity site and if his treatment plan includes surgery. \n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "644": {
        "output": "",
        "label": 1
    },
    "645": {
        "output": "The patient note describes a 52-year-old African American man with a history of heavy smoking and drinking, who has progressive dysphagia to solids and liquids, with weight loss and localization of the obstruction at the lower end of his sternum. This clinical presentation is suggestive of esophageal pathology, which may include esophageal cancer given his risk factors; however, there is no specific mention of a cancer diagnosis or staging in the provided note.\n\nThe clinical trial in question is studying the effects of intensity-modulated radiotherapy (IMRT) on swallowing in patients with previously untreated Stage III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx, or larynx, or unknown primary.\n\nBased on the information provided, the patient does not meet the inclusion criteria as stated for the clinical trial. The inclusion criteria specifically mention stages III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx or larynx, or unknown primary. The patient's symptoms are suggestive of an esophageal pathology, and there is no indication that he has been diagnosed with the type of cancer specified in the trial's inclusion criteria.\n\nTherefore, based on the available patient note and the clinical trial inclusion criteria:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 1
    },
    "646": {
        "output": "",
        "label": 0
    },
    "647": {
        "output": "Considering the information provided in the patient note and the clinical trial inclusion criteria, the patient described is a 52-year-old African American man with progressive dysphagia associated with weight loss. This patient's medical issues seem related to his swallowing difficulties, potentially due to an underlying esophageal condition.\n\nThe clinical trial in question is focused on smoking cessation interventions in dental clinic smokers. The inclusion criteria for the trial are:\n\n1. Patient seeking routine dental care at NYU College of Dentistry and meets medical clearance for routine care.\n2. Active smokers (active smoking as self-reported regular use of at least 10 cigarettes per day).\n3. Able to provide a telephone number or collateral contact information where they can be reached over the subsequent 12 months.\n4. Fluent in English or Spanish.\n\nThe patient note indicates a history of heavy smoking, which suggests that the patient might be an active smoker, fitting one of the inclusion criteria. However, there is no mention of the patient seeking dental care or being able to speak English or Spanish. To determine if the patient meets all inclusion criteria, further investigation is required to confirm:\n\n- If the patient is seeking routine dental care at NYU College of Dentistry.\n- If the patient meets the medical clearance for routine dental care.\n- If the patient is currently smoking at least 10 cigarettes per day.\n- If the patient is fluent in English or Spanish.\n\nBased on the available information and the need to confirm these points, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "648": {
        "output": "To determine the trial-level eligibility of the patient for the clinical trial, we need to assess the patient's characteristics against the inclusion and exclusion criteria of the trial.\n\nPatient Characteristics:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Difficulty swallowing solid foods and liquids\n- Weight loss of 25 pounds\n- The obstruction point is felt at the lower end of his sternum\n- No explicit mention of cancer diagnosis or stage\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx\n- No other histologic diagnosis than squamous cell carcinoma\n- Identifiable primary site\n- Locoregionally confined stage III (excluding T1-2, N1) or stage IV disease\n- No evidence of nodal disease below the clavicles or distant metastases (M0)\n- No stage IVC disease (stage IVB allowed)\n- Appropriate for non-operative management with curative intent\n- Resectable disease is not required\n- No primary cancer of the nasopharynx, paranasal sinus, or salivary gland\n- ECOG performance status 0-1\n- Adequate blood counts and organ function\n- Not pregnant or nursing, with a negative pregnancy test for females\n- Fertile patients must use effective contraception\n- No unstable/uncontrolled angina, clinically apparent jaundice, or active infection\n- No history of malignancy (with exceptions) unless disease-free for at least 5 years\n- No prior definitive surgery, radiotherapy, chemotherapy, immunotherapy, or EGF receptor inhibitors for this malignancy\n\nBased on the patient note, we do not have information regarding a confirmed histological diagnosis of squamous cell carcinoma or the stage of any cancer the patient may have. The symptoms described, such as progressive dysphagia and weight loss, could potentially be associated with head and neck cancer, but without a confirmed diagnosis and staging, we cannot definitively match the patient to the inclusion criteria.\n\nGiven the lack of explicit information on a cancer diagnosis and stage, we cannot determine with certainty that the patient would be eligible for the trial. The patient note does not provide enough details to satisfy the inclusion criteria that require histological confirmation and specific staging. Therefore, further investigation is needed to acquire more detailed patient information.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "649": {
        "output": "The patient in the provided note is a 52-year-old African American male with progressive dysphagia, significant weight loss, and a history of heavy smoking and drinking. While the note does not explicitly state a diagnosis of esophageal cancer, the symptoms described are highly suggestive of such a condition, particularly with the localization of the obstruction at the lower end of the sternum and the progressive difficulty swallowing various textures of food.\n\nThe clinical trial in question is focused on biological factors in predicting response to treatment in patients with esophageal cancer or rectal cancer who are planning to receive neoadjuvant treatment.\n\nThe inclusion criteria for the trial are:\n1. Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum.\n2. Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy.\n3. Not pregnant or nursing.\n4. No blood disorder.\n5. Not deprived of freedom or protected by law.\n\nBased on the patient note, the individual has not yet been confirmed to have esophageal cancer through histological examination, which is a key requirement for eligibility. Although the patient's symptoms strongly suggest esophageal cancer, without histological confirmation, we cannot assume the diagnosis. Furthermore, there is no information regarding the patient's treatment plan, specifically whether they are planning to receive neoadjuvant treatment.\n\nTherefore, the patient might be eligible for referral based on the strong clinical suspicion of esophageal cancer, but further investigation is required to confirm the diagnosis histologically and to ascertain the planned treatment approach. The patient would need a biopsy to confirm adenocarcinoma or squamous cell carcinoma of the esophagus and a treatment plan that includes neoadjuvant therapy to meet the trial's disease characteristics criteria.\n\nGiven the need for additional information, the assessment is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "650": {
        "output": "Based on the patient note provided, the 52-year-old African American man has progressive dysphagia and has experienced significant weight loss due to difficulty swallowing, which escalated from solids to liquids. The location of the obstruction is identified at the lower end of his sternum. This clinical presentation is suggestive of a possible esophageal disorder, which may include esophageal cancer or other structural abnormalities, and is not consistent with a sore throat.\n\nThe clinical trial in question is aimed at evaluating the efficacy of valdecoxib in patients with moderately to severely painful symptomatic sore throat. The inclusion criteria specify that the participants should have moderate to severe pain as measured by the Sore Throat Pain Intensity Scale (STPIS) on swallowing and meet certain criteria on the Tonsillo-Pharyngitis Score (TPS), among other things.\n\nSince the patient's primary complaint is progressive dysphagia with no mention of sore throat pain or related symptoms, he does not meet the inclusion criteria for the clinical trial, which is focused on sore throat pain and its treatment.\n\nTherefore, the patient's symptoms and history do not align with the focus of the clinical trial, and he would not be suitable for referral to this particular study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "651": {
        "output": "Based on the patient note provided:\n\nA 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.\n\nAnd the clinical trial's inclusion criteria:\n\nPatients with newly diagnosed, previously untreated squamous cell carcinoma of the head and neck (SCCHN) who are candidates for the molecular epidemiology study LAB00-062 of head and neck cancer.\nMust have the ability to understand and provide informed consent.\nPatients must be 18 years and older.\nAbility to read, write, and speak English.\nResident of the United States.\nAgrees to have tumor tissue, if available, tested for HPV. No additional biopsy will be requested.\n\nThe patient note does not mention a diagnosis of squamous cell carcinoma of the head and neck (SCCHN), nor does it specify whether the patient has been previously untreated for this condition. The symptoms described (progressive dysphagia, weight loss) could be indicative of a number of conditions, including head and neck cancers, but without a confirmed diagnosis stated in the patient note, we cannot reliably assess eligibility based on the trial's inclusion criteria.\n\nTherefore, based on the information provided in the patient note, we cannot conclude that the patient meets the specific inclusion criteria for the clinical trial. However, if the patient were to be diagnosed with SCCHN, they might become eligible. Thus, further investigation into the patient's medical condition would be necessary before making a referral.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "652": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 52-year-old African American man, which meets the age criterion (>18 years).\n- The patient has a history of heavy smoking and drinking.\n- The patient describes progressive dysphagia, which has worsened over time, indicating a possible esophageal obstruction.\n- He locates the obstruction at the lower end of his sternum and has experienced significant weight loss (25 pounds), which may suggest advanced disease.\n\nClinical Trial Inclusion Criteria:\n- 18 years of age and older (Patient meets this criterion).\n- Willing and able to provide informed consent (Unknown based on the patient note).\n- Willing to comply with follow-up requirements (Unknown based on the patient note).\n- Biopsy-confirmed esophageal cancer (adenocarcinoma or squamous cell carcinoma) in mid or distal esophagus (clinical stage 3 or less) (The patient's symptoms suggest esophageal cancer, but there is no confirmation of a biopsy in the note).\n- Indicated for chemotherapy and/or radiation therapy (Unknown based on the patient note).\n- Ability to dilate stricture to 15mm diameter at extent of disease evaluation (Unknown based on the patient note).\n- Placement of at least 18 x 23mm diameter and 120mm length PolyFlex stent (Unknown based on the patient note).\n\nThe patient's age fits the criteria, and his symptoms are suggestive of esophageal cancer, which is the disease targeted by the clinical trial. However, the patient note does not confirm a diagnosis of esophageal cancer through a biopsy, nor does it provide information about the clinical stage of the disease. Additionally, the patient's willingness and ability to consent, as well as compliance with follow-up, are not mentioned, and there's no information on the technical feasibility of stent placement or the patient's indication for chemotherapy and/or radiation therapy.\n\nTherefore, based on the information provided, we would consider referring this patient to this clinical trial upon further investigation to confirm the diagnosis and other missing details. \n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "653": {
        "output": "",
        "label": 0
    },
    "654": {
        "output": "",
        "label": 1
    },
    "655": {
        "output": "Based on the information provided, the patient is a 52-year-old African American man with a history of heavy smoking and drinking, who presents with progressive dysphagia that began several months ago. The dysphagia has progressed from difficulty swallowing meat to other solid foods, soft foods, and then liquids. The patient also reports weight loss of 25 pounds.\n\nThe clinical trial in question is targeting patients with advanced esophageal cancer, aiming to evaluate the effectiveness of a novel esophageal stent loaded with 125I seeds to relieve dysphagia and improve quality of life.\n\nThe inclusion criteria for the clinical trial are:\n1. Histologically confirmed primary cancer of the esophagus,\n2. Must be dysphagia caused by esophageal cancer,\n3. Without esophageal fistulas,\n4. Must be an inpatient,\n5. Life expectancy is over 6 months.\n\nWhile the patient note suggests the presence of dysphagia, there is no confirmation that the patient has esophageal cancer. A histological confirmation of primary cancer of the esophagus is necessary to satisfy the first inclusion criterion. Furthermore, there is no information provided about the presence of esophageal fistulas, whether the patient is an inpatient, or about their life expectancy.\n\nGiven the lack of specific information confirming the diagnosis of esophageal cancer and other inclusion criteria, I would consider this patient for the clinical trial upon further investigation to confirm the diagnosis and other eligibility requirements.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "656": {
        "output": "To determine the patient's eligibility for the clinical trial, let's assess the inclusion criteria against the patient's clinical presentation:\n\n1. Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction - The patient note does not mention a histological diagnosis, only symptoms suggestive of esophageal obstruction.\n2. Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region - There is no information provided on the staging of the patient's condition.\n3. Age >18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained - The patient is 52 years old, which meets the age criterion.\n4. Weight loss < 10% in 0.5 yr - The patient has experienced a significant weight loss of 25 pounds, but without knowing the patient's initial weight, it is not possible to assess if this meets the criterion.\n5. WHO performance status 0-1 - The performance status of the patient is not mentioned, but progressive dysphagia might indicate a performance status worse than 1.\n6. No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus - There is no mention of prior treatment, suggesting the patient has not had any.\n\nGiven the information available, the patient has progressive dysphagia, which is a symptom that could be associated with esophageal adenocarcinoma, but without histological confirmation or staging, we cannot conclusively determine eligibility. The significant weight loss is concerning and could potentially disqualify the patient depending on the patient's initial weight. The lack of detailed medical information requires further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "657": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer,\" we need to compare the patient's characteristics and history with the inclusion criteria of the trial.\n\nPatient characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids, weight loss of 25 pounds\n- Food obstruction sensation at the lower end of his sternum\n\nClinical trial inclusion criteria:\n- Adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus (requires histological proof)\n- Locally advanced disease (any T, N0 or N1, M0 or M1a)\n- No metastatic disease beyond specified in criteria\n- Inoperable disease OR surgery is contraindicated\n- ECOG performance status 0-2\n- Life expectancy \u2265 3 months\n- Adequate blood cell counts (ANC, platelet count, hemoglobin)\n- Adequate organ function (creatinine, total bilirubin, ALT/AST, prothrombin time)\n- Not pregnant or nursing, must use effective contraception\n- Sufficient caloric intake\n- No weight loss > 20% normal body weight within the past 3 months\n- No complete dysphagia\n- No exclusive requirement for parenteral nutrition\n- No prior treatment for esophageal cancer\n- No severe comorbidities that would preclude participation\n\nBased on the patient note, we cannot confirm if the patient has histologically proven carcinoma of the esophagus or the specific subtype. The patient does have dysphagia and weight loss, which are consistent with esophageal cancer symptoms, but the weight loss does not exceed the >20% threshold within the past 3 months as per the criteria. The trial also excludes patients with complete dysphagia, which our patient does not have since he can still swallow to some extent. The patient's history of no prior treatment for esophageal cancer is a match with the trial requirements.\n\nHowever, without further information on the histological diagnosis, stage of cancer, ECOG performance status, life expectancy, blood counts, organ function tests, and whether the disease is operable or not, we cannot definitively determine eligibility.\n\nGiven the available information, the patient's history suggests a possibility of esophageal cancer, but there is insufficient information to make a full assessment. Therefore, the patient should be considered for referral upon further investigation to confirm the diagnosis and other relevant clinical details.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "658": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nThe patient is:\n- A 52-year-old African American man\n- With a history of heavy smoking and drinking\n- Describes progressive dysphagia\n\nThe clinical trial is seeking:\n- Heavy smokers and/or heavy drinkers\n- Treatment-seeking smokers between the ages of 18 to 65 years\n- Individuals who smoke \u2265 10 cigarettes per day\n- Individuals with a Fagerstrom Test of Nicotine Dependence score > 3\n- Individuals with an Alcohol Use Disorders Identification Test (AUDIT) score > 8 for heavy drinkers or < 8 for social drinkers\n- Males who drink > 25 drinks per week for heavy drinkers or < 14 drinks per week for social drinkers\n- Individuals able to provide written informed consent\n\nExclusion criteria for heavy smokers/heavy drinkers include:\n- Any medical condition requiring immediate investigation or treatment\n- Beck Depression Inventory score >16\n- Insulin-dependent diabetes\n- Drinking > 70 standard alcoholic drinks per week for males\n- Pregnancy or lactation\n- Current DSM-IV Axis 1 psychiatric disorder\n- Regular use of any therapeutic or recreational psychoactive drug use during the last three months or other substance use disorder, with the exception of tobacco and alcohol\n\nBased on the patient note, the patient is a heavy smoker and drinker, which fits the inclusion criteria for heavy smokers/heavy drinkers. However, the patient note does not provide information on the Fagerstrom Test of Nicotine Dependence score, AUDIT score, exact number of cigarettes smoked per day, or exact number of alcoholic drinks consumed per week. There is also no information on whether the patient is seeking treatment for his smoking and drinking habits, or if any of the exclusion criteria apply to the patient.\n\nGiven the lack of detailed information about the patient's smoking and drinking habits, as well as missing information on other inclusion and exclusion criteria, further investigation would be necessary to determine the patient's eligibility for the clinical trial. Therefore, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "659": {
        "output": "",
        "label": 0
    },
    "660": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers,\" here are the key points to consider:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking.\n- The patient describes progressive dysphagia, which has worsened over several months.\n- He has experienced significant weight loss.\n\nClinical Trial Inclusion Criteria:\n- Adults > 45 years of age.\n- Non-smoking controls >50 years of age (not applicable to this patient as he is a heavy smoker).\n- Current smokers with > 30 pack years, no airflow obstruction (FEV1 > 90% predicted), or lung cancer, >50 years of age.\n- No prior history of head and neck or bronchogenic carcinoma.\n- Patients must understand the investigational nature of this study and sign an informed consent.\n\nAssessment:\n- The patient is over 45 years of age, which meets the age criterion.\n- The patient has a history of heavy smoking, which potentially meets the pack-year criterion, though this is not quantified in the patient note.\n- There is no mention of the patient having airflow obstruction or lung cancer, which aligns with the study's criteria.\n- There is no indication of a prior history of head and neck or bronchogenic carcinoma in the patient note.\n\nGiven that the patient's smoking history likely meets the > 30 pack years requirement, and assuming the patient does not have airflow obstruction or lung cancer, he may be a candidate for the study. However, further information would be needed to fully confirm eligibility (e.g., exact pack years, confirmation of no airflow obstruction or lung cancer). Therefore, the patient could potentially be eligible, but this determination would require additional information and assessments.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "661": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, the patient is a 52-year-old African American man with a history of progressive dysphagia, weight loss, and difficulty swallowing, which are symptoms that could be associated with esophageal cancer. However, there is no direct mention of a diagnosis of adenocarcinoma of the esophagus or any treatment, including cisplatin-based treatment, that the patient has received.\n\nThe inclusion criteria for the clinical trial specify that the patient must have a diagnosis of adenocarcinoma of the esophagus, be at any stage I-IV of the disease, and must have received cisplatin-based treatment on clinical trial ECOG-1201.\n\nGiven that the patient note does not confirm a diagnosis of adenocarcinoma of the esophagus or any treatment received, we cannot definitively determine the patient's eligibility for the clinical trial without additional information. Therefore, the patient may warrant further investigation to confirm the diagnosis and treatment history before considering referral to the trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "662": {
        "output": "To determine the trial-level eligibility of the patient for the given clinical trial, we must compare the patient's characteristics and medical history with the inclusion criteria of the clinical trial.\n\nPatient Characteristics:\n- Age: 52 years old\n- Gender: Male\n- Medical History: Progressive dysphagia, heavy smoking and drinking, significant weight loss, difficulty swallowing which has progressed from solids to liquids, and localization of obstruction at the lower end of his sternum.\n\nClinical Trial Inclusion Criteria for Inoculated Volunteers:\n- Healthy 18-54 years old (male or female) with no chronic medical conditions except well-controlled hypertension\n- Availability for study visits over the next 1 month\n- Normal hemoglobin, white blood cell count, creatinine, alanine aminotransferase (ALT), platelet count\n- Negative for HIV, hepatitis C, and hepatitis B\n- Negative urine protein and glucose by dipstick\n- Willingness to be housed in the clinical research unit for the first 3 nights of the inoculation period\n- For females of childbearing potential, a negative pregnancy test and agreement to use acceptable contraception\n\nAssessment:\nThe patient's age falls within the specified range (18-54 years old). However, the patient does not meet the criterion of being in good health, as progressive dysphagia and significant weight loss are indicative of underlying medical issues, which are likely related to his history of heavy smoking and drinking. These symptoms suggest that the patient could have a serious condition such as esophageal cancer or another esophageal disorder, which would not classify him as a healthy volunteer. Additionally, the trial requires that the volunteers have no chronic medical conditions (with the exception of well-controlled hypertension), which does not align with the patient's current health status.\n\nSince the patient does not meet the health status criteria of being a healthy individual without chronic medical conditions, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "663": {
        "output": "Based on the provided patient note and the clinical trial's inclusion criteria, let's assess the patient's eligibility for the clinical trial:\n\nPatient Note Review:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- He experiences progressive dysphagia and has lost 25 pounds.\n\nClinical Trial Inclusion Criteria Review:\n- ASA (American Society of Anesthesiologists) physical status I-II.\n- Aged between 20 and 70 years.\n- Scheduled for elective laparoscopic cholecystectomy under general anesthesia with endotracheal intubation.\n\nComparison:\n- The patient's age (52 years) falls within the trial's age range of 20 to 70 years.\n- The trial requires patients to have an ASA physical status of I-II, which typically denotes patients who are healthy or have only mild systemic disease. The patient's history of heavy smoking and drinking and significant weight loss due to progressive dysphagia may indicate a more severe systemic condition, which might not align with ASA I-II status. However, the ASA status itself is not explicitly stated in the patient note.\n- The patient's clinical presentation (progressive dysphagia and weight loss) does not suggest he is scheduled for an elective laparoscopic cholecystectomy, which is a surgery for gallbladder removal. Instead, his symptoms suggest a possible esophageal disorder.\n\nGiven that the patient does not seem to be scheduled for the specific procedure required by the trial (elective laparoscopic cholecystectomy), and there is no mention of the need for general anesthesia with endotracheal intubation for his current condition, it is unlikely that this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "664": {
        "output": "Based on the information provided in the patient note and the inclusion criteria of the clinical trial, let's analyze the patient's eligibility:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking\n- Progressive dysphagia\n- Difficulty swallowing various types of food\n- Significant weight loss\n\nClinical Trial:\n- Efficacy and Safety of Varenicline Among HIV-infected Patients\n- Inclusion Criteria:\n  - HIV-infected patients\n  - Adults\n  - Regular smokers (at least 10 cigarettes a day during the last year)\n  - Motivated to stop smoking\n  - Followed in one of the participating clinical ward\n  - Signed written informed consent\n\nThe patient in the note is a heavy smoker, which aligns with the criteria for smoking habits. However, there is no mention of the patient being HIV-infected, which is a primary inclusion criterion for the clinical trial. Without confirmation that the patient is HIV-positive, we cannot assume eligibility based on the provided information.\n\nTherefore, the patient does not meet the primary inclusion criterion of being HIV-infected as specified by the trial. The trial is looking specifically for HIV-infected patients who are regular smokers and who are motivated to stop smoking.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "665": {
        "output": "Based on the patient note provided, the 52-year-old African American man with a history of progressive dysphagia and significant weight loss due to difficulty swallowing is not a candidate for the clinical trial for several reasons:\n\n1. The clinical trial is assessing the safety and tolerability of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in healthy volunteers. The patient described does not meet the criteria for \"general good health\" due to his significant medical symptoms, which are indicative of an underlying health condition.\n2. The age criteria for the clinical trial is 18-50 years, inclusive, and the patient is 52 years old, which exceeds the upper age limit.\n3. The trial requires the ability to ingest the study drug dissolved in cow's milk or soy milk orally. Given the patient's progressive dysphagia, even to liquids, he may not be able to ingest the study drug as required.\n\nBecause the patient does not meet the age and health criteria and likely cannot ingest the study drug orally due to his dysphagia, he is not suitable for referral to this clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "666": {
        "output": "Based on the patient note, the 52-year-old African American man presents with progressive dysphagia and significant weight loss. However, there is no mention of a diagnosis of non-small cell lung cancer (NSCLC), which is a requirement for the clinical trial in question. Despite the patient's history of heavy smoking, which is a risk factor for NSCLC, there is no information provided that confirms he has been diagnosed with NSCLC, particularly at an advanced stage (IIIB/IV), nor is there any mention of the availability of tumor tissue required for the study.\n\nGiven the lack of information confirming an NSCLC diagnosis and stage, as well as the absence of details on the availability of tumor tissue for analysis, this patient does not meet the clearly stated inclusion criteria for the clinical trial focused on K-RAS oncogene mutation in patients with advanced NSCLC associated with exposure to wood smoke and tobacco smoking.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "667": {
        "output": "Given the patient note, the patient is a 52-year-old African American man with a history of progressive dysphagia and significant weight loss. The clinical trial in question is investigating the effects of dexamethasone on post-operative sore throat in patients undergoing outpatient laparoscopic gynecologic surgery.\n\nThe inclusion criteria for the trial specify:\n\n1. Female patients undergoing outpatient laparoscopic gynecologic surgery\n2. ASA PS I and II\n3. Age between 18 and 64 years\n4. Fluent in English\n\nThe patient described in the note is a male with swallowing issues, which is unrelated to the focus of the clinical trial on post-operative sore throat in female patients after gynecologic surgery. Moreover, he does not meet the gender requirement which is a critical inclusion criterion for this study.\n\nTherefore, this patient is not eligible for the clinical trial based on the provided inclusion criteria and patient information.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "668": {
        "output": "",
        "label": 1
    },
    "669": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, which is difficulty swallowing that has progressed from solids to liquids, and he has experienced significant weight loss. The main concern for this patient appears to be a potential esophageal obstruction or other serious condition related to his smoking and drinking history.\n\nThe clinical trial provided is a comparison between two methods of throat swabbing in the diagnosis of strep pharyngitis, which is a bacterial infection of the throat. The inclusion criteria for the trial are patients with a sore throat, classified 2-3 according to Cantor's criteria, which is likely a scale that assesses the severity of throat symptoms.\n\nThe patient's symptoms do not align with the trial's target condition (strep pharyngitis) and inclusion criteria. There is no mention of a sore throat or a diagnosis that would fit Cantor's criteria, nor is there any indication that the patient is suffering from an infection that would require throat swabbing.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial due to the absence of the specified condition (sore throat) and because the patient's primary health issue seems to be unrelated to the purpose of the trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "670": {
        "output": "The patient note describes a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. There is no mention of lung adenocarcinoma or any cancer diagnosis, nor is there any information about EGFR mutations or the stage of any potential cancer.\n\nThe clinical trial's inclusion criteria require the patient to have a diagnosis of stage IIIB/IV lung adenocarcinoma with EGFR mutations and to be previously untreated for lung adenocarcinoma. Furthermore, the patient must have an ECOG performance status of 0-2, at least one measurable lesion according to RECIST, and a life expectancy of at least 12 weeks.\n\nBased on the provided patient note, we do not have enough information to determine if this patient has lung adenocarcinoma with EGFR mutations or his ECOG performance status. The only matching criterion is that the patient is male and over 18 years old. Given the lack of information on a lung adenocarcinoma diagnosis, EGFR mutations, clinical stage, performance status, and prior treatments, we cannot assume the patient meets the inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "671": {
        "output": "Based on the patient note and the inclusion criteria of the clinical trial, let's assess the patient's eligibility for the clinical trial titled \"Improve the Treatment of Thoracic Esophageal Cancer\":\n\nPatient Note Analysis:\n- The patient is a 52-year-old African American man.\n- He has a history of progressive dysphagia with difficulty swallowing that has progressed from meats to liquids.\n- He reports that the obstruction is felt at the lower end of his sternum.\n- He has experienced a significant weight loss of 25 pounds.\n- There is no explicit mention of a diagnosis, but symptoms are suggestive of esophageal cancer.\n- There is no information about the patient's performance status (Karnofsky Performance Status), clinical staging, or laboratory results.\n\nClinical Trial Inclusion Criteria:\n- Age \u2264 70 years old (the patient is 52 years old, so he meets this criterion).\n- Karnofsky Performance Status (KPS) \u2265 80 (not mentioned in the patient note).\n- Pathological diagnosis is squamous cell carcinoma of thoracic esophagus which is treated initially (not confirmed in the patient note).\n- Clinical stage is c T1-3 N0-1 (not provided in the patient note).\n- The preoperative evaluation of organ function is tolerant of surgery and chemotherapy (not provided in the patient note).\n- The subject can understand and sign the informed consent form (ICF) (assuming the patient is competent, he should be able to meet this criterion).\n- Laboratory tests within specific ranges (not provided in the patient note).\n\nBased on the available information in the patient note, while the patient's age meets the criteria, there is insufficient information to determine whether the other criteria are met, such as the KPS score, clinical staging, pathological diagnosis, organ function evaluation, and laboratory test results. Therefore, further investigation would be needed to determine if this patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "672": {
        "output": "Based on the patient note and the clinical trial inclusion criteria provided, let's evaluate the patient's eligibility for the clinical trial:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- Describes progressive dysphagia and significant weight loss (25 pounds).\n\nClinical Trial Inclusion Criteria:\n- Ages 18 to 35 years old\n- BMI > 22 kg/m2 (not provided in the patient note)\n- Self-report smoking > 10 cigarettes each day\n- Have access to a telephone and the internet\n- Demonstrate ability to access a specific website\n- Demonstrate ability to receive and respond to email\n- Willing to accept random assignment\n- Intending to be available for a 24-month intervention\n- At risk for weight gain (e.g., plan to quit smoking)\n\nThe patient does not meet the age criterion for the clinical trial, as he is 52 years old, and the trial requires participants to be between 18 to 35 years old. Additionally, the trial focuses on individuals who are at risk for weight gain, particularly in the context of quitting smoking. The patient note does not indicate that the patient is planning to quit smoking or that he is at risk for weight gain; in fact, he has experienced significant weight loss.\n\nTherefore, the patient does not meet the key inclusion criteria for age and the context of weight gain associated with quitting smoking. There is no indication that the patient intends to quit smoking or that he is at risk for weight gain, as he has already lost weight due to dysphagia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "673": {
        "output": "Based on the information provided:\n\nPatient Characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Weight loss of 25 pounds\n- Possible obstruction at the lower end of sternum (suggestive of esophageal involvement)\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed esophageal cancer or gastroesophageal junction tumor (including adenocarcinoma, squamous cell cancer, poorly differentiated epithelial malignancy, Siewert type I or II tumors)\n- Failure after no more than 2 prior chemotherapy regimens and 1 chemoradiation course\n- Measurable or evaluable disease by CT scan\n- Stable brain metastases, if present, after cranial irradiation\n- WHO performance status 0-2\n- Specific blood test requirements (bilirubin, AST/ALT)\n- Ability to take oral tablets\n- No clinically active interstitial lung disease\n- No severe hypersensitivity to gefitinib or excipients\n- No prior other malignancy that could confound results or interfere with therapy\n- No medical condition that interferes with safe trial participation\n- Not pregnant and using effective contraception if fertile\n- No chemotherapy within the past 6 weeks\n- No radiotherapy to the site of measurable or evaluable disease within the past 4 weeks\n- No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy, or experimental medications\n\nThe patient note does not provide enough information to confirm the histological diagnosis of esophageal cancer or specify the patient's WHO performance status. There is also no information on prior treatments that the patient may have received. The symptoms described are indicative of esophageal involvement, which is relevant to the trial, but without a confirmed histological diagnosis of esophageal cancer or gastroesophageal junction tumor, and without knowledge of any prior treatments, we cannot definitively establish eligibility.\n\nTherefore, based on the available information from the patient note, we would need further investigation to determine if the patient has a confirmed diagnosis and meets the other inclusion criteria, especially regarding previous treatments and performance status.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "674": {
        "output": "Based on the patient note provided, the 52-year-old African American man has a history of progressive dysphagia, which is difficulty in swallowing, and has experienced significant weight loss. There is no mention of a cough, whether chronic or otherwise, in the note. The clinical trial is investigating the effect of Lidocaine as a treatment for chronic cough.\n\nTo match the patient to the trial, we must assess the inclusion criteria of the trial against the patient's medical condition:\n\n1. Male and female subjects, age 18 years and over - The patient is a 52-year-old man, which meets this criterion.\n2. History of cough for more than 8 weeks - There is no mention of a cough in the patient's history.\n3. Normal chest x-ray - There is no information provided regarding chest x-ray results.\n4. Chronic idiopathic cough or chronic cough resistant to treatment of specific triggers - The patient note does not describe any cough symptoms, let alone a chronic cough.\n\nSince the patient's primary complaint is dysphagia and there is no indication of chronic cough, which is the focus of the clinical trial, the patient does not appear to meet the specific inclusion criteria regarding the condition being studied. Therefore, it is appropriate to conclude:\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "675": {
        "output": "Upon reviewing the patient's condition and the inclusion criteria for the clinical trial titled \"Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing,\" it is clear that this patient does not meet the criteria required for participation in the study.\n\nThe patient note describes a 52-year-old African American man with progressive dysphagia associated with weight loss, which began with difficulty swallowing meat and progressed to include other solid foods, soft foods, and then liquids. The patient's symptoms point towards a possible esophageal disorder, potentially related to his history of heavy smoking and drinking. The point of obstruction is felt at the lower end of his sternum, which suggests an esophageal rather than oropharyngeal origin.\n\nThe clinical trial's inclusion criteria specifically list:\n- Stroke identified by neurological and radiological examination\n- Oropharyngeal dysphagia as confirmed by clinical and radiological examination\n- No prior history of oropharyngeal dysphagia by patient and/or caregiver report\n- No previous head/neck surgery or trauma that may impact swallowing ability\n- No other/concomitant neurological disorders (e.g., Parkinson's disease) that would impact oropharyngeal swallowing ability\n- Physician and patient/family agreement to participate\n\nThe patient in question has not been identified as having suffered a stroke, nor is there any indication of oropharyngeal dysphagia, which is a requirement for the trial. Instead, the patient's symptoms suggest a different etiology for his dysphagia. Therefore, this patient does not match the specific inclusion criteria needed for participation in the trial, which is focused on the rehabilitation of swallowing post-stroke.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "676": {
        "output": "",
        "label": 0
    },
    "677": {
        "output": "Given the patient's history of progressive dysphagia, trouble swallowing various types of food, and weight loss, there is a suggestion of an underlying malignancy, possibly esophageal carcinoma, which is mentioned specifically as one of the categories in the clinical trial's inclusion criteria. The patient has located the obstruction sensation at the lower end of his sternum, which is consistent with the location of the esophagus and further implies esophageal involvement. However, the note does not confirm a diagnosis of advanced or metastatic non-hematologic malignancy, nor does it mention any prior treatments or imaging studies.\n\nFor the patient to be eligible for the clinical trial in question, the following criteria need to be met according to the trial description:\n\n1. Confirmed diagnosis of advanced, measurable or evaluable, nonresectable, and/or metastatic non-hematologic malignancy.\n2. The malignancy must have been progressive in the last 6 months as demonstrated by serial imaging.\n3. The patient must have failed conventional treatment or for whom no therapy of proven efficacy exists or who is not amenable to established treatment options, or tumor tissue must be available for determination of E-cadherin expression.\n4. Recovery from reversible toxicities of prior anti-cancer therapies.\n5. Age \u2265 18 years (the patient is 52 years old).\n6. Life expectancy \u2265 3 months.\n7. Written informed consent.\n8. ECOG performance score 0-1.\n9. Willingness to provide paired tumor biopsies for pharmacodynamic determination.\n\nGiven that the patient note does not confirm a diagnosis of cancer, the status of progressive disease, or any prior treatment, more information would be required to determine if the patient fits the specific criteria for esophageal carcinoma (III) mentioned in the trial inclusion criteria. The patient would need a confirmed diagnosis and information on any previous treatments before a referral could be made. Therefore, based on the information provided in the patient note:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "678": {
        "output": "Given the information provided in the patient note:\n\n- The patient is a 52-year-old African American man with progressive dysphagia, significant weight loss, and a history of heavy smoking and drinking.\n- The patient has difficulty swallowing which has progressed from solids to liquids and locates the obstruction at the lower end of his sternum.\n- There's no specific mention of a diagnosis of gastric cancer or adenocarcinoma of the gastro-oesophageal junction, but the symptoms could be indicative of such conditions. Further investigation is needed to confirm the diagnosis histologically.\n\nThe clinical trial's inclusion criteria are:\n\n- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease not amenable to curative therapy.\n- Measurable disease according to RECIST assessed using imaging techniques.\n- ECOG Performance status 0, 1, or 2.\n- Life expectancy of at least 3 months.\n- Male or female age \u2265 18 years.\n- Signed informed consent.\n- Assessment of HER2 status by the central laboratory prior to initiation of study treatment.\n- Able to swallow and retain oral medication.\n- LVEF \u2265 50% assessed by MUGA or cardiac ultrasound.\n\nThis patient's symptoms suggest that he could potentially have a gastric or gastro-oesophageal junction cancer, but without a histological confirmation, we cannot be certain. Furthermore, we do not have information regarding his ECOG Performance status, life expectancy, HER2 status, ability to swallow and retain oral medication, or LVEF status. \n\nGiven the lack of specific diagnostic information and other essential eligibility criteria, the best course of action would be to consider referring the patient to this clinical trial upon further investigation to confirm the diagnosis and other relevant clinical details. \n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "679": {
        "output": "Based on the patient note provided, here is the assessment:\n\nPatient note details:\n- The patient is a 52-year-old African American man.\n- History of heavy smoking and drinking.\n- Progressive dysphagia to solids, soft foods, and liquids.\n- Point of obstruction felt at the lower end of his sternum.\n- Weight loss of 25 pounds.\n\nClinical trial inclusion criteria:\n- Age \u226518 years.\n- Confirmed esophageal/gastroesophageal (GEJ) cancer (Siewert Type I and Type II only) on biopsy.\n- Dysphagia score \u22652.\n- Stage IV cancer/Metastatic disease.\n\nComparison:\n- The patient is over 18 years old, which meets the age criteria.\n- The patient has progressive dysphagia, which suggests a potential for esophageal cancer, and his dysphagia is severe as it has progressed to include liquids, indicating a possible Dysphagia score \u22652.\n- The location where the patient feels the obstruction (lower end of the sternum) could be indicative of esophageal or GEJ cancer.\n\nHowever, the patient note lacks specific information that confirms a diagnosis of esophageal or GEJ cancer, the dysphagia score, and whether the patient has Stage IV or metastatic disease. Therefore, further investigation is required to determine if the patient truly meets the clinical trial criteria:\n\n- Confirmation of esophageal/GEJ cancer through biopsy.\n- Determination of the dysphagia score.\n- Assessment of cancer staging to confirm if it is Stage IV or metastatic.\n\nWithout this information, we cannot definitively refer the patient but should consider further investigation.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "680": {
        "output": "Based on the information provided in the patient note and the clinical trial's inclusion criteria, we can assess the patient's eligibility for the trial as follows:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia starting with solid foods and progressing to liquids\n- Weight loss of 25 pounds\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction\n- Inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy\n- Measurable disease according to RECIST\n- HER2 positive tumor\n- ECOG Performance status 0, 1, or 2\n- Life expectancy of at least 3 months\n- Age over 20 years\n- Signed informed consent\n\nAssessment:\n- The patient's age meets the trial's age criterion (over 20 years).\n- The patient has symptoms that could be suggestive of an advanced gastric problem, which could align with the trial's target population (adenocarcinoma of the stomach or gastro-oesophageal junction).\n\nHowever, several critical pieces of information are missing to determine if the patient fulfills the other inclusion criteria:\n- There is no mention of a histologically confirmed diagnosis of adenocarcinoma of the stomach or gastro-oesophageal junction.\n- The HER2 status of any tumor (if present) is not provided.\n- The patient's ECOG Performance status is not mentioned.\n- There is no confirmation of inoperable locally advanced or recurrent and/or metastatic disease, nor is there any mention of measurable disease according to RECIST.\n\nGiven these gaps in information, we cannot conclude that the patient is definitively eligible for this trial. Additional investigations, such as histological confirmation, HER2 status assessment, ECOG performance evaluation, and imaging studies, would be needed to determine eligibility.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "681": {
        "output": "Given the information provided in the patient note, we have a 52-year-old African American man presenting with progressive dysphagia that has progressed over several months from difficulty in swallowing solid foods to liquids. He also has a significant weight loss of 25 pounds, which could be a result of his dysphagia. However, there is no mention of symptoms such as hoarseness, throat clearing, throat pain, globus sensation, or chronic cough, nor is there any mention of a diagnosis of laryngopharyngeal reflux (LPR) or any related investigations such as a laryngoscopic examination or reflux symptom index score.\n\nLet's compare the patient's information to the clinical trial's inclusion criteria:\n\n- Patients with age of 12-75 years old (inclusive): The patient is 52 years old, which fits within the age range.\n- Patients with at least one symptom consistent with LPR, including hoarseness, throat clearing, throat pain, globus sensation in the throat, or chronic cough \u2267 4 weeks before entering study: The patient note does not mention any of these symptoms.\n- Patients with a total reflux symptom index (RSI) >10: There is no RSI score provided in the patient note.\n- Patients with a total reflux finding score (RFS) >5: There is no RFS provided in the patient note.\n- Patients or their legal representatives have signed the informed consent form: This is a procedural criterion that could be fulfilled if the patient agrees to participate.\n\nBased on the information provided, the patient does not clearly meet the symptomatic criteria for LPR as outlined in the trial's inclusion criteria. Given the lack of information on LPR-specific symptoms or any diagnostic scores related to LPR, it is not possible to definitively determine the patient's eligibility without further evaluation.\n\nTherefore, the assessment for this patient would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 0
    },
    "682": {
        "output": "In this case, the patient is a 52-year-old African American man with a history of progressive dysphagia, weight loss, and difficulty swallowing various consistencies of food, which he feels are obstructed at the lower end of his sternum. The clinical trial in question is seeking healthy, ambulatory subjects with sore throat pain due to an upper respiratory tract infection (URTI), and the pain must have started within six days of the screening period.\n\nThe patient's symptoms of dysphagia and weight loss are not consistent with the typical symptoms of an upper respiratory tract infection, nor does the patient note mention a sore throat or any related symptoms. Additionally, the patient's difficulty swallowing and obstruction at the lower end of the sternum suggest a potential esophageal disorder, which is not relevant to the clinical trial's focus on sore throat pain relief.\n\nGiven that the patient's primary complaint is unrelated to the inclusion criteria of the clinical trial (which specifically requires sore throat pain due to URTI), he would not be an appropriate candidate for this study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "683": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids, soft foods, and liquids\n- Obstruction at the lower end of the sternum\n- Weight loss of 25 pounds\n\nClinical Trial:\n- Title: Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer\n- Summary: Evaluate impact of stent insertion for palliative care in patients with malignant dysphagia due to end-stage inoperable esophageal cancer\n- Inclusion Criteria: Patients with end-stage inoperable esophageal cancer deemed candidates for intraluminal esophageal palliative stent insertions\n\nComparison:\n- The patient presents with progressive dysphagia and significant weight loss, which are common symptoms in esophageal cancer, particularly in the context of a history of heavy smoking and drinking.\n- The clinical trial is specifically looking to enroll patients with end-stage inoperable esophageal cancer for stent insertion.\n\nTo accurately assess the patient's eligibility, we would need a confirmed diagnosis of esophageal cancer, specifically end-stage and inoperable, as stated in the inclusion criteria of the clinical trial. The patient's symptoms are suggestive of esophageal cancer, but without a confirmed diagnosis, we cannot proceed with certainty.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "684": {
        "output": "Based on the patient note provided and the inclusion and exclusion criteria of the clinical trial, let's assess the patient's eligibility:\n\nPatient Note:\n- The patient is a 52-year-old African American man.\n- He has a history of heavy smoking and drinking.\n- Describes progressive dysphagia, difficulty swallowing various consistencies of food, and significant weight loss.\n- Points to obstruction at the lower end of the sternum.\n\nClinical Trial Inclusion Criteria:\n- Submit to a 24-hour urine cotinine test to determine smoking status.\n- Must be a non-smoker or a smoker meeting specific criteria.\n- Agree to consume a standardized vitamin and mineral supplement and avoid other supplements for the duration of the study.\n- No history of malabsorptive, gastrointestinal, or other metabolic disorders requiring special diet recommendations.\n- Body mass index (BMI) between 20 and 35 kg/m2.\n- Abstain from purple and red colored foods and beverages.\n- Abstain from the use of ANY mouthwashes during the 6-week study period.\n\nClinical Trial Exclusion Criteria:\n- Known allergy to strawberries, corn, and wheat products.\n- Active metabolic or digestive illnesses.\n- History of pituitary hormone diseases requiring hormonal administration.\n- Significant loss of gastrointestinal organs.\n- Altered immunity including cancer.\n- Heavy alcohol consumers defined as >15 glasses/week.\n- Antibiotic use in the last 6 months or on medications that affect bowel motility.\n- Are receiving or in need of dental treatment during the study period.\n- Noticeable open lesions, sores, active oral lesions, or history of leukoplakia or tumors.\n- Difficulty swallowing (dysphagia), pain with swallowing (odynophagia), salivary gland dysfunction, or xerostomia (dry mouth).\n\nEligibility Assessment:\n- The patient is a heavy smoker, which could potentially meet the smoker inclusion criteria if he smokes at least 10 cigarettes per day and has a urine cotinine level of >1000 ng/mL.\n- The patient has progressive dysphagia, which is a direct exclusion criterion for the trial since participants with difficulty swallowing are not eligible.\n\nBased on the information given, the patient would not be eligible for the clinical trial because he has difficulty swallowing, which is listed explicitly as an exclusion criterion. Even though he may meet the criteria for a smoker, the presence of dysphagia rules out his participation.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "685": {
        "output": "Based on the information provided:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia\n- Weight loss of 25 pounds\n\nClinical Trial:\n- Title: Tumor Markers in Lung Cancer: DCAMLK-1LK-1\n- Inclusion Criteria: >45 years of age\n\nThe inclusion criteria for the clinical trial are limited in detail but mention an age criterion of being over 45 years old. The patient is 52 years old, which meets the age criterion. However, the trial is focused on lung cancer and the patient's symptoms suggest a possible esophageal issue rather than lung cancer (dysphagia and pinpointing obstruction near the sternum are more indicative of esophageal than lung pathology). There is no mention of the patient having lung cancer or a suspected lung condition, nor is there any mention of other inclusion criteria that may be relevant (such as suspected malignant or benign lung diseases).\n\nTherefore, based solely on the information given and the age criterion, the patient meets the age requirement but there is no clear indication that the patient has a condition relevant to the trial's focus on lung cancer.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "686": {
        "output": "Based on the patient note provided and the inclusion criteria of the clinical trial, the patient's symptoms do not align with the requirements for participation in the trial. The patient has a history of progressive dysphagia with significant weight loss, which is suggestive of an esophageal disorder or other gastrointestinal tract issue rather than an upper respiratory tract infection (URTI) for which the clinical trial is designed.\n\nThe inclusion criteria for the clinical trial specifically require subjects to have symptoms of an upper respiratory tract infection (URTI), such as nasal congestion associated with colds and flu symptoms like pain, headache, fever, or sore throat, none of which are mentioned in the patient note.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial as the symptoms described in the patient note are not indicative of an upper respiratory tract infection.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "687": {
        "output": "Based on the patient note provided and the inclusion criteria for the clinical trial titled \"Evaluation of Two Different Thickening Products in Patients With Dysphagia,\" let's assess the patient's eligibility:\n\nPatient Note Assessment:\n- The patient is a 52-year-old man, which meets the age criterion of being over 18 years old.\n- He has a history of progressive dysphagia, initially with solids and progressing to liquids, indicating a history of dysphagia.\n- The patient notes a specific location where food is obstructed, suggesting a physical manifestation of dysphagia.\n- There is no mention of the patient's ability to complete a dynamic fluoroscopic swallow study, but given the detailed description of the dysphagia, it is plausible that he would be able to undergo such a study.\n- The patient's ability to provide informed consent is not mentioned, but there is no indication that he would be unable to do so.\n\nClinical Trial Inclusion Criteria:\n- History of dysphagia necessitating a dynamic fluoroscopic swallow study.\n- Age > 18 years.\n- Ability to complete a comprehensive dynamic fluoroscopic swallow study.\n- Ability to provide informed consent for study participation.\n\nThe patient meets the age requirement and has a history of dysphagia. However, the inclusion criteria specifically mention the need for a history of dysphagia necessitating a dynamic fluoroscopic swallow study, and it is not clear from the patient note whether such a study is indicated or has been performed.\n\nBased on the available information, the patient appears to meet most of the inclusion criteria, but further investigation is required to confirm the necessity of a dynamic fluoroscopic swallow study and the patient's capacity to provide informed consent. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 2
    },
    "688": {
        "output": "Based on the patient note provided, the patient is a 52-year-old African American man with progressive dysphagia, weight loss, and a history of heavy smoking and drinking. The key clinical information needed to assess eligibility for the clinical trial is not explicitly provided, such as the histological diagnosis of esophageal squamous cell carcinoma and staging of the disease.\n\nThe inclusion criteria for the clinical trial require a histological or cytologic diagnosis of Esophageal squamous cell carcinoma, among other specific medical and laboratory requirements. While the patient's symptoms of dysphagia and weight loss are consistent with esophageal cancer, there is no confirmation of a histological or cytologic diagnosis of Esophageal squamous cell carcinoma, and no information is provided on cancer staging, ECOG performance status, prior anticancer therapy, and specific organ function parameters.\n\nGiven the lack of detailed information in the patient note, I would consider referring this patient to the clinical trial upon further investigation to confirm the diagnosis, cancer staging, and other inclusion criteria.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "689": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's determine the patient's eligibility for the trial:\n\nPatient Characteristics:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids\n- Point of obstruction felt at the lower end of the sternum\n- Significant weight loss (25 pounds)\n\nClinical Trial Inclusion Criteria:\n- Histologically confirmed diagnosis of esophageal cancer\n- No prior palliative treatment or at least 6 months from the last operation, adjuvant radiation therapy, and adjuvant chemotherapy\n- Age between 18 to 75 years\n- Measurable or evaluable disease with specified tumor mass size requirements\n- Expected life expectancy of \u2265 3 months\n- Performance status of \u2265 80 on the Karnofsky scale\n- Normal marrow function and specific blood test results\n- Normal electrocardiogram results and no history of congestive heart failure\n- Good compliance and agreement for follow-up\n- Written informed consent\n\nAssessment:\n- The patient's age falls within the required range (18 to 75 years).\n- The patient has progressive dysphagia with weight loss, which may indicate advanced esophageal cancer, although this is not confirmed histologically in the note.\n- There is no indication in the patient note about prior treatments, performance status, blood tests, ECG results, or life expectancy, which are required to determine eligibility fully.\n\nGiven that the patient has symptoms that are suggestive of esophageal cancer, he could potentially meet the criteria if further medical evaluation (e.g., histological confirmation, imaging, performance status assessment) supports it. However, without confirmation of a histologically confirmed diagnosis of esophageal cancer and other required details, we cannot definitively determine his eligibility.\n\nTherefore, I would rate this as:\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "690": {
        "output": "",
        "label": 0
    },
    "691": {
        "output": "To determine the patient's eligibility for the clinical trial titled \"Satiety Innovation- Study 793. University of Aberdeen,\" we need to compare the patient's characteristics to the inclusion criteria of the study.\n\nThe inclusion criteria for the clinical trial are:\n- Males and females\n- 18-65 years old\n- Body Mass Index (BMI) 27-35kg/m^2\n- Overall healthy\n- Weight Stable (<3 kg change in the past 4 months, before the trial).\n\nThe patient's characteristics from the patient note:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids\n- Significant weight loss (25 pounds)\n\nFrom the given information:\n\n- The patient is a 52-year-old man, which fits within the 18-65 years age range specified in the inclusion criteria.\n- However, there is no information provided about the patient's BMI. The patient has experienced significant weight loss, which could affect BMI, but we do not have the patient's current or previous weight to calculate it.\n- The patient's history of heavy smoking and drinking, along with progressive dysphagia and significant weight loss, suggests he may not be \"overall healthy,\" as required by the trial.\n- The patient has lost 25 pounds, which indicates he has not been weight-stable in the past 4 months, violating one of the criteria.\n- The clinical trial is focused on appetite, satiety, and gut health in overweight and obese volunteers, whereas the patient has issues with dysphagia and weight loss, which are not related to the study's focus.\n\nBased on the information provided, the patient does not meet several key inclusion criteria for the clinical trial. Specifically, the patient's health issues and significant weight loss are not aligned with the characteristics of the target population for the study.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "692": {
        "output": "After reviewing the patient's note and the clinical trial inclusion criteria, here are the assessments:\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia to solids and liquids, weight loss of 25 pounds\n- Obstruction sensation at the lower end of the sternum\n\nClinical Trial Inclusion Criteria:\n- Age between 20-85 years old\n- First-time stroke confirmed by computed tomography or magnetic resonance imaging\n- Dysphagia > 3 weeks, with preservation of the swallowing reflex\n- Currently on a restricted diet, with a Functional Oral Intake Scale (FOIS) score of 5 or less\n- Mini-Mental State Examination (MMSE)> 21\n- No obvious mental depression, receptive aphasia or cognitive impairment\n\nThe patient's description of progressive dysphagia does not indicate that he has had a stroke, which is a requirement for this clinical trial. The trial specifically targets stroke-related dysphagia, and there is no mention of a stroke in the patient's history. Therefore, the patient does not meet the key inclusion criteria of having had a stroke with resulting dysphagia.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "693": {
        "output": "",
        "label": 1
    },
    "694": {
        "output": "Based on the provided patient note and the inclusion criteria of the clinical trial, let's compare the relevant points:\n\nPatient note:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia beginning several months ago\n- Difficulty swallowing that has progressed to liquids\n- Weight loss of 25 pounds\n\nClinical trial:\n- Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma\n- Stage T2-3N0M0 disease of thoracic esophageal squamous cell carcinoma (TESCC) confirmed by pathology studies\n- Patients who received R0 operations in Cancer Institute & Hospital, CAMS\n- KPS\u226570 before radiotherapy\n- Did not receive neoadjuvant or adjuvant treatment\n- No clear recurrent or metastatic lesions before radiotherapy\n- IMRT is accepted\n- Regular follow-up\n\nFrom the patient note, we do not have information that confirms a diagnosis of esophageal carcinoma, the stage of disease, or whether the patient has undergone any surgery (R0 resection) or other treatments related to esophageal carcinoma. The patient does have symptoms that could be suggestive of esophageal disease (e.g., progressive dysphagia, weight loss), but without more specific information, such as results from pathology studies or details on prior treatments, we cannot definitively determine if he meets the inclusion criteria for the clinical trial.\n\nAt this point, we would need additional information to confirm the patient's diagnosis, staging, and treatment history. The patient would need to be evaluated further to confirm eligibility for the clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Would consider referring this patient to this clinical trial upon further investigation.",
        "label": 1
    },
    "695": {
        "output": "",
        "label": 1
    },
    "696": {
        "output": "",
        "label": 0
    },
    "697": {
        "output": "",
        "label": 0
    },
    "698": {
        "output": "",
        "label": 0
    },
    "699": {
        "output": "To assess the eligibility of the patient for the clinical trial titled \"Financial Incentives for Maintenance of Weight Loss,\" we need to compare the patient's characteristics and medical history with the inclusion criteria of the study:\n\nInclusion Criteria for the Clinical Trial:\n- Adults age 30-80\n- BMI between 30 and 45 prior to starting Weight Watchers\n- Have a documented weight loss of at least 5kg in the past 4-6 months before enrolling\n- Stable health\n\nPatient Characteristics:\n- A 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia for several months\n- Difficulty swallowing that progressed from solids to liquids\n- Sensation of obstruction at the lower end of the sternum\n- Weight loss of 25 pounds (unspecified time frame)\n\nAssessment:\n- The patient is within the age range required (30-80 years old).\n- There is no information about the patient's BMI prior to the onset of symptoms or prior to starting Weight Watchers.\n- The patient has experienced significant weight loss; however, it is not specified whether this loss is documented or occurred within the specified 4-6 months before enrolling.\n- The patient's health cannot be considered stable due to progressive dysphagia and significant weight loss, which are concerning for an underlying medical condition, potentially esophageal cancer given his symptoms and risk factors.\n\nGiven that the patient's significant weight loss is likely due to progressive dysphagia rather than a structured weight loss program like Weight Watchers, and considering the absence of BMI information and concerns about the stability of the patient's health, the patient does not meet the inclusion criteria as specified.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    },
    "700": {
        "output": "Based on the provided patient note and the clinical trial inclusion criteria, let's assess the patient's eligibility for this trial.\n\nPatient Note:\n- 52-year-old African American man\n- History of heavy smoking and drinking\n- Progressive dysphagia (difficulty swallowing)\n- Weight loss (25 pounds)\n\nClinical Trial Inclusion Criteria:\n- ASA I-II patients\n- Aged between 20 and 65 years\n- Undergoing 1 or 2 level posterior spinal fusion in prone position with tracheal intubation\n\nThe trial is focused on patients who are undergoing spinal surgery in the prone position with tracheal intubation and aims to compare the effects of magnesium sulfate and dexamethasone on postoperative sore throat.\n\nThe patient in the note is experiencing progressive dysphagia, likely related to his history of smoking and drinking, and there is no indication that he is undergoing spinal surgery. Additionally, the patient's symptoms appear to be related to an esophageal condition rather than a condition requiring spinal surgery.\n\nGiven that the patient does not meet the specific requirement of needing spinal surgery, nor is there any indication that he is scheduled for such a procedure, he does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Would not refer this patient for this clinical trial.",
        "label": 0
    }
}